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Abstract 
The problem 
Around 300 million people worldwide have asthma and prevalence is increasing.  
Support for optimal self-management can be effective in improving a range of 
outcomes and is cost effective, but is underutilised as a treatment strategy.  
Supporting optimum self-management using digital technology shows promise, 
but how best to do this is not clear. 
Aim 
The purpose of this project was to explore the potential role of a digital 
intervention in promoting optimum self-management in adults with asthma.  
Methods 
Following the MRC Guidance on the Development and Evaluation of Complex 
Interventions which advocates using theory, evidence, user testing and 
appropriate modelling and piloting, this project had 3 phases.  Phase 1:  
Examination of the literature to inform phases 2 and 3, using systematic review 
methods and focussed literature searching.  Phase 2:  Developing the Living Well 
with Asthma website.  A prototype (paper-based) version of the website was 
developed iteratively with input from a multidisciplinary expert panel, empirical 
evidence from the literature (from phase 1), and potential end users via focus 
groups (adults with asthma and practice nurses).  Implementation and behaviour 
change theories informed this process.  The paper-based designs were converted 
to the website through an iterative user centred process (think aloud studies 
with adults with asthma).  Participants considered contents, layout, and 
navigation.  Development was agile using feedback from the think aloud sessions 
immediately to inform design and subsequent think aloud sessions.  Phase 3: A 
pilot randomised controlled trial over 12 weeks to evaluate the feasibility of a 
Phase 3 trial of Living Well with Asthma to support self-management.  Primary 
outcomes were 1) recruitment & retention; 2) website use; 3) Asthma Control 
Questionnaire (ACQ) score change from baseline; 4) Mini Asthma Quality of Life 
(AQLQ) score change from baseline.  Secondary outcomes were patient 
activation, adherence, lung function, fractional exhaled nitric oxide (FeNO), 
generic quality of life measure (EQ-5D), medication use, prescribing and health 
services contacts. 
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Results 
Phase1:  Demonstrated that while digital interventions show promise, with some 
evidence of effectiveness in certain outcomes, participants were poorly 
characterised, telling us little about the reach of these interventions.  The 
interventions themselves were poorly described making drawing definitive 
conclusions about what worked and what did not impossible.  Phase 2:  The 
literature indicated that important aspects to cover in any self-management 
intervention (digital or not) included: asthma action plans, regular health 
professional review, trigger avoidance, psychological functioning, self-
monitoring, inhaler technique, and goal setting.  The website asked users to aim 
to be symptom free.  Key behaviours targeted to achieve this include: optimising 
medication use (including inhaler technique); attending primary care asthma 
reviews; using asthma action plans; increasing physical activity levels; and 
stopping smoking.  The website had 11 sections, plus email reminders, which 
promoted these behaviours.  Feedback during think aloud studies was mainly 
positive with most changes focussing on clarification of language, order of pages 
and usability issues mainly relating to navigation difficulties.  Phase 3: To 
achieve our recruitment target 5383 potential participants were invited, leading 
to 51 participants randomised (25 to intervention group).  Age range 16-78 years; 
75% female; 28% from most deprived quintile.  Nineteen (76%) of the 
intervention group used the website for an average of 23 minutes.  Non-
significant improvements in favour of the intervention group observed in the 
ACQ score (-0.36; 95% confidence interval: -0.96, 0.23; p=0.225), and mini-AQLQ 
scores (0.38; -0.13, 0.89; p=0.136).  A significant improvement was observed in 
the activity limitation domain of the mini-AQLQ (0.60; 0.05 to 1.15; p = 0.034).  
Secondary outcomes showed increased patient activation and reduced reliance 
on reliever medication.  There was no significant difference in the remaining 
secondary outcomes.  There were no adverse events.  
Conclusion 
Living Well with Asthma has been shown to be acceptable to potential end users, 
and has potential for effectiveness.  This intervention merits further 
development, and subsequent evaluation in a Phase III full scale RCT.  
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Glossary 
Asthma control The extent to which manifestations of asthma are reduced or removed by 
treatment. This can vary.  
Asthma 
exacerbation 
Episodic worsening of asthma symptoms  that are troublesome to 
patients, and that prompt a need for a change in treatment. 
Asthma severity The difficulty in controlling asthma with treatment. For example even 
with excellent adherence to available therapies control of symptoms 
remains difficult.  
Behaviour 
change theory 
Behaviour change theories are sets of statements or principles devised to 
explain why behaviours change, and that can be scientifically tested. 
Co-morbidity The presence of one or more long-term conditions in addition to an index 
condition 
Digital 
interventions  
Interventions delivered via the internet or non-internet means such as via 
text messaging, or using automated interactive voice response systems 
for example. 
ehealth  is an emerging field in the intersection of medical informatics, public 
health and business, referring to health services and information 
delivered or enhanced through the Internet and related technologies. 
Feasibility study Used to estimate important parameters that are needed to design a main 
study, such as ease of recruitment, standard deviations of outcome 
measures, and follow up rates. 
Framework A basic structure underlying a system, concept, or text. 
Framework 
analysis 
A type of qualitative analysis involving the use of a framework to sift, 
chart and sort data. 
Grade A 
recommendation 
A recommendation which has best available evidence to back it up e.g. at 
least one meta-analysis, systematic review, or RCT rated as 1++, and 
directly applicable to the target population; or A body of evidence 
consisting principally of studies rated as 1+, directly applicable to the 
target population, and demonstrating overall consistency of results. 
(Studies rated as 1+ or 1++ have either a low, or very low risk of bias). 
Definition from SIGN guidelines.  
Interactive 
intervention 
The intervention provides feedback autonomously and therefore delivers 
the intervention, at least in part, independently of any health 
professional, and communicates using any of a variety of methods such as 
on screen, email or text. 
Metareview A systematic review of systematic reviews. 
mhealth Health care supported by mobile devices, such as mobile phones, patient 
monitoring devices, personal digital assistants (PDAs), and other wireless 
devices.” http://www.who.int/goe/publications/goe_mhealth_web.pdf, 
pg 6 
Normalisation 
Process Theory 
A middle range sociological theory that can be used to understand the 
processes involved in the implementation and embedding of a set of 
tasks. 
Pilot Trial A version of the main study that is run in miniature to test whether the 
components of the main study can all work together, and can work 
alongside existing practices.  
Self 
management 
support 
Giving people living with long-term conditions the tools, skills and 
support they need to improve their own wellbeing. It encourages them to 
find out more about their condition and learn new skills and tools to help 
them manage their own health better. (Definition adapted from 
www.selfmanagementuk.org). 
Self-efficacy Belief in one's ability to succeed in specific situations or accomplish a 
task. 
Chapter 1 Introduction  15 
 
Self-monitoring Part of effective self-management in asthma and requires the patient to 
monitor changes in their own clinical condition either using symptoms or 
peak flow readings and respond to them appropriately.  
Taxonomy An ordered arrangement / list of groups or categories. 
Telemedicine/ 
telehealth 
The delivery of health care from a distance. 
 
Thematic 
analysis 
A type of qualitative analysis that involves pinpointing, examining, and 
recording patterns (or "themes") within data 
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Chapter 1:  Introduction & Background 
1.1 Introduction 
Asthma is a chronic relapsing condition which is associated with considerable 
morbidity and mortality [1, 2]. There are effective treatment options for asthma 
mainly using inhaled medications [3].  Mostly these treatments have to be taken 
regularly, even when the person is well, and adjusted accordingly when the 
person becomes less well [4].  As with many other chronic diseases, the 
availability of effective pharmacological treatments alone does not lead to 
better outcomes [5].  Improving self-management behaviours, primarily taking 
medication regularly and as prescribed, is an effective strategy for improving a 
range of asthma outcomes [6] and is recommended in asthma management 
guidelines both in the UK and worldwide [4, 7].  However, how best to support 
self-management is not clear [8].  What is clear however, is that as a treatment 
strategy, self-management support is not offered enough by health 
professionals, or utilised enough by those with the potential to benefit, and this 
is where the management of asthma is considered to be failing most [5, 9, 10].  
This project aimed to help address these failings by developing and then 
investigating the role of a digital intervention to support self-management in 
adults with asthma. 
1.2 Research motivation 
The project came about through some hands-on experience in the field of 
asthma research and a fortuitous meeting in Oxford between one of my 
supervisors (Frances Mair) and a health psychology professor (Lucy Yardley) 
whose team were developing a software product called LifeGuide.  This software 
allowed health professionals without a background in computer programming to 
develop websites both to provide information and to support health behaviour 
change. 
My asthma research experience was gained during a one-year academic fellow 
post I commenced in August 2010.  I worked with a team evaluating azithromycin 
in adults with asthma in a randomised controlled trial (RCT), and my main role 
was helping with recruitment.  This involved phoning patients who had shown 
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interest in the study to review whether they met the inclusion / exclusion 
criteria.  As a General Practitioner (GP), I am used to speaking to people with 
either a new diagnosis of asthma, or those experiencing an exacerbation.  
However, I rarely converse with those in-between: people who drift along with 
bothersome symptoms not bad enough to seek help for, but bad enough to 
significantly impact on day to day life, and I was surprised to realise that the 
majority of those I was talking to fell into this category.  What was more 
surprising to me was how many of them did not take their preventer inhalers, 
this being the norm rather than the exception.  The reason was virtually always 
‘because I don’t really need them’.  This was despite just spelling out for me in 
detail the symptoms they were experiencing and the effect it was having on 
their life.  The discrepancy between people with asthmas’ assessment of their 
own control, and objective measures, I now know is well documented in the 
literature [11], however hearing it time and time again really made an impact on 
me as I had not been aware of this as such an issue previously.  The people I was 
speaking to could all experience fewer symptoms if they took their prescribed 
medication – so why was this not happening, and what could I do to help?  This 
realisation, combined with knowledge of the existence of LifeGuide software, 
led to the idea of developing a resource which targeted this group of people 
with a view to supporting self-management through adherence to prescribed 
medication and thus to improving asthma.  A proposal for funding was drafted in 
conjunction with my four supervisors, and successfully submitted to the Chief 
Scientist Office.  I was awarded funding for a 3-year fellowship to allow me to 
undertake the project, with the aim of achieving a PhD. 
1.3 eHealth: Definitions & the role of the Internet 
1.3.1 Introduction 
I am going to briefly discuss eHealth and related terminology used in this thesis, 
and address concerns about the ‘digital divide’ which is often the first criticism 
levied at researchers working in this area.  After this, I will describe my aims, 
research questions and provide the structure of this thesis to facilitate the 
reader in understanding how my planned project work was developed to meet 
each of my research questions.  
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1.3.2 eHealth definitions 
The term eHealth is wide-ranging and comparatively generic, and was initially 
defined in 2001 by Gunther Eysenbach as follows [12]: 
“e-health is an emerging field in the intersection of medical informatics, 
public health and business, referring to health services and information 
delivered or enhanced through the Internet and related technologies. In a 
broader sense, the term characterizes not only a technical development, 
but also a state-of-mind, a way of thinking, an attitude, and a commitment 
for networked, global thinking, to improve health care locally, regionally, 
and worldwide by using information and communication technology.” 
A later systematic review from 2005 found 51 unique definitions of eHealth [13], 
of which Eysenbach’s was one of them.  I value Eysenbach’s appreciation of the 
bigger picture, the fact that the development of eHealth represents not just a 
different mode of delivery for an intervention or a service but a completely new 
way of thinking.  How ubiquitous the Internet has become over these last 14 
years could barely have been predicted, yet I think this definition is still 
relevant, and with the development of smartphones, wearable technologies, and 
even ‘smart houses’ it can still be considered an emerging field. 
Other related terms which appear in the literature include telemedicine and 
telehealth which broadly describe the delivery of health care from a distance.  
Initially eHealth interventions were alternative modes of delivering health 
professional led interventions, but as technology has become more 
sophisticated, interventions are increasingly being developed which can function 
without health professional input: the computer itself delivering the 
intervention.  Terms such as web-based, online, Internet-based, digital, and 
computerised are often used interchangeably, although can mean different 
things in different contexts.  In this thesis, I use the term digital when looking to 
include interventions delivered via internet and non-internet means such as with 
short message services (SMS), or using automated interactive voice response 
systems.  Internet and web-based are interchangeable and refer to the fact that 
an internet connection is required (fixed or wireless) to at least download or use 
the intervention either on a computer, tablet or smartphone.  I use the term 
interactive to represent the idea that a computer provides feedback and 
therefore delivers the intervention, at least in part, independently of any health 
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professional, and communicates using any of the methods above (e.g. SMS).  
Another related term showing increasing prominence in the literature is 
‘mHealth’, which is a component of eHealth.  It has been defined as: 
“medical and public health practice supported by mobile devices, such as 
mobile phones, patient monitoring devices, personal digital assistants 
(PDAs), and other wireless devices.” 
http://www.who.int/goe/publications/goe_mhealth_web.pdf, page 6 
Within this thesis, I use the overarching term eHealth. 
Clarity in the terminology used has been lacking in the literature, although 
increasing calls for improved descriptions will hopefully have some impact [8, 
14, 15], as will the increased uptake of the ehealth consort statement [16]. 
1.3.3 Does the digital divide still exist? 
In short, the answer is undoubtedly yes, but is it the same issue it was 10 years 
ago?  The answer is almost certainly no.  By their nature, online interventions 
are only available to people who have access to the Internet, raising concerns 
that those without the Internet are at a disadvantage [17].  There are two 
hurdles to consider when thinking about physical access to the Internet.  The 
first is the infrastructure, and both the Scottish and UK governments appear 
committed to improving this through various strategies such as increasing the 
availability of superfast broadband to 95% of the UK by 2017 [18].  The next 
hurdle is at an individual level – can a given person access the Internet?  Again, 
the answer increasingly is yes.  As of last year (2014) 84% of households in the UK 
had access to the Internet, up year on year since 2006 when it was only 57% 
[19].  Concerns about older populations not having access are increasingly 
unfounded with the percentage of adults aged 65+ years using a computer daily 
jumping from 6% in 2006 to 43% in 2014 as shown in Figure 1.1  [20].  
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Figure 1.1 Daily computer use by age group, 2006 and 2014 
 
As well as traditional means of accessing the Internet via a desktop or laptop in 
the home, alternative routes are increasingly available such as mobile phones, 
tablets or smart TVs.  The number of adults accessing the Internet via mobile 
phone has more than doubled between 2010 to 2014 to 58%, and the increase in 
the over 65s age group has increased over 5 fold from just 2% in 2010 to 11% in 
2014 [21]. So although the over 65 year age group continues to lag behind, 
growth of Internet and computer use in this age group far exceeds that of the 
younger populations suggesting it may only be a matter of time before the age 
related digital divide ceases to exist.   
The other main concern regarding the increase in health services delivered 
online relates to concern that it will be contributing to health inequalities given 
that those who live in deprived areas have less access to internet than those 
from more affluent areas [22].  However again there is evidence of this gap 
narrowing, with the gap between the percentage of households with internet in 
the most deprived areas versus the rest of Scotland falling from 25% in 2007 to 
15% in 2012, data shown in Figure 1.2 [22]. 
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Figure 1.2 Households with internet by deprivation category 
 
In addition, improving access via public libraries and community centres is a key 
recommendation within the Digital Scotland report from the Royal Society of 
Edinburgh [17].  There is evidence of its importance as an option particularly in 
areas with high deprivation and lower Internet adoption such as Glasgow, UK 
[23].  It is also worth mentioning that Internet access is already available 
through most computer game consoles, and increasingly now through digital 
television.  In the UK, smart TVs make up 45% of the market share, a 60% 
increase year on year [24] and there is evidence that technology utilising digital 
TV is already being developed in the field of health and social care [25, 26]. 
Overall, the physical barriers to Internet access appear to be lessening year on 
year.  However there are further considerations about access in terms of health 
literacy, or particularly ‘ehealth’ literacy [27]. Poor health literacy in general is 
a global concern, and a recognised barrier to improved health outcomes, being 
associated with reduced knowledge, increased morbidity and increased use of 
health services [28].   
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Good eHealth literacy requires not only traditional literacy, but also health 
literacy and computer literacy [27].  However, it is false to assume that 
information or interventions delivered over the Internet are automatically 
harder for those with poorer literacy to access when compared to more 
traditional means.  For example poor aural literacy (listening skills) contributes 
to poor asthma outcomes [29] so Internet interventions with scope to provide 
written and oral content alongside each other may work to actually overcome 
literacy barriers. Similarly, concern that reduced health literacy is associated 
with less use of online resources is refuted in this study where teenagers with 
low health literacy used the Internet just as much as those with high health 
literacy [30].   
The links between deprivation and lower health literacy are long recognised, 
however there are exciting new developments challenging this assumption that 
eHealth materials are less accessible to deprived populations.  A recently 
published smoking cessation intervention was found to be only effective in those 
with low socioeconomic status (SES).  What was particularly interesting was that 
user testing of the intervention was done exclusively with smokers with low SES, 
in response to previous work that had suggested Internet support only worked in 
those with high SES [31].  This result was not in isolation, but backs up earlier 
work in this area by the same research group [32].  What this suggests is that if 
the target audience is truly involved at the planning and development level 
these barriers are surmountable. 
1.3.4 eHealth summary 
This data demonstrates that concern about the digital divide, while important to 
be aware of, should not in any way hinder ongoing development of interventions 
delivered by this medium, so long as consideration towards delivery via multiple 
mediums such as traditional computer, portable devices and smart TVs for 
example, and the specific needs of the target audiences are attended to. 
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1.4 Overview of this project work 
1.4.1 Aims and research questions of project 
The overarching aim of this project was to explore the potential role of a digital 
intervention in promoting optimum asthma self-management to adults with 
asthma. 
The project was testing the hypothesis that an intervention co-designed with key 
stakeholders, developed to be evidence-based and theory-informed, is likely to 
be acceptable to the target end users, and likely to merit progression to a full 
scale randomised controlled trial (RCT) of efficacy. 
I therefore generated four overarching research questions (RQs) which, if 
addressed, would allow me to meet my aim above.  This process of generating 
the research questions is fully described in Chapter 3. 
RQ 1 - What is known about the effects of online tools to promote self-
management of asthma and what helps or hinders their utilisation by patients? 
RQ 2 - What are the barriers and facilitators to the uptake and utilisation of a 
web-based self-management tool from the perspective of adults with asthma, 
and primary care nurses who undertake asthma reviews?   
RQ 3 - Can evidence from the literature (asthma management and theory) and 
input from potential end users, be successfully incorporated into an intervention 
to promote self-management? 
RQ 4 - What would be the feasibility of undertaking a randomised controlled 
trial of the digital intervention, and how would such a website be used by adults 
with asthma.  What would be the effect on symptom score and quality of life 
measures be? 
Basing the project work on these four RQs naturally led to the project having 
three distinct, but related, stages.  These are described in the next section 
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1.4.2 Outline of project stages 
Stage 1 is the initial examination of the literature.  For this I undertook a 
metareview (systematic review of systematic reviews) of digital self-
management interventions.  The aim of this stage was to answer research 
question 1, and inform the subsequent stage of the project: developing the 
website (stage 2). 
Stage 2 describes four separate work packages which illustrate how I used 
multiple sources to feed into the development of the website, and answers 
research questions 2 and 3.  These sources included focus groups and think aloud 
studies to incorporate potential end users’ input, evidence from the literature, 
including relevant theory, and incorporating the experience of an expert panel.  
The development of the website was not a linear process, but with various work 
packages occurring alongside each other.  By the end of second stage I had 
developed a working interactive website called ‘Living Well with Asthma’. 
Stage 3 was the work of evaluating the Living Well with Asthma website in a 
pilot RCT, with additional feasibility outcomes.  This aims to answer research 
question 4. I conducted a 12 week parallel group RCT with target sample size of 
50.  Participants were randomised either to the intervention group where they 
were given access to the website, or the comparison group which received usual 
care. 
 
1.5 Overview of the thesis 
This thesis takes the form of 9 chapters, listed in Table 1.1. 
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Table 1.1 Overview of Chapters 
Chapter 1 Introduction 
Chapter 2 Background 
Chapter 3 Methodological considerations 
Chapter 4 Metareview of digital asthma self-management interventions 
Chapter 5 Developing the ‘Living Well with Asthma’ self-management website 
Chapter 6 Evaluating the ‘Living Well with Asthma’ self-management website 
Chapter 7 Comparison with similar intervention evaluations 
Chapter 8 Discussion 
Chapter 9 Conclusion 
 
 
Chapter 1 is this brief introductory chapter.  It provides a context to the study, 
and my research motivations.  I introduce the topic of eHealth, and address 
concerns about the ‘digital divide’.  I describe my aims and objectives, and the 
motivation for the research.  Lastly, I illustrate the format of the project work, 
and then within this final section, the structure of the thesis itself.  
Chapter 2 provides firstly a background overview of the diagnosis, epidemiology, 
and pharmacological management of asthma.  It then provides an up to date 
literature review to investigate barriers, identified by adults with asthma, to 
taking asthma medication as prescribed, and finally it describes what 
interventions which aim to improve self-management might contain, and reflects 
on how these features might work in a digital intervention.  
Chapter 3 is where I discuss methodological issues arising from this body of work.  
In particular, I explain the rationale for mixed methods studies and provide an 
introduction to the use of theory when developing and evaluating complex 
interventions, and the importance of incorporating user preferences.  I describe 
how each of my four research questions were developed, and why specific 
methods were chosen to answer them. 
Chapter 4 provides the methods, results and discussion of the meta-review of 
digital asthma interventions.  This corresponds to stage 1 of my project.   
Chapter 5 describes the methods, results and discussion of the development 
work undertaken to make the Living Well with Asthma website.  An abridged 
description of this phase was published by BMC Medical Informatics and Decision 
Chapter 1 Introduction  26 
 
Making in July 2015, and is found in appendix 2.  This chapter corresponds to 
stage 2 of my project. 
Chapter 6 describes the evaluation of Living Well with Asthma website: A pilot 
Randomised Controlled Trial of an Asthma Internet Self-Management 
Intervention, the RAISIN study.  This chapter describes the methods, results and 
discussion from this evaluation stage of the project.  The protocol for this RCT is 
published in Trials Journal [33] (and included as appendix 1), and results are 
published in BMJ Open (and included as appendix 3).  This chapter corresponds 
to stage 3 of my project. 
Chapter 7 is an updated review of the literature to find RCTs of comparable 
interventions in order to compare my results with that available.  
Chapter 8 is a discussion which brings the results of all 3 project stages together 
(Chapters 4, 5 and 6).  I discuss how well I have answered my research questions 
and discusses the overall conclusions in the context of the current literature.  I 
will describe the strengths and weaknesses of the project overall. 
Chapter 9 concludes this thesis.  Here I provide overall conclusions, 
consideration for future directions and discuss implications for practice and 
policy.
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Chapter 2: Background 
2  Introduction 
This aim of this chapter is to present the rationale for the content of the 
intervention developed later in this thesis (and described in Chapter 5).  It has  
three sections.  First, it provides a background overview of the diagnosis, 
epidemiology, and pharmacological management of asthma.  Second, it provides 
an up to date literature review to investigate barriers, identified by adults with 
asthma, to taking asthma medication as prescribed.  Third, it describes what 
interventions which aim to improve self-management might contain, and reflect 
on how these features might work in a digital intervention, such as that being 
developed here. 
The chapter does not include a review of published evaluations of digital self-
management interventions as that literature review is covered separately in 
chapter 7, to allow for comparison with the intervention developed in chapter 5 
and the evaluated in primary 6.  
2.2 Asthma 
2.2.1 Introduction 
An overview of how asthma is diagnosed, its epidemiology and accepted 
pharmacological management is essential to understand some of the challenges 
faced by those with an interest in improving asthma outcomes. This is provided 
in this section, drawing on published guidelines/reports  [1, 4, 7, 34] and 
Cochrane Reviews [6, 35]. 
2.2.2 Definition and diagnosis 
Providing a definition of asthma is not as straightforward as it is with many other 
diseases.  The Global Initiative for Asthma (GINA) [7] provides one definition: 
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“Asthma is a heterogeneous disease, usually characterised by chronic airway 
inflammation.  It is defined by the history of respiratory symptoms such as 
wheeze, shortness of breath, chest tightness and cough that vary over time 
and in intensity, together with variable expiratory airflow limitation.” 
The recent British guidelines [4], on the other hand, shy away from providing a 
definition at all, going as far as to say that the absence of a ‘gold standard 
definition’ makes providing evidence based recommendations for diagnosis 
impossible.   
A third position was suggested in draft NICE guidelines initially available for 
consultation in early in 2015.  These draft documents, viewed in July 2015, 
suggested that NICE would recommend much more extensive investigations in 
people with suspected asthma with specific cut offs for a ‘positive’ or ‘negative’ 
test result to indicate the presence, or not, of asthma [36].  These tests include 
a measure of lung function (spirometry), of inflammation (fractional exhaled 
nitric oxide, FENO) and of airway hypersensitivity (bronchial challenge).  
Concerns raised in response to these draft documents was such that the 
publication date is now ‘To be confirmed’ to allow primary care based feasibility 
work to be undertaken to better understand the impact of these new guidelines.  
While there is lack of consensus over the definition of asthma, there is to date 
an agreement that the diagnosis is essentially a clinical one, based on the typical 
symptoms such as those described in the definition above. 
People with a diagnosis of asthma are often characterised by stating on which 
‘step’ of the British Thoracic Society (BTS) asthma treatment ladder (Figure 2.1) 
they are on [4].  The ladder offers primary care practitioners guidance on how to  
‘step up’ treatment for adults with asthma until either they achieve acceptable 
control, or they reach step 5, at which point referral to secondary care is 
indicated, if not already undertaken. 
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Figure 2.1 Summary of stepwise asthma management in adults 
This summary of the stepwise management of asthma is reproduced from SIGN British Guideline on the 
management of asthma 141 (pg 9) by kind permission of the Scottish Intercollegiate Guidelines Network [4]. 
 
It is worth taking a moment to clarify terminology used when describing 
someone’s asthma, in particular the terms control, severity and exacerbation.  
The American Thoracic Society/European Respiratory Society (ATS/ERS) 
convened a task force to do just that, and I summarise their definitions in Table 
2.1 [34]. 
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Table 2.1 Definitions of terms used in asthma 
Term Definition Further explanation 
control 'the extent to which 
manifestations of 
asthma are reduced or 
removed by treatment’ 
Two areas to consider when assessing control: 
1) current level of control (measured e.g. by 
symptoms, quality of life) 
2) risk of future adverse events including 
exacerbations but also loss of control 
severity ‘the difficulty in 
controlling asthma with 
treatment’ 
Severe asthma is where control is difficult to achieve 
with exclusion of modifiable factors such as non-
adherence, smoking. E.g. even on appropriate 
treatment control is still inadequate. 
exacerbation ‘episodes that are 
troublesome to 
patients, and that 
prompt a need for a 
change in treatment’ 
 Mild exacerbations: not defined, as considered part 
of the normal variation in control 
 Moderate exacerbations: a deterioration in 
symptoms and/or lung function for ≥2 days requiring 
increased reliever use, not warranting oral steroids 
 Severe exacerbations: oral steroids required  
 
 
These distinctions are important in order to both standardise clinical endpoints 
within trials, and to emphasise that asthma control is not the same as severity.  
Just because someone is considered to have mild asthma does not mean they are 
not at risk of loss of control and exacerbations; almost 10% of those in the 
National Review of Asthma Deaths (NRAD) were classified as having mild asthma 
when they died [1].  
2.2.3 Epidemiology 
Asthma is common, affecting an estimated 300 million people world-wide [37], 
and 5-10% of populations in developed countries.  Although one report suggests 
Scotland has the highest prevalence of asthma symptoms in the world (18.4%, 
compared to England 15.1%, USA 10.9%, and Germany 6.9%), it also ranks in the 
lowest quarter for case fatalities [37].  This may suggest that Scotland manages 
acute exacerbations to a high standard, but the day to day management of 
symptoms less well.   
Worldwide, the number of disability-adjusted life years lost due to asthma has 
been estimated at 15 million per year, similar to that for diabetes [37].  More 
women than men have asthma [2], and the reason for this is not known.  While 
around half of children labelled as asthma ‘grow out of it’ by adulthood, adults 
with it are rarely ‘cured’.  Previously it has been thought that asthma mostly 
starts in childhood, however within the National Review of Asthma Deaths the 
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median age of onset of asthma in those who died was 37 years, with 69% 
diagnosed after 15 years of age [1].  Recent epidemiological studies suggest that 
individuals with asthma have more comorbidity than expected, further adding to 
the challenges of managing an already complex condition [38]. 
2.2.4 Pharmacological management  
Asthma is a disease with variable symptoms and consequently a variable need for 
medication.  This is demonstrated visually in the stepwise management by the 
presence of an arrow going both ways (Figure 2.1).  When an individuals’ asthma 
deteriorates or improves over the longer term and the treatment changes in 
order to manage these symptoms this is termed ‘stepping up’ and ‘stepping 
down’.  As Figure 2.1 demonstrates, short acting bronchodilators (relievers), 
followed by the addition of inhaled corticosteroids (ICS) or ‘preventers’ remains 
the mainstay of asthma management.  Those who remain uncontrolled on these 
medications are offered increased ICS doses and/or the addition of further 
medications until ideally good control is achieved. 
Transient changes to medication during exacerbations include increasing 
frequency of reliever inhaler, and if severe the addition of a short course of oral 
steroids.  The benefits of doubling, or possibly even quadrupling, ICS during 
exacerbations has yet to be proven [35].  If there are multiple exacerbations a 
year, or there is a longer history of uncontrolled symptoms, this would be an 
indication to add or increase regular medications e.g. step up the treatment 
ladder. 
2.2.5 Treatment goals in asthma 
The GINA guidelines list the goals for successful management of asthma [7]:  
1. Good control of symptoms; 
2. Maintain normal activity levels; 
3. Minimise future risk of exacerbations, fixed airflow limitation, and 
medication side effects. 
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These goals are not widely achieved and care of patients with asthma is often 
considered suboptimal [37, 39, 40].  One underlying explanation for this is a 
consistent discrepancy in perceived levels of asthma control: patients 
overestimate their control, and underestimate symptoms.  Put another way 
people with asthma endure greater symptoms and lifestyle limitations than 
necessary [2, 41]. 
Although the goal of the GINA guidelines is to ‘maintain normal activities’ what 
this actually means is not clear.  If an individual stops playing football regularly 
because she experiences wheeze and shortness of breath, it becomes normal for 
her not to play football.  Then from that person’s point of view they are 
maintaining their normal activities, not recognising they have modified what is 
normal for them to reduce likelihood of them experiencing asthma symptoms.  
This is the challenge with improving asthma outcomes – helping people with 
asthma to recognise that their symptoms are modifiable with the right 
treatments.  This topic is explored in the following section on non-adherence. 
2.3 Literature review of barriers to adherence  
2.3.1 Research question 
What are the barriers to taking asthma medication as prescribed identified by 
adults with asthma (limited to treatments aimed at mild to moderate asthma 
e.g. step  1-4 on the BTS ladder, excluding newer immunotherapies aimed at 
those with severe disease)? 
2.3.2 Methods 
2.3.2.1 Search Strategy 
MEDLINE, EMBASE and Health and Psychosocial Instruments were searched using 
a  search strategy developed in a previous review I had undertaken which had 
also aimed to capture qualitative articles [8].  It involved finding articles from 3 
main search areas: 
1. asthma 
2. adherence to medications 
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3. qualitative methods/patient experience 
Asthma: asthma has features which make it distinct from other chronic diseases 
such as the use of inhalers rather than tablets, and the variable nature of the 
illness burden.  Given the volume of articles on adherence, it seemed reasonable 
to narrow this down on articles focussing on asthma, in particular those which 
featured adults with asthma.  Therefore I limited my search to articles which 
mentioned the term asthma* in the abstract.   
Adherence:  the literature on adherence is vast and it has its own MeSH subject 
heading: medication adherence.  This was used as a starting point, with the 
addition of any article with adher* or nonadher* or non-adher* in the title or 
abstract.  The terms compliance or comply was also used.  
Qualitative: I used terms such as experience* qualitative* and exploded terms 
such as interview, using the ‘or’ function to try and capture any paper which 
included this type of language in its title or abstract. 
These were limited further by excluding articles with terms such as ped* or 
paed* in their titles to remove articles featuring children from the search 
strategy.   The remaining articles were limited to ‘human’ and English language.  
This full search strategy is shown below.  
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Table 2.2 Search strategy for literature review 
Final search ran on 31/1/16. 
1. (patient$ adj3 (experience$ or attitude$ or view$1 or satisfaction$)).ti,ab. 
2. qualitative research.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, tn, dm, mf, dv, kw, ac, sh, de, md, ip, vo, pg, sd, jn, pb, yr, ar, bs, bt, cf, 
dp, ja, pa, so] 
3. exp Interviews as Topic/ 
4. qualitative.ti,ab. 
5. focus group.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, tn, dm, mf, dv, kw, ac, sh, de, md, ip, vo, pg, sd, jn, pb, yr, ar, bs, bt, cf, dp, ja, 
pa, so] 
6. asthma*.ti,ab. 
7. (non-adher* or nonadher* or adher*).ti,ab. 
8. medication adherence/ 
9. ((compliance or comply) adj3 (medic* or treat* or therap* or inhale*)).ti,ab. 
10. 7 or 8 or 9 
11. interview*.ti,ab. 
12. 1 or 2 or 3 or 4 or 5 or 11 
13. 12 not (rct or randomi* or pilot*).ti. 
14. 6 and 10 and 13 
15. limit 14 to english language 
16. limit 15 to human 
17. limit 16 to yr="2005 -Current" 
18. 17 not (ped* or paed* or child*).ti. 
19. remove duplicates from 18   (total 278 articles) 
20. from 19 keep 2,4,6,10,14-15,27,36,48-49,61,66,72,76,82,87,94,99,102,111,115,118-
119,127,132,135,142,154,173,195,199,206,240,247 
 
Key: 
/  indicates a subject heading   
exp  indicates an exploded subject heading 
*  truncation symbol 
adj3  words must appear with 3 words of each other 
.ti,ab.  searches are restricted to the title and abstract fields 
 
 
I included articles which provided insights into why people with asthma didn’t 
take their medications as prescribed: either featuring adults with asthma, or 
reporting others views on this topic such as health professionals’ opinions. A 
similar process for selecting qualitative papers has been used elsewhere [42]. 
2.3.2.2 Quality appraisal 
A quality appraisal instrument was used to allow me to describe the quality of 
the included articles in this review.  Unlike with quantitative reviews there is 
some debate about whether quality appraisal is appropriate, with some believing 
that each piece of qualitative research is important in its own right and cannot 
be compared to another [43], whereas others [44, 45], myself included, feel that 
it is a useful step when synthesising qualitative articles, providing additional 
information to base conclusions on.  There is no consensus about the best 
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strategy for undertaking quality appraisal, and I elected to use a questionnaire 
developed by my colleague Katie Gallacher [45], that I have experience of 
personally using in a systematic review of treatment burden in stroke [46] where 
I felt it worked well.  The tool itself is based on published guidance on 
systematically reviewing qualitative studies from respected qualitative 
researchers [47].  It consists of eleven questions, each considering an aspect 
such as rigour and generalisability.  There is no scoring or ‘pass mark’; the 
results are used to inform the discussion only.  
2.3.2.3 Analysis 
Each article was read and information about participants, study type and 
strengths and limitations were noted.  The results and discussions were read 
closely and any text which could be construed as describing a barrier was 
extracted.  These individual barriers were examined, and related barriers 
grouped to develop categories of barriers to adherence.  A narrative summary 
was then provided for each category. 
2.3.3 Results 
2.3.3.1 Search results 
Running the search described above found 418 articles, 288 after de-duplication.  
This number could not be refined further using electronic searching without 
risking the loss of useful articles, so was manually reviewed.  This led to 34 
articles being reviewed at full paper, and 10 articles being included. 
2.3.3.2 Quality appraisal 
The results of the quality appraisal are summarised in Table 2.2, and specific 
areas of strengths or weakness identified are commented on in Table 2.4.  Most 
studies were well conducted when using this appraisal tool.  The pattern 
suggests that newer studies are more methodologically sound, with the only 2 
studies with less than <10 positive responses being older (2008 [48], and 2005 
[49]).  The main areas for concern was the lack of information about the 
researchers own influence on the data, and the absence of declaration of 
conflicts of interest.  
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2.3.3.3 Description of included papers 
Full papers included are described in Table 2.4 below which lists author, date, 
aim, methods participants, barriers identified and strengths and weaknesses. 
Nine of the papers featured people with asthma, and one featured general 
practitioners as participants and one paper featured health professionals and 
patients.  Eight of the nine articles featuring participants with asthma provided 
a mean age, and in 6 of these 8 articles the mean age was >42 years.  The other 
two articles had particularly targeted younger adults [50, 51].  Six were set in 
North America, 2 in Australia, and one each in Sweden and the UK.  Three 
articles employed focus group methodology with the remaining using semi-
structured interviews.  
 
 
Table 2.3 Quality appraisal summary  
Question adapted from [46, 47]  Article number as per Table 2.4 
1 2 3 4 5 6 7 8 9 10 
Does the research, as reported, illuminate the subjective meaning, actions, and context of 
those being researched? ● ● ● ● ● ● ● ● ● ● 
Are subjective perceptions and experiences treated as knowledge in their own right? ● ● ● ● ● ● ● ● ● ● 
Is there evidence of the adaption and responsiveness of the research design during the 
course of the study? ● ● ● ● ● ●  ● ●  
Does the sample produce the type of knowledge necessary to understand the structures 
and processes within which the individuals or situations are located? ● ● ●  ● ●  ● ● ● 
Is the description provided detailed enough to allow the researcher or reader to interpret the 
meaning and context of what is being researched? ● ● ● ● ● ● ● ● ● ● 
Are any different sources of knowledge about the same issue compared and contrasted? ● ● ● ●  ● ● ● ● ● 
Has the researcher rendered transparent the processes by which data have been collected, 
analyzed, and presented? ● ● ● ● ● ● ● ● ●  
Has the researcher made clear their own possible influence on the data?    ●    ●   
Is it clear how the research moves from a description of the data, through quotation or 
examples, to an analysis and interpretation of the meaning and significance of it? ● ● ● ● ● ● ● ● ●  
Are claims being made for the generalisability of the findings to either other bodies of 
knowledge or to other populations or groups reasonable? ● ● ●  ● ● ● ● ● ● 
Is there the absence of any other aspect of the study that may affect the quality e.g. conflict 
of interest? ●   ● ● ●    ● 
● answer to question is yes 
 Table 2.4 Summary of included articles 
No Author (s) Date Aim of paper Type of Study/information Barriers identified in study Strengths and weaknesses 
1 
[52] 
George M 
Keddem S 
Barg FK 
Green S 
Glanz K 
2015 
 
Identify urban adults' 
perceptions of 
facilitators and 
barriers to asthma 
control, including the 
role of self-care, 
medications, 
environmental trigger 
remediation, and 
primary care 
Methods: Semi-structured open-ended 
qualitative interviews. Modified grounded theory 
approach. 
Participants: (n = 35) purposive sample from 
previous research study to include participants 
from range of areas in West Philadelphia, USA. 
Age: mean 55 years; Female: 71%. 
SES: 40% Medicaid; 17 % completed high school. 
Ethnicity: 94% AA; 6% white 
Other: 71% uncontrolled;  
 Prefer alternative 
therapies/dislike 
medications in general 
 Perceived overprescribing 
 Difficulty with 
routine/forgetting 
 Doubts about efficacy 
 Poor patient/HCP 
relationship 
+ Demographics fully 
described including age, 
gender, race, education 
level, Insurance and BMI. 
- Despite purposive sampling 
stratifying for gender most 
participants were female, 
black and overweight. COI 
information not provided 
2 
[53] 
Pelaez S 
Bacon SL 
Aulls MW 
Lacoste G 
Lavoie KL 
2014 Examine the 
perspectives of asthma 
patients, physicians 
and allied health 
professionals regarding 
adherence to asthma 
medication. 
Methods: 6 focus groups. Inductive coding, 
constant comparison. 
Participants:  patients (n= 13); respiratory 
physicians/ allied health professionals (n=25) 
purposive sample enrolled from a university 
affiliated general hospital in Montreal Canada. 
Age: mean 52.5 yrs; Female: 69% (patients) 
SES: n/a;  Ethnicity: n/a 
Other: 62% ACQ>1; 80% reported good 
adherence; mean asthma duration 30 years 
(range3-75) 
 Inhaler difficulties 
 Difficulty with 
routine/forgetting 
 Cost/access to care 
 Doubt/denial of diagnosis 
 Perceived overprescribing 
 Societal acceptability 
 Side-effects 
+ Participants well 
described. Triangulation of 
data between different 
sources. Purposive sample. 
- Recruited from single 
university affiliated 
institution and most patients 
well controlled/good 
adherence. 
3 
[54] 
McDonald 
VM 
Higgins I 
Gibson PG 
2013 Explore older peoples’ 
experiences of asthma 
or COPD with 
reference to their 
journey in the 
healthcare system. 
Methods: Qualitative interview. Line-by-line 
analysis of interviews performed, coded for 
common themes.  
Participants: (n = 21), enrolled from respiratory 
ambulatory care clinics in New South Wales, 
Australia 
Age: mean 68.6 years (range 59-82); Female: 
71% 
SES: n/a   Ethnicity: n/a 
Other: mean time since diagnosis 30 yrs 
 Poor patient/HCP 
relationship 
 Difficulty with 
routine/forgetting 
 Doubts about efficacy 
 Perceived overprescribing 
 Lack of information 
+ Participants well 
described.  
- Only discussed themes they 
perceived as being novel.  
Consecutive sampling 
 No Author (s) Date Aim of paper Type of Study/information Barriers identified in study Strengths and weaknesses 
4 
[51] 
Axelsson M 
Lotvall J 
Lundgren J 
Brink E 
2011 Elucidate adherence 
reasoning in relation to 
asthma medication. 
Methods: Qualitative interview via telephone. 
Purposive sampling (mix of adherence scores). 
Analysis informed by Grounded Theory methods. 
Participants: (n = 18) enrolled from previous 
study in Sweden 
Age: 22 ±1 years; Female: 72% 
SES: 56% current students; 61% university 
educated.  
Ethnicity: n/a 
Other: mostly well controlled; 11% ED visit and 
11% oral steroids in preceding 12months 
 Poor patient/HCP 
relationship 
 Doubt/denial of diagnosis 
+ Participants fully described 
including education level, 
income, occupation 10/18 
students 
- Atypical narrow sample, all 
22 years old, mostly 
students, only discusses this 
briefly whereas aim of study 
broad.  
5 
[55] 
Baptist AP 
Deol BB 
Reddy RC 
Nelson B 
Clark NM 
2010 Elucidate common 
challenges in asthma 
management faced by 
older adults across the 
demographic 
spectrum, including 
both community 
dwelling elders and 
those in residential 
facilities. 
Methods: 6 focus groups with participants>65 
years. Semi structured questions. 3 coders 
independently identified categories line by line 
and generated themes. 
Participants: (n = 46) enrolled from university 
based health systems, one in affluent area one 
in deprived area in Michigan, USA 
Age: mean 72.6 years; Female: 85% 
SES: mixed 
Ethnicity: 50% white; 43.5% AA; 6.5% other. 
Other: 57% reported no social support to help 
with asthma; majority uncontrolled asthma. 
 Lack of information 
 Side-effects 
 Cost/access to care 
 Difficulty with 
routine/forgetting 
 Prefer alternative 
therapies/dislike 
medications in general 
 Absence of good social 
support 
+ Purposively recruited from 
affluent and deprived areas.  
 - Excluded those with dual 
COPD asthma diagnosis 
smokers or ex-smokers with 
> 20 pack year, potentially 
missing difficulties of 
managing both conditions 
together.  
 No Author (s) Date Aim of paper Type of Study/information Barriers identified in study Strengths and weaknesses 
6 
[50] 
Naimi DR 
Freedman 
TG 
Ginsburg KR 
Bogen D 
Rand CS 
Apter AJ 
2009 Describe adherence to 
preventive asthma 
medications and 
explore relevant 
beliefs and attitudes in 
older urban 
adolescents. 
Methods: Two semi-structured interviews 1 
month apart. Analysed using grounded theory 
structure 
Participants: (n = 40) Philadelphia, USA; Age: 
15-21 years; Female: 48%. 
SES: Low income urban area; 28% Medicaid 
insured 
Ethnicity: 75% AA; 28% White (could choose 
more than one) 
Other: median adherence of 43% of doses; 60% 
previously hospitalised. 
 Perceived overprescribing 
 Difficulty with 
routine/forgetting 
 Inhaler difficulties 
 Side-effects 
 Absence of good social 
support 
 Societal acceptability 
+ Participants well 
described. Used health belief 
model to inform analysis. 
- Had normal inhaler 
swapped for one which 
monitored adherence so not 
entirely normal practice, but 
not an intervention study so 
included here.  
7 
[48] 
Choi TN 
Westermann 
H 
Sayles W 
Mancuso CA 
Charlson ME 
2008 Identify patients' 
beliefs about asthma 
medications and to 
assess these beliefs 
according patient and 
asthma characteristics, 
including asthma 
severity and patient-
reported medication 
adherence. 
Methods: Interviews, 3 researchers 
independently coded quotes and agreed on 
categories and overarching themes 
Participants: (n = 52), enrolled from scheduled 
office visits with physicians in New York City, 
USA 
Age: mean 43 years; Female: 87% 
SES: 42% college graduates  
Ethnicity: 31% Caucasian, 42% AA, 21% Hispanic 
Other: mean MMAS adherence score 1.6 (very 
low). Mean asthma duration 26 years. 
 Difficulty with 
routine/forgetting 
 Inhaler difficulties 
 Prefer alternative 
therapies/dislike 
medications in general 
 Side-effects 
 Doubts about efficacy 
 Perceived overprescribing 
 
+ Participants well 
described. 
- Convenience sample. 
Secondary analysis of 
qualitative study about 
physical activity and asthma, 
so participants not 
specifically asked about 
medication adherence. 
8 
[56] 
Gamble J 
Fitzsimons D 
Lynes D 
Heaney LG 
2007 Explore the 
experiences of patients 
with difficult asthma, 
who take 
corticosteroid therapy, 
and provide insight 
into why some patients 
comply with therapy, 
whilst others do not. 
Methods: Non-structured interviews. Analytical 
framework to guide analysis 
Participants: (n = 10) Enrolled from secondary 
care clinic in Belfast, UK 
Age: mean 44 (range 25-58); Female: 70% 
SES: n/a   Ethnicity: n/a 
Other: at least 1 oral steroid course in preceding 
year. 
 Side-effects 
 Doubts about efficacy 
 Lack of information 
 Prefer alternative 
therapies/dislike 
medications in general 
 Societal acceptability 
 Difficulty with 
routine/forgetting 
 Poor patient/HCP 
relationship 
+ Purposive sample, 
continued until data 
saturation.  
- Participants not well 
described. Recruited from 
single clinic. No COI 
information provided. 
 No Author (s) Date Aim of paper Type of Study/information Barriers identified in study Strengths and weaknesses 
9 
[57] 
Tumiel-
Berhalter L 
Zayas LE 
2006 Describe how 
perceptions and 
experiences of patients 
with asthma or  
caregivers affect 
asthma management in 
a Puerto Rican 
community in Buffalo, 
NY. 
Methods: 2 focus groups, semi structure 
interview style. Grounded theory approach to 
analysis. 
Participants: (n = 22) invited through 
flyers/word of mouth from Puerto Rican 
community in New York, USA 
Age: n/a; Female: n/a 
SES: n/a 
Other: n/a 
 Cost/access to care 
 Lack of information 
 Side-effects 
 Doubts about efficacy 
 
+ Multilingual researchers 
used to minimise risk of 
losing data during 
translation.  
- Little description of 
participants.  COI 
information not provided 
 
10 
[49] 
Goeman DP 
Hogan CD 
Aroni RA 
Abramson 
MJ 
Sawyer SM 
Stewart K 
Sanci LA 
Douglass JA 
2005 Ascertain what GP’ 
priorities are for 
achieving optimal 
outcomes in people 
with asthma, and the 
barriers they face in 
delivering this care. 
Methods: 6 discussion groups were asked “What 
do you think is needed to achieve best outcomes 
for asthma care?” Nominal Group Technique 
Consensus was reached on the emerging themes 
by 4 researchers 
Participants: GPs (n = 49): 34 city/suburban; 15 
rural. Australia. 
 Lack of information 
 Cost/access to care 
+ Purposive recruitment from 
inner city, urban and 
suburban areas.  
- Did not discuss own 
strengths and limitations.  
Minimal description of 
analysis methods.  
 
AA  African American; COI  conflict of interest; GP general practitioner; HCP health care professional; MMAS Morisky Medication Adherence scale; SES  socioeconomic status.
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2.3.3.4 Adherence barriers established 
A total of 12 categories of barriers were identified by people with asthma.  
Health care professionals also identified 8 of these 12 barriers, and did not 
identify any barriers not already described by those with asthma.  The four 
barriers that were not identified by health care professionals are marked with a 
double asterisk **.  The 12 categories of barriers are: 
1. Doubts about, or denial of, diagnosis of asthma [51, 58] 
2. Perceived over prescribing of asthma medications ** [48, 50, 52, 54, 
58] 
3. Doubts about efficacy of asthma medications ** [48, 52, 54, 56, 57] 
4. Concern about side-effects, including fear of addiction [48, 50, 55-58] 
5. General preference for ‘natural’ therapies, and dislike of taking 
medications in general [48, 52, 55, 56] 
6. Lack of ‘correct’ information about symptoms and treatment options 
[49, 54-57] 
7. Absence of trusting patient/health professional relationship **  [51, 52, 
54, 56] 
8. Absence of good social or family support [50, 55] 
9. Practical difficulties of incorporating regular medications into daily 
routines/forgetting **  [48, 50, 52, 54-56, 58] 
10. Inhaler difficulties e.g. not user friendly, ensuring physical access to 
them [48, 50, 58] 
11. Societal acceptability of taking inhaler medications [50, 56, 58] 
12. Cost/physical access to care and medicines [49, 55, 57, 58] 
Each is discussed in turn. 
1) Doubts about, or denial of, diagnosis of asthma [51, 58]. 
Rationale behind these concerns centred round the fact that many of the 
symptoms of asthma such as cough or shortness of breath were often 
experienced by other people without asthma leading participants to question 
whether they really did have an illness at all.  Both studies reporting this barrier 
had participants described as having well controlled asthma.  
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2) Perceived over prescribing of asthma medications ** [48, 50, 52, 54, 
58] 
In several studies this barrier was linked to doubts about diagnosis fuelling a 
belief that medications prescribed weren’t necessary.  However many others did 
not question their diagnosis, but did question whether they really needed all 
their prescribed medications, particularly that daily medication was required. 
Many participants preferred to only take their medications when they were 
particularly symptomatic, feeling that tolerating mild symptoms is preferable to 
a medicine.  A USA based study evaluating barriers between controlled and 
uncontrolled participants [52] found that those with uncontrolled asthma were 
more likely to report perceived over prescribing.  What this study did not do was 
investigate adherence, so it is impossible to know whether these individuals 
were uncontrolled because they were not taking their medications, which seems 
more likely, or whether they were uncontrolled despite taking their inhalers.   
3) Doubts about efficacy of asthma medications ** [48, 52, 54, 56, 57] 
Five individual studies with varying participant demographics reported this 
barrier.  In some cases the demographics themselves may contributed to this 
perception, such as in George et al [52] most participants were obese, a factor 
which is known to contribute to reduced response to treatment, and this group 
were also reported as having uncontrolled asthma.  In general terms they may 
have been correct to have felt their medications were not working.   In Gamble 
et al [56] patients were more likely to have severe asthma, and in Choi et al 
very low adherence rates were noted [48], possibly fuelling their perceptions 
that asthma medications weren’t not working. Despite experiencing asthma for 
decades two further studies still identified this barrier [48, 54].  
4) Concern about side-effects, including fear of addiction [48, 50, 55-58] 
This barrier was one of the mostly commonly identified barriers to adherence. 
Occasionally established side effects were the concern, such as oral thrush [57] 
or jitteriness following salbutamol [48], but often side-effects not normally 
attributed to inhaled steroids were of concern such as vomiting, bone pain or 
weight gain [57, 58].  Occasionally there was confusion where side effects of 
oral steroids such as osteoporosis, weight gain, mood swings and cataracts were 
being attributed to inhaled steroids [55]. 
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5) Dislike of taking medications/  general preference for ‘natural’ 
therapies [48, 52, 55, 56] 
This was also a common theme and was often coupled with a concern about side 
effects.  Use of natural therapies (i.e. not medications) was found in both 
uncontrolled and controlled populations by George et al [52], but interestingly 
those with controlled asthma tended to use more evidence based alternative 
strategies such as stress relief, breathing exercises, and social support.  
However, those with uncontrolled asthma reported using the evidence based 
strategies but they also used a range of strategies without an evidence base, 
such as cold compresses, or buying houseplants to enrich household oxygen 
levels.  A second study explored this barrier in detail and found that some 
individuals used potentially harmful strategies such as licking salt, and most 
worrying was that while most participants reported using alternative strategies, 
no one had discussed them with their health care professionals, citing that they 
wouldn’t be interested [55].  
6) Lack of ‘correct’ information about symptoms and treatment options 
[49, 54-57] 
There were several findings that contributed to this category.  Firstly, patients 
reported not having access to information about treatment options such as 
asthma action plans [55] or information about new treatments despite reporting 
a desire for such information [54].  This was consistent with the study of GPs 
where Goeman et al found that few GPs promoted action plan use, despite the 
evidence of benefit [49].  Older participants commented that health care 
professionals often presumed the patients knew everything already and 
therefore were felt to not volunteer further information [56]. The remaining 
study reported examples of misinformation (e.g. nebulisers are for cleaning 
lungs) [57].  
7) Absence of trusting patient/health professional relationship **  [51, 52, 
54, 56] 
Recurrent reports of participants feeling ‘not heard or recognised’ contributed 
to this theme [54], and the importance of targeting this barrier was explored by 
George et al [52] who established that those with uncontrolled asthma reported 
poorer relationships with their health care professionals than those with 
controlled asthma.  This poorer relationship seemed to link in with perceived 
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overprescribing of medications, particularly contributing to poor adherence.  
Other participants felt that only seeing a health care professional infrequently 
left them unable to build up a trusting relationship and were therefore unable to 
have confidence in the advice they received [51]. Those with more severe 
asthma felt they knew more than their GPs did about their condition [56]. 
8) Absence of good social or family support [50, 55] 
The two studies which highlighted this barrier were interestingly studies which 
focused on older adults > 65 years or older teenagers aged 15-21 years and it 
was at these extremes of age that the absence of good support was noted as a 
barrier.  Older adults as features in Baptist et al [55] were often managing their 
condition alone.  They described being unable to rely on family or spouses as, if 
present, the family/spouses had health problems deemed more severe than the 
asthma participants.  The younger age group [50] described instances where 
difficult social circumstances affected their ability to take their medication as 
prescribed, such as one teenage boy describing a difficult relationship with his 
father which meant he often had to flee his house at short notice and stay 
elsewhere, usually leaving his medication behind.  
9) Practical difficulties of incorporating regular medications into daily 
routines/forgetting **  [48, 50, 52, 54-56, 58] 
This was one of the more commonly mentioned barriers across the studies, but 
not identified by health professionals.  Participants of all ages reported this as a 
barrier with studies aimed at older teenagers [50] reporting that they simply 
forget to take them, especially when well.  In contrast, the other study aimed at 
younger adults did not identify this barrier [51], but this latter study were 
mostly well educated students who had asthma most of their lives.  One study 
aimed at older adults (mean age 72.6) reported that they wanted to take their 
medications regularly, but forgot, citing memory problems and polypharmacy as 
barriers this [55]. Gamble et al featured adults at the more severe end of the 
spectrum, of working age, and this group specifically reported a conflict for 
them between allocating time to take medications versus time to allocate to 
other demands on their time such as their family and home life, finding it 
difficult to prioritise their medication regimes [56].  Choi et al reported being 
disciplined about their regimes was burdensome, and this was considered the 
biggest drawback of their condition for these participants [48].  The remaining 
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articles mentioned simply forgetting inhalers, or being too busy to fit them in 
[52, 54] 
10) Inhaler difficulties e.g. not user friendly, ensuring physical 
access to them [48, 50, 58] 
Despite the participants featured in Pelaez et al’s study being generally well 
controlled and reporting good adherence, they specifically described inhalers as 
being difficult to use and a barrier to adherence [58], and participants in Choi et 
al reported that inhalers were bulky and difficult to carry around [48]. The study 
aimed at older adolescents [50] described a unique barrier here, in that this 
group frequently stayed at friends’ houses, often at short notice, and therefore 
were not able to take their preventer inhalers as they hadn’t anticipated not 
staying at home.  The health professionals in Pelaez et al [58] also cited this 
barrier, both the physical aspects of the inhalers being difficult to use, but also 
the fact that a prescription was required to access them, and if a person could 
not access a health professional either due to location, time or financial reasons 
then they would go without their medicine.  This concern about physically 
accessing a prescription and keeping their inhalers in date was also cited by 
participants in Choi [48]. 
11) Perceived societal acceptability of taking inhaler medications 
[50, 55, 56, 58] 
This was a barrier common to younger and older participants, and also identified 
by health professionals [50, 58].  It was discussed in detail with participants in 
Gamble et al study [56] where participants felt that ‘having to use an inhaler in 
public was perceived as showing a fragility they preferred to disguise’.  
12) Cost/physical access to care and medicines [49, 55, 57, 58] 
Some participants from a Puerto Rican community in New York City described 
having to wait until their symptoms became severe enough to attend the 
emergency department, due to a lack of health insurance [57].  Participants in 
other studies described having to ration their medications due to costs [58] while 
health professionals from the same study also recognised that cost was a 
significant barrier to adherence.  The GPs based in Australia also reported the 
same concerns [49]. 
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2.3.4 Discussion of adherence literature 
2.3.4.1 Summary of findings 
This review of literature describing barriers to taking asthma medications 
included 10 individual articles.  In general, these studies were methodologically 
sound.  From these articles, I identified 12 different categories of barriers and 
have discussed each in turn.  Discussing these barriers with adults with asthma 
would be the next step in terms of taking these forward and incorporating them 
into an online resource. This is described in Chapter 5. 
2.3.4.2 Barriers identified by patients but NOT health care professionals 
It would be worth giving further attention to the 4 barriers not identified by 
health professionals, as these would be important to address in a resource which 
is aiming to supplement a health professional review.  The difficulty of 
remembering to take an inhaler and fitting it into daily routine was the most 
commonly identified barrier by patients, but was not identified by health 
professionals at all.  This highlights a real learning point for health care 
professionals to recognise that following a treatment regime is just one of many 
priorities that an individual may have, and encouraging honest conversations 
about capacity might allow a more acceptable treatment regime to be agreed 
and ideally adhered too. 
Another two, linked, barriers not mentioned by health care professionals were 
the perceived overprescribing and doubts about efficacy of asthma medications.  
Health care professionals are likely to be confident that they have made an 
appropriate diagnosis, and are prescribing the correct medication, but are 
clearly not conveying this confidence to patients.  This leaves lingering doubts 
with patients which feed into poor adherence.  Actively eliciting these doubts, if 
they exist, and addressing them is an essential step.  Exploring this barrier with 
adults with asthma using qualitative methods would be essential to inform any 
asthma adherence intervention.  
The final barrier not acknowledged by HCP is the importance of the relationship 
between HCPs and patients.  Perhaps unsurprisingly health professionals did not 
question whether their relationship with patients impacted on levels of 
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adherence.  Challenging this barrier in a resource would be difficult; it is largely 
HCP’s responsibility and the resource developed here is for people with asthma.   
2.3.4.3 Area of conflict within articles.  
Several studies highlighted the paradoxical findings they reported.  Participants 
in Gamble et al [56] complained that they were not provided with the 
information they desired, and that health care professionals often assumed they 
knew everything already.  However, they also felt frustrated that they seemed 
to know more about their own condition than their GPs did.  Other examples 
were highlighted by Axelsson [51] referred to the same participants doubting 
their diagnosis, and being reluctant to take inhaled steroids regularly, but still 
reporting that they wouldn’t go anywhere without their reliever inhaler in case 
their symptoms flared.  Resolving these areas of conflict for people with asthma 
would be worthwhile endeavour for such an intervention as that being developed 
here, but would be challenging.  User testing to check responses to the content 
and ensure understanding would be essential, as there is clearly much scope for 
misinterpretation. 
2.3.4.4 Comparison with existing literature 
A comprehensive and well conducted synthesis of qualitative studies undertaken 
by Pound et al [59] provides a background to this subject.  This synthesis 
included 4 asthma studies and a further 33 studies covering disease areas such as 
HIV, hypertension, mental health and gastrointestinal symptoms, and studies 
about medicines in general.  This study aimed to understand ‘lay experiences of 
medicine taking’ and in doing so identified a range of barriers to adherence.  
Overall, they conclude: 
“the main reason people do not take their medicines as prescribed is not 
because of failings in patients, doctors or systems, but because of concerns 
about the medicines themselves.  On the whole, the findings point to 
considerable reluctance to take medicine and a preference to take as little 
as possible.” 
My findings are very similar to Pound et al’s and serve to demonstrate that 
barriers identified in this older review are still relevant.  Each barrier found in 
my review, was discussed, at least in broad terms, in Pound et al’s synthesis, but 
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not always directly attributed to the asthma studies, for example concerns about 
societal acceptance was discussed in terms of studies included participants with 
HIV or on medication for mental illness. There were no barriers in relation to 
asthma that my review missed, and there were two new specific issues 
identified in my literature review. These were the lack of ‘user friendly’ inhaler 
devices, and the specific barriers young people experience, especially those with 
poor social support.  This suggests that while asthma may have slight differences 
in terms of inhalers rather than tablets, these differences are perhaps less 
important than I initially thought, and that barriers to adherence are generally 
universal to most chronic illnesses.  
A more recent narrative review of research on non-adherence published in 2012 
[60] provides a description of the problem, and suggests strategies for improving 
the situation using the Information-Motivation-Strategy model.  Di Matteo 
concludes: 
“Nonadherence is a complex problem and addressing it requires the efforts 
of both patients and clinicians, as well as all members of the healthcare 
team, and the individuals who are part of the patients’ everyday lives.” 
Their findings emphasise in greater detail than Pound et al [59] the importance 
of good communications skills on the part of health professionals and how much 
impact a positive relationship can have on improving adherence.  Their strategy 
can be simplified as actively eliciting barriers to patients taking their 
medications, and working with them to overcome these barriers.   
My literature review, along with these two well conducted and comprehensive 
reviews provide a good understanding of the problem, and Di Matteo in 
particular suggests some ways that health professionals can support people to 
take their medicines as prescribed, within a consultation.  However, evidence 
based strategies for implementing these strategies are lacking.  Recent reviews 
of interventions to improve adherence have focussed on mobile health, or 
reminders (mainly short message service (SMS)).  Tao et al [61] examined the use 
of reminders, and included four asthma studies.  Three used SMS and one used a 
pager like device with audio-visual reminder (green light and beep).  Overall, 
they found a small but statistically significant positive effect with the use of 
reminders, which was found to be larger when asthma alone was examined as a 
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subgroup.  However they also noted that trials with smaller sample sizes had 
larger effect sizes, and that given three of the four asthma trials were small 
(<100 participants) this effect needs to be interpreted with caution.  Similarly 
the three asthma studies also used additional self-management tools 
(information, advice, tailoring) so it is impossible to separate out the active 
ingredient.  Their main conclusion was a call for more adequately powered good 
quality trials.  
Given that non-adherence is so widespread it would be expected that it would 
be the focus of lots of good quality research, however a recent Cochrane review 
published in 2014 concluded the opposite [62].  This review evaluated 182 RCTs 
testing interventions to improve adherence, and only 17 were considered to be 
at low risk of bias.  The authors lamented an ongoing issue of underpowered 
studies, which had not improved from their previous review in 2008, although 
how many of these were purposely so in the form of pilot studies is not clear.  
There were some positive findings however, and for long term treatments these 
included simplifying the dosing regimen, and a number of more complex 
strategies (including more detailed patient instruction, reminders, supervised 
self-monitoring, and rewards for success) appeared to be most successful.  What 
is concerning here is that many of these ‘complex’ strategies that are shown to 
work in trial settings do not seem to translate well into real life settings.  When I 
looked specifically at the 12 asthma trials, the findings are even less 
encouraging.  Only two showed a benefit in adherence and clinical outcomes, 
with the remaining showing no difference.  There is little to distinguish the two 
successful interventions from the remaining, other than they both had higher 
sample sizes (211 and 267).  In their discussion, the authors recommend there 
should be at least sixty participants per group if there is to be any hope of 
distinguishing between treatment groups, a scenario that seems to rarely happen 
in trials to date. 
2.3.4.5 Strengths and Weaknesses of literature review 
Whilst the search strategy was provided, and comprehensive, and quality 
appraisal was undertaken the articles were screened only by one person.  
Including articles published only in 2005 or later could be seen as a limitation.  
However health care has changed considerably in the last decade; new inhalers 
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are available and information is much easier to obtain than ever before.  I was 
specifically looking to use these barriers to inform the content of a website, 
therefore there was little to gain from capturing historical barriers which no 
longer apply to current health care scenarios.  
2.3.5 Conclusion 
This literature review shows the reasons for people not taking medications as 
prescribed are multifactorial, but that establishing what these barriers are is an 
essential starting point for any resource aiming to improve asthma outcomes.  
The barriers identified here are based on articles worldwide, and may not all be 
relevant to the target population of the resource being developed here.  So 
while these barriers can directly inform the potential contents of a resource, 
exploring them with potential end users is essential to understand what is 
relevant to those who will ultimately be using this resource. 
2.4 Self-management as a treatment strategy 
2.4.1 Introduction 
In this remaining section, I explore what an intervention aiming to promote self-
management might contain, and how these might translate to a digital 
intervention.  Adherence has been explored in the preceding section and its 
influence on the contents of a self-management intervention is described fully in 
Chapter 5.  This section will include other aspects of self-management: asthma 
action plans (AAPs); improving  inhaler technique; trigger avoidance; 
exacerbation risk factors; goal setting; psychological functioning; self-
monitoring; and finally a brief note about the health professional review itself. 
This topic has been the subject of several Cochrane Systematic Reviews [6, 63-
65]and is described in several published asthma guidelines [4, 7], therefore this 
background section mainly draws on these resources.  
2.4.2 What is self-management 
Gibson et al’s Cochrane systematic review entitled ‘Self-management education 
and regular practitioner review for adults with asthma’ [6] was pivotal in 
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changing the focus of asthma guidelines.  It included a good number of RCTs (36 
in total evaluating: education (n=36); self-monitoring (n = 33); regular review 
(n=24); and written action plan (n = 18)).  A preceding Cochrane review had 
already indicated that information alone was not sufficient to improve outcomes 
[66], and the encouraging results from individual evaluations of ways to support 
self-management were hinting that supporting self-management had real 
potential to make a difference. This subsequent 2002 Cochrane review provided 
the robust evidence that guided self-management, as part of systematic planned 
care, incorporating the use of personal asthma action plans, was the best 
combination of ‘optimum self-management’.  They reported that this ‘optimum’ 
self-management led to improvements in patient outcomes such as increases in 
knowledge, confidence and quality of life, as well as reductions in 
hospitalisations, emergency room visits, unscheduled visits to the doctor, and 
days off work or school [6].  It was particularly convincing that while individual 
types of self-management support (regular review, or using actions plans for 
example) often showed slight benefit, the real benefits came when all were 
present, hence the term ‘optimum self-management’.  Gibson et al optimum 
self-management is summarised visually in Figure 2.2 [6].  This allowed the 
guidelines to provide evidence based advice that directly influenced policy here 
in the UK, for example when providing asthma self-management support was 
included in the GP contract in 2004. 
Figure 2.2 Optimum self-management 
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The British Thoracic Society/ Scottish Intercollegiate Guidelines Network 
(BTS/SIGN) Guideline on the Management of Asthma continues to stipulate the 
importance of promoting self-management, and reiterates throughout that a 
written asthma plan should be provided to everyone as part of the annual 
primary care asthma review [4].  The increased priority that the guidelines are 
placing on self-management is visible by reviewing the changes from the most 
recent guidelines in 2014, compared to the previous 2008 version.  The chapter 
on self-management is now twice as long, and comes immediately after the 
diagnosis chapter, whereas in the 2008 guidelines it was half the size and was 
the last chapter – an afterthought.  Support for self-management aims to 
improve outcomes in a number of ways: improved recognition of deteriorating 
symptoms, more appropriate responses to exacerbations, and finally improving 
adherence  to medication [67].  Features of self-management support 
2.4.2.1 Asthma action plans (AAPs) 
AAPs are considered a crucial component of self-management and recent British 
guidelines make two grade A recommendation about their use [4]: 
1. All people with asthma (and/or their parents or carers) should be 
offered self-management education, which should include a written 
personalised asthma action plan and be supported by regular 
professional review. 
2. In adults, written personalised asthma action plans may be based on 
symptoms and/or peak flows: symptom-based plans are generally 
preferable for children. 
Teaching individuals to recognise deterioration and act in a timely manner is a 
crucial step in reducing severe exacerbations, hospitalisation and potentially 
even asthma related deaths [1, 68], and AAPs are a written agreed plan for 
doing this.  The importance of providing AAPs was a key message from the 
National Review of Asthma Deaths [1], as from the 195 deaths reviewed only 23% 
had a record of being provided with an AAP (from either primary or secondary 
care).  Out of the patients who died who had not sought medical assistance 
during their final attack only 17% (11/33), had been provided with an AAP, 
compared to 36% of those who had sought help but died before it could be 
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administered (8/22), perhaps indicating that having an AAP increases the 
chances of an individual seeking more timely medical advice.  
Despite their clear benefits AAPs are underused [1, 10, 69, 70], and a 
comprehensive systematic review tried to understand why [9].  They recognised 
two important mismatches: 1) content/design and 2) target audience.  Firstly, 
they found that professionally provided, medically focussed, action plans often 
do not fit with patients/ carers views of asthma, and do not incorporate 
patients’/carers’ experience.  Secondly, they found that health professionals 
appeared to believe they were mainly useful for educated patients, with well 
controlled asthma, and patients felt that action plans were most appropriate in 
severe asthma or where care is being provided out with the usual set up (e.g. in 
school), and did not consider themselves as candidates for benefitting from their 
use. 
The overall conclusion is that patients do not feel that action plans are relevant 
or useful to their own person circumstances.  Tailoring of action plans to 
increase relevance should increase their worth to the individual [64, 68, 71].  
However specific examples of how to achieve this are lacking in the literature, 
and the BTS guidelines simply state that use of personalisation of AAPs need to 
be considered within “the broader challenges of living with asthma” [4]. 
It is clear that Asthma UK have attempted to simplify and personalise their AAP 
within the limitations of a paper based template, and some of their changes are 
shown in Table 2.5.  
Table 2.5 Differences in Asthma UK AAPs 2011 to 2014 
2011 version 2014 version 
Four different ‘zones’: 
1. Your asthma is under control… 
2. Your asthma is getting worse… 
3. Your asthma is much more severe.. 
4. It is an emergency if… 
Three different levels: 
1. This is what I need to do to stay on top of 
my asthma… 
2. My asthma is getting worse if I notice any of 
these…. 
3. I am having an asthma attack if…. 
‘Normal activities’ ‘Day to day activities (e.g. at work, exercise)’ 
 
 
The impact on uptake and use of these readily available more personal AAPs will 
be difficult to assess.  At present, they would still need to be printed and taken 
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to an asthma review to fill in with a health professional.  It has been shown AAPs 
are likely to work best when agreed between an individual and a health 
professional they trust [64]. What is less clear is whether this ‘organic’ process 
of agreement of action plan ‘actions’ can be replicated successfully by a 
computer program without discussion between the health professional and the 
patient.  Verbally agreeing specific actions in response to the presence or 
absence of specific symptoms or peak flow readings, while maintaining the level 
of personalisation that Ring et al recommend for patients to actually use them in 
real life may not be amenable to any computer generated algorithm [9].  
Developing such a computer feature would be lengthy, time consuming, and 
require more piloting time than we could provide in this project, before being 
used by patients.  An alternative option  to improve access to asthma action 
plans could be providing a template that users could print out and discuss with 
their health professional.  This would require to be supplemented with, 
behaviour change advice outlining the benefits of AAPs, promoting their ease of 
use, and encouraging a discussion between the patients and their health 
professionals.   
2.4.2.2 Inhaler technique 
Poor inhaler technique is the main reason for patients unintentionally not taking 
medications.  It is known that poor inhaler technique contributes to poor asthma 
control, and this is compounded by an ever increasing array of inhalers [72, 73], 
with evidence that health professionals can be as confused as patients [73].  A 
further barrier to assessing and improving inhaler technique by health 
professionals is the difficultly in accessing placebo inhalers, and if the patients 
forget to bring their own, teaching inhaler technique becomes difficult.   
As an option for overcoming the barrier of no placebo inhalers, videos have been 
shown to be an effective way of improving recall regarding correct inhaler use, 
and avoiding triggers, particularly so in those with limited literacy [74].  
Improving inhaler technique clearly warrants inclusion in any intervention to 
promote self-management, digital or otherwise. 
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2.4.2.3 Trigger avoidance and predictors of exacerbations 
When aiming to improve asthma control there are two areas to consider: 1) 
current clinical control (e.g. symptoms), and 2) future risk of exacerbation [34, 
75].  With regard to assessing future risk, all of the following have been shown 
to be important contributors [75]: 
1. history of previous exacerbation 
2. poor asthma control 
3. poor inhaler technique 
4. a history of lower respiratory tract infection 
5. non-adherence 
6. presence of allergic rhinitis 
7. gastro-oesophageal reflux disease 
8. psychological dysfunction 
9. smoking 
10. obesity 
Often individuals are aware of their own personal triggers such as animal 
dander.  These predictors provide some guidance about topics to include in any 
self-management intervention, and raising awareness of an individual’s 
predictors of exacerbations, or loss of control, may be a suitable strategy. 
2.4.2.4 Goal setting 
Goal setting has been a component of successful interventions in asthma [76], 
and are undergoing further evaluation at present in a RCT [77].  Qualitative work 
in the area showed that goals relating to lifestyle (e.g. person, family, work) 
were far more meaningful to patients when compared to mediatory ones such as 
those relating specifically to asthma control [78].  The BTS/SIGN guidelines 
recognise the potential for goal setting when they state:  ‘Brief simple education 
linked to patient goals increases acceptability to patients’.  Incorporating goal 
setting into self-management interventions is one way to personalise the 
intervention ideally increasing engagement.   
2.4.2.5 Psychological functioning 
This topic has been summarised in a clinical review article by Thomas et al in 
2011 [79].  In summary, they found that psychological dysfunction is more 
common in people with asthma than would be expected by chance alone, and 
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the relationship between impaired asthma control and quality of life and 
depression and anxiety appears to be independent of potentially confounding 
factors of age, socioeconomic status (SES), asthma severity etc.  The presence of 
anxiety and depression are associated with worse outcomes, but effective 
treatment strategies are lacking.  Since their review there is further evidence 
that this is an ongoing issue worldwide [80], but little progress in the way of 
guidance on management.  The exception is work that Thomas et al are 
undertaking regarding the role of breathing exercises.  These have been shown 
to improve patient reported outcomes and psychological measures such as 
anxiety states [81] and an intervention focusing on breathing exercises is 
currently being evaluated in a RCT ongoing at present [82].   
In a similar vein, qualitative work shows that in order to allow a person with 
asthma to achieve as near normal activities as possible, family members need to 
be on board with the asthma management strategies [83].  In real life clinical 
practice many patients have little or no social support.  Therefore establishing 
and acknowledging this isolation as an additional barrier to patients’ practicing 
optimum self-management may allow for further personalising of action plan 
advice, and may modify what would be expected of a given patient.  
Discussing the potential interplay between psychological functioning, family 
support and asthma outcomes should be part of a health professional review, 
particularly where uncontrolled asthma is detected, as it could be a contributory 
factor.  Incorporating this aspect of asthma self-management into a digital 
intervention is likely to be challenging, other than highlighting it as an issue in 
the first place. 
2.4.2.6 Self-monitoring 
Self-monitoring is often considered an important aspect of self-management as 
it is felt that timely intervention in the face of deteriorating symptoms can avert 
progression to a severe exacerbation, and interventions with self-monitoring 
were more effective than interventions without [6, 84].  However, it is 
interesting to note that the latest BTS guidance has moved away from the term 
‘self-monitoring’; only discussing ‘recognition of deteriorating symptoms’ 
instead.   
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This may seem surprising as the rationale behind promoting self-monitoring is 
convincing.  An analysis of exacerbations (n = 425) within a large RCT of asthma 
treatments found that participants displayed evidence of deteriorating asthma 
control (a decline in PEF, increase in symptom scores or increase in reliever use) 
which initially occurred gradually for 5-7 days followed by a more rapid change 
over the 2-3 days before the exacerbation [85].  Other studies have found similar 
results [86].   
However, it is harder to find evidence of any effective interventions showing 
sustained self-monitoring by participants [87], and there is a lack of clarity 
about why individuals rarely sustain self-monitoring.  One theory is that patients 
are poor at recognising deterioration in symptoms in the first place, and 
therefore are then unable to act appropriately, a non-intentional lack of self-
monitoring [9].  Alternatively, patients do recognise deterioration in symptoms 
but alter their medication inappropriately due to lack of awareness of what their 
deteriorating symptoms mean [88].  These explanations are consistent with the 
literature which shows that those with asthma overestimate their control, and 
underestimate their symptoms [2, 89].  This is the case even in trial settings 
when presumed exemplary education on self-monitoring is provided [90].   
Either way, it seems that regular self-monitoring as I understand it at present, is 
not well used by individuals with asthma generally.  Variations that could make 
it more acceptable include reducing the recommended frequency, e.g. weekly 
monitoring may be enough in those with well or partly controlled asthma, and 
that this could safely become less frequent once good control is achieved [91].  
More imaginative strategies have been employed in recent studies where a 
sensor on a reliever inhaler detects increasing use, communicating via Bluetooth 
to a smartphone or similar device the evidence of deteriorating control indicated 
by increasing reliever use with encouraging preliminary results [92].  It seems 
plausible that this type of ‘passive’ monitoring may be far more acceptable to 
patients. 
Overall the evidence that self-monitoring is effective at improving outcomes is 
clear, but how best to facilitate it is not, and until methods more acceptable to 
patients become available it is difficult to know how best to increase uptake. 
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2.4.2.7 Health professional review 
At present in the UK, regular review means a face to face, pre-arranged 
appointment.  However not all patients are willing or able to attend, particularly 
given most people perceive themselves as being well, so attendance remains 
suboptimal.  In the National Review of Asthma Deaths published in 2014, only 
57% of those who died had evidence of a routine asthma review in the preceding 
year.  Being flexible about how to provide the regular review appears helpful, 
with evidence that telephone reviews are safe and effective [93], and whether 
there is a role for asthma reviews to be undertaken within a digital intervention 
remains to be seen. 
In terms of contact with health professionals between reviews a proportion of 
those with asthma would value having email access to health professionals [41], 
and with more practices offering online messaging this may be increasingly 
feasible even in the short term.  There are risks associated with this as it is not 
feasible for practice staff to regularly monitor online messaging so boundaries 
about what type of queries could be raised in this way would need to be clearly 
outlined.  As with other health areas promotion of resources available in the 
third sector could alleviate this gap, for example Asthma UK provide a daily 
telephone service to speak to a trained asthma nurse Monday – Friday during 
working hours, which could answer general queries and concerns an individual 
may have.   
Clearly there is scope for improving the uptake of asthma reviews, and whether 
a digital intervention should aim to complement health professional review, or 
could in part replace it, is not yet clear from the literature.   
2.4.3 Implications for future digital self-management 
interventions 
Taking these findings into account can provide a picture of what could be 
considered for inclusion in a digital intervention to promote self-management.  
There are some items where there is little debate about rationale for inclusion, 
with strong evidence to recommend their inclusion.  These would include inhaler 
technique, review of triggers and risk factors for exacerbations, and promoting 
awareness of the interplay between psychological state and asthma outcomes.  
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There is strong evidence that  AAPs work, and their use be promoted, but there 
is little evidence suggesting the feasibility of taking this a step further with a 
digital intervention generating one automatically.  Promoting daily self-
monitoring may not be helpful if patients are not going to do it anyway, 
therefore using AAPs which are based on signs and symptoms of deteriorating 
asthma control may be the most feasible solution, at least until methods of 
‘passive’ monitoring are more readily available.  There is some evidence that 
objective methods of assessing control such as structured questionnaires may 
overcome the issue of patients downplaying their symptoms, and this was used 
somewhat successfully in one large RCT of a comprehensive digital self-
management intervention [94].  Finally, the role of the health professional 
review requires consideration in the development of an online intervention.  
There is strong evidence for a regular health professional review, but no 
evidence as yet that a digital intervention could replace it.  Where there are 
varying degrees of evidence behind different components, these need to be 
discussed with potential end users in order to understand more clearly how 
these features could be successfully implemented into a digital intervention, as 
is reported in chapter 5.  
2.5 Chapter conclusion 
The aim of this chapter was to allow the reader to gain an understanding of the 
status of asthma and its management, and develop an understanding of what 
optimum self-management involves and how it may potentially be supported by 
a digital intervention. Barriers to adherence were explored in a review of the 
literature, in order to inform the contents of the intervention as described in 
Chapter 5.  The next step is to consider formally the processes involved in 
developing and subsequently evaluating a digital intervention, and the next 
chapter looks at these methodological issues. 
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Chapter 3: Methodological Considerations 
3.1 Chapter overview 
This chapter introduces the terminology used when discussing the philosophical 
and methodological origins of research, and describes how my understanding of 
this has changed during this fellowship.  I will then explain how I generated the 
four research questions outlined in chapter 1, followed by a discussion of the 
methodological considerations encountered while deciding on the most 
appropriate methods to answer each research question.  
Silverman describes methodology as ‘a general approach to studying research 
topics’, and method as ‘specific research technique’ [95].  This chapter 
primarily concerns itself with the former, while the actual methods used in this 
project are described in their relevant chapters (meta-review methods in 
chapter 4, website development methods in chapter 5, and randomised 
controlled trial (RCT) methods in Chapter 6).   
3.2 Introduction 
It is clear the research questions outlined in the first chapter demand a mix of 
methodologies to adequately answer them.  Historically there has been a 
viewpoint that qualitative and quantitative methods are so different in their 
philosophical and methodological origins that using both together cannot be 
recommended.  However, due to an increasing appreciation of the multiple ways 
in which we need to understand factors which impact on health and wellbeing, 
using a mix of methods is increasingly being advocated [96].   
While my research experience prior to embarking on this fellowship was 
primarily of using quantitative methods, I thought I had a good appreciation of 
why mixed methods were not only acceptable, but also positively advocated.  
Therefore, as a novice researcher, as I was then, I was surprised that it was still 
considered important to justify the use of mixed methods.  It seemed to be 
common sense that different methods would provide different knowledge: 
Chapter 3 Methodological Considerations  62 
 
gathering knowledge from as wide a range of sources as possible could only be 
beneficial.     
However, as I have explored the philosophical origins of research during this 
fellowship, I realise my understanding of qualitative methods at the start was 
actually very narrow.  I saw the role of qualitative research as primarily a way of 
explaining or validating quantitative results.  During this fellowship I have gained 
a greater understanding of the different research paradigms that researchers 
work across, strengths and weaknesses and the potential role each can have.  My 
stance is now firmly that when combining qualitative and quantitative methods, 
they should be seen as equal and distinct from each other; the choice of method 
should be based on the research question being answered. 
A rationale for using a mix of methods in this PhD has been provided by Ritchie 
et al [97] as follows: 
“Each of the two research approaches is seen as providing a distinctive kind 
of evidence and, used together, they can offer a powerful resource to 
inform and illuminate policy or practice” p40. 
It is clearer to me now why researchers want to use mixed methods, and funders 
may look favourably upon proposals incorporating them [96].  The challenge with 
this project was finding the right methods to provide the best data to answer 
each of the research questions. 
3.3 Background 
Silverman (2001) argues that a given methodology should not be considered right 
or wrong, but rather more or less useful for a given research question [95].  
Methodology is the way we go about discovering knowledge in a systematic way.  
Appropriate methodological choices are considered to be driven by one’s 
ontological and epistemological beliefs.  Simply put, ontology refers to beliefs 
about the nature of reality, and epistemology refers to beliefs about the nature 
of knowledge, and how it can be acquired [98].  I will discuss these further 
below.    
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I had previously been aware of two dominant research strategies: quantitative 
and qualitative.  A simplified description being that quantitative methods are 
involved with measuring, when qualitative are not [99].  However, I now realise 
that these research strategies align to differing ontological and epistemological 
principles, and here are more correctly discussed in terms of the two dominant 
research paradigms within social research: positivism and interpretivism. 
During my reading on this topic, I became aware that researchers used similar 
terms in slightly different ways.  For example Bryman uses the term 
‘objectivism’ to describe an ontological orientation [99] (pg 36), however 
Ormston uses the term to describe an epistemological stance [98] page 6.  In 
response to this variation in terminology used, I constructed a table which links 
terms to the paradigm they are mostly aligned with (see Figure 3.1 below): 
broadly describing positivism and interpretivism.   
Figure 3.1 Terms aligned to positivism and interpretivism 
 
Positivists search for the one constant truth, looking for facts about reality 
(ontology).  This results in the researcher ideally maintaining a distance from 
the researched, in order to prevent the researcher influencing the results 
(epistemology).  The methodologies aligned to this paradigm are therefore 
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experimental, or hypothesis testing.  Traditionally, within this paradigm 
quantitative measures were considered superior [98].   
The contrasting paradigm is interpretivism or constructivism.  Interpretivists 
believe that truths are subjective, dynamic and contextual (ontology),  and that 
we do not find or measure knowledge, but that it is constructed based on 
interactions with the social environment, so researcher and participants are 
considered co-creators of the findings, as the data itself is generated by this 
interaction (epistemology).  This therefore influences the methodologies usually 
used which are described as qualitative, explorative, or interpretative and 
attempt to include an understanding of the context in which data are generated 
[98]. 
It is true that although certain principles or perspectives align to one or the 
other overarching paradigm, they are not fixed.  For example, it is not unusual 
for a research question with a positivist orientation to be answered, at least in 
part, by qualitative methods.  Despite this, I find the figure above (Figure 3.1) a 
useful, if slightly simplistic, summary. 
To me, the fundamental difference between these opposing paradigms is that 
interpretivists reject the notion that an objective reality, or one true, reality 
exists, and believe that it is possible to have multiple realities that can be 
conflicting but all considered to be true at the same time.  For example, 
participants may interpret the same events in different ways, which may be 
flatly contradictory, but their experience of the event remains true.  This idea 
of whether the one true answer to the question is out there just waiting to be 
measured, or whether I needed to generate the knowledge through interacting 
with participants was fundamental in informing my choice of methods, and 
understanding them.  
3.4 Generating research questions 
I am first going to describe how I generated my research questions.  In the 
subsequent section I will then discuss the methodological considerations 
associated with each of them. 
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As described in chapter 1, the project involved developing a complex 
intervention in the form of a website aiming to support self-management in 
adults with asthma.  The obvious place for guidance on methodology was the 
Medical Research Councils (MRC) publication ‘Developing & Evaluating complex 
interventions: new guidance’ [100].  This guidance: 
“is primarily intended to help researchers choose and implement 
appropriate methods, given the state of existing knowledge and the nature 
of their target intervention” pg 6 
I found the following paragraph in the MRC guidance particularly illustrative of 
the problems faced by researchers in this field, and it became integral to my 
plans for how this project should progress: 
“Developing, piloting, evaluating, reporting and implementing a complex 
intervention can be a lengthy process. All of the stages are important, and 
too strong a focus on the main evaluation, to the neglect of adequate 
development and piloting work, or proper consideration of the practical 
issues of implementation, will result in weaker interventions, that are 
harder to evaluate, less likely to be implemented and less likely to be worth 
implementing.” pg 4. 
This process is illustrated in Figure 3.2 which shows the key stages recommended 
when developing a complex intervention [100], highlighting those covered in this 
project with **. 
Figure 3.2 Key elements of the development & evaluation process. 
(Reproduced from Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council G: 
Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008, 
337:a1655. With permission from BMJ Publishing Group Ltd.) 
 
** 
 
* 
** 
 
Chapter 3 Methodological Considerations  66 
 
I was determined that this project would follow best practice, and this 
framework strongly influenced what knowledge I felt was important to gain 
during the process, which in turn guided my research questions.  Considering the 
development phase first, this guidance recommends three main stages: 1) 
identifying the evidence, 2) identifying or developing theory, and 3) modelling 
process and outcomes.  This was followed by a fourth stage: feasibility and 
piloting.  I will describe how consideration to these four stages in turn 
influenced my research questions. 
3.4.1 Stage 1: Development - identifying the evidence base 
The first of these recommendations appeared most straightforward, with the 
framework itself recommending a systematic review if possible, the only time it 
really specifies a specific methodological approach.  When I considered what 
information I wanted from the literature this led to the generation of research 
question 1: 
RQ 1: What is known about the effects of online tools to promote self-
management of asthma and what helps or hinders their utilisation by 
patients?  
3.4.2 Stage 2: Development – identifying or developing theory 
The MRC guidance states; 
“a vitally important early task is to develop a theoretical understanding of 
the likely process of change, by drawing on existing evidence and theory, 
and supplemented if necessary by new primary research, for example 
interviews with ‘stakeholders’, i.e. those targeted by the intervention, or 
involved in its development or delivery.”  
I anticipated that my systematic review would contribute towards understanding 
the existing evidence, but what was less clear to me was what ‘a theoretical 
understanding of the likely process of change’ entailed for this project.  On page 
4, the guidance asks: 
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“Does your intervention have a coherent theoretical basis?  Have you used 
this theory systematically to develop the intervention?” 
As a novice researcher, with little formal training in social science or 
psychology, interpreting this recommendation was difficult for me.  Even 
understanding definitions of what ‘theory’ meant was problematic as the 
language used was to alien to me.  I found this definition useful initially [101]: 
“ a theory is a coherent conceptual arrangement that, when it is 
operationalized, makes possible a rational description and taxonomy of 
phenomena and constructs by which their systematic explanation is 
possible.  From these stem a set of knowledge claims that, in turn, offer the 
potential for hypotheses or propositions that might be open to further 
investigation.” Page 539. 
However, it suggests, as does the MRC Guidance, that researchers should choose 
a single ‘theory’ for a given intervention and I struggled to understand how that 
would work in practice for this project.  I felt the literature about using theory 
was inaccessible to me, and I was subsequently relieved to discover I was not 
alone, and this is recognised reaction.  As Davidoff et al [102] state in their 
useful overview: 
“We also acknowledge that the term ‘theory’ itself can make people’s eyes 
glaze over, because ‘theory’ is seen as something abstract, intimidating and 
irrelevant, especially when their immediate and true concern is the hard 
work at the sharp end of providing care, rather than theory itself.”  Pg 2 
I certainly felt intimidated by it, and it was only by using it in practice during 
this fellowship, and through many discussions with supervisors and the expert 
panel that I have come to an understanding of what ‘theory informed’ really 
meant for this project.  
There were two areas where theoretical underpinning was considered essential: 
deciding on the content of the website (understanding the likely processes of 
change), and when planning implementation processes.  Therefore both 
behaviour change theory and implementation theory was used.  I describe each 
of these in turn below. 
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3.4.2.1 Understanding the likely processes of change using behaviour 
change theory 
In terms of ‘understanding the likely processes of change’, behaviour change 
theory was investigated.  Behavioural theories such as Theory of Planned 
Behaviour [103] or Social Cognition Theory [104] have been shown to be useful in 
trying to understand and predict the steps involved in developing an intention to 
change behaviour, and then being able to act, including in asthma related 
interventions [105]. However, there is no evidence that asthma interventions 
based on these theories are any more successful than those which do not have a 
theoretical basis, and no evidence that any single theory is better in improving 
outcomes in asthma.   
A lack of consensus when describing behaviour change interventions has 
increasingly been recognised in the literature [106].  In response to these issues 
a research programme was initiated to try and describe the individual constructs 
within established theories which predict behaviour change (rather than simply 
predicting behaviour) [106]. This has led to the publication of a taxonomy of 
behaviour change techniques (BCTs) which are derived from these established 
behaviour change theories, along with empirical evidence, and uses accessible 
language [107].  The intention of this taxonomy is that if all interventions 
include a description of which BCTs they include, then subsequent meta-analyses 
will be able to identify which are likely to be most effective to change which 
behaviours. 
The absence of evidence that any individual behaviour change theory is superior 
when developing digital asthma interventions, and the presence of the taxonomy 
of behaviour change techniques, led to the decision  to include as many BCTs as 
seemed relevant and to carefully map which BCTs were used, rather than 
choosing one specific behaviour change theory.  How I decided on which 
behaviours to try to modify, with which BCTs, is described in later sections in 
this chapter.   
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3.4.2.2 Implementation theory – Normalisation Process Theory 
The MRC Framework is clear:  it is important to give early consideration to 
understanding implementation [100].  Normalisation Process Theory (NPT) is a 
mid-range implementation theory that is 
“concerned with the social organisation of the work (implementation) of 
making practices routine elements of everyday life (embedding) and of 
sustaining embedded practices in their social contexts (integration)” [101] 
pg 538 
It was developed in response to the evidence that this implementation, 
embedding and integration rarely happens in practice [101, 108].  Although 
relatively new, NPT is increasingly being established as a useful implementation 
theory to understand the implementation of complex interventions [101, 109].   
Its use to frame analysis in a meta-review of factors which promote or inhibit 
implementation of e-health systems i illustrated that much of the published 
literature focused on organisational issues, neglecting the potential effects of 
roles and responsibilities, engagement of health professionals, and the 
importance of ongoing evaluation and feedback for improving implementation 
[110].   
NPT suggests that for changes in behaviour (in this case improved asthma self-
management such as taking inhaled steroids regularly) to become routine, 
people need to: understand what the new behaviours are and make sense of 
them (coherence); buy into these new behaviours and be willing to commit to 
them (cognitive participation); are able to operationalise the new behaviours 
and for changes in their workload to be acceptable to them and those around 
them (collective action); and finally in order for new behaviours to become truly 
embedded over time people need to judge the utility and effectiveness of these 
new behaviours and place value on them for themselves and those around them 
(reflexive monitoring).  When we are considering a complex intervention to 
change behaviour these constructs can also be applied to the work of 
undertaking the desired behaviours, but also the work of engaging in the 
intervention which is promoting the desired behaviours.  Murray et al [111] have 
argued that applying this framework when developing a complex intervention, 
alongside behaviour change theory, can help with its eventual successful 
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implementation. Therefore I used NPT from the earliest development stages 
such as informing focus group and think aloud study topic guides, and 
subsequently undertaking an ‘NPT analysis’ on the intervention during 
development as recommended by Murray et al [111].  
A final role for NPT in a project such as this is to try and understand how 
feasible the evaluation is likely to be  [111].  In this role it can be seen as a ‘trial 
killer’, where the result of the NPT analysis may actually suggest that either the 
intervention itself is not likely to be implementable and progression to an 
evaluation is not appropriate, or the evaluation itself is not going to yield the 
required information and itself needs reviewed. I undertook an ‘NPT analysis‘ of 
the trial parameters as outlined by Murray et al [111], and this is described fully 
in chapter 6. 
NPT was also used as a framework to conceptualise qualitative data collected as 
part of a parallel process evaluation undertaken by a colleague.  
In summary, NPT is increasingly being used for both informing the development 
of interventions in relations to how easy they are to implement and use, and 
understanding the likely success of their evaluation.  I found it useful for both 
these functions.   
 
3.4.2.3 Role of primary research 
While I planned to use the metareview to gain an understanding of the existing 
literature, as per the MRC Guidance I also realised that primary research was 
essential here.  I wanted to really understand why people here did not manage 
their asthma optimally, and what those who were currently experiencing asthma 
believed could help them to do it more effectively.  I was particularly interested 
in exploring any differing perspectives between those whose behaviour we 
wanted to change (adults with asthma), and those who were currently best 
placed to support this (practice nurses).  Including practice nurses in the primary 
research would have a further additional benefit: while I anticipated that this 
intervention should be a standalone resource, for patients to engage with it 
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‘approval’ from health professionals would be desirable, in particular practice 
nurses.  This aspect of planning work has been shown to be often neglected in 
published eHealth interventions [110].  Belief in the usefulness of a resource is 
one of the strongest attitudinal predicators of intended future use [30] so having 
practice nurses promoting it could be an important determinant of its future 
uptake.  This information would feed into our ‘model’ of how we anticipated our 
intervention would lead to behaviour change. 
From this, I generated my second research questions: 
RQ 2:  What are the barriers and facilitators to the uptake and utilisation 
of a web-based self-management tool from the perspective of adults with 
asthma, and primary care nurses who undertake asthma reviews?   
Therefore it can be seen that even at this early stage in the project I planned to 
use different sources to help me develop this intervention, such as theories (e.g. 
NPT), frameworks (MRC Guidance, BCT taxonomy) and also findings from new 
primary research (focus groups initially).  These sources along with the 
experience of the expert panel would contribute to our understanding of how 
our intervention should work, allowing us to develop a model of the behaviours 
we want to change, and the expected impact on outcomes, similar to the 
process described in Davidoff et al of developing what they call a programme 
theory [102]. They define a programme theory as: 
“a ‘small theory’ for each intervention……such theories are purposefully 
practical and accessibly; they are specific to each programme or 
intervention”  pg 3 
While this paper was not published at the time of the development of this 
intervention, it validates the approach we took of using existing evidence, 
theories and our own experiences (via the expert panel) to contribute towards 
our understanding of how the intervention would work [102]:  
“Formal theory complements informal, experience-based theory, helping to 
define areas of dysfunction in health care systems, pinpoint their loci and 
identify their possible mechanisms.”  Pg 9 
So it is clear that this project drew on various sources.  This makes sense for a 
project such as this, as it is increasingly being recognised that to change 
Chapter 3 Methodological Considerations  72 
 
outcomes, interventions need to work on multiple levels, and a ‘one theory fits 
all’ approach is increasingly seen as inadequate [112]. How these various sources 
of information were used in practice will be covered in more detail in relation to 
their associated research question below, or in their relevant chapter.  
3.4.3 Stage 3: Development - modelling process and outcomes 
Answering these first two research questions should provide the knowledge I 
needed to understand how this intervention should work, what should its ‘active 
ingredients’ be, and to work towards developing what has been referred to as a 
‘programme theory’ [102] to explain essentially what I expected the 
intervention to do.  The logical next step was then to consider actually making 
the intervention, in this case a website.  This website should include these 
‘active ingredients’ and promote changes in the specific behaviours we were 
targeting.  Importantly I did not want to just develop an intervention based on 
this static collection of knowledge.  Intuitively it felt right that while an initial 
draft could be developed based on RQ 1 and 2, further input with potential end 
users was essential to further develop and refine the intervention, testing out 
whether my interpretation of the literature, theory and stakeholders views 
resonated with potential end users.  The MRC Framework states: 
“before undertaking a substantial evaluation you should first develop the 
intervention to the point where it can reasonably be expected to have a 
worthwhile effect” pg 9 
Additional user testing at this stage would therefore be warranted to ensure that 
the prototype developed from the findings from RQ 1 and 2 was optimised as 
much as possible prior to any pilot evaluation.  Similarly, NPT could be used here 
in its ‘trial killer’ role: assessing there were any intervention related factors 
which could be barriers to implementation, allowing any alterations to be made 
at this early development stage [111].  
With consideration to modelling outcomes, the MRC guidance specifically 
mentions the RE-AIM framework (Reach, Efficacy, Adoption, Implementation and 
Maintenance) [113].  This framework is promoted as a way of guiding evaluation 
methods, ensuring that researchers think beyond whether the intervention will 
work in the trial setting or not, to consider the broader picture of how it will 
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perform in real life settings.  Therefore we aimed to use this framework to 
inform the choice of outcomes we would use our evaluation, as is explained in 
further detail in Chapter 6 (RCT).  
While I was following best practice by drawing on multiple sources to inform the 
planning of the intervention, I genuinely did not know if or how these divergent 
sources of knowledge and experience could be pulled together to successfully 
inform the makeup of a behaviour change website.  This led to the generation of 
my third research question: 
RQ3: Can evidence from the literature (asthma management and theory) 
and input from potential end users, be successfully incorporated into an 
intervention to promote self-management?   
Ideally, by this stage in the project I would have an intervention ready for 
preliminary testing in a pilot randomised controlled trial (RCT).     
3.4.4 Stage 4: Feasibility and piloting 
In alignment with the MRC framework (Figure 3.2) the next phase would then be 
to embark on the feasibility and piloting stage.  The rationale behind including 
such a phase is clear: it aims to reduce the number of studies that are 
undermined by issues which would have been anticipated by appropriate 
piloting, such as poor recruitment, high attrition, and smaller than expected 
effect sizes [100].  With an intervention such as this there would be outcomes 
common to any complex intervention which would be important to measure such 
as recruitment and retention and how much was the intervention actually used 
by participants.  Secondly, as informed by our use of the RE-AIM framework 
[113] I was also interested in how this intervention might improve outcomes for 
those it targeted, particularly in terms of symptoms and quality of life.  This led 
to generation of the fourth and final research question: 
RQ4: What would be the feasibility of undertaking a randomised controlled 
trial of Living Well with Asthma, and how would such a website be used by 
adults with asthma.  What would be the effect on symptom scores and 
quality of life measures? 
As part of this evaluation it would be ideal to undertaken qualitative interviews 
with intervention group participants to explore experiences of using the 
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intervention, and also of participating in the evaluation itself [100].  Doing this 
myself however was impossible within my timescales, but fortunately a 
colleague was able to undertake this work separately. 
3.5 Choosing methods appropriate to the research 
questions 
In this section, I am going to look at each research question (RQ) in turn in more 
detail, and consider how the research questions themselves guided me when 
choosing my research methods 
3.5.1 Research question 1 
RQ 1 - What is known about the effects of online tools to promote self-
management of asthma, and what helps or hinders their utilisation by 
patients? 
My initial research question appeared to be answered best by undertaking a 
systematic review, a method recommended within the MRC framework I was 
using.  Historically this would have automatically referred to a review of 
quantitative papers, possibly resulting in either a meta-analysis or narrative 
synthesis.  However, I had three issues to consider when choosing the specific 
method for this stage.  The first was that the literature on asthma self-
management was vast.  The second was that was that I was keen to try to 
establish what helped or hindered the use of digital self-management 
interventions that was unlikely to be answered by quantitative methods alone.  
The final issue was that I was comparatively time limited, as I wanted to ensure I 
allowed adequate time for the subsequent website development and evaluation 
phases of the project. 
Epistemologically the second issue did not sit well within a positivist paradigm, 
as I did not want to simply quantify who was hindered, but I wanted to 
understand the why, and to generate new data about what would help or hinder 
use of digital interventions, a stance which lends itself more to research 
methods within an interpretivist paradigm.  However, to truly work in this 
paradigm requires a relationship between the researcher and the researched, a 
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tenet that would be impossible if systematic review was to be the underlying 
methodology.  This was a debate I had been involved in during work preceding 
my fellowship when I participated in a synthesis of qualitative papers exploring 
treatment burden in stroke [45, 46].  Although there were concerns raised about 
the ability of this method to generate rich new knowledge, in practice for this 
previous project such an approach had worked very well. The results of the 
stroke review provided new and illustrative findings which could not have been 
generated by looking at the articles in isolation.  It was thought these methods 
were transferrable to this current project, and would contribute to answering 
this research question. 
Therefore I decided that undertaking a systematic review of both quantitative 
and qualitative articles was essential to try and build a rich picture of how 
effective these interventions were in practice, and what helped and hindered 
their use.  In response to concerns about timescales and the vastness of the 
literature we concluded a meta-review (systematic review of systematic 
reviews) would be a useful method in view of  my tight timescale and given this 
method had recently been found to be helpful previously [110]. I anticipated it 
would reduce the number of articles being synthesised to a manageable number, 
yet still providing a comprehensive overview of what was known on the subject.  
In addition to this systematic review, as part of the University of Glasgow 
postgraduate research requirements I also completed a more generalised 
literature review on the topic of asthma and self-management which also 
informed the intervention.  This was updated and formed the basis of Chapter 2.   
3.5.2 Research question 2 
RQ 2 - What are the barriers and facilitators to the uptake and utilisation of a 
web-based self-management tool from the perspective of adults with asthma, 
and primary care nurses who undertake asthma reviews?   
Epistemologically this was far more straightforward.  Barbour [114] discusses the 
differences between data generation and data collection, and this was firmly in 
the former.  Here I wanted to understand how individuals managed their asthma, 
and explore their own personal barriers and facilitators to doing so.  
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Understanding the context was crucial particularly to allow me to be sensitive to 
change [114], a particular issue in the fast moving field of eHealth.  Here I also 
wanted to produce ideas about what the intervention I was going to make should 
or could contain, in order to be clear about its likely ‘active ingredients’.  The 
interaction between myself and the participants would be critical to the data 
generated and we would be co-creators of the findings.  However true 
interpretivism implies that this process is entirely explorative and pre-defined 
theories are actively discouraged.   This was a stance I could not justify, as I 
wanted to build on the data from the literature, and my own clinical experience 
could not be ignored.  Ultimately I decided that I would use key findings from 
the preceding literature review as discussion prompts, thereafter focussing on 
the generation of new data.  As discussed in the preceding section I anticipated 
the dialogue between adults with asthma and practice nurses undertaking 
asthma reviews (and therefore promoting self-management) would be the most 
valuable source of knowledge to answer this research question.  Therefore, 
heterogeneous focus groups were planned, with both practice nurses and people 
with asthma as participants.  Here I wanted to focus in on the barriers and 
facilitators to the participants undertaking self-management practices with a 
view of really understanding what might a digital intervention do to facilitate it, 
and how it would potentially be operationalised in practice.  To this end I 
elected to use normalisation process theory (NPT) [101, 108] to inform the focus 
group topic guide, and planned to use it as a framework to inform the analysis of 
the anonymised transcripts from the focus groups.   
Using this framework would ensure I would be in a position to explore any 
suggested features both in terms of how they could be incorporated into the 
intervention for this evaluation, but also how might that work both in a trial 
setting, and importantly in everyday life should the intervention be ultimately 
proven to be acceptable and effective [111].   
3.5.3 Research question 3 
RQ 3 - Can evidence from the literature (on asthma management and theory) 
and input from potential end users, be successfully incorporated into an 
intervention to promote self-management? 
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To answer this research question would require two different stages.  Firstly, it 
involved me gaining an understanding of how this intervention would work in 
practice – developing our own model for the intervention to explain our 
proposed mechanisms of action.  Secondly, it refers to the practical process of 
turning our understanding of the likely mechanisms of action into a working, 
interactive behaviour change resource.   From a practical point of view how I 
undertake the process for the first stage above, developing our intervention 
model, eluded me until I read Campbell et al’s article on designing and 
evaluating complex interventions to improve health care [115].  The authors 
summarise this as follows:  
“The essential process involves mapping out the mechanisms and pathways 
proposed to lead from the intervention to the desired outcomes, then 
adding evidence and data to this map.” 
This article emphasised the importance of defining and understanding the 
problem through 5 key tasks.  Having an understanding of the literature was 
essential to complete these tasks, and this process is described in full in chapter 
5. 
During the development process as I developed a prototype of the website I 
regularly undertook a ’NPT analysis’ of the developing website, using this theory 
in its potential ‘trial killer’ role [111], to ensure that even at these early stages 
we were developing something that should be implementable in the long term. 
Regarding the second phase: there is some guidance on strategies that involve 
end users during development phases, with think aloud studies being the single 
most recommended strategy [32, 116, 117].  Importantly two advisors to the 
project Prof Lucy Yardley and Dr McGee-Lennon had experience of using this 
technique and were able to provide direct guidance on the methods.  
Epistemologically this phase was aiming to corroborate our findings from earlier 
stages as users went through sample pages of the website providing their own 
personal viewpoint of its contents; however, I was also keen to encourage the 
participants to volunteer their own solutions to any issues or concerns they had 
with the content, or any gaps in its scope.  Again, the participants were co-
creating the findings with me as we worked through the prototype pages.  NPT 
was used here to inform the topic guide, and in particular the questions I asked 
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at the end of the think aloud study about how they would use the intervention in 
real life. 
 I chose to use an open source software called LifeGuide [118, 119] to develop 
this intervention.  Lifeguide was designed for researchers like me without a 
background in computer programming.  Using this software allowed me to 
directly develop and modify web pages without reliance on specialised 
programming support, which is costly and time consuming.  Capability for 
modifying a resource such as this during development is recommended by the 
MRC Framework [100], and a meta-review of factors which promote or inhibit 
implementation of e-health systems highlighted the importance of on-going 
evaluation and feedback for improving implementation potential [110]. 
3.5.4 Research question 4 
RQ 4 - What would be the feasibility of undertaking a randomised controlled 
trial of Living Well with Asthma, and how would such a website be used by 
adults with asthma.  What are the effect on symptom scores and quality of 
life measures?    
Randomisation is considered the ‘gold standard’ when evaluating a new 
intervention, however there was a choice to make when deciding whether this 
should feature in this project?  Should this be a single arm, feasibility study, 
where all enrolled get the intervention and the results work towards improving 
and refining both the intervention and trial processes?  Or should we aim to have 
a pilot study – the main trial run in miniature so to speak, in order to estimate 
recruitment retention and effect sizes.   As is clear from chapter 1 we decided 
to do both, a pilot study with feasibility outcomes, believing that we could 
achieve both. 
Given this research question centred on a RCT, quantitative measures were 
clearly going to take precedence.  As described earlier the RE-AIM Framework 
[113] was used to inform our evaluation methods, and it’s use is described fully 
in the methods section of Chapter 6.  This was particularly helpful in 
encouraging me to think beyond the obvious quantitative outcomes such as 
symptom scores to include relevant process outcomes such as web usage that 
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would contribute towards decisions about whether the intervention should be 
taken forward to full RCT in the future. 
In addition to RE-AIM framework to guide choice of outcome measures I also 
undertook a NPT analysis of the trial procedures to ensure the trial itself was 
feasible, and compatible with the environment we were undertaking it in.  Again 
full details are found in Chapter 6. 
3.6 Conclusion 
I have included this separate methodology chapter in order to fully describe the 
rationale behind my choice of research questions and subsequent methods, 
providing a more in depth understanding of the thought processes that went into 
some of the major decisions made within this project.  This illustrates the 
excellent learning experience afforded to me by undertaking this project, 
particularly given that I was primarily involved in these decisions, rather than 
undertaking project where the methods had been already confirmed. 
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Chapter 4:  Meta-review of Digital Asthma Self-
Management Interventions 
4.1 Introduction and aims 
This chapter details the methods, results and findings from a meta-review of 
quantitative, qualitative and narrative systematic reviews as well as meta-
syntheses or meta-ethnographies of articles describing digital self-management 
interventions.  A meta-review is a term used to describe a systematic review of 
systematic reviews.  Other terms used in the literature include overview, or 
umbrella review, however these terms can also be used to describe non-
systematic reviews (e.g. opinion pieces), therefore the term meta-review is used 
here for this chapter.  The aim of this meta-review was to establish what was 
already known in the literature about the effects of digital online tools for self-
management of asthma, and if possible, to establish what helps or hinders their 
utilisation by patients. 
4.1.1 Contributors 
I planned this review with the support of my PhD supervisory team.  I led all 
stages; however as is considered best practice, many of these stages required 
the assistance of a second person, such as for screening articles and quality 
appraisal.  This role was undertaken by a range of people and they are referred 
to in the methods sections by their initials.  Table 4.1 below lists those who 
contributed in alphabetical order. 
Table 4.1 Systematic review contributors 
Initials used Full name 
AMC Alex McConnachie 
AMM Alison M MacKenzie 
DM Deborah Morrison 
EC Euan J Cameron 
FM Frances S Mair 
KA Karolina Agur 
NCT Neil C Thomson 
RD Robert I Docking 
SW Sally Wyke 
VD Vandana Raghuvir 
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4.2 Methods 
4.2.1 Rationale 
As described fully in Chapter 3, meta-review was chosen as a methodology to 
allow me to quickly gain a snapshot of the literature to inform the subsequent 
phases of the PhD, in particular intervention development.  Undertaking 
systematic review of the literature prior to developing an intervention fits with 
the MRC Complex intervention development framework.  
4.2.2 Protocol development  
A copy of the final protocol for this meta-review can be found in appendix 4.  
Much discussion was needed to clarify inclusion and exclusion criteria, 
streamline data extraction and finalise the review protocol.  The process 
involved the development of multiple iterations of the protocol which were 
refined in discussions between the supervisory team and I, and then the final 
protocol was approved by all PhD supervisors.  As is considered good practice the 
intention was to register the protocol on PROSPERO which is an international 
prospective register of systematic reviews 
(http://www.crd.york.ac.uk/PROSPERO/).  Unfortunately, at the time the 
review was undertaken, they did not accept systematic reviews of systematic 
reviews.  Following advice from my external examiners I updated the protocol in 
January 2016 to remove the AMSTAR score as a criterion for inclusion.  This was 
to allow me to include all identified reviews, regardless of quality, and therefore 
provide a comment on their methodological quality. This was considered 
preferable as it would increase the number of reviews available to include in this 
metareview providing a broader picture of the literature to date.   
4.2.3 Inclusion & exclusion criteria 
We defined our inclusion and exclusion criteria using the PICOS framework 
(participants, interventions, comparators, outcomes, study design) as 
recommended by the Cochrane collaboration [120].  Table 4.2 describes the 
inclusion criteria. 
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Table 4.2 Inclusion Criteria 
Participants Those with asthma of any age, or their carers. 
Intervention Online or computerised interventions facilitating self-management through 
education and/or providing advice or other behavior change approach. We 
only included interventions which provided these features independent of any 
health professional input.  Interventions delivered by computer, tablet, 
smartphone, or purpose built electronic device were included.  
Comparison Usual care, or other forms of self-management interventions such as face to 
face education, or written information. 
Outcomes We examined any available evidence relating to the following primary 
outcomes: 
 Activity limitation (e.g. days off work/school/disturbed nights) 
 Adverse events 
 Barriers and facilitators to online asthma intervention use by patients and 
practitioners 
 Biomarkers of airway inflammation (e.g. exhaled nitric oxide) 
 Health service utilization (including scheduled/unscheduled, and 
primary/secondary care) 
 Lung function (e.g. spirometry & reversibility, peak expiratory flow (PEF)) 
 Medication use  (e.g. relief inhaled β agonist use, compliance with 
medication) 
 Quality of life 
 Symptoms (measures of asthma control, e.g. diary card scores, asthma 
control questionnaire, exacerbation rates) 
We also examined any available evidence relating to the following secondary 
outcomes:  
 Markers of self-management (e.g. adherence to monitoring tools, use of 
action plans, self-efficacy) 
 Patient knowledge  
 Patient satisfaction 
 Recruitment, retention rates 
 Cost effectiveness 
 Use of behavior change theory during intervention development and 
implementation processes 
Study 
design   
Systematic reviews describing interventions as outlined above (see below for 
full definition.  
 
For clarity, it was helpful to specify certain exclusions when considering the 
interventions, outcomes and study design as shown in Table 4.3. 
Table 4.3 Exclusion criteria 
Intervention Reviews featuring interventions which comprised only of telemonitoring or 
clinical decision support software for health professionals were excluded. 
Interventions which only provided a means of self-monitoring without providing 
feedback directly were excluded. For example electronic diaries for recording 
peak flows or symptoms, which did not provide automated feedback, were 
excluded.  The content of the intervention was required to be delivered at least 
in part by the digital medium itself. Devices which were simply digital modes of 
communicating between patients and health professionals were excluded.  
Outcomes Reviews which did not provide information specific to our outcomes of interest 
were excluded.  
Study 
Design 
See below 
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To define what we meant by a review we used the definition developed by Mair 
et al. [110] for use in their meta-review, outlined below.   
“We considered a review paper to be one that provides an analytic 
account of the research literature related to a specific topic or 
closely related set of topics.  It is intended to contribute to 
knowledge by answering a research question.  Thus, we include the 
following types of papers: 
1. Systematic reviews: where relevant literature has been identified 
by means of structured search of bibliographic and other databases; 
where transparent methodological criteria are used to exclude 
papers that do not meet an explicit methodological benchmark, and 
which presents rigorous conclusions about outcomes. 
2. Narrative reviews: where relevant literature has been purposively 
sampled from a field of research; where theoretical or topical 
criteria are used to include papers on the grounds of type, 
relevance, and perceived significance; with the aim of summarising, 
discussing, and critiquing conclusions. 
3. Qualitative meta-syntheses or meta-ethnographies: where 
relevant literature has been identified by means of a structured 
search of bibliographic and other databases, where transparent 
methods had been used to draw together theoretical products, with 
the aim of elaborating and extending theory. 
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We excluded the following: 
1. Secondary analyses (including qualitative meta-syntheses or meta-
ethnographies) of existing data-sets for the purposes of presenting 
cumulative outcomes from personal research programs. 
2. Secondary analyses (including qualitative meta-syntheses or meta-
ethnographies) of existing data-sets for the purposes of presenting 
integrative outcomes from different research programs. 
3. Discussions of literature included in contributions to theory 
building or critique. 
4. Summaries of literature for the purposes of information or 
commentary. 
5. Editorial discussions that argue the case for a field of research or 
a course of action. 
Where the abstract states it is a review, but there is no supporting 
evidence in the main paper, such as details of databases searched or 
criteria for selection of papers (either on methodological or 
theoretical grounds), the paper is excluded.” 
4.2.4 Information sources & search strategy 
4.2.4.1 Electronic Search Strategy 
A professional systematic review company (York Health Economic Consortium, 
YHEC), searched a wide range of databases covering health, mental health, 
education, and social science (14 in total), with no start date until July 2011.  
The search strategy was devised using a combination of subject indexing terms 
(e.g. MeSH in MEDLINE), and free text search terms in the title and abstract. The 
search terms were identified through discussion between the supervisory team, 
and by scanning background literature, and browsing database thesauri.  To 
ensure sensitivity the search strategy did not include a methodological search 
filter to limit to reviews. The searches were not limited by date range or 
language. 
The search strategy covered 3 broad areas: 
1. Asthma and related terms 
2. Online/computerised and related terms 
3. Self-care/self-management, patient experience, qualitative and related 
terms 
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Searching was undertaken in two phases.  The first was completed in July 2011.  
The second phase was in October 2013, due to a period of maternity leave.  This 
brought the electronic search up to date, with the specific addition of terms 
relating to mhealth, which had become more prominent in the interim. 
The full list of databases searched and an example of the full search strategy for 
MEDLINE is available in appendix 5. 
4.2.4.2 Supplementary search strategies 
We had agreed to use the term ‘respiratory’ alongside asthma and related 
terms, rather than ‘chronic disease’ in our electronic search strategy as a way of 
keeping the number of articles found at a manageable level. This meant there 
was the potential that a review including multiple disease areas may only index 
itself with terms such as chronic disease, which would not have been picked up 
by our search strategy.  As a way of trying to capture such reviews the journal 
Patient Education and Counseling was hand searched as it was not limited to 
respiratory articles. In addition, the Primary Care Respiratory Journal was also 
hand searched. This was chosen as it was considered to be a typical journal that 
might feature reviews such as we were targeting.  Experts in the field were also 
contacted to establish if any reviews had been missed.   
To further increase the chances of picking up articles not found by the initial 
electronic search strategy  the reference lists of included reviews were also 
hand searched, and the citations of included reviews also examined.   
Supplementary searching was not used in the second round of electronic 
searches in 2013, recognising the concerns that Cochrane Handbook discuss 
(section 10.2.2.3, citation bias) that “retrieving literature by scanning reference 
lists may thus produce a biased sample of studies” [121]. 
4.2.5 Study selection 
4.2.5.1 Software 
Distiller SR software was used for the article selection and data extraction 
(https://systematic-review.ca). This is a web based platform which allows 
multiple users to screen simultaneously.  It can also be used to allocate articles 
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to specific users. Therefore, study selection processes could be set up so that I 
always had to be one of the reviewers for each individual article, and the second 
review could be done by any of the other contributors.  
4.2.5.2 Article screening 
Screening was undertaken by myself, plus one other independent researcher (EC, 
SW, FM, NCT, KA, RD, AM or VR), with close reference to the protocol.  This was 
done at three individual levels – title, then abstract, then full paper.  The 
process is illustrated in Table 4.4 below. 
Table 4.4 Article screening procedure 
Screening 
level 
How many reviewers 
need to ‘include’ to 
proceed to next level 
Process for managing conflicted reviews 
Title 1 Automatically put through to abstract screening 
Abstract 2 
Discussed between initial reviewers, if conflict 
remains put through to full paper screening. 
Full paper 2 
Discussed between initial reviewers and if 
conflict remained, discussed with third party. 
 
 
4.2.5.3 Quality appraisal 
Given this was a review of reviews, and was an additional step away from the 
original data it was felt to be important to be able to comment on the quality of 
the included reviews, especially given the evidence that poor quality research 
may appear to inflate effect sizes [122, 123]. Lack of quality assessment of 
included reviews was a significant area of concern in a review paper describing 
this comparatively new method [124].  
Quality appraisal was undertaken in two ways.  First, at the full paper screening 
stage, papers were required to meet criteria laid out in our definition of a 
review.  For example, evidence of a systematic search or criteria for selection of 
papers must be included (see section 4.2.3 earlier for the full definition). 
Following this, all papers that were included at the full paper screening level 
then underwent formal quality appraisal using A Measurement Tool to Assess 
Systematic Reviews (AMSTAR) [125-127].  This 11 point checklist covers 7 key 
domains as listed in Table 4.5 below, and is available in full in appendix 6.  
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Scoring systematic reviews using guides such as AMSTAR has been recommended 
in the literature [128].  An AMSTAR score was assessed for each included review 
by me, and independently by a second reviewer (KA).  Conflicts were to be 
discussed between reviewers initially and then with a third party (FM) if 
agreement could not be reached.  AMSTAR score was used to assist in appraising 
the quality of the included reviews, and to inform the discussion.  Articles were 
not excluded on the basis of their AMSTAR score.  
Table 4.5 AMSTAR domains 
 Establishing the research question and inclusion criteria before the conduct of the review 
 Data extraction by at least two independent data extractors 
 Comprehensive literature review with searching of at least two databases 
 Detailed list of included/excluded studies 
 Quality assessment of included studies and consideration of quality assessments in 
analysis and conclusions 
 Appropriate assessment of homogeneity 
 Assessment of publication bias and a statement of any conflict of interest 
 
4.2.6 Data collection 
For each included review we collected: 
1. General information about the review (year, aim, number of studies, search 
strategy information, outcomes, strengths and limitations). 
2. Results for each outcome of interest (including quotes from 
qualitative/narrative reviews). 
 
4.2.7 Data synthesis 
Any quantitative data relating to outcomes of interest were extracted and 
reported either as a meta-analyses if the data allowed or more likely as a 
narrative summary if the data were too heterogeneous. Where qualitative data 
was extracted meta-synthesis would be undertaken. 
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4.3 Results 
4.3.1 Article searching & screening 
4.3.1.1 Search results 
Results refer to articles found from both searches combined. 
Electronic and supplementary searching found 6983 articles: following removal 
of duplicates this left 3810 individual articles to screen.   
The full report from YHEC detailing search terms and results per databases can 
be found in appendix 5.  
The flow of articles is illustrated in Figure 4.1 
Figure 4.1 Flow of articles 
 
 
 
4.3.1.2 Reasons for exclusion 
There were three main reasons for articles being excluded.  Firstly on 
examination of the full paper it was clear that many included studies featured 
participants with diseases other than asthma.  Secondly, on close examination it 
was evident that reviews included studies involving interventions that did not 
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meet our criteria of being an interactive digital intervention that could function 
at least in part without input from health professionals.  It had not been 
anticipated that such a large number of reviews would fail to meet this inclusion 
criteria.  The main reason for this was the dominance of studies involving tele-
monitoring interventions, which did not provide feedback without input from a 
health professional.  The final and most common reason for exclusion was that 
the article did not meet our definition of a review.  The majority of the reviews 
excluded for this reason were articles that called themselves a review, but on 
close reading did not fulfil our definition of a review, as described in the 
preceding section.  The following extract from our aforementioned definition of 
a review led to many articles being excluded: 
“Where the abstract states it is a review, but there is no supporting 
evidence in the main paper, such as details of databases searched or 
criteria for selection of papers (either on methodological or theoretical 
grounds), the paper is excluded.” 
This was particularly true of those papers using qualitative methodology, and 
was the main reason why this review had fewer articles than anticipated. 
4.3.2 Description of included review 
This section describes the 1 review which met our full paper screening criteria, 
summarised in Table 4.6 below [129].  The article contained 9 RCTs, only two of 
which were aimed at adults.  Bussey-Smith summarised follow up as ranging 
from 4 to 12 months, but then commented on several studies with a 12 week 
follow up which is confusing for the reader.  Dropout rates were summarised by 
Bussey-Smith [129] as ranging from 0% to 31%.   
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Table 4.6 Summary table of scope of review & quality assessment  
Review 
Year  Aim (participants) 
No. of 
studies 
included 
Search   
strategy Outcomes 
AMSTAR 
score 
Bussey-
Smith & 
Rossen  
2007 
[129]  
To evaluate the 
effectiveness of 
published interactive 
computerised asthma 
patient education 
programs that thave 
been subjected to 
randomised 
controlled trials in 
adults and children 
with asthma 
9 Multiple 
electronic 
databases 
Search terms 
provided 
RCT filter used 
English 
language 
restriction 
Primary: 
Hospitalisation 
Acute care visits 
Rescue inhaler use 
Lung function 
Secondary: 
Knowledge 
Symptoms 
27% 
 
 
4.3.2.1 Quality appraisal 
The AMSTAR score of the one included review [129] was 27%, and the full details 
underpinning the AMSTAR score are shown in Table 4.7.  The article received 3 
points (comprehensive literature search, characteristics of included studies, and 
methods to combine appropriate). Table 4.7 shows that the main areas where 
points were lost were around absence of a review protocol, restriction of search 
terms by use of language and study type filters and the absence of any 
assessment of quality of their included articles.  While they were clear there was 
duplicate data extraction, it was not clear whether this was the case for 
screening.   AMSTAR requires publication bias be assessed or at least some 
comment about why it was not, and this was also missing from this review.  
Although the authors of the review provided information about their own 
conflicts of interest, they did not do so about their included studies and 
therefore they did not receive a point for question 11.  Importantly the review 
makes no mention of the quality of the included studies, either in the 
description of the included studies or in the discussion.  
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Table 4.7 AMSTAR results of included review 
 Question Answer 
1 Was an “a priori” design provided? No 
2 Was there duplicate study selection and data extraction? Can’t answer 
3 Was a comprehensive literature search performed? Yes 
4 Did the authors state that they searched for reports regardless of their 
publication type?   Was the status of publication (i.e. grey literature) 
used as an inclusion criterion?  
No 
5 Was a list of studies (included and excluded) provided? No 
6 Were the characteristics of the included studies provided? Yes 
7 Was the scientific quality of the included studies assessed and 
documented? 
No 
8 Was the scientific quality of the included studies used appropriately in 
formulating conclusions? 
No 
9 Were the methods used to combine the findings of studies 
appropriate? 
Yes 
10 Was the likelihood of publication bias assessed? No 
11 Was the conflict of interest included? No 
 
 
4.3.2.2 Descriptions of participants & interventions 
The featured review [129] included two RCTs aimed at adults and 7 RCTs aimed 
at children.  The 9 RCTs included evaluated a total of 957 patients (471 control, 
486 intervention), aged between 3 and 75 year of age. Dropout rates ranges 
from 0% to 31.7%.  Study lengths ranged from 4 to 12 months.  Included 
interventions were heterogeneous, with some to be used daily and others only as 
a one off, and some included the use of games/vignettes or provided self-
monitoring tools.  
4.3.2.3 Results for outcomes 
As there was only one study meeting inclusion criteria [129] I will provide a 
summary of their results which are available for my outcomes of interest: 
symptoms, health service use, lung function, medication use and patient 
knowledge. 
Primary outcomes 
Bussey-Smith et al found evidence of improvement in symptoms.  Hospitalisation 
rates and acute care visits were reported, but there was no clear picture about 
effectiveness on either outcome with the majority of studies reporting no 
significant difference.  This was also true of lung function and medication use 
where the majority of studies reported no difference. 
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There were no results available for the remaining primary outcomes of interest: 
 Activity limitation (e.g. days off work/school/disturbed nights) 
 Adverse events 
 Barriers and facilitators to online asthma intervention use by patients and 
practitioners 
 Biomarkers of airway inflammation (e.g. exhaled nitric oxide) 
 Quality of life 
Secondary outcomes 
Knowledge was a frequently measured outcome, and the majority of studies 
showed an improvement.  There was a suggestion that time spent interacting 
with the digital intervention may be correlated with the improvement in 
knowledge, but not with any improvements in clinical outcomes, and they could 
draw no further conclusion about the type of delivery or content that appeared 
to be most successful.  
There were no results available for the remaining secondary outcomes of 
interest: 
 Markers of self-management (e.g. adherence to monitoring tools, use of 
action plans, self-efficacy) 
 Patient satisfaction 
 Cost effectiveness 
 Use of behavior change theory during intervention development and 
implementation processes  
 
Importantly this study commented on the improvements seen in many control 
groups, suggesting that this may be diluting any potential benefit, particularly as 
many control groups were not receiving merely usual care but rather an 
enhanced form of alternative care.   
Overall, this systematic review concludes that interactive digital devices appear 
to improve knowledge and perceived symptoms, but that there is less evidence 
for improvement of objective clinical outcomes such as lung function, health 
care contacts or medication use.  Importantly, the authors emphasize that the 
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published literature to date does not provide us with adequate detail to allow 
conclusions to be drawn regarding  what features may be more likely to result in 
improved outcomes.  Although not specifically reported as an outcome there was 
no evidence of harms to participants from being intervention groups, compared 
to control groups.  
4.4 Discussion 
4.4.1 Summary of findings 
The search for this meta-review identified 3810 individual articles to screen, 
which following application of pre-defined inclusion and exclusion criteria led to 
only one systematic review being included.  This was disappointing.  There were 
three main reasons for the high exclusion rate: 1) firstly many reviews were a 
mix of asthma/non asthma studies, 2) many reviews included interventions not 
meeting our definition of a digital interventions, and 3) a higher number than 
expected did not meet our definition of a review, mainly in relation to 
suboptimal methods, or recording of methods.  
The one article included featured nine RCTs aimed at adults or children and 
concluded that interactive resources appeared to improve symptoms and 
knowledge, with less evidence of benefit for clinical outcomes such as lung 
function, health care contacts or medication use.  One important finding from 
this review is to highlight the importance of an appropriate control group during 
such evaluations.  In particular, they noted that many control groups were 
receiving care superior to that provided in routine asthma care, possibly diluting 
any benefit attributable to the intervention under evaluation.  This study was 
unable to draw any firm conclusions about what type of delivery or content 
appeared to be most successful at improving outcomes, other than a possible 
correlation between time spent interacting with the resource and improved 
knowledge. 
The lack of economic data was disappointing, although the results on health care 
resource use (hospitalizations and ED visits) suggests that evidence of cost-
effectiveness may be lacking.  However without data including routine health 
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care resource utilization, and formal economic analysis, no firm conclusions can 
be drawn.  So this is clearly an outstanding gap in the published literature. 
The authors of the study did not provide any quality appraisal of their included 
studies which is a weakness.  My own quality appraisal of this review used the 
AMSTAR score and the review scored 3 out of 11 points.  Other limitations of the 
included review relate to lack of clarity about attrition rates and length of 
follow up, and the fact that they did not acknowledge any limitations 
themselves in their discussion, which in turn limits the conclusions which can be 
drawn from this meta-review. 
4.4.2 Methodological issues with meta-reviews 
Due to the growing number of meta-reviews being published there is increasing 
interest in the methodology being employed [124, 128, 130].   
Smith et al in their methodology paper published in 2011 aimed to provide a 
guide to clinicians and researchers who wish to conduct systematic reviews of 
systematic reviews, and share their experiences [128].  This useful article 
discusses challenges that may be encountered at five different stages when 
conducting this type of review: 1) sources, 2) study selection 3) quality 
assessment, 4) presentation of results, 5) implications for practice and research.  
I will discuss the strengths and weaknesses of this meta-review using these 
headings, and reflect generally on methodological concerns at each stage 
individually.   
4.4.2.1 Sources 
The methodological challenges of undertaking a systematic review of reviews are 
similar to a systematic review of the primary literature.  A team (YHEC) with 
excellent experience of undertaking systematic reviews, using multiple 
databases, and using a strategy designed iteratively with researchers to be as 
inclusive as possible, without being unwieldy, undertook the search.  Therefore 
the comprehensive nature of the search strategy is one strength of this review.  
Studies published in languages other than English (LOE) were included, which is 
also considered a strength of this review, and is recommended by the Cochrane 
Collaboration (section 6.4.9 [131]).  However, even they acknowledge that there 
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is increasing debate about how essential including reviews in LOE actually is, and 
suggest that it may be more of an issue historically, describing the marked 
decline in publications in LOE since 2006.  A more recent meta-analysis [132] has 
investigated this question specifically and concluded from their review that 
there was no evidence of systematic bias from the use of a language restriction.  
However, this review only focussed on meta-analysis and they did note that their 
findings may not be generalizable to all fields of medicine.  In particular, they 
reported that studies published in Chinese are important in certain research 
areas such as molecular medicine, and that LOE may be more important when 
reviewing studies focussing on psychiatry, orthopaedics and rheumatology.  In 
addition they also commented there is conflicting information regarding whether 
there is a link between publication language and methodological quality, with 
some studies finding those published in LOE to be lower quality.  This resonates 
with the experience from this review where four full papers were translated into 
English for assessment, and three articles, two in German and one in Chinese, 
did not meet our definition of a review due to poor methodology (e.g. no 
evidence of systematic search etc.).  The final LOE paper was in Portuguese and 
this included interventions targeting other disease areas in addition to asthma.  
Given the considerable workload implications and cost of including papers in 
LOE, it does seem on balance that using a language restriction may be 
acceptable, depending on the area of research. 
Despite the comprehensive nature of the search it is possible the search may 
have missed reviews of chronic illness interventions including asthma but not 
specifically indexed with asthma or respiratory terms.  The decision to include 
only those papers linked to respiratory terms was essential to ensure the search 
was not unwieldy, and remained manageable and our supplementary searching 
attempted to counter any potential disadvantages from taking this approach.  
4.4.2.2 Study selection 
Smith et al advise not to underestimate the importance of the planning stage, 
and in particular formulating the scope of the review with particular care over 
inclusion and exclusion criteria, and experience from this meta-review  
reinforces this message [128].  The rationale for undertaking a meta-review is to 
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create a summary of reviews in a single paper, thereby providing an overview of 
the published research in a given area and enable key gaps in knowledge to be 
identified.  The low number of included papers in this review somewhat limits 
the learning possible from this meta-review, and the inclusion/exclusion criteria 
used in this meta-review using the PICOS format, are discussed below, along 
with reflections on what could have been done differently to enhance learning 
from the literature. 
Participants 
We included studies where participants of any age had asthma.  Asthma is a 
common condition, and although some articles were excluded due to combining 
asthma with non-asthma participants it can be argued that this was a reasonable 
choice for this review. This is because asthma has its own specific issues less 
relevant to other disease areas, such as the potential ambiguity around 
diagnosis, underestimation of symptoms and treatment options which includes 
inhalers rather than tablets. 
Interventions 
The inclusion/exclusion criteria regarding the intervention type were very 
specific, for example the active exclusion of tele-monitoring interventions.  The 
Cochrane handbook provides a table outlining typical objectives for undertaking 
meta-reviews, and in summary, they suggest that the rationale is usually either: 
1) combining evidence for different interventions for the same condition; 2) 
where different outcomes are addressed in different reviews or; 3) similar 
interventions in different disease areas (page 611) [131].  As An de Sutter 
highlights in her editorial on this topic ‘the key word is different’, and that 
simply combining reviews on the same intervention for the same condition, may 
provide an overview of the topic, but adds little over a well conducted primary 
review of the literature [133].  It might have been useful to have included tele-
monitoring interventions and this would have allowed us to compare and 
contrast the evidence for different types of interventions.  We could have gone a 
step further to include digital and non-digital interventions and this may have 
provided useful insights into the potential added benefits of digital delivery of 
contents.  The Cochrane Public Health Group consider having a broad research 
question a specific feature of this type of methodology, and allows for 
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generalisability [134] and while our research question was indeed broad, our 
inclusion/exclusion criteria did not reflect this.  In hindsight if we wanted 
information about such a specific type of intervention a primary review of such 
interventions might have been more appropriate.  However, we were eager to 
get a very broad overview of the subject including both qualitative and 
quantitative reviews and this would not have been feasible with a primary 
review within the context of this PhD, which has so many other components, 
hence the rationale for undertaking a meta-review.   
Comparison Group 
For this review, we did not have restrictions on what if any intervention the 
comparison group had, and on reflection, this still seems the correct approach 
for this meta-review.  
Outcomes 
This is an area where the available guidance could be interpreted as being 
conflicting.  Smith et al [128] recommends having one primary outcome and 
focussing on this, suggesting that it allows the researcher to manage the 
workload by limiting data extraction to only those results relevant to the topic 
of interest from all the reviews that report on various different outcomes.  This 
may be true in certain areas where there is a more limited range of potential 
outcomes.  The example used in Smith et al’s meta-review methodology paper 
cited throughout this chapter is for interventions to reduce pre-term labour, 
where the potential ways of measuring success are arguably fewer than for 
asthma [128].  The vast range of asthma outcomes used across clinical trials has 
long been recognised as a barrier to successful synthesis of asthma literature, 
and as a result a workshop was convened in 2012 in order to provide guidance to 
researchers to try and streamline the outcomes used, and they found 7 distinct 
clinical research domains applicable to asthma, with several outcomes in each 
domain [135].  Therefore choosing to focus on one asthma outcome would likely 
miss important relevant information.  In contrast to Smith et al’s 
recommendation, Cochrane specifically suggest that one rationale for 
undertaking an overview is to synthesise reviews where different outcomes are 
used for similar interventions – and this was what we aimed to do here.  We 
elected to include a range of outcomes in order to be as inclusive as possible and 
Chapter 4 Metareview  98 
that was right for this review, and narrowing down to a single primary outcome 
would not be appropriate for asthma. 
Study type 
When finalising the inclusion/exclusion criteria regarding study type, the 
definition of a systematic review was based on a previous meta-review 
undertaken by one of my supervisors [110].  Although this definition was very 
specific, it can be argued to be fair and necessary.  When undertaking a review 
of reviews the data is an extra step away from the original research, and in 
order to be able to understand and critically appraise findings appropriately the 
reviews need to provide a minimum amount of methodological information in 
order to do this.  Our definition for a systematic review aimed to ensure that 
included articles would be more likely to have this type of methodological 
information. The specific issues of quality assessment of included reviews will be 
addressed later in this chapter. 
Summary 
In summary, reflecting on the inclusion and exclusion criteria there were two 
potential alternative approaches that could have been adopted which might 
have achieved the original aims of this review more successfully.  The first 
would have been to undertake a systematic review of the primary literature, or 
secondly to have applied less specific  inclusion and  exclusion criteria, in 
particular in this case there may have been a value in broadening the 
intervention type in order to provide an evidence based discussion on the merits 
of different types of interventions. 
4.4.2.3 Quality assessment 
Smith et al provide some guidance about undertaking quality appraisal, and 
based on their recommendation the AMSTAR score was used here [128].   
Along with the Smith et al methods paper above, there is further guidance on 
methods for quality appraisal within the Cochrane handbook, where they advise 
that two different quality assessments are required; first the methodological 
quality of the reviews within the overview, and secondly a description of the 
quality of the evidence in these included reviews (Chapter 22, page 620) [131].  
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Using quality appraisal tools such as AMSTAR has been suggested as a way of 
systematically evaluating the methodological quality of a systematic review, 
with the potential to provide a cut off for eligibility for inclusion based on the 
score [128].  It has successfully been used in this way in a recent comprehensive 
overview of systematic reviews exploring asthma and dietary intake [136].  
While Cochrane recommend the two different levels of quality appraisal are 
undertaken they do not go as far as to advise inclusion or exclusion based on 
quality appraisal, but rather using the assessment in formulating conclusions 
about the strength of evidence underpinning any findings.  By their nature, 
Cochrane meta-reviews generally only include Cochrane systematic reviews, and 
therefore the information about quality of included primary studies is available.  
When undertaking a non-Cochrane meta-review many of the included reviews do 
not describe the quality of their included primary studies, as happened here, 
and it is how best to manage this situation that remains uncertain. The use of 
AMSTAR at least allows the lack of information about quality of included studies 
to be highlighted systematically, whether or not it is used as an inclusion 
criterion in its own right. 
When we were planning this review originally in 2011, AMSTAR was a relatively 
new scoring system.  Subsequent to our use of this scoring system it has been 
used by other research teams who have requested that the authors of AMSTAR 
‘produces additional guidance for its’ application in order to improve its 
reliability and usefulness’ [137], a sentiment that seems worthy of support.  
They do now have a website (http://amstar.ca accessed 27/04/2016) which 
provides further guidance notes on their individual questions, and also states 
that they are in the process of developing an instrument called AMSTAR_NRS for 
assessing systematic reviews of non-randomised studies, which would be a 
welcome addition to the existing appraisal tools. 
We investigated using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) as a different way of evaluating the quality of the 
systematic reviews [138]: the quality of the reporting within it, rather than the 
quality of the methodology.  However, this was not easily used to provide an 
overall score, and was not readily adaptable to include the non- quantitative 
reviews. 
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Undertaking formal quality appraisal is a strength of this review, particularly 
given reports that it is frequently omitted [128].  Research by Pieper at al 
quantifies the scale of this problem, where they aimed to describe the 
methodological characteristics of published overviews of systematic reviews in 
their own systematic review published in 2012 [124].  They described 126 
overviews and worryingly found that 1/3 did not provide any systematic quality 
appraisal of their included systematic reviews.  Harling et al undertook a similar 
review also published in 2012, where they also aimed to describe the 
methodological approaches in overviews of interventions [130].  They reported 
that quality assessment was performed in 75% of the included overviews, and at 
least 9 different tools were used.  Quality of the body of evidence was only 
undertaken in 17% of overviews.  They conclude, along with Pieper et al, that 
there is a need for methodological rigour and consistency in overviews, along 
with reporting guidelines to improve the quality of this type of publication, a 
conclusion supported here [124, 130].  
4.4.2.4 Presentation of results 
Smith et al recommend that when presenting results from meta-reviews they 
should provide the major conclusions of the review (e.g. answer to the research 
question) as well as the evidence base for their conclusion, along with an 
assessment of the quality of the evidence for each conclusion [128].  This relies 
on included reviews providing an assessment of the quality of the body of 
evidence, and the absence of this is a major potential weakness for this method, 
and the absence of it in this review limits the conclusions that can be drawn.  
4.4.2.5 Implications for practice and research   
Smith et al highlight that an important role for this method is to help clinicians 
and policymakers to address the issue of understanding discordant reviews, and 
this is highlighted as an important role for this method elsewhere in the 
literature [124].  Exploration and understanding of the reasons for discordance 
between already published reviews can help clinicians and policy makers base 
decisions on the evidence most suitable to their own situation and can be 
considered a major strength of this method [124]. Unsurprisingly, Smith et al 
reiterate the importance of quality appraisal when aiming to provide useful 
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summaries that can inform clinical practice stating: “the strength of the 
conclusions and the ability to provide decision-makers with reliable information 
depends on the inclusion of reviews that meet a minimum standard of quality” 
(page 3) [128].    
4.4.3 Comparison with the literature 
Concern about methodological rigor is not limited to the newer method of meta-
reviews.  The article included here performed poorly on AMSTAR scoring, and 
the quality of reviews of reviews can only be as good as the included reviews.  
The meta-review presented in this thesis shows this is still problematic.  
With regard to outcomes, Bussey-Smith el al [129] findings are comparable with 
other reviews in this area.  The Cochrane systematic review by McLean et al in 
2010, focussing on tele-healthcare in asthma, reported mixed findings but 
overall concluded there was no evidence of benefit in clinical outcomes [84].  
However, they did suggest that there was possibly more of a role for those 
suffering more severe disease.  One could speculate that the daily work involved 
with most tele-monitoring interventions is only considered worthwhile by those 
with more severe disease with ‘more to gain’.  The same team considered tele-
healthcare in chronic diseases including asthma [139] and found mixed results 
again, but importantly highlighted the importance of contextual factors such as 
the ability of the patients to interface with technology, an area of discussion 
missing from Bussey-Smith’s review.  Importantly, there was no information 
about development of interventions and whether there had been any user 
testing involved, which is increasingly seen as an integral part of good quality 
intervention development [100]. 
The included study in this review (Bussey – Smith et al) did not address the issue 
of adverse events when using digital interventions to support self-management, 
and a recent systematic review published in 2014 reports the lack of systematic 
reviews addressing adverse events is a key gap in the literature [8].  Those few 
reviews which have addressed adverse events suggest that while there is no 
evidence of control groups having better clinical outcomes, a higher rate of 
dysphonia or oral candidiasis in intervention groups has been noted in effective 
interventions [84, 140].  This side-effect is related to higher doses of, or better 
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adherence to, inhaled corticosteroids, which itself is a positive outcome.  
Surprisingly, the issue of patient satisfaction also appears neglected in published 
literature.  Morrison et al [8] only found one systematic review reporting patient 
satisfaction [84], where they reported participants preferred a web-based 
system to a paper based one. 
Descriptions of intervention development and particularly the use of theory has 
been shown to increase effectiveness of behaviour change interventions [141] 
and the importance of reporting this information about development processes 
(e.g. the degree of user testing, and the use of theory to inform content) has 
been further highlighted by the publication of a CONSORT EHEALTH statement 
which includes it [16].  Bussey-Smith et al made no mention of theory during 
development of the included interventions, and made no attempt to collect or 
report that data [129]. Given that Bussey Smith et al was published in 2007 
[129], it could be speculated that it was not until the MRC Framework was 
updated in 2008 [100] that the importance of reporting this aspect of 
development gained further prominence.  There is encouraging evidence that 
more recent studies are more likely to provide this extended information, 
facilitated by the increasing availability of online appendices and less stringent 
word counts in journals [8]. Another reason for increasing emphasis on using 
theory during development is the increasingly widespread uptake of the 
behaviour change taxonomy [107], described in more detail in Chapter 3.  This 
taxonomy brings behaviour change theory to a wider audience than it previously 
experienced.  
What appears consistent across several systematic reviews on digital support for 
self-management of chronic illness in general is that interventions with multiple 
behaviour change techniques appear, on the whole, to be more effective than 
those using fewer, and that the use of theory to inform the choice and 
combination of BCTs appears to be associated with increasing effectiveness of 
the interventions [14, 141, 142].  The meta-review presented in this thesis was 
unable to provide any results on this topic.  
Dropout rates were summarised by Bussey-Smith [129] as ranging from 0% to 
31%.  This is in keeping with other systematic reviews of digital interventions in 
other areas, for example a recent Cochrane review examining computer based 
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weight loss interventions found attrition rates ranging from 2-25% (median 16%) 
[143],and attrition may be worse in interventions targeting older age groups, 
with one review including digital and non-digital interventions noting rates 
between 0 and 52% (median 15%) [142].  Reassuringly attrition rates are no 
worse than those found with non-digital self-management asthma interventions 
as described in Gibson’s Cochrane review examining  asthma self-management 
education and regular health professional review, where attrition rates ranged 
from 0% to 54% (median 15%) [6].   
Only one of the included studies had a follow up period of more than 12 months 
(Bartholomew went up to 15.6 months although the mean was 7.6).  Therefore, 
it is difficult to draw conclusions about sustained benefits in knowledge and 
symptom scores.  Since Bussey Smith published their review in 2007 [129] several 
other digital interventions have been trialled.  These are described in detail in 
Chapter 7, but one worth mentioning here is the van der Meer study of a digital 
intervention to support self-management as is it is the only one to date to 
provide additional follow up results [94].  They have now published data looking 
at participants 1.5 years after losing access to the intervention.  Encouragingly 
this has shown sustained benefits in the intervention group in asthma control 
questionnaire and asthma quality of life scores, providing hope that there is 
scope for a sustained benefit with such digital interventions [144].  
4.4.4 Answering the research question 
This review provides some evidence about the effectiveness of digital 
interventions, but little data about what helped or hinders their uptake with 
participants.  In order to understand how the literature could help inform the 
content of the intervention being developed within this thesis it was necessary 
to undertake a subsequent literature review focussing on barriers to adherence, 
a background search of the literature for advice about what were considered to 
be essential features of any asthma self-management intervention (Chapter 2), 
and a literature review of primary studies featuring interactive interventions 
aimed at adults with asthma (reported  in Chapter 7), to allow comparison with 
that subsequently developed and evaluated here as described in chapters 5 and 
6. 
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4.4.5 Conclusion 
This meta-review found only one poor quality systematic review featuring digital 
interventions to support self-management of asthma.  When using systematic 
review of systematic review methods careful consideration is required to ensure 
inclusion and exclusion criteria are broad enough to provide articles meeting 
inclusion criteria.  Alternatively, if maintaining the narrow scope is important 
then a review of the primary literature may be more appropriate.  The main 
conclusion from this meta-review was that further robust investigation is needed 
firstly in the form of a detailed primary systematic review of published digital 
interventions aimed at those with asthma, ideally detailing the presence or 
absence of BCTs.  Such a review has subsequently been undertaken in my 
department and is currently in press as of April 2016 [145]. To a large extent this 
also demonstrates that further more robust investigation is merited.  Secondly, 
examination of the primary qualitative literature to describe what is already 
known about the patient’s perspective would be invaluable to inform future 
interventions, and I am aware that Prof Lucy Yardley’s team in Southampton are 
currently undertaking a systematic review of barriers to uptake and use of self-
management interventions in asthma – the findings of which will be very 
relevant to this PhD.   
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Chapter 5: Development of the Living Well with 
Asthma Website 
5.1 Introduction & aims 
This chapter details the methods, results, and discussion from the second stage 
of my PhD project: developing the “Living Well with Asthma” website.  The 
overall aim of this stage is to describe the collaborative development of an 
online asthma self-management intervention, produced iteratively using 
feedback from potential end users, resulting in an intervention ready to be 
evaluated by patients within a pilot RCT, the methods and results of which are 
presented in the following chapter.  
5.1.1 Contributors: The expert panel 
I recognised at the earliest planning stages of this project that I needed input 
from researchers with specific experience of developing digital interventions.  
With my PhD supervisors, I convened an ‘expert panel’ who would provide advice 
during this stage.  The expert panel are listed in Table 5.1. 
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Table 5.1 Living Well with Asthma expert panel 
Name Affiliation Expertise 
Prof Frances 
Mair 
Professor of Primary Care 
Research 
University of Glasgow 
PhD Supervisor. Expertise in evaluating and 
implementing complex interventions. Expert 
in implementation theory. 
Prof Sally 
Wyke 
Interdisciplinary Professor of 
Health and Wellbeing 
University of Glasgow 
PhD Supervisor. Expertise in behaviour 
change, self-management intervention 
development and evaluation. 
Prof Neil C 
Thomson 
Professor of Respiratory 
Medicine 
University of Glasgow 
PhD Supervisor. Expertise in asthma 
management and clinical trials. 
Dr Marilyn 
McGee-Lennon 
Senior Lecturer in Computing 
and Information Sciences 
University of Strathclyde 
Expertise in Human-Computer Interactions, 
and digital intervention development and 
testing. 
Prof Lucy 
Yardley 
Professor of Health 
Psychology 
University of Southampton 
Expertise in behaviour change theory, and 
developing and evaluating behaviour change 
interventions. Co-developer of LifeGuide 
software (used in this project). 
Prof Mike 
Thomas 
Professor of Primary Care 
Research 
University of Southampton 
Expertise in asthma self-management, and 
evaluating interventions.  Medical director 
with Asthma UK. 
Dr Deborah 
Morrison 
Clinical Academic Fellow 
University of Glasgow 
PHD student. General Practitioner with 
interest in asthma and self-management. 
 
 
5.2 Methods 
5.2.1 Rationale for methods used 
Much of this has already been discussed in chapter 3, which makes it clear how 
central the MRC guidance on the development and evaluation of complex 
interventions was to this projects methodology [100].  In particular, the 
following statement from this guidance was integral to my plans for how this 
phase would progress: 
“Developing, piloting, evaluating, reporting and implementing a complex 
intervention can be a lengthy process.  All of the stages are important, and 
too strong a focus on the main evaluation, to the neglect of adequate 
development and piloting work, or proper consideration of the practical 
issues of implementation, will result in weaker interventions, that are 
harder to evaluate, less likely to be implemented and less likely to be worth 
implementing.”  Pg 4. 
As shown previously in Chapter 3, the illustration of the process is shown again 
in Figure 5.1, which shows the key stages recommended when developing a 
complex intervention, with the ‘Development’ element circled below 
particularly relevant to this chapter. 
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Figure 5.1 Key elements of the development and evaluation process.  
(Reproduced from Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council G: 
Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008, 
337:a1655. With permission from BMJ Publishing Group Ltd.) 
 
What is not clear from Figure 5.1 is the importance the MRC guidance places on 
user involvement during planning and development of complex interventions.  In 
response to this guidance, and advice from the expert panel, I undertook focus 
group discussions and think aloud studies as methods of co-designing the 
intervention with potential end users, as explained earlier in chapter 3.  Think 
aloud studies involve asking users to vocalise their reactions and thinking 
processes in real-time while using the online resource (or preceding prototype 
materials) [32, 146, 147] and are considered an essential step when developing 
any type of website [116]. These think aloud studies are described in full in the 
relevant sections below. 
As seen from the quote from the MRC guidance the consideration of 
implementation issues is advised at the earliest of stages.  In order to fulfil this 
requirement I chose to use Normalisation Process Theory (NPT), as I have used 
this in other projects previously [45, 46, 148], and as described in Chapter 3 it 
can be valuable even at the earliest stages of complex intervention design [101, 
111].  NPT is increasingly seen as a means to understand implementation 
processes and enhance the implementability of interventions [109, 111].  So, 
while it did not directly influence the specific contents of the website, it was 
used to guide our co-design methods, consider long-term implementation issues 
of the intervention itself, and also as described in the next chapter to analyze 
our trial procedures to ensure the evaluation itself was feasible.  
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5.2.1.1  Choice of software 
I used LifeGuide software to develop this intervention.  Traditionally, 
development of online behaviour change interventions would be very resource 
intensive with each intervention requiring to be programmed individually by a 
team of programmers from scratch.  The cost involved in this would have 
rendered this project, and many like it, unworkable.  A team based at 
Southampton University recognised this barrier to developing digital 
interventions and in response have developed an open access software package 
called LifeGuide, funded by the Economic and Social Research Council [118, 
119].  LifeGuide allows researchers with no computer programming experience, 
like myself, to easily and flexibly create internet-delivered interventions.  It has 
been used successfully in a number of health related interventions [42, 119, 149, 
150].  
The LifeGuide software consists of 3 parts[151]: 
1) an authoring tool which is used to create the pages of an intervention, 
such as text, videos, images and questionnaires. 
2) The logic which is a written set of commands that works behind the 
scenes of an intervention to make it run as expected.  
3) an intervention manager, which is a server to run the intervention. This 
allows the information that users enter into the website to be stored 
securely, then downloaded for analysis as required. It also tracks 
participant usage of an intervention, page by page. 
A key design feature of LifeGuide is that researchers can easily test parts of an 
intervention and immediately modify and improve it based on the findings.  This 
makes user testing during the development phase easier and efficient, a feature 
which should, as reported by the MRC guidance, increase the likelihood that an 
intervention can, and should be implemented in the longer term [100].  
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5.2.2 Methods overview 
In chapter 3, I outlined the rationale for the choices of the methods used. This 
section describes what I actually did.  Here, I describe the two phases of work I 
undertook to incorporate the processes recommended by the MRC.  As Figure 5.2 
illustrates, this process is not linear, with various steps occurring in parallel with 
iterative incremental progress at different phases happening simultaneously. 
Phase 1 describes the intervention planning, and completion of a low fidelity 
(draft) version of the website and phase 2 describes the processes involved in 
taking the low fidelity prototype and converting it into a finished website ready 
for evaluation in a randomised controlled trial (RCT).  This is shown visually in 
Figure 5.2. 
Figure 5.2 Overview of stage 2. 
 
 
 
5.2.2.1 Ethics and management approvals for user testing (focus groups 
and think aloud studies) 
Ethical approval was granted from the West of Scotland Research Ethics 
Committee (REC)(12/WS/0068) and management approval from NHS Greater 
Glasgow and Clyde (GN11RM394) in March 2012.  I applied using a new system 
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that was being piloted called ‘proportionate review’.  This alternative process is 
for studies with ‘non material ethical issues’, e.g. studies that have minimal 
risk, burden or intrusion for research participants, and includes non-sensitive 
questionnaire and interview studies.  This expedited process meant no 
attendance at a REC panel meeting, and a decision made within 2 weeks of 
applying. 
There was a separate study information leaflet for adults with asthma (appendix 
7) and practices nurses (appendix 8). Prior to providing written, informed 
consent, all participants had at least 24 hours (usually longer) to review the 
material and had opportunity to ask questions. 
5.2.2.2 Data Storage & Confidentiality 
Data was stored electronically in password protected files on the secure 
university server.  Audio tapes/digital recorders, consent forms and field notes 
were kept in secure locked cabinets.  Importantly, there was no requirement for 
me to access medical records for patient information, as medications and health 
contacts were self-reported.  Identifiable data will be securely kept for 5 years 
after the conclusion of the study, and anonymised research data for 10 years.  I 
followed the Caldicott principles at all times. 
5.2.2.3 Participants 
In the co-design stages we were aiming to include both those who might use the 
intervention themselves (e.g. adults with asthma); and the health professionals 
who might recommend it.  In a UK setting, this would be primary care practice 
nurses, who undertake asthma reviews.  Having heterogeneous focus groups is 
not always recommended [152] but in this situation I was particularly interested 
in understanding the disparity between what practice nurses recommend to 
adults with asthma, and what the patients actually do in real life, therefore this 
was appropriate.  
Recruitment to the focus groups and think aloud studies was undertaken 
simultaneously.  Practice nurses were recruited via snowballing and word of 
mouth.  When recruiting for adults with asthma I used a range of sources: 
primary care, Asthma UK Research and Policy volunteers, Chest Heart Stroke 
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Scotland volunteers and a secondary care asthma clinic at Gartnavel General 
Hospital.  I also put up posters around the University of Glasgow, and two local 
hospitals (Western Infirmary and Gartnavel General).  Potential participants 
could consent to take part in a focus group, up to two think aloud studies 
(described in phase 2), or both.  Practice nurses were only eligible for focus 
groups.  I was aiming to include 4 to 6 adults with asthma and 2 to 4 practice 
nurses per group (e.g. minimum of 6 per group), and planning a maximum of 12 
think aloud studies.  All participants were provided with a gift voucher to 
compensate them for their time, and allowed to claim travel expenses.   
5.2.2.4 Inclusion and exclusion criteria 
For adults with asthma:  
Inclusion Criteria: 
1. diagnosis of asthma 
2. using any inhaled medication for their asthma on average twice a 
month or more often 
3. age 18 or over 
Exclusion criteria: 
1. a history of mental impairment that would suggest that they would 
be unable to give informed consent to participate 
2. a history of hearing or speech impairment to a degree that would 
render normal conversation impossible 
3. unable to speak English well enough for normal conversation 
4. a terminal illness 
The only requirement for practice nurses was that they had to be regularly 
undertaking asthma reviews with patients in GP surgeries. 
5.2.3 Phase 1 Methods: Intervention planning 
Phase 1 describes the process of developing a ‘first draft’ of the website.  This 
phase consisted of three main work packages (WP), all overseen by the expert 
panel. 
Chapter 5 Website Development   112 
 
5.2.3.1 Work package 1 – Understanding the evidence & incorporating 
theory (scoping review and expert panel) 
Campbell et al [115] recommend working through 5 key tasks when planning a 
complex intervention, in order to define and understand the ‘problem’ that your 
intervention is aiming to solve.  These 5 tasks are: 
 defining and quantifying the problem; 1.
 identifying who is mostly likely to benefit; 2.
 understanding the pathways which contribute to the problem; 3.
 consideration of whether (and how) these pathways are amenable to 4.
change; 
 and attempting to quantify the potential for improvement. 5.
The results from Chapter 2, and the experience of our expert panel, was drawn 
on to complete these tasks.  In addition to using the literature to complete the 5 
tasks described above, I also used it to directly influence the specific content of 
the resource.  I did this by scanning relevant articles from the literature 
(including asthma guidelines) and extracting any statement which could be seen 
to be a barrier or facilitator to good asthma control and self-management, and 
any statement which described the ideal contents of a self-management 
intervention (digital or otherwise), as outlined at the end of chapter 2. 
5.2.3.2 Work package 2 – Getting user perspectives on a web resource 
(focus groups) 
In order to investigate the credibility of this list with potential end users I 
convened 2 focus groups, consisting in total of 9 adults with asthma (6 female, 3 
male), and 4 practice nurses who undertake asthma reviews.  Focus groups were 
held at the Department of General Practice & Primary Care, University of 
Glasgow, and were audio recorded and transcribed. 
NPT [111] was used to inform the topic guide for these focus groups.  NPT aims 
to explain the routine embedding of practices by reference to the role of four 
constructs: coherence; cognitive participation; collective action and reflexive 
monitoring. 
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 Coherence: refers to the work of making a complex intervention hold 
together and cohere to its context, how people "make sense" or not of the 
new ways of working.  
 Cognitive participation: is the work of engaging and legitimising a 
complex intervention, exploring whether participants buy into and/or 
sustain the intervention.  
 Collective action: examines how innovations help or hinder professionals 
in performing various aspects of their work, issues of resource allocation, 
infrastructure and policy, how workload and training needs are affected 
and how the new practices affect confidence in the safety or security of 
new ways of working.  
 Reflexive monitoring: is the work of understanding and evaluating a 
complex intervention in practice, and how individuals or groups come to 
decide whether the new ways of working are worth sustaining.  
These constructs are applicable regardless of whether its use is at the stage of 
developing a complex intervention such as here, during development of an 
intervention, optimising trial parameters, or the actual implementation of 
complex interventions [111]. 
Therefore, NPT provides a conceptual framework to help clinicians, researchers 
and managers describe and potentially to judge the implementation potential of 
an intervention, either allowing for improvement and development prior to 
implementation, or if required an acceptance that the intervention simply lacks 
implementability and that further work is not warranted.  
The full topic guide is available as appendix 9, and summarised in Table 5.2 
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Table 5.2 Summary of how NPT informed focus group topic guide  
NPT Construct Construct explanation Focus group guide 
Coherence Meaning and sense making 
by participants 
Explore perspectives on the 
information presented (from the 
literature review), and views on the 
potential role of an online resource 
Cognitive 
participation 
Commitment and 
engagement of participants 
Discover potential users’ views of the 
idea of an online self-management 
website including barriers and 
facilitators to utilisation. 
Collective action  The work participants do to 
make the intervention 
function 
Investigate what people currently do to 
manage their asthma, and what role 
an online resource might have.  
Reflexive 
monitoring  
Participants reflect on or 
appraise the intervention 
Discover what participants would like 
to see, that ensures the intervention is 
helpful, and worth using. 
 
 
The focus groups were transcribed.  I intended to use NPT to inform the analysis 
of the focus groups, and initiated a coding frame based on NPT.  However, in 
practice I realised that comments could be essentially distilled down into either 
barriers or facilitators to self-management or suggested features.  Therefore, I 
simply extracted statements which fell into one of these categories and used 
this to develop a list of features a website should ideally include.  
5.2.3.3 Work package 3 –Developing a draft version of the website (expert 
panel) 
The list of suggested features to include in the website generated by WP 1 and 2 
was reviewed and by the expert panel and an agreed list finalised.  I generated  
low fidelity prototype pages, initially using Microsoft Word or PowerPoint (also 
referred to as draft pages) to cover all the topics in our agreed features list.  
These draft pages were reviewed initially by those in the panel with a clinical 
background to ensure the content was factually correct.  Subsequently the pages 
were shown to members of the expert panel with specific expertise in behaviour 
change theory to ensure maximum opportunity for promoting behaviour change 
was incorporated into each page or section.  From this a draft version of each 
potential webpage was finalised, ready for think aloud study evaluation.   
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5.2.4 Phase 2 methods: Iterative refinement of the resource 
contents of the website (think aloud studies and expert 
panel) 
Draft pages developed during phase 1 were gradually translated into interactive 
webpages, with input from potential end users in the form of think aloud 
studies, and ongoing review by the expert panel.  I undertook think aloud studies 
at either the participant’s home, or the Department of General Practice & 
Primary Care, University of Glasgow, depending on participant preference.  
There were two waves of think aloud studies: the first 4 used draft webpages 
consisting of mainly paper or PowerPoint slides, the latter 6 were mainly 
undertaken using the prototype webpages on LifeGuide.  While LifeGuide can be 
used by researchers with no computing science background, due to time 
constraints Andrew Ramsay a computer science researcher transferred the 
majority of the draft pages into LifeGuide initially.  I introduced these initial 
think aloud tasks by explaining that the website was at an early stage of 
development, and therefore there was much scope for modifying the contents 
and that critical comments were the most helpful.  Participants were asked to 
say whatever they thought or felt about what they were seeing, with prompts 
and questions used to elaborate on responses.  The participants were then 
encouraged to voice any additional suggestions or opinions to improve the 
resource, for example what they liked and disliked, what was intuitive and what 
was not, and how they envisaged using such a website in real life in the future.  
During the first few think aloud studies the emphasis was on the content of the 
website.  I used mainly Microsoft Word documents or PowerPoint to show ideas 
for potential pages.  For example the ‘Common concerns and queries’ section 
initially consisted of a word document with a list of questions and I had sample 
answers on separate slips of paper.  I asked users to ‘press’ the relevant 
question they were interested in, and I presented the relevant slip of paper with 
the suggested answer.  Although rudimentary, this allowed an early appreciation 
of how this section would work in practice, and how it could be improved.   
Once pages were on the LifeGuide software they were given a unique name 
(page_2_2, page_2_3, etc), which was noted as each new page was viewed to 
allow correlation between a specific website page and what was recorded during 
the think aloud study.  For example page_2_2 corresponded to section 2 
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(treatments), page 2.  As well as digital audio recordings, I kept written notes of 
the issues raised that would directly impact on the website development, page 
by page.  Areas requiring rewritten, typographical errors, and suggestions for 
improvements were all noted this way, allowing me to actually go ahead and 
make the required changes usually within 24 hours, and in the majority of cases 
before the next think aloud study.  The only exception to this was when two 
think aloud studies were held on the same day.  At times, this was helpful to 
quickly get two opinions in quick succession about a specific page or idea, to 
allow me to decide how to proceed.   
I also thematically analysed the transcribed think aloud studies, with the aim of 
providing information for further development of the resource following the 
pilot RCT.  NPT was not used for analysing the transcribed think alouds studies, 
as the majority of comments were very ‘practical’ in nature, and page specific 
rather than about the intervention itself.  A coding frame was developed from 
reading through the first three studies (Figure 5.4).  SW and I both 
independently coded the first two transcripts, and compared our results, after 
which I coded the remaining transcripts.  Comments were also noted to be 
either:  
1) A positive comment, where the user liked or identified with what they 
saw. 
2) A negative comment where the user disliked or disagreed with what 
they saw. 
3) Where the user suggested an improvement or alternative way of 
presenting the data.  
Towards the end of this phase, I made links with other health professionals 
based in the local health board with an interest in asthma self-management i.e. 
primary care practice nurses, secondary care respiratory nurses, and respiratory 
pharmacists.  This was to ensure that the website was consistent with health 
professionals’ usual advice to patients, and to establish informally if they had 
suggestions for improving it.  
The final version of the Living well with Asthma website was formally mapped to 
Michie and colleagues latest behaviour change technique (BCT) taxonomy [107] 
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in order to describe which BCTs were present.  There are 93 individual BCTs, 
which can be grouped into 16 different BCT areas.  To map the BCTs I reviewed 
every page of the website and where relevant assigned a BCT.  These were all 
subsequently reviewed by SW, and discrepancies discussed until we both agreed. 
We did this to provide a reliable record of the content of this behaviour change 
intervention, and to confirm that I included a range of BCTs as planned. 
Throughout both phase 1 and 2, I iteratively undertook ‘NPT analysis’ of the 
intervention as it was being developed in order to enhance the likelihood that 
what we were developing would be implementable long term [111].    
5.3 Results 
This section describes the results of the two phases of work that were 
undertaken to develop the website and illustrates the iterative nature of the 
website development.  Phase 1 describes the initial planning and deciding what 
the content should be, and phase 2 describes how this planned content was 
converted into interactive webpages. 
5.3.1 Phase 1 results: Initial planning  
5.3.1.1 Work package 1 – Understanding the evidence & incorporating 
theory (literature review and expert panel) 
The planning stage had two outcomes: firstly I focused on the 5 key tasks 
outlined by Campbell et al [115], and secondly I generated a list of potential 
features the website might contain.  The 5 tasks were completed using a 
combination of existing published literature including guidelines, along with 
input from the expert panel.  The literature was used inform the completion of 
these tasks, as outlined in turn below.  
Task 1: Define and quantify the problem 
A review of the asthma literature over the last 15 years in particular makes it 
clear that when optimum self-management of asthma is undertaken it improves 
a range of asthma outcomes (fewer visits to emergency room, hospitalisations, 
unscheduled visits to doctors, and days off work and school, reduces nocturnal 
asthma and improves quality of life) [6].  As outlined in more detail in Chapter 
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2, optimum self-management of asthma means regular health professional 
review and good self-management education including agreeing an asthma 
action plan (AAP) [6]. Unfortunately, in real life settings it is an underused 
treatment strategy, particularly the use of AAPs.  This is evidenced by: 
 Suboptimal use of preventative therapies.  Adherence to therapies in long 1.
term conditions is around 50% [153], and as low as 30% in asthma [154]. 
Low use of preventative inhaled corticosteroids (ICS) therapies and high 
use of short acting beta agonists (SABA), also called reliever inhalers, is a 
pattern commonly seen, and which is associated with poorer asthma 
control [2]. 
 High levels of symptom burden (46% daytime symptoms and 30% nocturnal 2.
symptoms) [39], with lack of recognition of scope for improvement: 50% 
of patients reporting severe persistent symptoms report their own asthma 
as being completely or well controlled [39]. This results in people with 
uncontrolled or deteriorating asthma not seeking timely medical advice. 
 Suboptimal attendance at asthma reviews with low use of asthma action 3.
plans (AAPs) [1, 10] as verified by the National Review of Asthma Deaths 
(NRAD) where only 23% of those who died having been provided with an 
AAP [1], and attendance at asthma reviews in Scotland were only 65%. 
Task 2: Identify and quantify the population most affected, most at risk, or most 
likely to benefit from the intervention 
The Global Initiative for Asthma (GINA) guidelines were used particularly for this 
task as they list the risk factors for poor asthma outcomes [7].  These are: 
 Uncontrolled asthma symptoms 
 Increased use of short acting beta agonist  e.g. reliever therapy 
 Inadequate inhaled corticosteroids, including poor technique. 
 Low FEV1 (especially if <60% predicted) 
 Major psychological or socioeconomic problems 
 Smoking 
 Comorbidities: obesity, rhino-sinusitis, food allergy 
 Previous exacerbations or intensive care admissions for asthma 
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The majority of these factors are directly related to uncontrolled asthma 
symptoms, and therefore we agreed a key way of identifying those most likely to 
benefit from a self-management intervention is to target those with 
uncontrolled asthma symptoms.  There are widely used validated questionnaires 
which can easily define individuals as being uncontrolled, for example the 
asthma control questionnaire [155]. 
Task 3: Understand the pathways by which the problem is caused 
With reference to problems outlined in Task 1, the literature and guidelines 
provided explanations for why these problems are sustained, is correspondingly 
shown below: 
 Reasons for low adherence to asthma therapies are often related to 1.
concerns about side effects, or perceptions that they do not need to be 
on treatments [59, 156]. 
 The global asthma insights and reality surveys [2] provides evidence of 2.
suboptimal asthma control and suggests reasons for it.  First, people with 
asthma overestimate how controlled their asthma is, therefore do not 
consider themselves to be candidates for gaining improvement with 
asthma treatments[2, 41].  Second, those who do acknowledge they have 
symptoms and limitation of activities accept them as unavoidable 
consequences of having asthma, rather than seeing the potential for 
improvement [2, 41]. 
 Patients’ reasons for not attending asthma reviews revolve around 3.
feelings that their asthma is not serious enough [157].  AAPs are 
underused for several reasons as determined by Ring et al in their 
systematic review [9]: 
a. Differences in beliefs and attitudes between health care 
professionals and people with asthma. 
b. Perceived irrelevance of AAPs of the part of those who would 
potentially benefit from them  
c. Health professionals only offer AAPs to select groups of patients 
(e.g. with well controlled asthma, or those with higher levels of 
educational achievement).  
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In summary, people with asthma often underestimate their symptoms and 
overestimate their control, not making use of available therapeutic options 
(medications, AAPs and advice from health professionals).  Those who do 
recognise they have symptoms may not adhere to prescribed medications due to 
misunderstandings around medication side effects, or perceived benefits of using 
AAPs. 
Task 4: Explore whether these pathways may be amenable to change and, if 
so, at which points 
Again with specific reference to the three ‘problems’ outlined in Task 1, I 
derived strategies which would aim to overcome the problems identified in task 
1, aiming to include behaviour change techniques (BCTs) [107] where possible, 
targeting the underlying mechanisms as explained in Task 3.  These strategies 
were: 
 Prompting users to consider reasons why they do not take medications 1.
regularly (barriers) and consider strategies to overcome these barriers.  
Providing information about benefits of inhaled corticosteroids, 
challenging misconceptions and negative beliefs.  Focussing on benefits 
meaningful to individuals such as fewer days off work, managing that 
exercise class etc.  Providing instructions (ideally including videos) to 
demonstrate correct inhaler technique.   
 Promoting the message that users should be aiming for no symptoms.  2.
Providing information to challenge the belief that having asthma 
symptoms is normal, and asking validated questions to determine if users 
are currently putting up with symptoms, providing feedback on response.   
Prompting users to recognise if they avoid activities due to their asthma, 
or are limited in everyday tasks such as housework, gardening, visiting 
friends.  Turn these limitations into ‘goals’ to aim towards, and describing 
how these goals are achievable for them. 
 Provide information that people who use AAPs and attend for reviews 3.
have fewer symptoms and fewer asthma attacks.  Provide quotes from 
practice nurses encouraging attendance for reviews.  Remove physical 
barrier to using AAPs by providing a template that can be taken to health 
professionals (identical to those provided by local health board). 
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The expert panel ensured that behaviour change theory was incorporated into 
the web page contents and full analysis of behaviour change techniques present 
was undertaken on the final website [107]. 
Task 5: Quantify the potential for improvement 
The literature provided the information for this task.  An estimated 300 million 
people worldwide have asthma and its prevalence appears to be increasing with 
an estimated additional 100 million people with asthma by 2025 [37].  Depending 
on criteria used to define poor control, evidence suggests that levels of 
uncontrolled asthma range from at least 25%, but are probably higher [2, 11, 
39].  My primary outcomes if this intervention was subsequently taken to a full 
scale RCT would be to assess symptom level using a questionnaire.  A good 
candidate would be the Asthma Control Questionnaire (ACQ) and we would aim 
for a drop of 0.5 in score, which is the minimally important clinical difference 
[158].  Symptoms was the most commonly described outcome in my previous 
metareview of digital interventions reported in 12 out of 19 of the RCTs [8]. 
Literature review 
In addition to using the literature to complete the 5 key tasks it was also used to 
directly inform the specific contents of the website.  At this stage this was used 
mainly to develop a list of barriers and facilitators to asthma self-management.  
How this list actually informed the content is fully described at the end of work 
package 2, section 5.3.1.2 below.   
 
5.3.1.2 Work package 2: Getting user perspectives on a web resource (focus 
groups) 
We shared the key findings from Tasks 1 to 4 above, and our list from the 
literature, with potential end users in the focus groups.  Excluding the practice 
nurses the average age of participants was 42 years (range 23 to 56).  Six 
participants were female, 4 male, and included participants from highest and 
lowest deprivation deciles (median 4, IQR 1, 8).  Table 5.3 describes the 
participants, illustrating which focus group (or think aloud study) they 
participated in.  Achieving participant numbers was relatively quick, however 
the asthma UK research volunteers responded most quickly, and this led to half 
of the participants being recruited this way.  Recruitment was stopped once we 
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had enough members to hold the 2 focus groups.  I then intended a second wave 
from primary care if I needed further participants for the think aloud studies, 
however I was able to recruit for them from the pool of participants who had 
responded to the initial mailing.  Overall, participants were recruited from 
Asthma UK volunteers (n=5), primary care (n = 3) and hospital asthma clinic 
(n=2), with none recruited via poster.  All 4 practice nurses were female and had 
been nursing for an average of 25.5 years (range 21 - 30), and undertaking 
specific primary care asthma reviews for on average 7.7 years (range 5-10).  As 
described in the methods section NPT was used to inform the development of 
the focus group topic guide.  This was useful as it encouraged me to consider a 
range of questions I would not have done otherwise.  For example, we planned 
to ask what features would be in the ideal self-management resource.  NPT then 
ensured that relevant exploratory questions were asked about how that feature 
would work in practice, who would use it, and would someone really be likely to 
sustain its use in the long term. 
 Table 5.3 Demographics of participants in focus groups and think aloud studies 
Participant 
number 
†
 
FG 1 FG 2 TA 1 
#
 TA 2 
#
 Female 
Years since 
diagnosis 
Age (yrs) SIMD 
§
 Ethnicity 
1  ● ● (2) 
 
● 7 44 1 
White 
British 
2 ●  ●(3) 
 
● 9 23 1 
White 
British 
3  ● ● (4) ● (11) ● 50 51 8 
White 
British 
4 ●  ● (5) ● (9)  40 46 4 
White 
British 
5  ● ● (6) 
 
 12 23 1 
White 
British 
6  ● ● (7) 
 
● 31 56 8 
White 
British 
7 ●  ● (8) 
 
● 19 55 3 
White 
British 
8 ●   
 
 34 41 6 
White 
British 
9 ●   
 
● 28 29 10 
White 
British 
10   ●(1) ● (10)  9 48 10 
White 
British 
† Refers to adults with asthma participating.  Participants recruited from: AsthmaUK (1,3,5,7,9); primary care (2,4,10); asthma clinic (6,8). Two practice 
nurses also present in each focus group, details not provided. 
# Number in brackets refers to think aloud (TA) study  number, participant number 3, 4 and 10 participated in two think aloud studies each. 
§    Scottish Index of Multiple Deprivation. Range from 1 (most deprived) to 10 (most affluent) 
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During the first focus group it became clear that questions informed by the final 
construct – reflexive monitoring - were met with particular difficulty by the 
participants.  It proved difficult for participants to imagine what would be 
evidence that a resource which they had not seen, or experienced themselves, 
was working for them.  The other issue that became apparent during the focus 
group was that separating the work of asthma symptoms, asthma self-
management, and then asthma self-management using a new website was 
difficult, not only for the participants but also for me facilitating the focus 
group.  It was hard to steer participants away from their experiences of asthma 
symptoms, particular with one member of the group who had very severe 
asthma.  In addition while the participants had lots of ideas about what should 
be in the resource (coherence), they were less clear about what would 
encourage commitment to undertaking these processes and engaging with a 
resource (cognitive participation) which is the domain I was particularly 
interested.  One example of this was the issue of ‘putting up with symptoms’ 
and it was clear this was a key area that the website should focus on, and 
challenging people to not put up with symptoms was key strategy to use, but 
practical strategies to do this were not forthcoming. 
When I reviewed the transcription of the first focus group I intended to use NPT 
for the analysis.  I initiated developing a NPT based coding frame while 
reviewing this first transcript.  This helped me realise that too much time was 
being spent on the users illness burden, and the treatment burden that those 
with severe asthma in the group experienced.  In light of this I approached the 
second focus group differently.  I steered participants towards a more forward 
looking ‘what could we do better’ discussion, rather than looking at what has 
not gone so well in their past.  We explored more about why people put up with 
symptoms, and why people do not take their inhalers as prescribed.  I asked 
more about tools to help people manage their asthma better, what would they 
like to see, beyond simply information.  I started trying to code this transcript 
using NPT. However, when I only considered comments which were directly 
related to my research question (“What are the barriers and facilitators to the 
uptake and utilisation of a web based self-management tool from the 
perspective of adults with asthma, and primary care nurses who undertake 
asthma reviews?”) it became clear that the information provided from the focus 
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groups fell mainly into 2 categories: barriers to self-management (using digital 
resources or otherwise), and facilitators to self-management.  Therefore, it 
made sense to simply group the statements into these two categories, rather 
than use NPT as planned.  
Barriers to optimum self-management identified by focus groups included: 
 not accepting diagnosis 
 concerns about side-effects of medications 
 difficulties keeping track of medications and remembering to order more 
 the length of time between asthma reviews resulting in knowledge loss. 
Facilitators to using an online resource included 
 staggering of information 
 a resource to bridge the gap between annual reviews and reinforcement 
of material covered in the review 
 provision of email reminders i.e. ordering medication and flu vaccinations 
 resource being promoted during annual reviews 
 making users aware of different types of inhalers available and 
importance of finding one that suits.  
One area of discussion in both groups was whether online forums should be 
provided in the website.  Participants who had used currently available online 
forums had mixed views on them, often initially finding them useful and then 
subsequently becoming irritated with others users’ contributions.  They did 
however recommend them overall, as is consistent with research in this area 
[159], and suggested we include them in our resource.  However, I had 
previously discussed online forums with the expert panel and we had agreed the 
need for monitoring of forums simply meant they were beyond the scope of this 
project.  In addition, Asthma UK has a popular and well used forum so it was 
unnecessary to duplicate this in our resource. It was useful to have decided this 
before the focus group as I was able to move on to more relevant topics by 
explaining this. 
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The barriers and facilitators to good self-management identified from the focus 
groups were combined with those from the literature (including asthma 
guidelines).  Each individual barrier/facilitator statement was then assigned a 
potential website feature.  While this full process is shown in appendix 10 
(intervention planning document) an example is shown below in Table 5.4.  Once 
the process was completed the intervention features were then grouped 
together, providing an evidence based rationale for the inclusion of each 
feature. 
Table 5.4 Example of literature directly informing proposed website contents 
Barriers from asthma literature Suggested intervention component 
People with asthma overestimate their 
control and tolerate unnecessary 
symptoms [2]. 
Provide tool to assess control/symptoms e.g. 
ACT, ACQ, or RCP 3 Questions. 
Health professionals do not always offer 
AAPs to patients [10, 69, 70]. 
Provide alternative means of accessing AAP 
via freely available website, and promote users 
proactively approaching health professional 
about them. 
People with asthma with a new diagnosis 
lacked confidence in using AAPs [70]. 
Provide information about how to use AAPs. 
Illustrate benefits & low risk of harms. 
Provide examples of using AAP use, quotes 
aiming to increase confidence. 
People with asthmas beliefs about 
medications can impact on adherence  
(E.g. effectiveness, tolerance, fears of 
side-effects) [40, 160]. 
Provide information to challenge beliefs:  both 
facts and example experiences. 
Impaired literacy is associated with 
reduced asthma knowledge and improper 
inhaler use  [161], reduced aural literacy is 
associated with poorer asthma control 
measured by nights with symptoms [29]. 
Provide information in a graded way, where 
user can determine depth of information 
required.  Use images, videos where possible. 
ACT = Asthma control test, ACQ = Asthma control questionnaire, AAP = asthma action plan 
 
 
5.3.1.3 Work package 3 –Developing a draft version of the website (expert 
panel) 
WP 1 and 2 provided evidence for targeting six main behaviours.  These were: 
1. Recognise symptoms, do not put up with them (aim for no symptoms) 
2. Optimise medication use (including inhaler technique) 
3. Attend for regular asthma review 
4. Use asthma action plans 
5. Increase physical activity 
6. Stop smoking 
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As outlined in Chapter 3, I needed to understand what we were expecting the 
intervention to do: how were changes in the behaviours of interest going to lead 
to better outcomes for users?  As a result, I developed a model which illustrated 
our proposed mechanism of action. 
 
 
The expert panel reviewed the list of suggested features from appendix 10 
(Intervention planning doc) which led to the removal of 4: a diary for tracking 
medication use, a diary for tracking peak expiratory flow (PEF) rate, a tailored 
action plan, and a dedicated family & friends sections.  The expert panel felt 
that evidence and personal experience suggested that use of diary tools was 
rarely sustained except by a few very motivated individuals.  Instead regular 
prompts to think about current asthma symptoms based on the ‘Royal College 
Physicians 3 Questions’ (RCP 3Q) screening tool [162] was incorporated 
throughout the resource and in the automated emails.  This asks the user about 
difficulty sleeping because of asthma, asthma symptoms during the day, and 
interference with usual activities.  If users answer yes to even one question then 
further assessment of asthma control is indicated [163, 164]. 
Action plans work best when personalised to the individual [64] and the IT 
requirements of a truly tailored action plan was considered beyond the scope of 
this project.  Instead a section was dedicated to promoting the use of action 
Figure 5.3 Model for mechanism of action of intervention 
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plans, and encouraging individuals to visit their health professional to agree one 
if they did not have one.  Rather than a dedicated family and friends section, 
the importance of positively involving family and friends was covered in general 
terms.  
By the end of Phase 1, I had developed paper based versions of the proposed 
web pages ready for consideration by the expert panel and for use in think aloud 
studies.  The pages were sent to all expert panel members for comment, usually 
to clinicians first then to the rest of the expert panel for comments.   
5.3.2 Phase 2 results: Iterative refinement of the resource 
contents of the website 
5.3.2.1 Think aloud studies and expert panel input 
Eleven think aloud studies (see Table 5.3 for participant details) were conducted 
although one study (TA 08) was not completed as the website was not 
compatible with her type of computer which converted website text into braille 
(BrailleNote).  Surprisingly only 4 of the 11 studies were undertaken in the 
participants’ own home, with most choosing to come to my place of work.  
Three of the participants (participants 3, 4 and 10) undertook 2 studies each.  
Each think aloud interview covered a slightly different range of topics as the 
resource was developed iteratively as demonstrated in Table 5.5. 
  Table 5.5 Topics covered per think aloud study 
 Introduction 
My 
asthma 
Treatments 
Asthma 
review 
Exercise 
Concerns 
Queries 
Stress 
Anxiety 
Action 
plan 
4 week 
challenge 
TA01 
†
 ● ●  ● ●   ●  
TA02  ●  ●  ● ● ●  
TA03 ● ●  ●  ●  ●  
TA04 
#
 ● ● (s2) ● ●  ●   ● 
TA05 
§
 ● ● (s3) ● ● ●     
TA06 ● ● (s2) ●      ● 
TA07 ● ● (s2)    ● ●  ● 
TA08 
‡
          
TA09 
§
 ● ● (s3)      ● ● 
TA10 
†
 ● ● (s3) ●   ●  ● ● 
TA11 
#
 ● ● (s2) ● ● ● ● ●  ● 
† TA01 and TA10 were same participant 
# TA04 and TA11 were same participant 
§ TA05 and TA09 were same participant 
‡ TA08 used a Braillenote computer, which was not compatible with our software so we were unable to complete the Think Aloud study. 
¶ My asthma section eventually split into 3 sections (s1, s2, s3). With s1 being based mainly on the contents reviewed at the first 3 think alouds.  
 s1 – I have never been prescribed or used a preventer inhaler 
 s2 – I have a preventer inhaler but don’t really use it as prescribed 
 s3 – I have a preventer inhaler and mostly use it as prescribed 
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The thematic analysis of the think aloud transcripts identified 4 main themes:  
1) ‘content’ – the actual words on the pages, and how relevant and 
understandable the information was; 2) ‘layout and navigation’ – the layout of 
pages or sections, and how easy it was to navigate around sections; and 3) ‘user 
experience’; and 4) graphics.  The first 2 themes (contents and format) were 
further divided into 3 subsections each as shown in Figure 5.4.  These 6 
subsections were also noted as being positive, negative, or a suggestion for 
improvement.  Graphics was a separate theme as personal communication from 
Lucy Yardley had advised that comments about appearance and graphics were 
often too specific to an individual’s tastes, and less useful in improving a 
websites acceptability or usability.  With health behaviour change websites such 
as this, feedback on the message the page or section is trying to convey (e.g. 
the content) is the key area to focus on, along with the usability of the resource 
(layout and navigation). 
Figure 5.4 Think aloud coding framework 
 
Comments could apply to more than one code if appropriate.  An example is a 
quote from a slide in an early think aloud study (Figure 5.5): 
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Figure 5.5 PowerPoint slide from think aloud study 3 
 
  “And a wee fun fact kind of so, wow didn’t know that. Yeah I think that’s 
good to have that wee bubble because that’s it's like, it's scary enough to 
make you go oh actually this is really important but it's not too scary that 
you are like oh my goodness I don’t even want to look at that so yeah that’s 
good.” (Participant 2, TA 03) 
This whole quote was coded as ‘contents – information provided - positive’.  
However the second sentence was also coded under ‘contents - tone/language – 
positive’. 
Using NVivo software, I generated quantitative data from the think aloud 
transcripts.  Fifty one percent of the comments were positive, 15% negative and 
34% containing suggestions for improvement.  That almost half of comments 
were negative or suggestions for improvements implies that participants felt 
comfortable criticising the website in front of me, even though most knew I had 
developed it.  Most comments related to the content of pages (78%), and the 
majority of these were positive (56%).  In contrast, most comments about the 
website format (excluding graphics) were negative (69%) (Figure 5.6).  This 
confirmed that the ground work done in Phase 1 around content had been 
successful, but that greater emphasis was needed on usability and presentation 
issues, as anticipated. 
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Figure 5.6 Type of comment made during think aloud studies 
 
Content –making the website relevant and understandable  
Participants were positive about the contents, and in particular the ‘level’ it was 
aimed at: 
“it’s very clear in its intention, a website to help you stay healthy and 
manage your asthma better that’s exactly what level I’m at, I don’t have a 
detailed knowledge of what I’ve got or quite what I’ve got or quite how to 
look after it so it’s perfect for me.” (Participant 10,TA 01) 
Users liked and identified with the key messages, for example that people with 
asthma should be ‘aiming for no symptoms’:  
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“I like a message of you know that’s what you should be aiming for, it might 
not be what you get right enough but at least you should be aiming for, or 
aiming for it the majority of the time, you know but you can if, you know 
going to have relapses, but I think that that’s really good because I don’t 
think many people actually say that to you to be honest.”  (Participant 1, 
TA02) 
“That’s good to know because again I just was putting up with it like if  I 
was, if I wasn’t being able to breathe I would just be like oh I'm just having 
a bad day rather than being like ‘oh I should really be on the brown inhaler 
to stop this from happening’,” (Participant 3, TA04) 
While there was universal agreement that quotes from patients and practice 
nurses were desirable within the website, there was some disagreement about 
how they should be presented: 
“But I would give them maybe slightly more weight if they weren’t 
anonymous bizarrely.  And it’s a real living patient that is living with 
asthma. And that kind of makes it more of a human.” (Participant 10, TA01) 
In the following think aloud study this point was brought up by the interviewer: 
“the quotes do you think, would you prefer to see something like female 
age 53 or is it not relevant? (researcher) 
 It’s not relevant to be honest because if I was twenty one and I was reading 
and they were fifty I would be thinking oh that doesn’t apply to me yet.  
The guy will be reading it and thinking oh that’s a woman thing.”  
(Participant 1, TA02) 
Consequently, we kept quotes in the website but removed descriptions of who 
said them, as illustrated in Figure 5.7 below. 
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Figure 5.7 Illustrating use of quotes within website 
 
While patients on the whole agreed with the information provided, the one area 
where there was scepticism was in regard to how approachable participants’ 
practice nurses were: 
“just trying to imagine sort of sitting down with my asthma nurse and saying 
I have a goal and this is what I want to achieve, I know what she’d say, 
she’d say I haven’t got time to discuss this!  Let’s just stick to the tick 
boxes shall we?“ (Participant 4, TA05) 
Layout and Navigation – making the website easy to use 
The majority of the comments regarding layout were page specific such as 
feeling that a given paragraph was too long.  Where appropriate these were 
acted on immediately after the think aloud study in preparation for the next 
one.  This was done by taking notes during the think aloud study using the 
unique page identifier along with the issue that was identified requiring action.   
The importance of getting the home page right was clearly important to 
participants and generated much discussion. 
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 “it doesn’t quite feel like a home page, that’s maybe not helpful.  I’m 
trying to think what’s the best way to, it looks the same as every other 
page, I don’t know if you did something different to the header or 
something like that.”  (Participant 4, TA05) 
The home page therefore went through several iterations, summarised below in 
Figure 5.8.
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Figure 5.8 Changes to home page during phase 2, from PowerPoint slide initially to final 
version 
Final version 
(LifeGuide) 
Early version 
(PowerPoint) 
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The second recurring theme in layout and navigation related to users ‘knowing 
where I am’.  
“I say I might have said before maybe a little site map, you are on step 3 of 
9, 4 of 9 and people know where they are going.”    (Participant 4, TA09) 
As a result I made it more obvious which section a user was in at a given time, 
and within the ‘4 week challenge section’ I changed it to visually show users 
progression as they made their way their way through this 4 stages of preparing 
to sign up to the ‘4 week challenge’.  
User experiences 
After completing the think aloud study users were asked how they might use the 
website in a real life setting and what would be barriers to its sustained use.  
Users felt that they would have more confidence in such a resource if a health 
professional recommended it: 
“I guess like in my annual review, if my nurse was like oh have a look at 
this.  Like a wee leaflet or a wee business card or something like that and 
just was like have a look at that.”   (Participant 2, TA03) 
This finding is relevant for both future large scale RCTs, and the subsequent 
implementation and embedding of such a resource. 
Several participants felt that it would be used to encourage recognition of 
symptom deterioration and timely visits to the GP: 
“help people to be more aware of their good days and bad days, their 
triggers when they need to look at their self-medicating you know regimes, 
when to visit the GP because actually you realise it’s going down the 
slippery slope.”   (Participant 1, TA02) 
In particular this would be the case for people newly diagnosed:  
“And I think people before you can start to manage a condition I think you 
need to know a lot about it you need to have the information don’t you and 
I think it provides a lot of interesting, useful information“   (Participant 6, 
TA07 
One potential barrier that was identified was if the content of the website was 
static, and not being updated, or new material being added: 
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“there is quite a lot but then you know after a while people have seen the 
website and then use drops off and I think it’s called the website winter so 
generally what happens most people go like that well I’ve done the website 
what more can I do”    (Participant 4, TA05) 
Table 5.6 explains the nature of the changes made during this phase as a result 
of input from the think aloud participants and the expert panel to each section.   
Although not formally part of the ‘expert panel’, I shared the website with 
several other health professionals with an interest in asthma, mainly practice 
nurses, respiratory nurses and pharmacists.  The main area of input by this group 
was providing a blank template action plan which users could print off, and 
sharing their own written self-management booklets with me, to ensure that the 
messages and information I was providing with the website was aligned with that 
from health professionals participants might see in local clinics. 
 Table 5.6 Description of changes made during think aloud studies 
Section  Topics Description of changes made  
1 
(13 pages) 
Introduction 
pages† and 
Home page  
 
 
Original one page introduction became 13+ page section. Both TA participants and expert panel highlighted that people with 
asthma are well known for underestimating their asthma severity, and suggested it was important I challenge this idea right at the 
start and illustrate to users how this resource could benefit them.  
First page presented user with questions designed to tease out limitations due to asthma. Then feedback provided for each 
question user ticked, along with tailored advice about which sections of the resource might benefit them most. 
Subsequent pages focused on identifying lifestyle goals relevant to users. 
Other changes included addition of a ‘landing’ page, combining links to sections to reduce the ‘buttons’ in the navigation bar from 
11 down to 7, and rearranging the home page. 
2 
(24 pages) 
My Asthma † 
 
 
Initially just one section, but became apparent that resource needed to be more tailored, and preventer therapy use was a good 
method of stratifying users, so users had to choose one of three options: 
I have never used/been prescribed a preventer 
I have been prescribed a preventer but don’t really use it 
I mostly/always take my preventer inhaler as prescribed 
The think aloud study confirmed the contents of this section, with most changes focusing on improving readability, removing 
repetition and trying to achieve the right balance when explaining  negative side effects versus potential benefits of inhaled 
steroids.  
3 
(14 pages) 
Treatments 
 
 
Layout of this section completely altered. It initially took the form of 6 pages users worked through with sideway steps for more 
information about different treatments. 
Section changed to have: 
1. its own homepage ( i.e. spoke and wheel layout) which allowed users to go directly to a treatment type without having to 
work through potentially  irrelevant pages.  
2. a visual representation of the asthma treatment ladder adapted from the BTS/Sign guidelines. 
We were unable to meet requests to have pictures of individual inhalers. 
4 
(21 pages) 
 
Asthma 
Reviews 
 
Focused on modifying the language used and simplifying messages. Altering layout of both individual pages and order of pages. 
Main message was to “aim for no symptoms” and this was very well received by users.  
Included a quiz covering what put people at risk of attacks – this was streamlined and made optional. 
5 
(5 pages) 
Action Plans 
 
Altered layout and clarity of wording, and quotes added to dilute the very factual nature of the information provided. 
Added a template of a blank action plan that users could print out and take to their health professional. 
 Section  Topics Description of changes made  
6 
(17 pages) 
Physical 
Activity 
Initially one generic section with the aim of promoting physical activity but was altered to become tailored to the individual’s activity 
status.  
7 
(18 pages) 
Common 
concerns and 
queries 
 
 
Originally had 8 concerns and queries, and a further 7 were added addressing topics originally not included as were felt to be 
covered elsewhere, or had  seemed ‘too basic’. Reviewing this section served as a reminder that people quickly forget (or have 
never been told) even basic information about their asthma, and that having it here for those who need it was essential.  
Another major change was the wording of questions. One user commented that questions were just statements and did not make 
it clear than scenarios were amenable to change. So for example ‘I don’t exercise because of my asthma’ was changed to ‘I don’t 
exercise because of my asthma. Could I?’ 
8 
(5 pages) 
Stress & 
Anxiety 
Received mainly positive feedback. 
Links to online resources aimed at reducing stress and anxiety (e.g. online CBT) added. 
9 
(8 pages) 
Take the 4 
week 
Challenge 
 
 
This section was specifically for users who had chosen option 1 or 2 during the ‘My Asthma’ section.  Initially much confusion 
about the nature of the challenge with some users misunderstanding it completely.  Thus pages were modified and more 
explanation added.   
Layout of pages were altered, in particular, to make it clear that there were 4 steps to work through, and it was made clearer how 
you were progressing through them (e.g colour strip across the top, which illustrated progress).  
One of the steps to the four week challenge was to anticipate barriers to taking preventer medication regularly and consider some 
solutions. Template barriers and solutions were provided, and these were added to by the think aloud participants.   
10 Like to stop 
smoking? 
This section was a link to an external site called ‘StopAdvisor’[165] and therefore not covered during the think aloud studies. 
11 
(1 page) 
Useful info 
and links 
Expanded during the think aloud to include more links to online mental health resources and information about the GP exercise 
referral scheme. 
†  Section 1 and 2 are core sections and all users are directed through them at first login, and can optionally visit again during future sessions. 
#  Refers to unique pages per section.  Some pages are referred to in more than one section, but are only counted once here in the first section they appear. 
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5.3.2.2 NPT Analysis of Intervention Development 
Throughout Phases 1 and 2 I had developed this intervention with reference to 
NPT, undertaking analysis of the intervention as outlined in Murray et al’s 
framework paper [111].  The final NPT analysis undertaken is shown below in 
Table 5.7.  
Table 5.7 NPT analysis of intervention development 
Questions asked Evalutation of Living Well with Asthma Development 
1. Coherence  (i.e meaning and sense making by participants) 
Is the intervention easy to 
describe? 
Yes. 
Is it clearly distinct from other 
interventions? 
Yes. 
Do participants have a shared 
sense of its purpose?  
FG suggest will have, but cannot be fully assessed until 
further evalution where practice nurses are 
‘recommending’ it. 
What benefits will the intervention 
bring, and to whom? 
Described within the ‘5 key tasks’ (section 5.2.3.1). 
Are the benefits likely to be 
valued by potential participants? 
Practices nurses – yes 
Patients – persuading those with asthma of the benefits 
will be one of the biggest challenges as identified in 
section 5.2.3.1.  
Will it fit with the overall goals and 
activity of the organisation? 
Yes, promoting self-managing is considered a key 
strategy for managing increasing health service 
demands. 
2. Cognitive Participation  (i.e commitment and engagement by participants) 
Are target users likely to think it is 
a good idea? 
Yes, from FG and TA studies, both patients and nurses 
describe a gap in service provision this intervention 
should fill. 
Will they see the point of the 
intervention easily 
Yes, practice nurses seem frustrated that patients do not 
engage with asthma reviews, and adhere to medications. 
Patients feel they are not provided with information and 
practice nurses can be inaccessible. 
Will they be prepared to invest 
time, energy and work in it? 
Practices nurses – realistically within a consultation they 
have little capacity for additional work, therefore this has 
to overall lighten their workload. 
Patients – qualititive work suggests yes, but literature 
suggests in real life setting the answer is no.  Therefore 
this requires as little work and time as is feasible.  
3. Collective Action (ie the work participants do to make the intervention function) 
How will the intervention affect 
the work of user groups? 
Living well with Asthma should be a website that practice 
nurses feel able to refer patients to during their asthma 
reviews, for example to provide further information 
advice, rather than used during the consultation. It could 
potentially reduce the pressure for practice nurses to 
cover everything in a review, as they can refer them to 
the website. It may reduce lack of patient satisfaction 
described during FG and TA with quality of asthma 
reviews. 
Will it promote or impede their 
work? 
As above, should promote. 
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What effect will it have on the 
consultation? 
Very little, as works to supplement the asthma review. 
Will staff require extensive 
training before they can use it? 
Living Well with Asthma was developed specifically so 
that it required no training.  
How compatible is it with existing 
practices? 
Entirely, as it is used entirely by patients in their own 
time at home. 
What impact will it have on 
division of labour, resources, 
power, and responsibility 
between different professional 
groups? 
It has been developed to supplement the asthma annual 
review, not replace it.  However it will hopefully facilitate 
optimum self-management of their asthma by users, as 
an additional resource and will support patients wishing 
to taking more responsibilty for their asthma 
management 
Will it fit with the overall goals and 
activity of the organisation? 
Yes, we are promoting patients actively learning more 
about their own asthma and how they can manage it 
better.  
 
4. Reflexive monitoring (i.e. participants reflect on or appraise the intervention) 
How are users likely to perceive 
the intervention once it has been 
in use for a while? 
One think aloud users queried the general static content 
that users will not go back unless new content is 
available.  The entire site can be navigated in about 1 
hour, therefore I anticipate that it may be used once or 
twice a year (perhaps prompted by the asthma review), 
or at times of increased disease burden such as during 
exacerbations.  
is it likely to be perceived as 
advantageous for patients or 
staff? 
All user group testing suggested it would be perceived 
positively by patients and practice nurses. 
Will it be clear what effects the 
intervention has had? 
Yes as ideally patients will attend more regularly for 
asthma reviews, experience fewer symptoms, better 
quality of life and take medications more optimally. 
Can users/staff contribute 
feedback about the intervention 
once it is in use? 
This should be possible. 
Can the intervention be adapted 
or improved on the basis of 
experience? 
Yes, one of the reasons for chosing LifeGuide software 
is how easy it is to modify interventions.  
 
 
Undertaking this analysis informed some of the key decisions we made early on 
in the development such as deciding to make it independent of health 
professionals so they would not need training to use it for example, and 
encouraged me to ensure that it would not impede practice.   
5.3.2.3 Living Well with Asthma – final version ready for evaluation 
Completion of this phase resulted in the final website ready for evaluation in the 
RAISIN trial [33].  Table 5.8 describes the final contents of the resource. 
 
Table 5.8 Final content of Living Well with Asthma website 
Topic  Summary of content 
Introduction pages 
†
 This section encourages users to recognise whether they are putting up with symptoms unnecessarily, and introduces concepts such as goal 
setting and its potential benefits 
My Asthma 
†
 There are three versions of this section tailored to current use of preventer therapy as chosen by the user.  
1. I have never used/been prescribed a preventer 
2. I have been prescribed a preventer but don’t really use it 
3. I mostly/always take my preventer inhaler as prescribed 
This section covers adherence and challenges negative beliefs about inhaled steroids.  
Treatments Provides information about different treatments. Links to videos to demonstrate inhaler technique and encourages users to consider whether 
they are on the correct ‘step’ of the asthma treatment ladder. 
Asthma Reviews Promotes attendance at asthma reviews outlining potential benefits to symptoms and quality of life.  Prompts user to recognise if putting up 
with symptoms, and to recognise if they are at risk of asthma attacks. 
Action Plans Describes what action plans are and their potential benefits. 
Provides a template action plan that can also be used by practice nurses during asthma reviews in local health boards. 
Physical Activity Promotes benefits of physical activity, and challenges negative beliefs about exercising with asthma. 
Provides practical advice and tips to encourage users to increase their activity levels.  
Common concerns 
and queries 
Answers 15 common queries and concerns that people with asthma may have, developed from the literature, focus groups and during think 
aloud studies.  
For example: I am worried about taking inhaled steroids long term, should I be? Why are some days better than others? 
Stress & Anxiety Promotes recognition of the role of stress on asthma, and how having asthma symptoms can lead to stress. Provides suggestions for reducing 
stress and anxiety. 
4 week Challenge The user is prompted to commit to taking their preventer inhaler regularly for 4 weeks.  Users can choose from a list of provided ‘barriers’ to 
taking their inhalers and review suggested strategies or can free text their own. They may sign up to receive weekly emails during the 
challenge. 
Like to stop 
smoking? 
This links to an external website called ‘StopAdvisor’ [165].  This has been developed using LifeGuide software and further details are 
available elsewhere. 
Useful info/ links This re-lists information and useful links that have been included elsewhere in the website.  
Email reminders These emails are sent every two months.  They all include the RCP 3 Questions to encourage the user to assess their current control and 
prompt them to visit the website or see their nurse or doctor if appropriate.  There are also reminders to order inhalers, or other medications 
(e.g. in time for hay fever season), or if going on holidays.  
† Section 1 and 2 are core sections and all users are directed through them at first login, and can optionally visit again during future sessions. 
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5.3.2.4 BCTs present in website 
Assigning BCTs to the webpages generated much discussion between myself and 
SW. Areas of discussion centred mainly round whether a section went far enough 
to have BCT 1.2 (Problem solving) attributed.  I had put pages providing video 
demonstration of inhaler use as BCT 6.1 (Demonstration of the behaviour) which 
upon discussion were changed to BCT 4.1 (Instruction on how to perform a 
behaviour).  We debated the meaning of BCT 5.3 (Information about social and 
environmental consequences), as to whether it included consequences at a 
personal level e.g. work and social situations, or only at a more societal level. 
Ultimately, we agreed on the former. 
In the end we agreed that 20 BCTs had been incorporated into Living well with 
Asthma website, covering 10 of the 16 behaviour change areas, and these are 
described fully in Table 5.9.  The most commonly used BCTs were  5.1 
(information about health consequences) and  6.1 (demonstration of the 
behaviour), followed by 1.2 (problem solving) and 4.1 (instruction on how to 
perform a behaviour). 
Overall, in terms of BCT groupings I mainly used BCTs within ‘goals and planning’ 
as a key behavioural technique within the website (e.g. BCTs 1.1, 1.2, 1.3, 1.6 
and 1.7) as seen in Table 5.9.  This reflects my desire to ensure that we were 
not providing information on its own, but encouraging users to reflect on their 
own behaviour, and how they might work towards changing their behaviour to 
achieve better outcomes for themselves.   
BCT groupings we did not cover at all were: Feedback and monitoring, reward 
and threat, regulation, identity, scheduled consequences, and covert learning. 
This reflects the limitations of a standalone digital intervention without 
integrated health professional support.
 
Table 5.9 Behaviour change technique mapping of Living Well with Asthma website 
  
No/ Label [107] Definition Sections Example within LWWA website 
Goals and planning  
1.1 Goal setting 
(behaviour) 
Set or agree on a goal defined in terms of the behaviour to 
be achieved  
4 week 
challenge 
Users commit to taking their preventer inhaler regularly for 4 
weeks 
1.2 Problem 
solving 
Analyse, or prompt the person to analyse, factors 
influencing the behaviour and generate or select strategies 
that include overcoming barriers and/or increasing 
facilitators (includes ‘Relapse Prevention’ and ‘Coping 
Planning’)  
My asthma 
Concerns & 
queries 
4 week 
challenge 
Users are prompted to consider reasons why they find it difficult to 
take their inhaler regularly (choosing from a list or free texting 
own).  Users are then presented with sample strategies to 
overcome identified barriers. 
1.3 Goal setting 
(outcome) 
Set or agree on a goal defined in terms of a positive 
outcome of wanted behaviour  
Intro Users are asked to identify how their asthma can negatively affect 
their everyday lives. They are then asked to review positive 
outcome goals to overcome these negative effects 
1.6 Discrepancy 
between current 
behaviour and 
goal 
Draw attention to discrepancies between a person’s current 
behaviour (in terms of the form, frequency, duration, or 
intensity of that behaviour) and the person’s previously set 
outcome goals, behavioural goals or action plans (goes 
beyond self-monitoring of behaviour)  
Asthma Review Asks validated questions to determine if currently putting up with 
asthma symptoms while believing themselves to be well 
controlled.  
1.9 Commitment Ask the person to affirm or reaffirm statements indicating 
commitment to change the behaviour Note: if defined in 
terms of the behaviour to be achieved also code 1.1, Goal 
setting (behaviour) 
4 week 
challenge 
Users tick three statements confirming they are committed to 
taking their preventer inhaler regularly for the duration of the 4 
week challenge. 
Social support  
3.1 Social support 
(unspecified) 
Advise on, arrange or provide social support (e.g. from 
friends, relatives, colleagues ,’buddies’ or staff) or non-
contingent praise or reward for performance of the 
behaviour. It includes encouragement and counselling, but 
only when it is directed at the behaviour  
Concerns & 
queries 
‘Where can I talk to other people about asthma’ section details 
and links to online forum, local support groups, and advice lines.  
 
Shaping knowledge  
4.1 Instruction on 
how to perform a 
behaviour 
Advise or agree on how to perform the behaviour (includes 
‘Skills training’)  
Treatments 
Asthma Review 
Exercise 
Users are given step by step instructions on how to use an inhaler 
correctly. This is followed up by a video demonstration. 
4.3 Re-attribution Elicit perceived causes of behaviour and suggest alternative 
explanations (e.g. external or internal and stable or 
unstable) 
Concerns & 
queries 
Describe common reasons why people with asthma put up with 
symptoms, illustrating that these beliefs are mistaken and 
providing alternative explanations for the symptoms. 
Natural consequences  
5.1 Information 
about health 
consequences 
Provide information (e.g. written, verbal, visual) about 
health consequences of performing the behaviour  
Intro 
My asthma 
Treatments 
Asthma review 
Exercise 
Concerns & 
queries 
Action plans 
Information provided that people who attend for regular asthma 
reviews have fewer symptoms and fewer asthma attacks. 
 
5.3 Information 
about social and 
environmental 
consequences 
Provide information (e.g. written, verbal, visual) about 
social and environmental consequences of performing the 
behaviour  
Asthma review 
Exercise 
Information provided that people who attend for regular asthma 
reviews have fewer days off school and work, and fewer 
limitations in activities. 
5.6 Information 
about emotional 
consequences 
Provide information (e.g. written, verbal, visual) about 
emotional consequences of performing the behaviour  
Concerns & 
queries 
People with asthma describe feeling embarrassed or ashamed 
taking inhalers in public. Information provided to overcome these 
concerns and increase confidence to use medications in public.  
Comparison of behaviour  
6.1 
Demonstration of 
the behaviour 
Provide an observable sample of the performance of the 
behaviour, directly in person or indirectly e.g. via film, 
pictures, for the person to aspire to or imitate (includes 
‘Modelling’). 
My asthma 
Treatments 
Asthma review 
Exercise 
Action plans 
Quotes for adults with asthma demonstrating how their lives 
changed for the better when they started taking their inhalers 
regularly. 
 
6.2 Social 
comparison 
Draw attention to others’ performance to allow comparison 
with the person’s own performance 
My asthma 
Concerns & 
queries 
In those who have identified that their asthma affects their work 
they are advised that this is the case with up to 40% of people with 
asthma.   
6.3 Information 
about others’ 
approval 
Provide information about what other people think about 
the behaviour. The information clarifies whether others will 
like, approve or disapprove of what the person is doing or 
will do 
Asthma review 
 
Quote from practice nurse praising people who proactively attend 
for asthma reviews.  
Associations  
7.1 Prompts/cues Introduce or define environmental or social stimulus with 
the purpose of prompting or cueing the behaviour. The 
prompt or cue would normally occur at the time or place of 
performance  
4 week 
challenge 
Emails   
Users who sign up to the 4 week challenge are sent weekly emails 
to remind them of the challenge and prompt them to continue. 
Repetition and substitution  
8.2 Behaviour 
substitution 
Prompt substitution of the unwanted behaviour with a 
wanted or neutral behaviour  
Exercise Users are provided with sample strategies to increase their levels 
of physical activity such as walking to the shops rather than taking 
the car, or giving up a TV programme for a dance class 
8.3 Habit 
formation 
Prompt rehearsal and repetition of the behaviour in the 
same context repeatedly so that the context elicits the 
behaviour  
4 week 
challenge 
Strategies for prompting users to remember to take inhalers are 
suggested such as using them at the same time as teeth brushing 
or the evening meal. 
Comparison of outcomes  
9.1 Credible 
source 
Present verbal or visual communication from a credible 
source in favour of or against the behaviour  
Exercise Bradley Wiggins quote describing how asthma does not stop him 
exercising.  
Antecedents  
12.5 Adding 
objects to the 
environment 
Add objects to the environment in order to facilitate 
performance of the behaviour. 
4 week 
challenge 
Strategies for prompting users to remember to take inhalers are 
suggested such having an extra inhaler at work, if they regularly 
forget their morning dose. 
Self-belief  
15.1 Verbal 
persuasion about 
capability 
Tell the person that they can successfully perform the 
wanted behaviour, arguing against self-doubts and 
asserting that they can and will succeed 
Exercise 
(external 
video) 
Users are directed to a video that promotes the message that 
anyone regardless of health status and fitness levels can 
successfully increase their levels of physical activity. 
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5.4 Discussion 
5.4.1 Summary of findings 
In this chapter I have demonstrated the feasibility of developing an evidence-
based, theory guided, user friendly behaviour change intervention in the form of 
Living well with Asthma - a website to support self-management in adults with 
asthma.  I have been guided by the MRC Framework on developing and 
evaluating complex interventions, and as a result directed much effort to the 
key, yet often overlooked, planning stages [100, 115].  I, with input from an 
expert panel, undertook recommended key tasks to guide content and methods 
[115] and through synthesis of empirical evidence, expert knowledge and 
experience, and incorporating theoretical concepts have co-designed with end 
users an evidence based behaviour change website for those with asthma. 
Using the literature as a starting point I developed an understanding of barriers 
and facilitators to asthma self-management.  Working through the 5 key tasks 
outlined by Campbell et al provided clear understanding of the problems and 
mechanisms for how the intervention could overcome these problems.  This 
knowledge was successfully translated into the Living Well with Asthma 
intervention, utilising user experience at various stages.  NPT analysis was 
undertaken to enhance the likelihood that what was developed was 
implementable in the longer term, should it prove to be effective.  The BCT 
mapping exercise demonstrated that the resource incorporated multiple BCTs, a 
strategy which in some health domains has been associated with increased effect 
sizes [141].  In particular, I used goals and planning as a key behavioural 
technique within the website. 
5.4.2 Strengths 
This study followed recommended processes for developing complex evaluations, 
and was undertaken by a multidisciplinary team with a range of essential skills, 
knowledge and experience (including behaviour change theory and 
implementation theory).  A key strength of this phase and the website I 
ultimately developed is in its co-design with potential end users, who had 
opportunity for input both at the early development planning stages in the form 
of focus groups, and also towards the end where their input via think aloud 
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studies was invaluable in improving the contents and usability of the resource.  
This ‘method’ has recently been the focus of a tutorial paper by members of the 
expert panel, and given a name: the ‘person based approach’ [166], providing 
rationale for incorporating multiple phases of qualitative work into the 
development of such interventions. 
Using LifeGuide software allowed for a streamlined and iterative process of 
website development where I could undertake a think aloud study and then 
subsequently modify the website, or I could act quickly from feedback from the 
expert panel.  Most computer programmers do not have a background in 
healthcare, and therefore removing the need to communicate user feedback 
about a health behaviour change website to a programmer made the process far 
more efficient.  
Although within this PhD project as a whole, the focus was on developing and 
piloting the intervention, consideration of how this intervention might be 
implemented in the future was given consideration from the beginning.  The 
consideration of the potential subsequent implementation of the website 
informed choices I made at these early stages in a number of ways.  Firstly, I 
recognised the potential benefits of using an implementation theory 
(normalisation process theory) [101], choosing one I had experience of [148]. I 
found it most useful for designing the focus group topic guide, rather than the 
analysis, and for undertaking a NPT analysis during the development.  Secondly, 
I spent time thinking about how such a website might work post trial i.e. in real 
life settings.  This encouraged me to think about who would host the website 
and subsequently keep it up to date in the long term.  This resulted in my 
choosing not to include forum/chat rooms, or include pictures of currently 
available inhalers.  As a result I made links with Asthma UK and explored their 
possible role in long term management of the website.  Thirdly, I also thought 
about what would prompt someone with asthma to visit this website – how would 
they find out about it?  So, in addition to links with a high profile website such as 
Asthma UK’s I believed from my own personal experience as a general 
practitioner, that health professional recommendation would be important.  This 
contributed to the decision to include practice nurses in the focus groups, 
recognising that practice nurses would need to ‘buy in’ to the idea of it, and 
promote it to patients if its use was going to be sustained long term.  This was 
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found to also be very important to patients where most in the think aloud 
studies felt they were most likely to visit a website like this if the practice nurse 
advised them too.  In addition, thinking about the long term plans  I made links 
with the NHS respiratory nurses and pharmacists who were members of the local 
Managed Clinical Network for Respiratory conditions, to make them aware of the 
project and arrange to discuss issues with them as required in an informal 
manner. 
5.4.3 Limitations 
In the focus groups we included both practice nurses and adults with asthma, 
which could be construed as a limitation.  However there are advantages to 
bringing together a diverse group of participants and we felt this was the case 
here [167].  This can maximise the exploration of different perspectives, which 
was pertinent here where differences in health professional and patient opinion 
is a recognised barrier to optimal uptake of self-management practices [9]. 
However if time and resources allowed it may have been useful to have hosted 
focus groups without nurses, as I may have got more information about what 
patients felt was missing from an asthma review or what aspects were done less 
well. 
The adults with asthma participating in the focus groups and think aloud studies 
had more severe asthma and were on more treatments than typical primary care 
patients.  This is because I only recruited 3 of the 10 participants from primary 
care.  I did not put an upper limit on asthma severity in my inclusion /exclusion 
criteria which would have allowed me to focus in more on those with mild to 
moderate asthma.  I managed this situation by tempering the suggestions and 
feedback from these end users with the practical experience of the practice 
nurses present in the focus groups, and the respiratory physicians and GPs 
(myself included) on the expert panel.  If doing something similar again, I would 
ideally aim for those participating in the co-design aspects to be more 
representative of those who would ultimately be using the website.  However, it 
is clear from my reading that the important thing with usability testing is that it 
is done in the first place, and it matters less who tests the website, so long as it 
is tested [116]. This is in contrast with user testing to consider the actual 
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contents of the page and message the website is trying to convey, and ideally for 
that purpose the sample would be more typical of end users.  
I undertook the think aloud studies, even though I was the person who had 
developed the website, and the participants knew this.  Professor Lucy Yardley 
(expert panel) would ordinarily use independent researchers to undertake think 
aloud studies to avoid any risk that the user would feel unable to openly criticise 
the website.  Therefore, I was concerned this could impact on the usefulness of 
the think aloud studies.  In order to counter this I really emphasised that it was 
easy to make changes with the LifeGuide software and that critical comments 
were generally the most helpful.  Exploring the scope of this limitation by 
counting negative comments was useful, as the high proportion of negative 
comments or suggestions for improvements indicates that participants did feel 
comfortable being critical of the website, and I did not get a sense that 
participants were holding back in any way.  Overall the benefits outweighed this 
negative for me in this specific project as it allowed me to quickly and 
efficiently make changes to the resource without having to go through a third 
party. 
5.4.4 Future considerations 
The ultimate aim of following the updated MRC guidance on the development 
and evaluation of complex interventions is to reduce the number of 
interventions which are developed which are not sufficiently grounded in 
everyday experience to be translated into everyday use, and avoiding costly 
large RCTs which due to unforeseen circumstances are unable to answer the 
research question posed [100].  I believe the iterative methods of development 
used here should minimise this risk.   
5.4.5 Conclusion 
I have developed a resource which the results from the think aloud studies 
suggests is relevant and usable by its target audience.  I have outlined the key 
steps which I went through, which included synthesis of knowledge and 
experience from our expert panel, exploring the literature, with overarching use 
of appropriate theory (behaviour change and implementation) and also with 
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input from potential stakeholders (adults with asthma and practice nurses) from 
an early planning stage.  Such methods are rarely fully detailed in the literature, 
however I have published an abridged version of these methods to allow other 
researchers fully understand my processes [168].  In conclusion, this chapter 
demonstrates how data from a wide range of sources can directly and practically 
influence the contents of a self-management website.  The next chapter details 
the evaluation of this resource.
 Chapter 6: Evaluation of ‘Living Well with Asthma’: 
Randomised controlled trial of an Asthma Internet 
Self-Management Intervention (RAISIN study) 
6.1 Overview & rationale 
This chapter outlines the methods and results from the pilot, phase II, 
randomised controlled trial (RCT) of the Living Well with Asthma website, and 
discusses the findings in the context of the current literature.  This evaluation 
study is referred to as the RAISIN study (Randomised controlled trial of an 
Asthma Internet Self-Management Intervention)’ 
A pilot study is ‘a version of the main study that is run in miniature to test 
whether the components of the main study can all work together’ [169], 
whereas a feasibility study is used to estimate important parameters that are 
needed to design the main study, such as ease of recruitment, standard 
deviations of outcome measures, and follow up rates [169, 170].  With this study 
I aimed to explore both feasibility and piloting.  Both are essential to ensure 
that planned progression to a full scale, phase III RCT is appropriate in the first 
place, and then if warranted, can be undertaken with appropriate power to 
achieve definitive results.   
6.1.1 Using NPT to inform trial design 
As described in Chapter 3, NPT was used to facilitate this process, by informing 
the design of the trial with the aim of reducing issues with recruitment or data 
collection that so frequently impact of the usefulness of trial results, a process 
described as ‘optimisation of trial parameters’ [111].  Undertaking a NPT 
analysis as described here forces the trialist to understand the context where 
they are planning on undertaking their trial and investigating whether the trial 
procedures are compatible with existing practice.  How will the trial affect the 
workload of those involved in the trial and those on the peripheries (health 
professionals, patients, support staff, admin).  This framework provides a list of 
questions to consider when designing a trial.  I used this framework iteratively 
when planning our trial design, and provide a written record of how it influenced 
the design here in Table 6.1. 
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Table 6.1 NPT analysis of RAISIN trial procedures 
 
Coherence   (i.e meaning and sense making by participants) 
Is the trial easy to describe? Yes 
Is it clearly distinct from other 
studies? 
Yes 
Does it have a clear purpose 
for all relevant participants? 
Practices can participate by either allowing researchers access 
to contact details of adults with asthma meeting inclusion 
criteria, and to send these potential particiapnts an invite to the 
study.  Alternatively practice nurses could hand out patient 
information leaflets to their patients during asthma reviews.  
The aim was to minimise workload to practices to optimise 
recruitment.   
Do participants have a 
shared sense of its purpose? 
There is little interaction if any between participants. 
What benefits will the trial 
bring and to whom? 
From a practice point of view participant may improve number 
of patients attending for asthma reviews and improved clinical 
outcomes for patients. For patients/participants themselves we 
hope participants may improve symptoms and quality of life.  
Are these benefits likely to 
be valued by potential 
participants? 
Practices are reluctant to take on any extra workload at 
present, even with financial recompense as many simply have 
no extra capacity for additional non patient workload. Adults 
with asthma often downplay their symptoms, so illustrating the 
potential benefits will be key to achieving recruitment targets.  
Will it fit with the overall 
goals and activity of the 
organisation? 
Overall aim is to promote optimum self-management, so yes.  
 
Cognitive Participation (i.e commitment and engagement by participants) 
Are target user groups likely 
to think the trial is a good 
idea? 
Practice staff describe people with asthma as reluctant to 
engage and may have doubts about the overall aim of the 
intervention itself. Patients themselves however are more 
positive about the provision of an extra resource for their 
condition, and understand that the trial is required for 
evaluation. 
Will they see the point of the 
trial easily? 
Health professionals should. Rationale for RCT covered in 
patient info leaflet 
Will they be prepared to 
invest time, energy and work 
in it? 
Primary care staff mostly will not be prepared to do this, 
therefore much effort has gone in to ensuring that recruitment 
has as little impact on practice workload as possible. 
Patient participants will have to give up approximately 2 hours 
of their time to participate, and given we provide no financial 
incentive we aim to be as accomodating as possible e.g. 
arranging trial visits during evenings and weekends and 
travelling to the participants homes.  
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Collective Action (ie the work participants do to make the intervention work 
How will trial procedures 
affect the work of user 
groups? 
Practices will need to provide research staff with access to a 
practice computer for approximately one hour. If practices 
chose to give out patient information leaflets during reviews 
they will simply hand the leaflet to the patient and ask them to 
contact the research team if they are interested.  
Will they promote or impede 
their work? 
The trial should have no effect on their work.  
What effect will it have on 
consultations? 
Very little if any at all.  
Will participation in the trial 
require extensive training for 
staff involved? 
No. 
How compatible is the trial 
with existing work practices? 
Very compatible.  
What impact will it have on 
division of labour, resources, 
power, and responsibility 
between different 
professional groups? 
Nil 
Will the trial fit with the 
overall goals and activity of 
the organisation? 
There should be no impact. 
 
Reflexive monitoring  (i.e. participants reflect on or appraise the intervention) 
How are users likely to 
perceive the trial once it's 
been on-going for a while? 
They may find that patients attend the practice prompted by the 
website.  
Is it likely to be perceived as 
advantageous for patients or 
staff? 
Practice staff may perceive it as advantageous if patients who 
previously didn’t attend for asthma reviews did attend.  
Will it be clear what effects 
the study has had? 
There may be little obvious impact at a practice level.  
Can users/staff contribute 
feedback about study 
procedures? 
Yes, participating practices will be provided with a summary of 
the results and offered opporunity to feedback. Intervention 
group participants are asked during followup interviews about 
their experiences of participating in the study.  
Can the study procedures be 
adapted/improved on the 
basis of experience? 
This is a pilot study so this would be one of the main aims of 
the study.  
 
This exercise was useful in this trial mainly to maximise the chances of us 
reaching our recruitment targets, by ensuring I had fully worked through the 
processes and the work that I was expecting mainly GP practices to undertake. 
6.2 Aims & research questions 
The aim of this evaluation was primarily to capture recruitment and retention 
data, but also to evaluate various outcome measures to allow for future sample 
size calculations, and to assess their suitability for inclusion in a future RCT.   
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I used the RE-AIM framework [113] to guide my methods, particularly in relation 
to choosing outcome measures. This framework has 5 domains: reach, efficacy, 
adoption, implementation and maintenance which ensures that an evaluation 
thinks beyond whether the intervention will work in a trial setting or not, to 
consider the broader picture of how it will perform in a real life setting.  I 
considered each domain in turn and generated questions to answer or outcomes 
to measure which would provide evidence from this RAISIN evaluation for each 
of the domains.  This is shown in Table 6.2.  
 
Table 6.2 RE-AIM Framework as related to the RAISIN study 
Domain Description 
Relevance to outcomes measured in 
RAISIN 
Reach An individual level measure of 
participation 
Recruitment and retention rates. 
Characteristics of those eligible and 
ineligible. 
Efficacy Measuring both positive and 
negative outcomes, 
considering both clinical and 
behavioural outcome 
measures, and including quality 
of life, patient satisfaction/ 
functioning perspectives. 
Assessing feasibility of a range of outcome 
measures including: 
Clinical: symptom scores /control, lung 
function, airway inflammation, health 
service contacts, medication use/changes’ 
Behavioural: adherence, activation 
Patient centred measures: asthma specific 
and generic QOL measures. Patient 
experience questionaire (PETS) 
Adoption Refers to the proportion and 
representativeness of settings 
that may adopt a program. This 
dimension is organisational in 
nature, but there are individual 
considerations. 
Out of those who were randomised to the 
intervention to what degree did they 
actually use the intervention? 
Do people who use the website differ to 
those who don’t? 
Implementation This refers to what extent the 
intervention is delivered as 
planned, and is  practical 
enough to be effective in a 
representative setting.  
What proportion of those allocated to the 
website used it, and how much? 
Understanding barriers to using the 
website – quantitatively using PETS and in 
depth interviews with those in the 
intervention arm.* 
Standalone internet delivered intervention 
means everyone offered same experience. 
Maintenance This refers to the extent 
interventions can become 
routine and embedded in every 
day practice.  
PETS. 
Analysing website usability data. 
Qualitative interviews.* 
*  separate project undertaken by colleague KS. PETS = problematic experiences of therapy scale, QOL = quality of life 
 
This exercise led to me generating the research questions for the study. 
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6.2.1 Primary research questions 
1. What are the likely recruitment and retention rates, over 12 weeks, for a 
trial comparing access to an internet asthma self-management resource 
(which aims to reduce symptom burden and improve quality of life in adults 
with asthma) with usual care, and how do those randomised differ from those 
screened and found to be ineligible? 
2. For those in the intervention arm, how much is the website used, as 
determined by reviewing website usage statistics.  Do those using the website 
differ from those who do not?   
3. What are the changes, if any, in asthma control from baseline?  
4. What are the changes, if any, in the asthma specific quality of life score from 
baseline? 
6.2.2 Secondary research questions 
1. What are the changes from baseline for the following  clinical outcome 
measures: 
a. Lung function (via pre-bronchodilator spirometry) 
b. Fractional exhaled Nitric Oxide (FeNO) 
c. Health service contacts (scheduled and unscheduled) 
d. Asthma medication prescriptions/treatment levels? 
2. What are the changes from baseline for the following behavioural measures: 
a. Self-reported adherence to medication   
b. Patient Activation Measure (PAM) 
3. What are the changes from baseline for the following  patient centred  
measures: 
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a. Health related QOL (EQ-5D) 
b. How difficult do those allocated to the intervention find using it?  The 
Problematic Experiences of Therapy Scale (PETS) used to assess this. 
4. What sample size would be required for a larger comparative study of access 
to the intervention, or usual care, for adults with asthma? 
6.3 Methods 
6.3.1 Ethical and management approval  
The study received ethical approval from the West of Scotland Research Ethics 
Committee (REC) (reference WS/13/004) in March 2013.  The study was 
reviewed initially at a panel meeting in January 2013, attended by me and 
supervisor Professor Mair.  The REC was keen to discuss several issues.  Firstly, 
one member questioned the validity of our approach at using a website to 
engender behaviour change, and expressed the view that they felt 
uncomfortable approving such a study without having a clearer idea of the 
contents of the website.  This was resolved by discussion and agreement that I 
would submit screenshots of the website to the committee for review prior to 
approval. NHS Greater Glasgow and Clyde Research and Development (R&D) 
agreed to sponsor the study. 
The other main concerns were regarding recruitment methods.  Firstly they 
queried my method of screening out unsuitable patients at GP practice level.  As 
once a search for potential participants was completed, the GPs would look at 
the list to screen out unsuitable patients such as those with palliative illness or 
cognitive impairment.  One committee member questioned the reliability of this 
method feeling that the computer would be more reliable than the GPs looking 
at the list.  It was explained that one of the main barriers to achieving focussed 
GP searches was the variability in coding between practices particularly in terms 
not featured in the Quality and Outcomes Framework (QOF), and it was agreed 
at the meeting that our approach was appropriate.  Following this meeting, the 
initial correspondence from the REC highlighted a further issue which had not 
been raised at the meeting itself: they stipulated that patients were not to be 
Chapter 6 Evaluation  159 
 
contacted a second time if they did not respond to our initial mailing.  I 
responded in writing by explaining our previous experiences of exceptionally 
difficult recruitment to asthma studies.  The REC agreed that, if required to 
achieve recruitment targets,  I could follow up an initial mailing with either a 
telephone call or a second letter, provided the reply slip was modified to make 
explicit that it would be possible that the research team could contact them a 
second time. As a result the following line was added:  “We may contact those 
who don’t respond to the initial mailing one further time either by telephone or 
by post.” as illustrated in the reply slip.  All correspondence to and from the REC 
is found in appendix 11.  
6.3.2 Recruitment  
6.3.2.1 Mailings from primary care 
Twenty primary care practices agreed to help with this research.  This involved 
allowing either me, a colleague (KS), or a member of the Scottish Primary Care 
Research Network (SPCRN) to visit the practice and undertake a search for 
patients with a diagnosis of asthma aged 16 years or over.  Due to high numbers 
of asymptomatic patients being identified the search strategy was refined over 
the recruitment period, to try and target our mailings more towards participants 
with active asthma who were requesting reliever therapy within a recent 
timescale.  
Patients identified through the search, and approved by the practice, received a 
letter (appendix 12) on their own GP headed note paper inviting them to 
indicate their interest in the study.  The mailing pack included a reply slip, a 
reply paid envelope, and a patient information leaflet (appendix 12).  Potential 
participants indicated their interest in the study by replying with their contact 
details directly to me, via mail, email or telephone. 
As discussed in section 6.3.1 we had ethical approval to follow-up an initial 
mailing with either a telephone call or a second mailing.  Patients were to be 
called no more than once and informed that we were still recruiting and asked if 
they were interested in hearing more about the study.  The second mailing was 
the same as the first.  
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Based on experience from previous asthma studies [171-173], I projected a 10% 
positive response rate, of which 25% would translate into randomisations.  
Therefore to randomise 50 we would need to screen 200, and therefore invite 
2000.  
6.3.2.2 Other recruitment strategies 
Posters (see appendix 13) were put up locally in pharmacies and in the 
university.  I had ethical approval to approach patients who had previously 
participated in asthma studies, and patients attending the difficult asthma clinic 
at Gartnavel General Hospital.  I also had ethical approval to recruit via 
snowballing – a method where those in the study can recommend it to friends or 
family.  
6.3.3 Screening for eligibility 
Once a positive response was received, potential participants were screened 
over the telephone.  This involved checking for obvious exclusion criteria, 
verbally assessing their symptoms using the asthma control questionnaire (6 
question version), and finally ensuring they met the rest of the inclusion criteria.  
Once confirmed that they met eligibility criteria a date for a baseline visit was 
arranged.  Potential participants were advised that they should contact us if 
their asthma flared up between screening telephone call and baseline visit, and 
that on the day of the visit inhalers should be withheld to allow for pre-
bronchodilator spirometry to be undertaken.  This telephone screening process 
was standardised by developing a checklist, a copy of which can be found in 
appendix 14. 
6.3.4 Inclusion criteria 
As outlined in the previous chapter, our development planning exercise had 
shown that adults with uncontrolled asthma were most likely to benefit from 
this intervention.  An Asthma Control Questionnaire (ACQ) ≥ 1 has been shown to 
be an acceptable cut off for established poor control so we only included adults 
above this cut off [155].  Participants needed to have symptoms for at least a 
year, to increase the likelihood we were including individuals with genuine 
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asthma, rather than viral related wheezing episodes.  The inclusion criteria 
were: 
1. Written informed consent 
2. Age 16 years or older 
3. Diagnosis of asthma by a health professional, and duration of asthma 
symptoms > 1 year 
4. ACQ (6 questions version)  ≥ 1 suggesting poorly controlled asthma 
5. Ability to access the internet via desktop or laptop (tablets and 
smartphones not sufficient) 
6.3.5 Exclusion criteria 
This intervention was designed to be used by individuals with mild to moderate 
asthma.  Given there was no monitoring of individuals between study visits we 
had to minimise the risk to patients, therefore we excluded people with 
unstable or severe asthma.  Our exclusion criteria were: 
1. Unstable asthma as defined as the presence of 1 or more of the 
following events in the 4 weeks prior to randomisation: 
a. asthma related hospital admission, 
b. A&E attendance for asthma 
c. ‘out of hours’ visit of patients to the GP for asthma 
d. GP visit to patient at home for asthma 
2. frequent asthma exacerbations with > 4 courses of oral 
prednisolone in the 12 months prior to randomisation 
3. Presence of active lung disease other than asthma 
4. Mental impairment or language difficulties that make informed 
consent impossible 
5. Terminal illness 
6. Cognitive impairment 
6.3.6 Study design 
The study was a 12 week1 parallel group randomised controlled trial.  Blinding of 
the participants was not possible due to the nature of the intervention.  Blinding 
                                         
1
 Follow up visit was at 12 weeks, or as soon as possible after this date 
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of myself as researcher was not possible as I was involved in all stages from 
recruitment, randomisation, follow up and data analysis.   Potential sources of 
bias were minimised where possible for example by collecting baseline data 
prior to randomisation, and ensuring concealment by using an automated 
interactive voice response system (IVRS) for group allocation.  The data 
collected was managed independently by an experienced clinical trials unit 
(CTU) at the Robertson Centre for Biostatistics (RCB), University of Glasgow.  
I was fortunate that alongside this project my colleague KS was able to 
undertake qualitative interviews with those in the intervention group, although 
they do not feature as part of this project itself. 
6.3.7 Trial management  
6.3.7.1 Routine trial management  
The routine management of the trial was coordinated by the Trial Management 
Group (TMG).  This comprised of me and all four PHD supervisors. The TMG 
monitored the progress of the trial ensuring that the protocol was adhered to 
and met bimonthly, with monthly recruitment reports via email.  
6.3.7.2 Delegation log  
I was chief investigator (CI) and led this evaluation. I coordinated recruitment, 
with support from SPCRN and Dr K Saunderson (KS). Screening assessment, 
baseline visits and follow-up visits were completed me or KS.  RCB handled 
anonymised trial data.  I undertook the statistical analysis of trial data, with 
support from statisticians at RCB.   
6.3.7.3 Protocol amendments 
Any changes to the study protocol were made following agreement with the 
TMG, and subject to approval from R&D and REC where required.  
6.3.7.4 Criteria for discontinuation  
The study planned to end when the TMG agreed that either: 
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 The planned sample size has been achieved. 
 The recruitment is so poor that completion of the trial is not feasible. 
6.3.7.5 Adverse events 
Adverse events (AEs) are defined as an adverse change in health that occurs 
while a patient is taking part in a study.  I planned to record only AEs which 
were outcome measures. 
6.3.7.6 Serious adverse events 
A serious adverse event (SAE) is any adverse event, which results in:  
1. Death, 
2. Is life-threatening, 
3. Inpatient hospitalisation or prolongation of inpatient hospitalisation, 
4. Persistent or significant disability/incapacity that interferes with the 
person’s ability to conduct normal activities of daily living, 
5. Congenital anomaly or birth defect. 
The term life-threatening’ in the definition of ‘serious’ refers to an event in 
which the patient was at risk of death at the time of the event; it does not refer 
to an event that hypothetically might have caused death if it were more severe.  
Hospitalisation for a pre-existing condition, including elective procedures, which 
has not worsened, does not constitute a serious adverse event.  An important 
medical event may be considered a SAE when, based on appropriate medical 
judgment, it may jeopardise the subject and/or may require medical or surgical 
intervention to prevent one of the outcomes listed.   
Any SAE that was ongoing on completion of the trial was to be followed until it 
resolved or stabilised, returned to baseline or could be attributed to factors 
unrelated to the study. 
Serious adverse reactions (SARs) and suspected unexpected serious adverse 
reactions (SUSARs) were not applicable in this study as this was not a clinical 
trial of an investigational medicinal product (CTIMP). 
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6.3.7.7 Reporting of serious adverse events 
The plan was for KS or I to record SAEs at follow-up.  All SAEs were assessed for 
seriousness, causality, expectedness and severity.  This assessment was the 
responsibility of the chief investigator (CI), which was me, or Prof F Mair during 
my maternity leave.  Any SAEs were sent to the sponsor and REC in an annual 
safety report.  Detailed records of all SAEs were held in the trial master file.   
6.3.8 Baseline characteristics 
Describing baseline characteristics is important to illustrate that both groups are 
roughly equal, which should be the case if robust randomisation procedures are 
followed.  Anecdotally there is concern that only fit, healthy adults put 
themselves forward for this type of study, therefore it is helpful to show that 
this sample have co-morbidities and in this way are representative of the wider 
population.  Co-morbidity counts were calculated by agreeing with FM and SW a 
list of what conditions counted as a condition and totalling them up.  This list 
was based on medical problems listed in the case report form (CRF) alongside 
the free text medical conditions.  No weighting was given to particular 
conditions, and they are listed in appendix 15. 
All baseline characteristics are presented descriptively. 
6.3.9 Primary outcome measures 
6.3.9.1 Recruitment and retention 
I recorded the number of invites sent, number of positive responses received, 
proportion who did not meet criteria, and ultimately numbers randomised.  
Retention refers to those who were available for follow-up visit, and therefore 
completed the study (including those who didn’t actually use the website).  
6.3.9.2 Website usage 
I measured use of the website in a number of ways 
1. Number of eligible users who log in 
2. Number of times users log in 
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3. Length of time users spend on website 
4. Most visited/least visited website sections. 
5. Users responses to questions about impact of asthma on their lives 
6. Choice of tailored sections: 
a. I have never been prescribed a preventer inhaler 
b. I have been prescribed an inhaler but don’t really use it 
c. I have a preventer and usually use it as prescribed 
I have also compared users of the website versus non-users using age, gender, 
SIMD and baseline measures of asthma control (ACQ), quality of life (mini-AQLQ) 
and adherence markers (MMAS, and % percentage prescribed ICS taken).  I define 
a non-user as someone who didn’t log in at all, or used the website for <10 
minutes.  Ten minutes was chosen as this is the approximate time taken to 
complete the core modules.  This data is important to try and understand how 
the intervention works or doesn’t work in practice, and inform any changes that 
may be beneficial before further evaluation. 
6.3.9.3 Asthma Control Questionnaire (ACQ) score 
The ACQ is widely used by both researchers in clinical trials and clinicians in the 
routine management of patients, and was the symptoms control outcome of 
choice for this study.  The alternative would have been the Asthma Control Test, 
which has similar sensitivity and specificity for detecting poorly controlled 
asthma [174, 175], and is also recommended as a core asthma outcome [135]. 
Overall, I chose the ACQ, due to being familiar with it, and cost, as the ACQ was 
free to me as a PhD student.  
The ACQ is a 7 item scoring system (6 questions filled in by participants and one 
lung function measure filled in by a health professional) [158].  The final score is 
the mean of the 7 responses (0 = good control, 6 = poor control).  In both 
settings the absolute score is meaningful i.e. ACQ ≥ 1 implies poorly controlled 
asthma [155], and the minimally important difference (MID) is recognised to be a 
change in score of ≥0.5 [176].  The MID is defined as: 
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‘the smallest difference or change in score which clinicians perceive as 
beneficial and would mandate, in the absence of troublesome side-effects 
and excessive cost, a change in the patient’s management’ [176] 
As a result the ACQ has been used as one of two clinical primary outcomes in this 
pilot study as it would be a likely candidate for any future full scale RCT 
evaluating this intervention.  I report both the change in scores, and the 
proportion whose change in score meets the MID. I also report the proportion of 
participants who would be classed as controlled by follow up (i.e. ACQ <1). 
6.3.9.4 Mini Asthma Quality of Life Questionnaire (AQLQ) score 
This was the obvious choice for me for outcome for measuring asthma specific 
QOL, as it is commonly used asthma specific measure [8].  The mini-AQLQ is a 15 
item self-administered questionnaire developed from an original 32 item AQLQ 
[177], and is recommended as a supplemental outcome for asthma evaluations 
[135].  It has 4 domains: symptoms (5 items), activity limitation (4 items), 
emotional function (3 items) and environmental stimuli (3 items).  As with the 
ACQ the MID for the mini-AQLQ is a change in score of ≥ 0.5.  One potential issue 
with this mini-AQLQ is item 7 which asks ‘How much of the time during the last 2 
weeks did you feel bothered by or have to avoid cigarette smoke in the 
environment?’  Since March 2006 smoking in public places has been banned in 
Scotland, and in all countries in the UK by July 2007, which renders this question 
potentially less relevant than previously.   
6.3.10 Secondary outcome measures 
6.3.10.1 EQ-5D 
The EQ-5D [178, 179] is a generic measure of health developed by the Euroqol 
Group (www.euroqol.org). I chose to include the EQ-5D as it is a frequently used 
generic measure of health related quality of life.  It is the preferred method for 
the UK National Institute for Health and Care Excellence (NICE), particularly 
when attempting to calculate quality adjusted life years (QALYs).  While cost–
effectiveness is not an outcome measured in this study, it will be in future 
studies, and therefore piloting of this outcome was indicated. 
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The EQ-5D has two parts, both designed to be completed by the participant.  
The first defines health in terms of 5 dimensions: mobility, looking after myself, 
doing usual activities, having pain or discomfort and feeling worried, sad or 
unhappy.  Each dimension is broken down into 3 categories covering whether the 
individual has no problem, some problems, or a lot of problems within the given 
dimension.  These dimensions are found on the first page of the questionnaire, 
and potentially 243 health states can be defined by this instrument.  Each of 
these 243 health states can converted into a single health utility score, by 
applying a European valuation set to the scores.  Health utility scores are 
anchored by 0 (dead) and 1 (perfect health).   
The second part of this health measure captures a self-rating of health status 
(‘How good is your health today’) on a visual analogue scale (VAS) ranging from 0 
(the worst health you can imagine) and 100 (the best health you can imagine).  
A copy of the questionnaire can be found within appendix 16.  
There is no defined minimally important difference (MID) for the EQ-5D specific 
to asthma populations.  However, one study looking at a range of datasets 
(included chronic obstructive pulmonary disease but not asthma) suggests that 
MID for the health utility score is 0.074 [180]. This is similar to a study 
concentrating on cancer patients which estimated the MID for UK populations of 
0.08 for the health utility scores and 7 for changes in the VAS [181].  How these 
figures relate to a UK sample of adults with mild to moderate asthma is not 
clear.  
There is rationale from COPD studies for using both generic (e.g. EQ-5D) and 
disease specific measures of health related QOL (e.g. AQLQ) in this case in order 
to capture the full effects of illness on an individual [182], justifying the use of 
two QOL measures. 
6.3.10.2 Morisky Medication Adherence Scale (MMAS) 
The Morisky Medication Adherence Scale (MMAS) is an 8 item generic medication 
adherence scale [183].  I chose this measure because it can be easily adapted to 
cover inhalers (many questionnaires talk only about pills), it is quick and easy to 
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use and interpret.  Although self-report has its limitations, it can be useful and 
accurate, particularly where participants feel they can be honest about their 
answers [60].  To this end, I made it clear at the start of the trial visits that this 
information was not reported back to GPs, and that being realistic about their 
inhaler use was most helpful to the study.  With the MMAS the results were also 
categorised as high adherence (score of 6 to 8) or low adherence (score of < 6), 
along with overall scores.  The MID for the MMAS is reported as a change in score 
≥2 [184]. 
6.3.10.3 Patient Activation Measure (PAM) 
The PAM is a 13 item questionnaire which gauges to what degree an individual 
has the knowledge, skills and confidence to manage their own health and health 
care.  Answering the 13 questions provides a ‘raw’ score which is then converted 
into the ‘activation’ score.  This activation score is used in two ways – firstly to 
determine if there has been a change in the overall activation score, and 
secondly it allows users to be stratified into one of 4 progressively higher 
activation levels (Table 6.3).  Ideally an intervention such as Living Well with 
Asthma should help an individual move up a level towards the stage of 
maintaining a desired behaviour, therefore the proportion of individuals moving 
up a level is also reported as well as the change in the activation score itself.  
 
Table 6.3 Description of PAM activation levels 
Level 
Activation 
Score 
Summary Explanation 
1 0 - 47.0 
Disengaged and 
overwhelmed 
Individuals are passive and lack confidence. 
Knowledge is low, goal-orientation is weak, and 
adherence is poor.  
2 47.1 – 55.1 
Becoming aware 
but still 
struggling 
Individuals have some knowledge, but large gaps 
remain. They believe health is largely out of their 
control, but can set simple goals. 
3 55.2 – 67.0 Taking action 
Individuals have key facts and are building self-
management skills. They strive for best practice 
behaviours, and are goal orientated.  
4 > 67 
Maintaining 
behaviours and 
pushing further 
Individuals have adopted new behaviours, but may 
struggle in times of stress or change. Maintaining 
a healthy lifestyle is a key focus. 
 
An alternative questionnaire we could have used instead of the PAM was the 
Knowledge, Attitudes and Self-Efficacy Asthma Questionnaire (KASE-AQ) which 
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up until more recently has been widely used and is asthma specific [185].  Each 
domain (knowledge, attitudes and self-efficacy) has 20 questions each.  It is now 
generally accepted that the knowledge domain is outdated and no longer fit for 
purpose, with recent studies using only the attitudes and self-efficacy questions 
[186].  Overall, I felt that the 13 item PAM best matched what we were hoping 
this intervention would achieve and chose it over the modified KASE-AQ, with 
the added benefit of minimising questionnaire workload for participants.   
6.3.10.4 Lung function via spirometry 
Spirometry measures how an individual exhales volumes of air as a function of 
time, and I aimed to measure pre-bronchodilator spirometry, which is 
considered a ‘core asthma outcome’ for asthma treatment evaluations [135].   
I used a Vitalograph Micro MO5523 portable device, and aimed to measured pre-
bronchodilator spirometry.  I received training from the manufacturer.  In 
accordance with the ATS/ERS statement and manufacturers guidance, a 
calibration check was undertaken daily.  The best of 3 measures were recorded 
(automatically by the device), and the device presented the ‘best’ version. 
Spirometry testing measures two main volumes: the forced vital capacity (FVC) 
and the forced expiratory volume in 1 second (FEV1).  The FVC is the volume of 
air delivered during a complete and forceful expiration, from full inspiration.  
The FEV1 is the volume expired in the first second of the FVC measurement.  
Two further measures can be derived from these two. Firstly the ratio of FEV1 to 
FVC (FEV1/FVC), which is mainly used to define airflow obstruction, with values 
less than 70% being suggestive of airway limitation such as that seen in asthma 
[187]. The second is the FEV1 % of predicted, where the predicted value is 
calculated from age, gender, height and weight, which are inputted to the 
device before testing.  
The Vitalograph also measured peak expiratory flow (PEF). Single results are of 
less use as a lung function measure, although serial measurements can be useful.  
Spirometry and PEF are considered core pulmonary physiology outcomes for 
describing asthma populations and assessing the response to an intervention in 
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clinical trials [188].  In particular, FEV1 and PEF are commonly used as outcome 
measures in asthma studies [6].  
In this study I report FEV1, FEV1 % of predicted, FVC, FEV1/FVC, and PEF.  The 
ATS/ERS provide guidance about what is considered an acceptable spirometry 
test [189]. In particular they state that, after three acceptable spirograms have 
been obtained, the two largest values of FVC must be within 0.150 L of each 
other, and the two largest values of FEV1 must be within 0.150 L of each other. 
If these criteria are not met then continue testing until acceptability is reached, 
8 tests have been performed, or the patient can no longer continue.  The other 
important stipulation is that certain bronchodilators should not be taken within a 
defined time period of the test occurring, for example no short acting 
bronchodilators within 4 hours.  
6.3.10.5 Lung inflammation: Fractional exhaled nitric oxide (FeNO) 
FeNO is an inflammatory biomarker, and provides information on airway 
inflammation, and is now an established measure for monitoring asthma (and 
adherence to ICS), particularly in trials and in secondary care [4, 135].  It is 
measured in parts per billion (ppb).  I used a NIOX MINI® Airway Inflammation 
Monitor to measure the FeNO.  ATS/ESR guidance [190] suggests a minimum of 2 
measurements per individual; however, NIOX MINI® manufacturer recommends 
only one.  Given this was a pilot study I undertook a single measure only.   
FeNO levels are high in those with uncontrolled asthma, and reduced following 
steroid therapy [191].  The normal range for adults varies. The ATS/ESR 
guidance defines the normal range as between 5 ppb and 35 ppb, whereas the 
NIOX MINI® manufacturer recommend stratifying adults as either low (<25 ppb), 
medium (25-50 ppb), or high (>50 ppb).  The clinical guide to interpreting FeNO 
values provided by the NIOX MINI® manufacturer advises that scores < 25 suggest 
either that the patient is adherent to adequate inhaled corticosteroids (ICS), or 
that another diagnosis should be considered.  Scores > 50 are consistent with 
inadequate ICS treatment, for example as the dose is too low, adherence is 
suboptimal, or inhaler technique is poor.  This outcome is expensive, each single 
use mouthpiece costing approximately £7, however the manufacturer of the 
NIOX MINI® Aerocrine Ltd provided the device and mouthpieces.  
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6.3.10.6 Changes to regular asthma medications 
This outcome is described in 4 ways: 
1. Change in number of puffs of reliever medication used in an average 
week. 
2. Percentage of prescribed ICS actually taken in an average weak. 
3. Equivalent beclometasone dose (mcg) prescribed at baseline and 
follow up. 
4. Change in step of the British Thoracic Society (BTS) treatment ladder 
(range 1-5). 
The ideal situation is for patients to be on adequate ICS that controls their 
symptoms so that reliever inhaler use is minimised, and ideally less than 4 puffs 
a week.  Consequently stepping up the BTS treatment ladder is not necessarily a 
sign of deteriorating asthma, but could be a sign that a patient has moved onto 
the correct treatment to manage their symptoms better.  
6.3.10.7 Oral prednisolone use and health service contacts. 
Courses of oral prednisolone are a marker of severe asthma exacerbations [34].  
A second course prescribed within 7 days of the first finishing was counted as a 
single course, as outlined by the ATS (American Thoracic Society taskforce [34].  
We also recorded whether the participants had any contact with health services 
for their asthma over the study period, including routine asthma reviews, non-
routine asthma appointments or unscheduled hospital or emergency room visits.  
6.3.10.8 Problematic experiences of therapy scale (PETS) 
This questionnaire was only for individuals in the intervention arm.  It measures 
difficulties experienced in relation to following the advice provided by an 
intervention [192].  It has 4 ‘domains’ which cover 1) whether symptoms 
themselves impede ability to follow advice, or are worsened by the advice, 2) 
uncertainty about how to follow the advice, 3) doubts about the efficacy of the 
website advice and 4) practical obstacles to following the advice such as time or 
opportunity.  It was the only patient experience questionnaire available which 
was suitable for this type of standalone non-pharmacological intervention, as 
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most experience questionnaires focussed on experience of face to face 
consultations [193] or inpatient stays [194] or about pharmacological treatments 
[195, 196]. 
6.3.11 Statistical analysis  
Analysis was conducted on an intention to treat basis on randomised individuals.  
Continuous data were summarised as mean and standard deviation (SD) or range, 
or as median and inter-quartile range (IQR). Categorical data was presented as 
counts and percentages.  Linear regression was used to estimate differences in 
continuous outcomes between groups at follow up, adjusting for baseline scores.  
Estimated between-group differences are reported with a 95% confidence 
interval (CI) and p-value.  For continuous outcomes that were not normally 
distributed, changes from baseline were compared between groups using 
Wilcoxon Rank Sum Tests.  Categorical variables were compared between groups 
using Fisher’s exact test.  All analyses were carried out using SPSS Statistics 22 
and Microsoft Office Excel.  
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6.4 Results: Baseline characteristics of participants 
This section details the baseline demographics, medical history, asthma history, 
asthma medications and contacts with health services for the participants as a 
whole (n =51, all those who completed a baseline visit) and per group.  These 
results confirm the groups were evenly matched, as expected in view of the  
robust randomisation procedures used. 
6.4.1 Baseline demographic characteristics 
The baseline demographic characteristics are shown in Table 6.4.  The average 
age of participants was just over 45 years, and the majority were female which 
is consistent with evidence that asthma is more prevalent in women [2], 
although contrasts with participant rates in studies published to date 54% of the 
participants in the RCTs included in the metareview were male [8].  The 
proportion of smokers in this study is lower than you would expect to find in the 
general asthma population, despite the spread across deprivation quintiles being 
reasonably even.  The majority of participants were employed and had 
completed some form of further education beyond high school at 65%, which is 
just higher than the Scottish school leavers rates of 54.7% in 2013 [197].  
However, this data only includes those attending further education before the 
age of 30 years age. 
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Table 6.4 Baseline demographic characteristics of study population per group, data are 
n(%) unless otherwise stated 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
Age (years) mean(SD) 45.5 (15) 46.4 (14) 44.6 (17) 
Female 38 (75) 20 (77) 18 (72) 
Ethnicity 
  White  48 (94) 24 (92) 24 (96) 
  Other 3 (6) 2 (8) 1 (4) 
Smoking status: 
   Current 5 (10) 2 (8) 3 (12) 
   Former smoker 18 (35) 11 (42) 7 (28) 
   Never smoked 28 (55) 13 (50) 15 (60) 
SIMD quintile (1 = most deprived, 5 = least deprived): 
   SIMD 1  14 (28) 7 (27) 7 (28) 
   SIMD 2 11 (22) 6 (23) 5 (20) 
   SIMD 3 9 (18) 4 (15) 5 (20) 
   SIMD 4 5 (10) 3 (12) 2 (8) 
   SIMD 5 12 (24) 6 (23) 6 (24) 
Employment status: 
  Employed 25 (49) 11 (42) 14 (56) 
  Unemployed 8 (16) 3 (12) 5 (20) 
  Retired 9 (18) 5 (19) 4 (16) 
  Student 2 (4) 1 (4) 1 (5) 
  Other 7 (14) 6 (23) 1 (4) 
Education level: 
  Secondary education 18 (35) 7 (27) 11 (44) 
  Tertiary/further education 33 (65) 19 (73) 14 (56) 
SIMD = Scottish Index of Multiple Deprivation 
 
 
6.4.2 Baseline medical history 
Table 6.5 shows the baseline medical history for the participants as a whole, and 
each individual group.  This demonstrates that the intervention group and 
comparison groups were well matched in terms of their body mass index (BMI) 
and medical conditions.  
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Table 6.5 Medical history of participants, data are n (%) unless otherwise stated 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
BMI (mean, SD) 30.4 (6.8) 31.3 (8.0) 29.4 (5.2) 
Hypertension 14 (28) 7 (27) 7 (28) 
Ischaemic heart disease 3 (6) 1 (4) 2 (8) 
Allergic rhinitis 25 (49) 12 (46) 13 (52) 
Perennial rhinitis 14 (28) 5 (19) 9 (36) 
Eczema disease 11 (22) 5 (19) 6 (24) 
Reflux 21 (41) 9 (35) 12 (48) 
Nasal polyps 5 (10) 2 (8) 3 (12) 
Dyspepsia/ ulcer disease 5 (10) 3 (12) 2 (8) 
Depression 14 (28) 8 (31) 6 (24) 
Anxiety 10 (20) 6 (23) 4 (16) 
Diabetes 2 (4) 2 (8.0) 0 (0) 
Osteoporosis 1 (2) 1 (4) 0 (0) 
Liver/renal disease 0 0 0 
Epilepsy 3 (6) 1 (4) 2 (8) 
BMI = body mass index (kg/m
2
) 
 
 
The number of co-morbidities is shown in Table 6.6.  As expected given the age 
group included in this study only 2 participants had asthma on its own, with all 
other participants having at least 1 co-morbidity.  
Table 6.6 Co-morbidities, data are n (%) unless otherwise stated 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
Number of comorbidities (over and 
above index condition) (mean, SD) 
2.6 (1.7) 2.6 (1.9) 2.6 (1.4) 
0 comorbidity 2 (4) 2 (8) 0 (0) 
1 comorbidity 14 (28) 8 (31) 6 (24) 
2 comorbidities 12 (24) 5 (19) 7 (28) 
3 comorbidities 10 (20) 3 (12) 7 (28) 
4 comorbidities 8 (16) 4 (15) 4 (16) 
5+ comorbidities 5 (10) 4 (15) 1 (4) 
 
 
6.4.3 Baseline asthma history and medications 
Table 6.7 describes the asthma history for the 51 participants who completed 
the baseline visit.  This demonstrates that those in the study had asthma for a 
considerable length of time, and the majority were on step 2 or 3 of the asthma 
treatment ladder indicating they were already prescribed ICS.  The treatment 
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ladder extends to step 5, however potential participants on this step would have 
met the exclusion criteria for unstable asthma.  This table suggests a slight 
difference between the groups with the comparison group possibly being on 
higher doses of ICS to start with, and using less reliever inhaler.  The comparison 
group also report taking more of their prescribed ICS dose than the intervention 
group.  Few participants had been prescribed oral prednisolone in the preceding 
12 months, therefore using mean or median to describe this variable was not 
helpful and the proportion being prescribed at least one course in the last 12 
months was used instead.  
Table 6.7 Asthma diagnosis and medications, data is either n (%), or median (IQR) 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
Length of asthma diagnosis (yrs) 18.5 (8.6 to 28.6) 17.0 (8.6 to 27.8) 20.3 (9.7 to 28.6) 
Family history of asthma 38 (75) 18 (70) 20 (80) 
BTS/SIGN treatment level: 
   Step 1  2 (4) 0 (0) 2 (8) 
   Step 2  20 (39) 9 (35) 11 (44) 
   Step 3  20 (40) 12 (46) 8 (32) 
   Step 4  9 (18) 5 (19) 4 (16) 
Equivalent beclometasone dose 
(mcg per day) 
400 (400 to 1000) 650 (400 to 800) 400 (200 to 1000) 
Puffs of reliever inhaler used per 
average week 
8 (4 to 20) 4 (2 to 12) 10 (4 to 28) 
% prescribed ICS taken in 
average week
*
 
88 (50 to 100) 100 (50 to 100) 86 (25 to 100) 
≥ 1 prednisolone course in last 12 
months 
16 (31) 9 (35) 7 (28) 
ICS = inhaled corticosteroids 
* Based on 50 participants (24/25 in intervention group), as one person not prescribed ICS 
 
 
The number of contacts with health professionals is shown in Table 6.8.  There 
were very few hospitalisations or visits to the emergency department in this 
group, therefore the data is presented as the proportion overall and per group 
with at least 1 event.  Around a half of participants had seen their GP for their 
asthma out with the usual routine review.  Only three participants had not 
attended for an asthma review in the preceding 12 months (all intervention 
group).  
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Table 6.8 Asthma related health service contacts in preceding 12 months, data is n (%) 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
≥ 1 hospitalisations or ED  visits  3 (6) 1 (4) 2 (8) 
≥ 1 urgent GP visits 25 (49) 15 (58) 10 (40) 
≥ 1 routine review 48 (94) 26 (100) 22 (88) 
ED = emergency department. GP = general practitioner 
 
 
6.4.4 Baseline questionnaire scores  
The baseline questionnaire scores again demonstrate that the groups were well 
matched (Table 6.9).  The ACQ shows these participants on average had 
uncontrolled asthma beyond the minimum requirement of ≥1, with mid-range 
quality of life scores.  The intervention group appear to have lower MMAS scores 
(self-reported adherence measure) which is consistent with the lower reported 
percentage of ICS taken reported earlier, although interestingly this does not 
translate into any obvious differences in symptoms, QOL, or PAM scores.   
Table 6.9 Baseline questionnaire scores, data are n (%), or median (IQR) unless otherwise 
stated 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
ACQ mean (SD) 
(range 0 – 6)  
2.0 (0.6) 2.1 (0.7) 1.9 (0.6) 
Mini-AQLQ mean (SD) 
(range 1 – 7)  
4.8 (1.0) 4.6 (1.0) 5.1 (1.0) 
EQ-5D index 
(range 0 – 1.000) 
0.796 
(0.689 to 1.000) 
0.796 
(0.620 to 1.000) 
0.848 
(0.725 to 1.000) 
 EQ-5D VAS 
(range 0 – 100) 
80 
(70 to 85) 
80 
(70.0 to 90) 
75 
(70 to 84) 
MMAS total score 
(range 0 – 8) mean (SD): 
4.80  (1.91) 5.02  (2.14) 4.53 (1.61) 
MMAS low adherence (score <6) 26 (57.8) 12 (48) 14 (70) 
Patient Activation Measure (PAM) 
(range 0 – 100), mean (SD) 
66.3 (12.6) 66.8 (14) 65.8 (11) 
   Level 1  3 (6) 1 (4) 2 (8) 
   Level 2 5 (10) 4 (15) 1 (4) 
   Level 3 27 (53) 11 (42) 16 (64) 
   Level 4 16 (31) 10 (39) 6 (24) 
ACQ = Asthma Control Questionnaire. AQLQ = Asthma Quality of Life Questionnaire. MMAS = Morisky Medication 
Adherence Scale. PAM = Patient Activation Measure, 1 is lowest, 4 is best. VAS = visual analogue scale. 
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6.4.5 Baseline spirometry 
In order to measure true pre-bronchodilator spirometry, participants had to 
remain off certain inhalers for a specific number of hours prior to the 
measurement.  We recorded this in 49 out of the 51 participants and found that 
2 participants in total (4%), (1 in each group), had taken medication that could 
interfere with their spirometry.  In addition, tests had to meet reproducibility 
criteria outlined in the methods section.  
Of the 51 baseline visits completed, 32 met ATS/ERS acceptability standards, 
with no between group differences seen (Table 6.10).  The reasons for the 19 
not meeting ATS guidelines were primarily due to not meeting reproducibility 
criteria (n=16), with the remaining 3 having either taken medication which could 
have interfered with spirometry result (n=1), or the data was missing in error 
from the CRF (n=2).  Achieving reproducibility targets was limited by the 
spirometry device we used.  This only provided a graph and reproducibility 
figures after being connected to a separate laptop and transferring the data – a 
process which could take 5-10 minutes.  Any second attempt would require 
starting from scratch again with a minimum of three measures again.  Given that 
ATS recommend a maximum of 8 measures in one sitting, we really only had two 
chances to get the reproducibility figures required. 
Table 6.10 Achieving ATS standard spirometry at baseline 
ATS standard 
Met 
Total 
(n= 51) 
Comparison 
(n = 26) 
Intervention 
(n = 25) 
p – value * 
Yes 32 (63) 15 (58) 17 (68) 
0.565 
No   19 (37) 11 (42) 7 (32) 
* Fisher’s Exact Test   
 
 
The spirometry results for these 32 participants is shown in Table 6.11.  This 
shows the groups were well matched.  The overall mean FEV1/FVC ratio was 
76.0%, over the 70% cut off considered to reflect obstructive airway diseases 
such as asthma. This does not reflect misdiagnosis as often spirometry is normal 
between exacerbations in asthma [4].  
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Table 6.11 Baseline spirometry of those meeting ATS/ERS acceptability criteria, data are 
mean (SD) unless otherwise (n=32). 
 
Overall 
(n = 32) 
Comparison 
(n = 15) 
Intervention 
(n = 17) 
FEV1 (L) 2.58 (0.59) 2.51 (0.64) 2.66 (0.55) 
FEV1 % predicted 83.8 (14.2) 82.0 (15.5) 85.8 (12.9) 
FVC (L) 3.42 (0.71) 3.36 (0.70) 3.48 (0.74) 
FEV1/FVC *100 75.9 (9.1) 75.0 (11.0) 76.9 (6.5) 
PEF (L/min) (via spirometry) 408 (94) 399 (87) 417 (105) 
FEV1 = forced expiratory volume in 1 second. FVC = forced vital capacity. PEF = peak expiratory flow.  
 
 
The full 51 baseline spirometry measures are shown in Table 6.12, which shows 
similar results to those achieving acceptability criteria.  
Table 6.12 Baseline lung function and inflammation results of all participants, data are 
mean (SD) unless otherwise (n=51) 
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
FEV1 (L) 2.51 (0.69) 2.46 (0.75) 2.56 (0.64) 
FEV1 % predicted 82.7 (14.4) 81.1 (14.6) 84.4 (14.4) 
FVC (L) 3.40 (0.99) 3.28 (0.91) 3.61 (1.07) 
FEV1/FVC *100 74.3 (11.0) 75.3 (10.0) 73.1 (12.5) 
PEF (L/min) (via spirometry) 389 (108) 390 (101) 388 (116) 
FEV1 = forced expiratory volume in 1 second. FVC = forced vital capacity. PEF = peak expiratory flow. 
 
 
As this was pilot study we were interested in how feasible it was to measure 
spirometry in participants own homes, using a hand held device.  In this study 
those not meeting ATS criteria were technically considered to be missing data.  
6.4.6 Fractional exhaled Nitric Oxide (FeNO) 
Table 6.13 reports the baseline FeNO results, which is a measure of lung 
inflammation.  The low/normal FeNO may seem slightly at odds with the ACQ 
which indicated a lack of control.  This could be explained by the fact that 
50/51 (98%) were on ICS at baseline and median self-report adherence was 88%, 
as those taking ICS are known to have lower FeNO scores.   
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Table 6.13 Baseline Fractional exhaled Nitric Oxide (FeNO) results, data are median and IQR   
 
Overall 
(n = 51) 
Comparison 
(n = 26 ) 
Intervention 
(n = 25) 
FeNO (ppb) 
median (IQR) 
26 
(13 to 45) 
26 
(11 to 38) 
26 
(19 to 45) 
FeNO = fractional exhaled nitric oxide. IQR = interquartile range.  ppb = parts per billion. 
 
 
6.4.7 Missing data 
There was minimal missing data.  On two occasions, the information about 
whether participants had taken relevant inhalers prior to their spirometry was 
missing, as described above.  With regards to the mini-AQLQ, one participant 
(ID17) had a missing response for 1 question at visit 2.  This was managed used 
the recommended method of interpolating (pro-rata) missing values.  There was 
one questionnaire response from MMAS missing from one participant (ID56).  As 
per MMAS guidelines, the median value for that question was used.  This was 
well within the 75% completion criterion for this questionnaire to be considered 
valid.  Finally, there was one response missing for one participant for the PAM 
score (ID 53).  This was managed as recommended by PAM literature where the 
total score is divided by the number of answers available, and then multiplied by 
the number of questions (13).  
6.5 Results: Primary outcomes  
6.5.1 Primary outcome1: Recruitment and retention 
6.5.1.1 Flow of participants 
The flow of participants through the study is outlined in Figure 6.1 
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Figure 6.1 Flow of participants through study 
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6.5.1.2 Recruitment from Primary Care 
I coordinated recruitment aided by my colleague KS and the SPCRN.  We sent 
5383 invites from 20 practices across Greater Glasgow and Clyde health board 
areas, with one practice population receiving a second follow up mailing.  These 
practices along with list sizes and deprivation percentages are shown in Table 
6.14.  The even spread of deprivation across the 20 participating practices is 
shown in Figure 6.2. 
Figure 6.2 Levels of deprivation within participating practices 
 
Recruitment to previous asthma studies has been very challenging, so in order to 
detect if there were similar issues with this trial I planned monthly recruitment 
updates.  Based on previous experience I calculated how many positive 
responses I should be aiming for in order to meet recruitment targets, and then 
tracked the positive responses as they arrived.  This is illustrated in the graph 
below (Figure 6.3), and shows that our initial response was poorer than 
anticipated, but then caught up and exceeded the target.  
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Table 6.14 Mailings from primary care results 
Practice 
Code 
List 
size * 
% practice 
population deprived
†
 
% of list 
size 
mailed 
Invites  
posted 
Date invites 
posted 
Randomised  % of mailing 
randomised 
% practice list 
randomised 
52382 3049 31.30 7.2% 221 01/05/13 5 2.3% 0.16% 
40008 6439 14.94 3.0% 192 29/07/13 2 1.0% 0.03% 
52330 4000 67.68 7.4% 297 14/08/13 2 0.7% 0.05% 
49681 8341 5.09 4.4% 371 03/09/13 2 0.5% 0.02% 
87112 6567 0.01 5.8% 382 30/10/13 6 1.6% 0.09% 
43538 2149 69.94 8.9% 191 30/10/13 3 1.6% 0.14% 
40116 4102 51.66 5.7% 234 15/11/13 1 0.4% 0.02% 
43576 
‡
 21620 22.35 2.3% 493 01/12/13 1 0.2% 0.00% 
40121 5209 10.17 4.1% 211 03/12/13 6 2.8% 0.12% 
49074 2620 48.62 3.8% 100 03/12/13 0 0.0% 0.00% 
40031 4448 8.03 1.5% 65 04/12/13 0 0.0% 0.00% 
40046 8971 38.80 5.0% 448 03/01/14 3 0.7% 0.03% 
49642 6593 29.75 5.9% 391 03/01/14 8 2.0% 0.12% 
42255 6550 36.63 3.8% 248 03/01/14 4 1.6% 0.06% 
40210 1700 37.56 8.6% 146 16/01/14 0 0.0% 0.00% 
43011 5992 55.17 4.1% 246 30/01/14 4 1.6% 0.07% 
87471 7716 30.37 1.7% 133 30/01/14 0 0.0% 0.00% 
43100 7529 4.15 4.9% 372 01/02/14 0 0.0% 0.00% 
43576 
‡
 21620 22.35 0.9% 200 01/02/14 3 1.5% 0.01% 
87339 5012 24.66 2.6% 129 03/02/14 0 0.0% 0.00% 
40140 11379 5.45 2.8% 313 03/02/14 1 0.3% 0.01% 
    5383  51   
* correct at time invites posted 
† % practice population in lowest deprivation quintile, correct as of 18/2/15 
‡  more targeted search criteria used in second mailing from same practice accounts for lower percentage of list size mailed. 
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Figure 6.3 Target positive responses alongside actual positive responses 
While the positive response rate from the first practice was lower than 
anticipated (5.5%), there were 5 randomisations from it: 42% of positive 
responses, 2.3% of the mailing, and 0.16% of the practice list.  This provided us 
with falsely optimistic recruitment projections, whereby if the following 3 
practices had maintained this I would have expected to randomise 30 
participants from them, whereas as Table 6.14 shows only 6 were randomised.  
The reasons why the first practice randomisation rate was so much higher than 
subsequent practices is not clear, and subsequently there was considerable 
variation across the practices with no obvious relationship to deprivation. 
This lower than projected positive responses and randomisation was detected by 
September and a further drive to recruit more practices and send out more 
mailings was undertaken as a result.  This is shown in Table 6.14, and illustrated 
visually in Figure 6.4. 
Chapter 6 Evaluation  185 
Figure 6.4 Target for randomisation alongside actual randomisation 
 
As well as recognising that we needed to recruit more practices, I responded to 
this by reviewing the search criteria used to identify potential participants, with 
a view to making it more targeted.  When refining search terms, beyond a 
certain number of limiters, I noted that the results of the search became less 
reliable and reproducible, becoming a particular issue once more than 6 search 
terms were used.  The original search had 2 terms: 
Asthma (active problem) 
AND ≥ 16 years 
By the final search this has been modified to: 
Asthma (active problem) 
AND ≥ 16 years 
AND salbutamol inhaler (in preceding 8 months) 
NOT Spiriva, tiotropium (COPD specific inhalers) 
NOT oral prednisolone (current repeat medication) 
NOT palliative care register. 
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Targeting the mailing in this way roughly halved the number of potential 
participants identified.  Targeting the mailing in this way had two particular 
benefits.  Firstly, it reduced the financial and time costs of preparing and 
posting mailing packs which were targeting patients who were unlikely to fulfil 
our requirements.  It also reduced the size of the list of patients that GPs had to 
screen, thereby reducing their work and speeding the process up. 
6.5.1.3 Other recruitment methods 
All participants were recruited from primary care mailings.  We had 1 telephone 
enquiry and 2 email enquiries from contacts of those who had been screened 
(snowballing technique) but none were ultimately eligible. We did not recruit 
anyone from posters, and we did not attempt to recruit from secondary care, or 
previous asthma participants. 
6.5.1.4 Screening for eligibility 
As we received positive responses my colleague KS and I screened them for 
eligibility over the telephone.  We screened 185 potential participants, 
eventually randomising 51 (28%).  On average, those who were randomised were 
more likely to be younger and more likely to be female, but importantly there 
was no difference in the deprivation category between those randomised versus 
those ineligible (Table 6.15).  
Table 6.15 Screening data (n, % unless otherwise stated)  
 
Ineligible 
(n = 134 ) 
Randomised 
(n=51) 
p values 
Age (years) * mean (SD) 51.5 (17.0) 45.5 (15.4) 0.03 
Female (%) 50.0 74.5 0.03 
SIMD quintile ( 1 most deprived, 5 least deprived)
† 
  
   SIMD 1  34  (27.9) 14  (27.5)  
   SIMD 2  22  (18.0) 11  (21.6)  
   SIMD 3  15  (12.3) 9  (17.6) 0.721 
   SIMD 4  20  (16.4) 5  (9.8)  
   SIMD 5  31  (25.4) 12  (23.5)  
* Data for 177/185 individuals  
† Scottish Index of Multiple Morbidity, data for 173/185 individuals 
 
 
Of the 134 people who were not eligible to participate, the most common reason 
was that their ACQ was less than 1, i.e. they were not symptomatic enough.  The 
full breakdown for reason for exclusion is shown in Table 6.16.  Thirteen of 
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these 134 potential participants had originally passed the telephone screening 
stage, but weren’t randomised, for reasons outlined in Figure 6.1.  
Table 6.16 Reason for exclusion (data available for 131/134 individuals) 
Reason for exclusion* n (%) Age yrs (mean, SD) 
ACQ score <1 92 (70) 50 (17) 
No internet access 10 (8) 73 (12) 
Changed mind/unable to contact 10 (7) 39 (14) 
Other lung disease 9 (7) 58 (9) 
Unstable asthma 8 (6) 51 (15) 
No Asthma, or symptoms < 1 year 1 (1) 78 
Cognitive impairment 1 (1) n/a 
 n/a = not available  
 
 
Table 6.16 also shows the average age of the individuals per exclusion reason. 
This demonstrates that those who ‘changed their mind’ were younger in general.  
This usually happened when potential participants were willing and able to 
participate but we were unable to agree a date for arranging the study visits. Or 
occasionally we would arrange one or two visit dates and the participant would 
cancel repeatedly, often due to work or family commitments.  The other main 
interesting finding is that those who were ineligible due to not having internet 
access appeared to be older than those ineligible for other reasons.  
6.5.1.5 Attrition rates 
In the intervention group, 5 of the 25 were not available for follow up visits 
(20%), and 1 out of 26 (4%) in the comparison group (shown earlier in Figure 6.1), 
so overall attrition was 12%.  Reasons for loss to follow up in intervention group 
was mainly that participants appeared unavailable for follow up visits, rather 
than being unable to contact them at all.  All 5 had not used the website and I 
speculate that they may have felt uncomfortable about this and preferred to 
avoid the second visit.  This was despite reassurances that the follow up 
appointment was still very helpful to us.  We were unable to contact the 
individual in the control group at all for a follow up visit.  
6.5.2 Primary outcome 2: Website use 
Table 6.17 provides some results about how the website was used.  Twenty five 
participants were allocated to the intervention group and 19 of those logged on 
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(76%).  This is comparable to the experiences of those in the expert panel 
working on a range of other health behaviour change websites, who had 
suggested about 75% of those allocated will log on (personal communication)  
Out of the 19 who logged in, 17 went beyond the initial introduction module to 
reach the section where the website became specifically tailored.  At this point 
users were asked to identify which one of 3 options they most identified with.  
The majority of people reported that they usually used their preventer as 
prescribed.  
Figure 6.5 illustrates the number of log ins and total time spent on the website 
for the 20 participants who completed the study and suggests that those who 
logged in more than once tended to use the website overall for longer.  
Table 6.17 Website use by those who completed study, during study period 
Number (%) of eligible participants who logged in 19/20 (95%) 
Mean umber of logins  ( median, range) 1.8 (1, 0 – 7) 
Mean time spent logged in minutes (range) 22.6 (0 – 48.9) 
Number choosing individual options (n = 17):  
   I have never been prescribed a preventer inhaler 1 (6%) 
   I have been prescribed an inhaler but don’t really use it 6 (35%) 
   I have a preventer and usually use it as prescribed 10 (59%) 
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Figure 6.5 Total time logged in and number of logins per participant (in order of length of 
time on website) 
 
Table 6.18 confirms that the majority of participants agreed that asthma 
impacted on their lives in some way. 
Table 6.18 User responses regarding impact of asthma on life, n = 19. 
Questions asked by website: Yes (n) * 
1. Does your asthma ever stop you doing things you would like to do? 
(exercising, working, gardening, housework, visiting friends for 
example) 
10/19 
2. Does it sometimes affect your sleep? 12/19 
3. Do coughs and colds sometimes cause your asthma to flare up? 16/19 
4. Do you often have to use your blue/reliever inhaler more than twice 
a week? 
15/19 
5. Have you had an asthma attack (e.g. needing steroid tablets) in the 
last 6 months? 
1/19 
Users ticking at least one limitation due to asthma (options 1-5 above) 
n (%) 
18/19 (95) 
*  Users could choose more than one.  
 
Table 6.19 lists how often the individual sections were visited and how long was 
spent there.  Every section of the website was visited at least twice.  Beyond the 
core ‘introduction’ and ‘my asthma’ sections the most popular sections were 
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‘physical activity’ and ‘common concerns and queries’.  ‘Take the 4 week 
challenge’ was also popular.  It was visited 17 times, with 4 users completing the 
section and signing up to the 4 week challenge and 3 opting in to have email 
reminders.  Although 2 users visited the stop smoking page, neither went on to 
subsequently register for the smoking cessation support.  
Table 6.19 How often different sections were visited and for how long 
Topic  
Total time 
spent (mins) 
Number of visits 
to section * 
Number of users 
visiting section 
Introduction page 
(including home page) 
†
 
127.9 19 19 
My Asthma (total) 
† ‡ 
76.8   
   No preventer 12.5 2 2 
   Sometimes preventer 16.6 7 7 
   Usually preventer 47.7 16 10 
Treatments 17.1 7 3 
Asthma Reviews 
§
 30.0 7 7 
Action Plans 19.4 6 5 
Physical Activity 46.0 13 9 
Common concerns and queries 20.2 15 11 
Stress & Anxiety 6.0 4 3 
Take the 4 week Challenge 57.4 17 13 
Like to stop smoking ? ‖  1.0 3 2 
Useful info and links 22.7 11 9 
* most number of visits to the introduction pages of a section 
† Users were tunnelled through these sections at initial login 
‡ Users had to chose one of three options to progress through this section 
§ 6 users visited quiz within this section 
‖
 
This section only consisted of 1 page which linked to an external smoking cessation website, also developed using 
LifeGuide software. 
 
 
6.5.2.1 Website users compared to non-users 
This section presents results on all of those allocated to the intervention (n=25) 
not just the 20 participants who completed the study.  These results are shown 
in Table 6.20.  Nine out of the 25 intervention group participants could be 
classed as non-users (6 of whom didn’t use it at all).  There does seem to be a 
suggestion that non-users while more likely to be from a deprived area, were 
overall experiencing better controlled asthma, and enjoyed higher quality of life 
scores (none of which was statistically significant).  They did have statistically 
significantly higher MMAS scores  indicating as a group they were more likely to 
take their medication. This perhaps implies less need for such a resource.  
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Table 6.20 Website users compared to non-users at baseline, data are n(%) unless 
otherwise states 
 Non-users (n = 9) Users (n = 16) p values 
Age years (mean, SD) 46.4 (16.6) 43.6 (17.4) 0.688 
Female 7 (78) 11 (69) 1.000 
SIMD quintile  (1 = most deprived, 5 = least deprived)  
   1 4 (44) 3 (19) 
0.683 
   2 2 (22) 3 (19) 
   3 1 (11) 4 (25) 
   4 0 2 (13) 
   5 2 (22) 4 (25) 
ACQ at v1 1.69 (0.57) 2.00 (0.56) 0.205 
mini-AQLQ at v1 5.46 (0.66) 4.83 (1.07) 0.084 
MMAS at v1 5.4 (1.4) 4.0 (1.6) 0.034 
ACQ – asthma control questionnaire. AQLQ = asthma quality of life questionnaire. MMAS = moriskly medication 
adherence score. SIMD = scottish index of multiple deprivation. v1 = visit 1 
 
 
6.5.3 Primary outcome 3: Asthma Control Questionnaire (ACQ)  
My first clinical primary outcome was the 7 question ACQ, and baseline scores 
between the two groups were well matched.  Baseline adjusted analysis showed 
the mean ACQ in the intervention group was lower (desirable) than the 
comparison group by 0.42 (95% CI -0.11 to 0.95) at follow up.  This was not 
statistically significant, with full details shown in Table 6.21 below.  I have 
presented the results graphically in Figure 6.6 below. 
Table 6.21 ACQ 7 question version score (n = 45) 
 
Baseline 
Mean 
(SD) 
Followup 
Mean 
(SD) 
Change 
Mean 
(SD) 
Estimated difference 
(a)
 
(95%CI), p – value 
(Intervention – Comparison) 
ACQ  
ACQ  
(range 0 – 6)   
Intervention 
1.89 
(0.57) 
1.23 
(0.80) 
-0.65 
(0.92) 
-0.42   (-0.95  to 0.11), 
 
0.121 Comparison 
2.08 
(0.66) 
1.78 
(1.06) 
-0.30 
(0.85) 
(a) Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value 
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Figure 6.6 Boxplot of ACQ at baseline and follow up between groups 
 
 
 
The minimally important difference (MID) [176] is a reduction of 0.5 or more.  
Table 6.22 shows that for 55% in the intervention group, ACQ score decreased by 
0.5, compared to 48 % in the comparison group, not statistically significant. 
Table 6.22 Improvement in ACQ by ≥ 0.5 at follow up, data are n (%) 
 
Comparison 
(n = 25) 
Intervention 
(n = 20) 
Between group 
p value * 
ACQ < MID  13 (52) 9 (45) 
0.767 
ACQ  ≥ MID  12 (48) 11 (55) 
* Fishers exact  test   
 
 
All participants in the study had an ACQ ≥ 1 at baseline.  Table 6.23 shows that 
by follow up 45% in the intervention group compared to 24% in the comparison 
group had a score of <1, i.e. they had moved from ‘uncontrolled’ to ‘controlled’.  
Table 6.23 Proportion at follow up (v2) with ACQ <1, data are n (%) 
 
Comparison (n = 
25) 
Intervention (n = 
20) 
Between group 
p value * 
ACQ < 1 at v2 6 (24) 9 (45) 
0.205 
ACQ ≥ 1 at v2 19 (76) 11 (55) 
* Fishers exact  test  
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Due to the high number of spirometry not meeting ATS criteria, I also analysed 
the equally valid 6 question version of the ACQ [198], as this does not include a 
spirometry related item, and found a similar result. 
Table 6.24 ACQ 6 item version scores (e.g no spirometry measure) (n = 45) 
 
Baseline 
Mean 
(SD) 
Followup 
Mean 
(SD) 
Change 
Mean 
(SD) 
Estimated difference * 
(95%CI), p – value 
(Intervention – comparison) 
ACQ  
(range 0 – 6)   
Intervention 
1.87 
(0.59) 
1.22 
(0.91) 
-0.65 
(1.08) 
-0.36   (-0.96  to 0.23), 
 
0.225 Comparison 
1.97 
(0.68) 
1.65 
(1.15) 
-0.32 
(0.94) 
*  Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value 
 
The MID results for the 6 question version are the same as for the 7 question 
version, as reported previously in Table 6.22. 
6.5.4 Primary outcome 4: Mini Asthma Quality of Life 
Questionnaire (AQLQ) score 
Our second clinical primary outcome was the 15 item mini AQLQ.  Baseline 
adjusted analysis showed the mean mini-AQLQ score in the intervention group 
was higher (desirable) than the comparison group by 0.38 (95% CI -0.13 to 0.89) 
(Table 6.25) at follow up. 
The scores were then analysed for the 4 individual domains (Table 6.25 also). 
This shows that the activity limitation domain was both statistically and 
clinically significantly improved in the intervention group at follow up, with all 
other domains trending in the direction of favouring the intervention, with the 
symptom domain difference reaching clinical but not quite statistical 
significance. 
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Table 6.25 Mini-AQLQ total and individual domain scores 
 
Baseline 
Mean 
(SD) 
Followup 
Mean   
(SD) 
Change 
Mean 
(SD) 
Estimated difference 
*
 
(95%CI), p – value 
(Intervention – Comparison) 
Mini-AQLQ total score (range 1 – 7) 
mini-AQLQ 
Intervention 
4.97 
(1.03) 
5.40 
(1.01) 
0.43 
(0.78) 
0.38  (-0.13 to 0.89) 
 
p = 0.136 Comparison 
4.65 
(1.02) 
4.76 
(1.30) 
0.11 
(0.88) 
Mini-AQLQ Individual Domains Scores (range 1 – 7) 
Symptom 
 
Intervention 
4.56 
(1.10) 
5.15 
(1.20) 
0.59 
(1.10) 
0.56  (-0.08  to 1.22) 
 
p = 0.084 Comparison 
4.30 
(0.84) 
4.38 
(1.35) 
0.08 
(1.05) 
Activity 
limitation 
Intervention 
5.30 
(1.24) 
5.98 
(0.92) 
0.68 
(1.01) 
0.60  (0.05  to 1.15) 
 
p = 0.034 Comparison 
5.31 
(1.33) 
5.38 
(1.33) 
0.07 
(1.10) 
Emotional 
function 
Intervention 
5.48 
(1.09) 
5.75 
(1.01) 
0.27 
(0.78) 
0.35  (-0.33  to 1.03) 
 
p = 0.301 Comparison 
4.80 
(1.48) 
4.84 
(1.82) 
0.04 
(1.30) 
Environmental 
Stimuli 
Intervention 
4.75 
(1.39) 
4.85 
(1.30) 
0.10 
(0.89) 
0.08  (-0.46  to 0.62) 
 
p = 0.768 Comparison 
4.11 
(1.54) 
4.23 
(1.67) 
0.12 
(0.90) 
* Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value.  AQLQ = Asthma Quality of Life Questionnaire 
 
 
Fifty percent of participants in the intervention group compared to 35% in the 
comparison group achieved the MID, again not statistically significant as shown 
in Table 6.26. 
Table 6.26 Proportion with mini-AQLQ improvement ≥0.5 (MID) at follow up, data are n 
(%) 
 
Comparison 
(n = 25) 
Intervention 
(n = 20) 
Between group 
p value * 
mini-AQLQ < MID  16 (64) 10 (50) 
0.379 
mini-AQLQ ≥ MID  9 (36) 10 (50) 
* Fisher’s Exact Test  
 
 
6.6 Results: Secondary outcomes 
6.6.1 EQ-5D 
There was no difference in the change in EQ5D health utility scores between 
groups (p = 0.972) as shown in Table 6.27. 
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The second part of the EQ-5D is the visual analogue scale (VAS). This asks 
participants to rate their health ‘today’ (i.e. day they are filling out the scale) 
from 0 (worst possible) to 100 (best imaginable).  The median difference in the 
score at follow up in the intervention group was 2.5, compared to 1.0 in the in 
comparison group (p = 0.409) as outlined in Table 6.27. 
Table 6.27 EQ Health Utility and EQ-5D visual analogue scale (VAS) results 
 
Baseline 
Median (IQR) 
Follow up 
Median (IQR) 
Change 
Median (IQR) 
p – value* 
EQ-5D Health Utility 
Intervention 
0.848 
(0.725 to 1.000) 
1.000 
(0.796 to 1.000) 
0.000 
(0.000 to 0.111) 
0.972 
Comparison 
0.796 
(0.620 to 1.000) 
0.796 
(0.727 to 1.000) 
0.0000 
(-0.052 to 0.194) 
EQ-5D VAS  
Intervention 
75 
(70 to 84) 
80 
(73 to 88) 
2.5 
(-6.5 to 13.0) 
0.409 
Comparison 
80 
(70 to 90) 
80 
(70 to 90) 
1.0 
(-10 to 10) 
*  Wilcoxon test on change in scores (v2 – v1)      
 
 
6.6.2 Patient Activation Measure (PAM) 
The PAM score ranges from 0 to 100, and a high score is desirable indicating a 
patient is highly activated in relation to managing their own health.  Baseline 
adjusted analysis showed that the mean difference in the score in the 
intervention was an improvement of 7.72 (95%CI 0.53 to 14.90, p value 0.036). 
Table 6.28 Patient activation measure scores 
 
Baseline 
mean 
(SD) 
Followup 
mean 
(SD) 
Change 
mean 
(SD) 
Estimated difference * 
(95%CI), p – value 
(Intervention – Comparison) 
PAM score 
(range 0-100)   
Intervention 
65.7 
(10.0) 
73.0 
(13.9) 
7.3 
(11.3) 
7.72 (0.53 to 14.90) 
 
0.036 Comparison 
66.2 
(14.1) 
65.7 
(16.5) 
-0.5 
(12.5) 
*  Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value 
 
 
This individual PAM activation score can be used to stratify individuals into one 
of 4 levels as outlined in Table 6.29.  The numbers in each individual level are 
small but there is a suggestion that those in the intervention group moved up 
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from level 3 to level 4, more than the comparison group, although it is worth 
noting there were more in the comparison group at level 4 at baseline.   
Table 6.29 PAM activation levels per group 
 Baseline Follow up 
 
Comparison 
(n,%) 
Intervention 
(n,%) 
Comparison 
(n,%) 
Intervention 
(n,%) 
Level 1 
Disengaged and 
overwhelmed 
1 (4.0) 1 (5.0) 2 (8.0) 1 (5.0) 
Level 2 
Becoming aware but still 
struggling 
4 (16.0) 0 (0.0) 4 (16.0) 0 (0.0) 
Level 3  
Taking action 
11 (44.0) 16 (80.0) 11 (44.0) 8 (40.0) 
Level 4 
Maintaining behaviour, 
pushing further 
9 (36.0) 3 (15.0) 8 (32.0) 11 (55.0) 
 
 
Another way of presenting this data is to look at the score at visit 1, and score at 
visit 2 and show the change per group (Table 6.30). This shows visually that 
more participants in the intervention group changed up a level (n=8).  Where in 
the comparison group there was change in both directions, with 4 participants 
moving up, and 6 dropping down a level.  
Table 6.30 PAM level change per group, data are n% 
Comparison group (n=25) 
 
Intervention group (n = 20)  
     v2 
 v1 
Level 
1 
Level 
2 
Level 
3 
Level 4 
      v2          
 v1 
Level 
1 
Level 
2 
Level 
3 
Level 4 
Level 1 1 (4)     Level 1 1 (5)    
Level 2 1 (4) 1 (4) 2 (8)   Level 2     
Level 3  2 (8) 7 (28) 2 (8)  Level 3   8 (40) 8 (40) 
Level 4  1 (4) 2 (8) 6 (24)  Level 4    4 (20) 
Greyed out boxes are no change in level between visits 
 
This data is summarised in Table 6.31, showing more in the intervention group 
moved up a level (40%), than in the comparison group (16%) (p = 0.096). 
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Table 6.31 Participants who moved up an activation level by visit 2, data are n (%) 
 
Comparison 
(n = 25) 
Intervention 
(n = 20) 
p – value* 
No increase in PAM Level  21 (84) 12 (60) 
0.096 
Increase in PAM level  4 (16) 8 (40) 
* Fisher’s Exact Test  
 
 
6.6.3 Morisky Medication Adherence Scale (MMAS) 
As reported earlier the baseline adherence data may suggest the intervention 
group had lower adherence at the  start.  By follow up, baseline adjusted 
analysis showed mean MMAS score in the intervention group was higher than in 
the comparison group by 0.19 (95% CI -0.50 to 0.88, p = 0.586), (Table 6.32).  
However, looking at the scores per group these show the intervention group 
improved more than the comparison group (0.58 vs 0.23) but had lower scores at 
baseline, therefore this may represent regression to the mean. 
Table 6.32 MMAS Total score (max = 8 = high adherence) 
 
Baseline 
Mean 
(SD) 
Followup 
Mean 
(SD) 
Change 
Mean 
(SD) 
Estimated difference * 
(95%CI), p – value 
(intervention – comparison) 
MMAS total 
score  
(range 0-8) 
Intervention 
4.88 
(1.97) 
5.46 
(1.80) 
0.58 
(1.37) 
0.19 (-0.50 to 0.88) 
 
p = 0.586 Comparison 
5.59 
(1.85) 
5.82 
(1.85) 
0.23 
(1.03) 
* Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value 
 
 
If I look specifically at those who did improve by 2 or more,( i.e. the proportion 
who achieved the MID) then Table 6.33 shows that 30% in the intervention group 
achieved this compared to only 4% in the comparison group (p = 0.034). 
Table 6.33 MMAS score improvement ≥ 2, n (%) 
 
Comparison 
(n = 25) 
Intervention 
(n = 20) 
p – value * 
MMAS score change < 2  24 (96) 14 (70) 
0.034 
MMAS score change ≥ 2   1 (4) 6 (30) 
* Fisher’s Exact Test  
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6.6.4 Problematic experiences of therapy scale (PETS)  
PETS aims to facilitate understanding of what barriers there are to using an 
intervention.  This can be reported two ways.  Firstly, as shown in Table 6.34, 
the mean score for each domain can be calculated, and the median score (IQR) 
for each domain presented. 
Table 6.34 PETS scores (range 1-5)  (intervention group only, n = 19) 
Domain Median (IQR) 
Symptoms too severe to follow  website advice, or 
symptoms aggravated by website advice 
1.0 
(1.0 to 1.0) 
Uncertain how to follow the website advice 
1.0 
(1.0 to 2.0) 
Doubt about personal relevence of website advice 
1.0 
(1.0 to 1.7) 
Practical obstacles to following website advice 
(e.g time, opportunity) 
3.3 
(2.0 to 4.0) 
1 = strongly disagree with statement, 5 = strongly agree with statement 
 
 
The lowest possible score for each domain is 1 and corresponds to strongly 
disagreeing with the statements.  Reassuringly the majority of people disagreed 
with statements relating to the first 3 domains.  However, where people started 
to agree more strongly was when identifying practical barriers to using the 
intervention such as time and opportunity. 
Another way of displaying the results of PETS is to look at the proportion of 
people who identified any barrier at all to using the intervention within a given 
domain, as shown in Table 6.35, confirming again that the biggest barriers are 
related to time and opportunity.   
Table 6.35 PETS Any barriers identified i.e agree or agree strongly with statement 
describing barriers (n = 19) 
 Any barriers  n (%) 
Symptoms too severe to follow  website advice, or 
symptoms aggravated by website advice 
4 (21) 
Uncertain how to follow the website advice 7 (37) 
Doubt about personal relevance of website advices 8 (41) 
Practical obstacles  to following website advice (e.g time, 
opportunity) 
18 (95) 
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6.6.5 Lung function results 
Out of the 45 participants who completed, 22 participants had spirometry tests 
meeting ATS criteria at both baseline and follow up visits, with no significant 
differences between treatment groups (Table 6.36), with 11 in each group.  Of 
the 23 who didn’t meet criteria, not meeting reproducibility was the most 
common reason (n=21) with either medication taken prior to spirometry (n=3) or 
the data was missing from either visit 1 or visit 2 (n=2), with some participants 
having more than one reason for failing. 
Table 6.36 Achieving ATS standard spirometry 
 
Comparison 
(n = 25) 
Intervention 
(n = 20) 
p – value * 
Achieved ATS standard  11 (44) 11 (55) 
0.554 
Not achieving ATS standard   14 (56) 9 (45) 
* Fisher’s Exact Test  
 
 
The results from spirometry for the 22 meeting acceptability criteria are shown 
below (Table 1.36).  This demonstrates that while trends favoured the 
intervention group, there were no statistically significant results.  
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Table 6.37 Spirometry results (n=22) 
 
Baseline 
Mean 
(SD) 
Followup 
Mean   
(SD) 
Change 
Mean 
(SD) 
Estimated difference 
*
 
(95%CI), p – value 
(Intervention – comparison) 
FEV1 (L) 
Intervention 
2.62 
(0.56) 
2.72 
(0.58) 
0.10  
(0.18) 
0.08  (-0.12 to 0.27) 
 
0.428 Comparison 
2.66 
(0.69) 
2.68 
(0.49) 
0.02  
(0.31) 
FEV1 % 
predicted 
Intervention 
87.4 
(13.6) 
90.6 
(13.8) 
3.3 
(6.3) 
3.4  (-2.8 to 9.5) 
 
0.265 Comparison 
85.2 
(17.1) 
85.7 
(11.9) 
0.6 
(9.4) 
FVC (L) 
Intervention 
3.44 
(0.76) 
3.47 
(0.79) 
0.02 
(0.15) 
0.20  (-0.10  to 0.50) 
 
0.177 Comparison 
3.44 
(0.72) 
3.27 
(0.62) 
-0.18 
(0.46) 
FEV1 
/FVC (%) 
Intervention 
76.7 
(7.0) 
79.1  
(6.7) 
2.4 
(5.3) 
-0.4 (-3.9  to 3.1) 
 
0.829 Comparison 
77.6 
(10.9) 
80.2 
(9.5) 
2.6 
(4.5) 
PEF (L/min) 
Intervention 
400  
(107) 
408  
(120) 
7 
(56) 
-6.5  (-60  to 47) 
 
0.803 Comparison 
420 
(92) 
431 
(76) 
10 
(56) 
* Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value.  FEV1 = forced expiration in 1 second. FVC = forced vital capacity. PEF = peak expiratory flow. 
 
 
The importance of focussing on the participants who met acceptability criteria is 
demonstrated by performing the analysis on all 45 participants’ data (Table 
6.38).  This shows statically significant baseline adjusted improvements in both 
FEV1 and FEV1 % predicted scores.  
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Table 6.38 Lung function results (n=45) 
 
Baseline 
Mean 
(SD) 
Followup 
Mean   
(SD) 
Change 
Mean 
(SD) 
Estimated difference 
*
 
(95%CI), p – value 
(Intervention – comparison) 
FEV1 (L) 
Intervention 
2.54 
(0.57) 
2.63 
(0.59) 
0.09 
(0.20) 
0.185  (0.027 to 0.343) 
 
0.023                                          Comparison 
2.46 
(0.77) 
2.37 
(0.77) 
0.09 
(0.30) 
FEV1 % 
predicted 
Intervention 
83.6 
(14.4) 
86.5 
(13.7) 
2.9      
(7.0) 
6.45 (1.06 to 11.8)   
 
0.020                                                                  Comparison 
81.0 
(14.9) 
78.0 
(15.6) 
-3.08 
(10.62) 
FVC (L) 
Intervention 
3.68 
(1.11) 
3.53 
(0.97) 
-0.14 
(1.00) 
0.163  (-0.252  to 0.578)                                                            
 
0.432 Comparison 
3.28 
(0.93) 
3.11 
(0.92) 
-0.17 
(0.45) 
FEV1 
/FVC (%) 
Intervention 
72.0 
(13.4) 
75.6  
(8.2) 
3.6 
(11.28) 
2.1 (-2.3  to 6.4)                                                                 
 
0.344 Comparison 
75.3 
(10.2) 
75.3 
(10.4) 
0.0 
(6.44) 
PEF (L/min) 
Intervention 
388   
(99) 
400  
(106) 
12 
(56) 
3.3 (-31.4 to 38.0)                                                                       
 
0.850 Comparison 
390 
(103) 
398  
(106) 
8 
(59) 
* Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value.  FEV1 = forced expiration in 1 second. FVC = forced vital capacity. PEF = peak expiratory flow. 
 
 
6.6.6 Fractional exhaled nitric oxide (FeNO) results 
FeNO scores were not normally distributed unless both v1 and v2 scores were 
logged, and I present both original and logged results (Table 6.39) and neither 
demonstrate a difference. 
Table 6.39 Fractional exhaled Nitric oxide results 
 
Baseline 
Mean 
(SD) 
Followup 
Mean   
(SD) 
Change 
Mean 
(SD) 
Estimated difference 
*
 
(95%CI), p – value 
(Intervention – comparison) 
FeNO (ppb) 
Intervention 
37.5 
(34.3) 
33.8 
(32.0) 
-3.8 
(27.1) 
5.5 (-5.8 to 16.8)                                                                        
                                                                    
0.333 Comparison 
29.5 
(24.1) 
22.9 
(21.4) 
-6.6 
(13.8) 
logFeNO 
Intervention 
3.33 
(0.76) 
3.17 
(0.83) 
-0.16 
(0.49) 
0.14  (-0.17 to 0.46)                                                                  
 
0.361 Comparison 
3.06 
(0.85) 
2.87 
(0.71) 
-0.19 
(0.44) 
* Regression model estimate of difference between groups in the mean change in outcome, adjusting for baseline 
value.  FeNO = fractional exhaled nitric oxide. Ppb = parts per billion. 
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6.6.7 Changes to regular treatments  
The results of these outcomes were not normally distributed, and log 
transformation did not improve this.  Therefore the results are presented as 
median and IQR, with the difference between the groups being assessed using 
Wilcoxon Rank Sum test.  
As described in baseline characteristics the intervention group appeared to use 
more puffs of reliever inhaler, and less inhaled corticosteroids (ICS) than the 
comparison group at baseline.  There is a statistically significant difference 
between the change in reliever use at follow-up in the intervention group 
compared to comparison group (p = 0.022), with the intervention group using 
significantly less than they started with (desirable) as shown in Table 6.40.  
However, in the context of much higher use to start with, it is unclear if this is a 
true difference between the groups, or represents regression to the mean.  With 
regards to percentage of prescribed ICS taken, and equivalent beclometasone 
dose there was very little change. 
Table 6.40 Changes to medication use (self-reported) 
 
Baseline 
Median (IQR) 
Follow up 
Median (IQR) 
Change 
Median (IQR) 
p – value* 
Puffs reliever per average week 
Intervention 
11 
(7 to 28) 
5 
(0.5 to 14) 
-7 
(-14 to 1 ) 
0.022 
Comparison 
4 
(2 to 12) 
4 
(0 to 28) 
0 
(-4 to 4) 
Percentage prescribed ICS reportedly taken 
Intervention 
85.7 
(14.3 to 100.0) 
92.9 
(71.4 to 100.0) 
0.0 
(0.0 to 14.3) 
0.730 
Comparison 
100.0 
(71.4 to 100.0) 
100.0 
(85.7 to 100.0) 
0.0 
(0.0 to 7.1) 
Equivalent Beclometasone Doses prescribed  (mcg) 
Intervention 
400 
(300 to 1000) 
400 
(300 to 1000) 
0 
(0 to 0) 
0.209 
Comparison 
800 
(400 to 800) 
800 
(400 to 800) 
0 
(0 to 0) 
*  Wilcoxon on change in scores (v2 – v1)     ICS = inhaled corticosteroids 
 
 
I collected data about whether participants changed their step on the BTS 
ladder.  Given that to be in the trial participants had to have uncontrolled 
asthma it was surprising that 3 participants were stepped down.  This trial  
coincided with a locally enhanced service for GPs where they were incentivised 
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to reduce the number of people on high dose inhaled steroids.  From one 
participant actively mentioning this at a visit, I am aware that this drove the 
stepping down in that occasion.  Otherwise 91% of participants remained on the 
same step. 
Table 6.41 Change in BTS treatment step by follow up 
 
Comparison 
(n = 25) 
Intervention 
(n = 20) 
p – value * 
Step down  1 (4.0) 2 (10) 
0.768 No change 23 (92) 18 (90) 
Step up 1 (4) 0 (0) 
* Fisher’s Exact Test.  BTS = British Thoracic Society  
 
 
Figure 6.7 Change in BTS step between groups 
 
 
 
6.6.8 Oral prednisolone use and health service contacts 
In total there were 4 courses of prednisolone prescribed: 3 in the comparison 
group (to 3 different participants) and 1 in the intervention group (p = 0.617).  
The numbers of health service contacts were generally low.  There were no 
hospital or A&E visits for asthma in either group.  Six participants from the 
comparison group visited their GP or practice nurses for non-routine asthma care 
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a total of 10 times, and 3 from the intervention group each visited their GP or 
practice nurse once (p = 0.710).  Eight participants from the comparison group 
attended for a routine review during the study period compared to 5 in the 
intervention group (p = 0.616). 
Table 6.42  Prednisolone courses and health service contacts for asthma over the 
study period 
  
Comparison 
(n = 25) 
Intervention 
(n = 20) 
p value* 
Prednisolone 
courses 
Total 
courses  
3 1  
N (%) with at 
least one 
3 (12) 1 (5) p = 0.617 
Hospital/ED 
visits 
Total  visits 0 0  
Non-routine 
GP/nurse visits 
Total 
Visits 
10 3  
N (%) with at 
least one 
6 (24) 3 (15) p = 0.710 
Routine 
GP/nurse visits 
Total routine 
reviews 
8 5  
N (%) with at 
least one 
8 (32) 5 (25) p = 0.745 
* Fishers exact test    
 
 
6.6.9 Serious Adverse Events (SAEs), and evidence of harm 
There were no serious adverse events recorded during the study period. There 
was no evidence of harm from using the intervention, there was no significant 
difference in health service contacts, or courses of oral prednisolone prescribed 
(suggesting a severe exacerbation).  
6.7 Sample size calculations 
Our primary outcomes included ACQ and AQLQ, and this allows me to estimate 
sample size for any future full scale RCT to show a clinically relevant difference.  
Both the ACQ and AQLQ have a widely accepted minimal important difference 
(MID) of 0.5 [176].  In the first section I use the ACQ results to inform the 
calculations  
There are two ways to calculate a sample size, the first is to use only follow up 
data, and the second is to take into account the correlation between follow up 
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scores with baseline scores.  Once a sample size has been calculated attrition 
rates should then be taken into account. 
6.7.1 Sample size calculation using follow up data only 
The calculation used is:       N = 2 x f(α,β) x σ2/d2  
The explanations are shown in Table 6.43. 
Table 6.43 Sample size calculation abbreviations 
Shorthand Explanation RAISIN 
N sample size per group to be established 
α significance level 0.05 
β 1 – power 0.1 
σ standard deviation 1.0 
d minimal important difference 0.5 
f(α,β)  [Φ-1(α/2)+Φ-1(β)]2 *      10.5 
* where Φ
-1
() is the inverse of the cumulative Normal distribution function and can be calculated by SPSS 
 
 
Therefore: 
 
N = 2 x f(α,β) x σ2/d2 
N = 2 x 10.5 x (1/0.25)              = 84 
Per group the sample size would be 84, total sample size required 168. 
6.7.2 Sample size calculation adjusted for baseline scores 
I used the correlation (0.46) between the ACQ scores at visit 1 and visit 2 to 
adjust my estimated sample size, using the following calculation: 
N2 = (1 – ρ
2)N 
Where ρ is correlation and N is the original sample size.  Therefore: 
N2 = (1 – 0.21) x 84        = 67 per group  (134 in total) 
6.7.3 Sample size calculation including attrition rates 
The attrition rate in the intervention group in the pilot RCT was 20%, therefore 
it seems prudent to adjust our sample size to allow for this same level of 
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attrition.  Working on the assumption that any future RCT would have the same 
study length we could use the lower estimate of 67 per group and dividing by 0.8 
would give us overall sample size per group of 84, or total 168.  Alternatively, I 
could use the overall attrition rate of 12%, this would this would reduce the 
sample size calculation down to 67 ÷ 0.88 = 77 per group (154 in total). 
However should the study period in the future RCT be longer than the 12 weeks 
it was in this pilot, then the correlation between visit 2 results and visit 1 results 
is likely to be smaller, and there is an argument that sample size should be 
based on visit 2 scores only.  Therefore, taking into account attrition of 20% this 
would result in 84 ÷ 0.8 = 105, or total sample size 210.  However if I used the 
overall attrition rate of 12 %, this would reduce the sample size required to 84 ÷ 
0.88 = 96 per group (192 in total). 
6.7.4 Sample size using mini-AQLQ results 
Mini-AQLQ is a frequently used primary outcome for self-management asthma 
studies.  Table 6.44 shows the above results using ACQ summarised and also 
provides the equivalent calculations based on using my mini-AQLQ scores. 
Depending on which outcome is used, whether correlation between visits is 
included, and which attrition rate is chosen the estimated sample size varies 
from 130 to 304. 
Table 6.44 Sample size calculations for ACQ and mini-AQLQ results 
Outcome 
Baseline 
adjusted 
Sample size 12% Attrition 20% attrition 
ACQ  168 192 210 
ACQ  134 154 168 
Mini-AQLQ  242 276 304 
Mini-AQLQ  114 130 144 
ACQ = asthma control questionnaire. AQLQ = asthma quality of life questionnaire 
 
6.8 Discussion 
6.8.1 Chapter overview & summary 
In this section, I will first summarise the findings in relation to the research 
questions.  I will then describe the strengths and weaknesses of this evaluation, 
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and the implications for the design of a future RCT, finally providing an overall 
summary of my conclusions.  
This pilot evaluation of the Living well with Asthma website demonstrates that 
progression to a full scale RCT is feasible and merited.  Recruitment targets 
were achieved, and attrition rates were comparable to rates of other published 
digital interventions [8]. Unlike similar asthma studies, we had no upper age 
limit.  This is important as our recent metareview only found one study that 
included participants over 50 years of age, and descriptions of participants’ 
characteristics were limited [8].  Such information is important to understand 
the ‘reach’ of the intervention and its’ likely wider applicability. Unusually, we 
also described the deprivation spread of our participants, and recruited 
participants from both deprived and affluent areas. 
6.8.2 Primary research questions 
Our primary research questions focussed on recruitment, retention and website 
use and usability.  We also included two clinical measures (ACQ and mini-AQLQ) 
as it is likely that one of these would be a primary outcome in any future full 
scale RCT. 
6.8.2.1 Recruitment 
Despite poorer than projected responses to recruitment, I exceeded our 
minimum target for randomisation of 50 by 1.  Our recruitment was more 
challenging than expected in two main ways.  Firstly in terms of fewer positive 
responses to our patient mailings than predicted.  This lower response rate had 
several implications: firstly, in terms of workload and cost where we had to 
invite twice as many people as anticipated (~ £1 per invite) and secondly that 
we had to recruit twice as many GP practices as we had anticipated.  
I responded to the poorer than expected positive response in several ways.  
Mainly I revised our search strategy to be more targeted to those experiencing 
symptoms.  I also tried a second (more targeted mailing) from one practice, and 
follow up telephone calls from another.  In the first instance the second mailing 
was more successful than the initial (1.5% randomised versus 0.2% with first): 
however understanding why that happened is difficult.  The first mailing went 
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out at the start of December (a busy time for people), a printing anomaly meant 
flat numbers were missing from some addresses, and we were using our original 
wider search strategy.  The second mailing was more targeted (200 invites 
posted compared to 493), was undertaken at the start of February (arguably a 
better time of year) and we had resolved the issue with the addresses.  
Therefore, it is difficult to know how much each of these different issues 
contributed to the improved randomisation rate. 
The latter strategy of follow up phone calls was overall not considered good use 
of time in this study.  As a significant time had passed between the mailing and 
phone calls there was considerable work involved in crosschecking lists to ensure 
we did not invite anyone who had already advised us they had declined to 
participate, and further time was required from the GP to review the list again, 
in case anything had changed.  Although we had anticipated we might use follow 
up telephone calls or second mailings (and had ethical approval in place), we 
had not fully incorporated their use into our recruitment systems and therefore 
implementing them generated considerable workload for the reason above, and 
also because our search strategy changed during the recruitment. When I did 
speak to people on the phone it seemed they had heard of the study and simply 
were not interested, and it is important to state that none of the patients I 
spoke to appeared annoyed about receiving the phone call. 
Follow up phone calls was a strategy found to be useful in a Cochrane review of 
recruitment methods [199].  For this reason, and because they had worked well 
on a previous study, [171], I had been keen to include the option of telephone 
calls.  However, there was one important difference: participants in that study 
could expect to receive approximately £120 over the course of the study, and 
most people I spoke to on the phone had not got that far in the information 
leaflet they had received.  So when it came up in discussion this new 
information was of interest.  I did not offer any financial recompense for the 
RAISIN study and in retrospect I feel it would have been fairer to provide a small 
voucher (£10-20) to recompense people for their time, and may have aided 
recruitment slightly.   
Careful planning of how this additional method would be integrated into 
recruitment processes in the future would be key for it to be truly helpful. The 
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main facilitator would be obtaining REC and GP practice approval for removing a 
password protected excel chart of the patient mailing details and phone 
numbers – something we did not have with this study.  This would allow for 
researchers to undertake a second mailing or follow up phone calls without 
having to revisit the practice. If a significant time had passed the updated 
mailing list (minus those who had already responded) could be sent back to the 
practice using secure email (e.g. nhs.net), for the GP to review again.   
As well as this poorer than expected positive response to the mailing, only 1/3 
passed the initial telephone screening, and even fewer actually went on to be 
randomised.  This telephone screening was a considerable amount of work for 
me and my colleague.  A solution to this would be to send out the ACQ in the 
initial mailing to potential participants, allowing these 75% of patients to be 
quickly excluded.  Self-administered results are as reliable as supervised for ACQ 
and mini-AQLQ [200], and there is precedence in the literature for this approach 
[82].  This would markedly streamline the process following receipt of a positive 
response.   
Investigating how the internet could facilitate recruitment would be worthwhile 
and there are two specific areas it could streamline processes.  Firstly to find 
potential participants in the first place, for example using social media, both 
snowballing via researcher pages, and also relevant disease specific social media 
pages e.g. Asthma UK, and this has worked well in a recent cancer study [201].  
Secondly it could also be used to streamline the screening process so for those 
participants who are interested they could be directed to a website which asked 
initial screening questions including the ACQ for example and then only those 
meeting initial criteria are called back by the research team.  
It is worth pointing out that none of the difficulties we experienced with 
recruitment related to the workload implications on health professionals 
suggesting that using NPT to optimise our trial design [111] had been useful. 
While we had to recruit twice as many GP practices as planned this was not 
major barrier to progressing with recruitment, I speculate because the workload 
implications for them participating were minor.    
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6.8.2.2 Retention 
Although challenging, recruitment targets were achieved, and retention rates 
were comparable to rates of other published digital interventions [8].   
However, the difference in attrition between the intervention group (20%) and 
the control group (4%) was unexpected.  My colleague who was managing the 
trial at this point found that with the 5 individuals in the intervention group a 
first contact was made, but the participants stated they had not used the 
website and assumed a follow up visit was not required.  When it was explained 
that a follow up was still helpful these individuals were unable to commit to a 
date, and then subsequently did not respond to 2 further contact attempts.  I 
speculate that guilt about not using the website contributed to them feeling 
unable to complete the study.  In a future study, individuals could be counselled 
at the baseline visit in order to reduce this.  
6.8.2.3 Website use 
The figure of 76% of individuals logging in is comparable with other behaviour 
change websites [42, 166]. There is no ‘minimum dose’ of exposure to a website 
that suggests it is more likely be efficacious, and given that the entire website 
could be navigated in approximately 45 minutes, a mean log in time of 23 
minutes seems reasonable, particularly given that some statistical benefits were 
shown in our analysis.   
6.8.2.4 ACQ and mini AQLQ 
We included 2 clinical outcomes in our primary research questions – changes in 
ACQ and mini-AQLQ.  Our results indicate a trend towards improvement in ACQ 
scores in the intervention group which is very promising given this is a pilot study 
not powered to show a difference.  The other outcome we would consider for 
the primary outcome in a full scale RCT would be asthma specific quality of life 
(mini AQLQ).  We showed a significant improvement in one domain of the mini 
AQLQ (activity limitation) and approached significance with another (symptoms).  
The baseline mini-AQLQ score overall was 4.8 (SD 1.0) and is markedly below the 
cut off for what is considered to be impaired QOL (<5.5) [82], and lower than 
similar populations described elsewhere in the literature [202].  
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From the literature there is no single obvious choice for a primary outcome in 
evaluations of asthma interventions, with one recent workshop (funded by the 
National Institute for Health Research, NIHR) identifying 11 separate ‘core 
asthma outcomes’ [135]. My metareview in chapter 4, describes results for 11 
different outcome areas (with many more individual measures used).  Recently 
published protocols which I described in the next chapter (7) have asthma 
control and mini AQLQ as primary outcomes [203], numbers who have 
obtained/updated written action plan [204], or adherence to ICS [205].  The 
mini-AQLQ as used in our study does have one limitation in that the 
environmental stimuli domain has variable relevance depending on where an 
individual lives, and potentially less likelihood to demonstrate change.  For 
example, questions about cigarette smoke in the environment may be less of an 
issue since the smoking ban came into force in the UK in 2007, although passive 
smoking in households is still likely to be an important factor.  Questions about 
pollution may only be relevant to those who live in the areas troubled most by it 
(e.g. south east of England, and those in large cities such as Glasgow where this 
trial was undertaken).  Interestingly the working group formed by the NIHR to 
provide guidance did not find any of the available QOL measures met their 
recommendations, feeling that the AQLQ (including mini version) could be a 
supplemental outcome only [135].  There are practical considerations too for 
example the 6 question version of the ACQ (no lung function measure) has only 6 
questions, whereas even the mini version of the AQLQ has 15, and the full 
version has 32.   
6.8.3 Secondary research questions 
My secondary research questions covered 14 individual outcomes (EQ5D, MMAS, 
PAM, spirometry, FeNO, medication changes (BTS step, puffs reliever, ICS daily 
dose, ICS percent prescribed taken), and health service contacts (primary care 
scheduled, primary care unscheduled, admissions/A&E visits, exacerbations) and 
adverse events).  This range was included to facilitate choosing appropriate 
outcomes for the future RCT. 
The results from the majority of outcomes favoured the intervention with 
several achieving statistical significance (mini-AQLQ activity limitation domain, 
PAM activation score, % of participants achieving MID for MMAS, and number of 
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reliever puffs taken).  There were 3 outcomes where the baseline adjusted 
between group differences favoured the comparison group and this was the 
FeNO, FVC/FEV1 ratio, and PEF.  In these 3 outcomes the effect sizes were very 
small and the confidence intervals wide.  There were 3 outcomes which showed 
completely no difference in either group at follow up e.g. both intervention and 
comparison group median differences was 0: EQ-5D health utility, % prescribed 
ICS taken, and daily ICS dose. 
That only 22/45 of the participants who completed the study had both baseline 
and followup results meeting ATS/ERS was disappointing.  Therefore I have not 
proven the feasibility of a researcher undertaking spirometry in the participants 
own home, a difficulty that has been reported in other studies [206].  Potential 
solutions include: more intensive training of research staff; use of a device 
providing test by test acceptability information (cost prohibited me in this 
respect in this study); or undertaking trial visits in a dedicated clinical research 
facility by staff experienced in spirometry.  However, this latter solution could 
have a negative effect on recruitment, as 20 out of 96 (21%) of our study visits 
were undertaken in the evening and weekend, which would not be possible in a 
clinical research facility.  This flexibility around visit times and locations 
facilitated recruitment of participants who can rarely make it into such RCTs, 
such as those in full time employment.  Even with the option of evening and 
weekend visits I had 10 potential participants who passed the original telephone 
screening, but due to difficulties around finding a time to do the trial visit, they 
changed their mind about participating.  Therefore, there is a balance between 
precision of measurements versus encouraging a more representative sample, 
and facilitating recruitment.  Whether spirometry is required at all in a study 
aimed at people with mild to moderate asthma is not clear, and there is 
precedence in the literature for not including these outcome measures in similar 
primary care based trials, or for using simpler to perform lung function measures 
such as PEFR [77, 186]. 
Significant results around adherence and reliever use should be interpreted with 
caution given the intervention group had poorer levels at baseline, as they could 
represent regression to the mean.  The chance of similar differences in the 
baseline characteristics would be less likely with the larger sample size required  
in a full scale RCT.  We did demonstrate a significant improvement in the 
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patient activation measure (PAM), which indicates that those in the intervention 
group had improved knowledge, confidence and skills to manage their asthma.  
However there were some issues around the PAM license which would not allow 
them to provide us with the ‘key’ for translating raw scores into activation 
scores, instead providing us with a spreadsheet that required individual question 
scores to be inputted (copy and pasting worked). However the column for the 
participant number could not be added immediately beside the response 
columns leaving room for error.  This process was feasible for a sample size of 
51, I would suggest that if this outcome was going to be used in the future 
negotiating access to the conversion table to allow this to be done automatically 
within the statistical software would be essential. 
An important finding is that there was no evidence of harm, or serious adverse 
events related to this intervention, which is important to note as this outcome is 
rarely reported [8].  No outcomes significantly favoured the comparison group.   
6.8.4 Strengths and limitations 
Within the confines of a small research team I attempted to reduce bias where 
possible.  Randomisation occurred after baseline data collection, and was 
handled by a third party automated system.  Data management was undertaken 
by an established clinical trials unit with vast experience of conducting RCTs 
(Robertson Centre for Biostatistics).  All results were reviewed by an 
experienced RCT statistician (AM or CH).  As the researcher undertaking analysis 
it was unfortunately not possible for me to be blinded to the group allocation as 
I had preceding knowledge of the recruitment numbers and differences in 
comparison group (n = 26) and intervention group (n = 25).  In a future large 
scale RCT both the analysis and assessors could be kept blind to allocation. 
Although the majority of the spirometry did not meet ATS standards there was 
no evidence of difference in the standard between the groups, and this issue has 
previously been well documented in the literature.  Removal of the spirometry 
component of the ACQ to convert it into the 6 question version (a well validated 
questionnaire in its own right) [198] reduced the effect size only slightly down to 
-0.36 (-0.96 to 0.23), suggesting that any concerns that substandard spirometry 
could be significantly impacting on the overall ACQ score was not borne out.  
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As with many digital intervention the ‘reach’ of the intervention is a potential 
issue.  In the literature review, I have described how many interventions so far 
have excluded older age groups or not provided details of education attainment 
or socioeconomic status of participants.  However my awareness of this as a 
potential issue is a strength, and I took extra steps to ensure the later 
information was available, and in particular to examine whether those from 
more deprived areas were being screened out (they weren’t), and also we had 
no upper age limit.  This led to our oldest participant being 78.  While there are 
few older participants in digital trials, there are studies of individualised 
education programmes having positive effects in this age group [207] and it 
seems reasonable to speculate that as the current internet aware population 
grows older that any positive effects seen using digital interventions will 
continue to be effective as people do get older. Only one of digital asthma self-
management RCT provided this data [94] who reported that out of the 931 
individuals they invited, there were no difference between the 200 randomised 
and the remainder who weren’t in terms of socioeconomic status (5% living in an 
under privileged area in participants vs 7.1% not randomised).  In this study we 
know that those who were excluded due to not having access to the internet 
were older than those who were excluded for other reasons, but there is 
acceptance that this is less of an issue with year on year increases in the number 
of households with access to the internet (84% in 2014, Office of National 
Statistics).  What is missing from this picture is the characteristics (age, gender, 
SIMD) of the 5383 invited overall which would give us a true picture of the reach.  
It is impossible to collect this data accurately retrospectively, but for future 
studies, with appropriate ethics committee approvals this could be easily 
collected.   
The poor response rate is a concern, and does suggest that our reach, via GP 
mailings, may be limited.  However as discussed previously in chapter 5, both 
the literature and user testing suggested that an important route for motivating 
patients to accessing the website would be via practice nurses at asthma 
reviews, a strategy that would be worth evaluating in a future RCT.  However, 
given that the average attendance at asthma reviews in Scotland 2013/14 was 
78%, this should not be the only method of directing patients to such a resource. 
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6.8.5 Conclusion 
This pilot evaluation shows that the Living Well with Asthma intervention merits 
further evaluation in a full scale, phase III clinical trial, and that it is indeed 
feasible to do so.  More streamlined recruitment methods, possibly including 
newer online methods, and further consideration to the requirements for lung 
function as an outcome are the main areas requiring work prior to moving to a 
full scale RCT, discussed further in the final chapter.  In order to reduce the 
‘practical barriers’ to using the intervention the provision of an app to work 
alongside the website is would be worthwhile to explore,  along with 
consideration of making it modular in nature.  
The next chapter formally compares this intervention with recently published 
comparable studies.
   
Chapter 7: Comparison with Recent RCTs of Digital 
Asthma Self-management Interventions 
7.1 Introduction 
In order to be able to compare the results of my evaluation with comparable 
studies in the literature I specifically undertook a search of the published 
literature focussing only on RCTs (including protocols) which were evaluating 
interventions similar to the one developed here i.e. standalone, digital 
interactive interventions aimed at adults with asthma.  I chose to look directly 
for RCTs, rather than simply update the earlier systematic review (Chapter 4) for 
three reasons.  Firstly, to allow me to include any RCTs very recently published 
which would not have had time to feature in any systematic reviews.  Secondly, 
to allow me to examine the primary literature directly and increase my ability to 
derive directly useful information from them.  Finally, I anticipated this 
literature search would identify protocol papers or abstracts that would provide 
insights into where this field of research was heading in the future. 
7.2 Methods 
The PICOS criteria (participants, intervention, comparison, outcomes and study 
type) I used are similar to that used for the systematic review (see SR protocol, 
appendix 4) with the main difference being that I focussed on those comparing 
digital interventions to usual care only, participants with mild to moderate 
asthma, and studies within the last 10 years.  This was to focus on interventions 
which were broadly similar to Living Well with Asthma.  These PICOS criteria are 
summarised below. 
Table 7.1 PICOS summary of search for included RCTs 
Participants adults aged 16 or over with mild to moderate asthma 
Intervention 
digital intervention to promote self-management. Must be interactive, and be used at 
least in some way independently of health professional 
Comparison usual care only 
Outcomes 
Asthma related outcomes as described fully in the systematic review protocol 
(appendix 4) 
Study type Randomised Controlled trial 
 
Chapter 7 RCT update  217         
 
I already had a list of RCTs from my own previous metareview [8], which 
included 4 RCTS aimed at adults [94, 208-210].  In addition a primary systematic 
review of this topic was nearing completion in my department, and I had a list of 
the 5 interventions included here, two of which were included from my 
metareview and three new articles [211-213].  I therefore refined my search 
strategy iteratively until it included all 7 of these interventions as a way of 
ensuring that my search strategy was wide enough to reasonably expect to find 
any similar interventions published since the more comprehensive search for the 
systematic review was run in August 2014.  My final search strategy is shown in 
Table 7.2, and was finally run on the 3rd April 2015.   
Table 7.2 Medline Ovid search ran on 03/04/15 
1. asthma.ti. 
2. self care.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw, ac, de, md, sd, so, tx, ct, bt] 
3. self-management.ab. 
4. randomi* control* trial.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw, ac, de, md, sd, 
so, tx, ct, bt] 
5. self monitoring.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw, ac, de, md, sd, so, tx, 
ct, bt] 
6. (digital or online or web* or internet or computer* or interact* or phone or smartphone or mobile).ab. 
7. education.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw, ac, de, md, sd, so, tx, ct, 
bt] 
8. monitoring.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, de, md, sd, tn, dm, mf, dv, kw, ac, ip, vo, 
pg, jn, pb, yr, ar, bs, bt, cf, dp, ja, so, pu, ib, is, et, tx, ct] 
9. 1 and (2 or 3 or 5 or 7 or 8) and 4 and 6 
10. 9 not (paed* or ped* or child*).ti. 
11. remove duplicates from 10 
12. 11 
13. limit 12 to yr="2005 -Current" 
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7.3 Results 
After de-duplication there were 95 articles to screen, of these thirteen were of 
relevance: 
Completed RCTs = 6 
Published protocols = 5 
Conference Proceedings = 2 
The six completed RCTs referred to three individual interventions (with main 
evaluations published between 2005-2010).  Two of these Rasmussen et al [209] 
and van der Meer et al [94]) had featured in the earlier metareview , and one 
new RCT (Bender et al) [212], which had not been reported within the 
metareview.  
As referred to above I had used seven interventions when refining this search 
strategy.  I did not subsequently include four of them in this review.  This is due 
to two being aimed at those with moderate/severe asthma [211, 213], one 
where the comparison group did not receive usual care when examining the 
primary literature [208], and the final one was not independent of health 
professional input [210]. However, I thought it was appropriate to use them in 
my search strategy, as they were the type of articles I was otherwise looking to 
include.  
7.3.1 Interventions evaluated within included RCTs 
That the most recent RCT was published in 2010 was surprising.  The oldest 
intervention was evaluated in a trial published in 2005 by Rasmussen at al [209], 
based in Denmark.     
The intervention developed and evaluated by the SMASHING study group (Self-
Management in Asthma Supported by Hospitals, ICT, Nurses and General 
Practitioners) was based in the Netherlands.  They have published 4 papers in 
relation to this study: initial results, subgroup analysis, cost –effectiveness and a 
long term follow up paper (published between 2009-2013) [91, 94, 144, 214], 
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plus an additional RCT focussing on adolescents and therefore excluded from this 
review [215],alongwith their original RCT results paper [209].  
The final intervention described by Bender et al was much less intensive and the 
only entirely standalone intervention [212]. 
I will refer to these interventions as Rasmussen [209], SMASHING group [91, 94, 
144], or Bender, for clarity in the remainder of this chapter. 
7.3.1.1 Baseline characteristics 
Despite having access to the primary papers the reporting of baseline 
characteristics was still incomplete (Table 7.3).  The Smashing group provided 
data on deprivation, smoking status, and educational attainment, which was 
absent from the other two articles.  While Bender did not report any of these 
characteristics, it did report ethnicity.  
There were upper age limits for all three studies, the highest again being 65 
years.  The majority of participants were female, and the average age ranged 
from 30 years to 41.5 years.
 Table 7.3 Baseline characteristics of the 3 main evaluations 
 Rasmussen et al  SMASHING Study Group Bender 
Year 2005  2009-11 2010 
Target age range 18-45 18-50 18-65 
Sample size 
300 
(100 per group) 
200 
(99 usual care, 101 intervention) 
50 
(25 per group) 
Attrition 
253 (84.6%) completed 
(similar dropout across groups) 
183 (91.5%) completed 
(92 control, 91 internet) 
 
age (yrs) 30 
i = 36 
c = 37 
i = 39.6 
c = 43.5 
% female 69 
i = 68 
c = 71 
i = 60 
c – 68 
Deprivation  5% lives in underprivaleged area  
Current smoking  
i = 12 
c = 14 
 
Ethnicity, 
% white 
  
i = 44 
c = 40 
Educational 
attainment, % 
high 
 
i = 52 
c = 53 
 
 no data provided.  
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7.3.1.2 Use of theory, development processes and piloting work for each 
intervention.  
Reviewing the primary articles allows me to consider the actual interventions in 
more detail than was possible in the metareview described in chapter 4.  
Rasmussen  
The Rasmussen intervention was based on a website that had been freely 
available in Denmark from 2000 [87], until date unknown (literature suggests 
was taken offline between 2003 and 2005).  In May 2003 it had almost 8000 
registered uses, with diary use (self-monitoring) never exceeding 4.5% of the 
registered users at any one time.  Key feedback from quantitative surveys and 
qualitative interviews of users yielded some interesting findings.  The website 
was criticised for being too complicated with too many unnecessary features.  
The complicated log in system was off putting to users.  The researchers found 
that users did not fill in the monitoring data daily as requested, but often did it 
in batches so that the automated advice messages were triggered perhaps 
several days after the symptoms were actually experienced.  As discussed above 
diary use was rarely sustained and individuals preferred to use the site for brief 
periods at a time often 5-8 minutes.  Participants also described generalised 
concerns about internet access and using computers (such how to log in) that 
reflected how new the internet was in 2000, and are less relevant today.  In 
their evaluation paper Rasmussen [209] mention a pilot study of 90 individuals 
with asthma stating that it was found to be user friendly, but provide no further 
information, citing a presentation at a conference in Sweden as the source of 
this information.  Unfortunately, there is no online abstract.   
SMASHING Group 
Unlike the preceding intervention, the development process is not discussed 
beyond stating ‘we developed a guided self-management tool for adult patients 
with asthma’.  It is also surprising that while they undertook qualitative research 
to inform development of a subsequent internet based tool aimed at adolescent 
participants [216], and as part of the trial of implementation methods (discussed 
in section 7.3.2) [217], there is no evidence that such work was done to inform 
the version trialled here, and there was no mention of pilot work.  
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Bender 
This results paper provided an outline of how the intervention was developed.  
They developed a draft of the interactive voice response (IVR) script based on 
the literature, and the benefit-risk model of health behaviour. This assumes that 
a person’s perception of benefits of using preventer inhalers requires to be 
addressed in order to improve adherence.  This transcript was then reviewed by 
potential end users through four focus groups.  Feedback was then used to refine 
the script until the final draft of it was then ready for a ‘test phase’.  During this 
50 test calls were undertaken, resulting in some final refinements.  No one in 
the test phase was subsequently included in the RCT.  This indicates that the 
researchers planning this intervention understood the importance of including 
end users in the design stage, and appreciated the value of adequate testing.  In 
addition, they cite an earlier study with some overlap of authors on a similar 10 
week study that used a face to face interaction between a clinician and a 
patient, rather than an IVR set up as used here.  They used that trial to provide 
power calculations for this study. 
7.3.1.3 Intervention description 
Rasmussen 
This intervention can be summarised as an ‘online interactive self-monitoring 
tool’.  This trial had three groups: internet group (IG), the specialist group (SG), 
and the control group/GP group (GPG) as described in Table 7.4, and the study 
period was 6 months. 
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Table 7.4 Rasmussen intervention by group 
 
Internet Group (IG) Specialist Group 
(SG) 
GP Group (control) 
(GPG) 
Participant 
Intervention 
Intense internet based 
intervention including 
electronic diary, an action 
plan for patients which 
provided advice directly 
based on data from the 
online peakflow diary 
Received a written 
action plan with 
advice to contact 
their specialist if 
deterioration beyond 
a certain level 
Told they have asthma 
and to see their GP, 
provided with results of  
baseline assessment 
(lung function, 
reversibility, bronchial 
challenge and skin 
prick tests) 
Additional 
education 
Instructed in asthma 
pathophysiology, treatments 
and trigger avoidance, and 
action plan education 
Instructed in asthma 
pathophysiology, 
treatments and 
trigger avoidance, 
and action plan 
education 
No additional education 
 
 
Smashing Group 
The intervention group itself received a comprehensive intervention which was a 
specially designed website which included the ability to monitor symptoms (via 
the website, or mobile phones), an internet based asthma action plan (AAP), 
online education, and web communication with a specialised asthma nurse.  The 
users monitored their symptoms daily, and filled out an ACQ weekly, with 
immediate feedback.  Both groups received basic self-management education 
(information about asthma, inhaler technique, information about monitoring), 
but after randomisation the comparison group received just usual care.  Follow 
up was at 12 months. 
Bender et al intervention 
The final intervention described by Bender et al was much less intensive and an 
entirely standalone intervention [212].  This interactive voice response (IVR) 
system enquired about asthma symptoms, delivered core educational messages 
and encouraged refilling preventer scripts.  Users received two calls a month, 
and those who were symptomatic at either of the first calls received a third call.  
Each call lasted less than 5 minutes, and covered the three main topics: 
symptoms, encouraging refills, and education.  The comparison group received 
usual care (e.g. no phone calls).  The study length was 10 weeks. 
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7.3.1.4 Recruitment and attrition rates 
Interestingly participants for the Rasmussen trial [209] were recruited from a 
community sample based on symptoms initially, so only 51% were on asthma 
treatments when enrolled.  Other trials (including my own) recruited those with 
physician diagnosed asthma. 
Attrition rates were provided by two of the three interventions featured in Table 
7.3, [94, 209].  Rasmussen reported 84.6% completing their study and van deer 
Meer et al reported 91.5 %, both impressively low attrition rates when compared 
to non-digital interventions such as those included in a 2002 Cochrane review on 
asthma self-management [6].  The third, the IVR intervention, suggests that all 
participants completed both baseline and follow up visits, as they report n=50 at 
both baseline and follow up.  
 Table 7.5 RCTs summary of results of outcomes 
Outcomes Rasmussen et al SMASHING Study Group Bender 
Symptoms Questionnaire based interview: 
IG improved vs SG: OR 2.64, p=0.002 
IG improved vs GPG: OR 3.26, p<0.001 
SG vs GP no difference 
ACQ adjusted difference showed improvement of 
0.47 (0.30 to 0.64) in IG, and more acheived, a 
clinically significant improvement (48% vs 17%; 
adjusted relative risk 2.87 (1.86 to 5.14). 
Symptom free days increased in by 10.9% 
ACT - NS 
Quality of life 
(AQLQ) 
IG improved vs SG: OR 2.21, p=0.03 
IG improved vs GPG: OR 2.10, p=0.04 
SG vs GP no difference 
Adjusted difference showed improvement in IG 0.38 
(0.20 to 0.56). More IG patients achieved clinically 
significant improvement (54% vs 27%; adjusted 
relative risk 2.00 (1.38 to 3.04). 
NS 
Adherence Significant improvement for all groups, 
‘good compliance’ significantly higher in 
the IG vs GPG, and SG vs GPG 
 
Mean ICS adherence*  higher in 
intervention group (64.5%), vs control 
(49.1%), p = 0.0032 
Self care 
behaviours 
Reported use of AAP in: 
IG (88%); SG (66%); and GPG (6%). 
Inhaler technique – NS  
Self efficacy/ 
beliefs 
  
BMQ. Greater upward shift in positive 
medication beliefs  (p=0.007) 
Health service 
contacts 
Acute unscheduled visits – NS Physican visits – NS 
Exacerbation rates - NS 
 
ICS dose 
prescibed 
No change in ICS dose (but more IG on 
the recommended treatment level). 
No change in ICS dose  
FEV1 IG improved vs SG: OR 3.26, p=0.002 
IG improved vs SG: OR 4.86, p=<0.001 
SG vs GPG: NS 
FEV1 adjusted difference showed improvement in 
intervention group  of 0.25L, 95 CI (0.03 to 0.47)  
Adverse 
events 
Higher in IG for dysphonia and 
oropharyngeal candidiasis 
  
* measured by device attached to inhaler or change in cannister weight.  ACQ = asthma control questionnaire.  ACT = asthma control test.  AQLQ = asthma quality of life questionnaire. BMQ = 
beliefs in medication questionnaire. GPG = General Practioner Group.  ICS = inhaled corticosteroids. IG = intervention group.  NS = no significant difference. OR = odds ratio.  SG = specialist group.  
 = data not provided or outcome not used 
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Summary of findings from the three interventions 
The results are summarised in Table 7.5.  All three of these studies had some 
positive findings.  The Rasmussen trial had three arms, and the internet group 
consistently did better than the GP group (control group), and the specialist 
group for symptoms, quality of life and lung function, and better than the GP 
group but not the specialist group for airway responsiveness.  Unfortunately, 
they did not provide any usage data or qualitative research that would 
contribute to understanding how the intervention is used in practice, and what 
topics were more valued by their users.   
The Smashing group main evaluation showed improvements in ACQ, AQLQ, FEV1 
and symptom free days.  There was no difference in inhaler technique, 
exacerbations, physician visits or inhaled corticosteroid dose. 
Bender et al demonstrated improved adherence and self-efficacy with no 
differences in symptom scores (ACT) or AQLQ.  
In general terms this mimics the results of the metareview – some improvement 
in some outcomes, more detail (particularly qualitative data) required.  What 
can be said is that symptom scores and AQLQ were only improved in the larger 
more intensive interventions, however the small sample size of Bender may have 
had more to do with this than the intervention itself, particularly given that a 
Cochrane review on adherence reported that to have a reasonable chance of 
demonstrating an improvement in adherence, evaluations should have a 
minimum of 60 participants per arm [62]. 
When interventions are complicated and intensive such as those by Rasmussen 
and the Smashing group, cost-effectiveness is more important to consider.  The 
Smashing group are one of the few research groups in this area that report cost 
effectiveness [214] concluding that while the intervention was more expensive 
than usual care ($254 annually), a willingness to pay $50 000 per Quality 
Adjusted Life Year (QALY) meant that it could be considered as being cost-
effective. 
However, I think the most interesting finding here is that of the smaller, less 
intense and most likely cheapest intervention included: Bender’s interactive 
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voice response (IVR) telephone calls.  This simple intervention demonstrated 
improved adherence, particularly interesting given they were using objective 
measures of adherence (device attached to inhaler, or canister weight).  Of the 
three interventions, Bender et al [212] seems most ‘implementable’ and it is this 
intervention which interests me most in terms of future research directions.  
7.3.2 Protocols of RCTs yet to be reported 
My search also found three protocols of trials yet to be published.  First was the 
protocol for my own RCT which is found in appendix 1  and the results described 
in Chapter 6 [33]. 
The oldest protocol paper found by my search was published in 2011.  This 
described the protocol for a pilot RCT testing an intervention called My Asthma 
Portal (MAP) [203].  This intervention consisted of a web page accessed by 
participants, which was linked to a limited version of their electronic health 
record, and a nurse case manager system.  The MAP included tailored education 
and feedback based on monitoring data entered.  It incorporated an asthma 
action plan, and allowed users to set target goals.  This protocol paper reported 
that recruitment had commenced in 2010, and therefore I actively sought any 
results.  A citation search did not yield any results however searching for other 
publications from the authors yielded a conference abstract from 2011, 
providing preliminary process evaluation results.  They had recruited 35 of their 
target of 80, and 75% had logged on once, and usage patterns indicated that 
users visited the interactive sections (about monitoring feedback) more often 
than the learning centre which provided general asthma information.  Again, this 
is more intensive than the intervention developed within this project.  
I also found a protocol which relates to the interventions evaluated by the 
SMASHING study group published in 2012 [217]. It is not trialling the intervention 
per se but the implementation of this intervention that has already been shown 
in clinical studies described above to be effective.  This protocol sees three 
different implementation strategies being trialled in order to understand how 
best to disseminate this intervention.  The three arms are: minimum support to 
practices, intermediate support, or extensive support.  While not directly 
meeting my PICOS criteria the results of this study which is the first I have found 
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of its type will be of interest to any type of internet based self-management 
support, and therefore merits mention here.  
7.3.3 Abstracts 
One final article worth mentioning is an abstract published in 2014 [92] which 
describes an interesting trial with a large sample size (490 and counting) which 
is using sensors on reliever medication and asthma control test (ACT) scores to 
provide personalised feedback, and educational content via the internet 
(smartphone or computer).  The age range of participants to date is 5 to 80 
years and they report interim results at 4 months showing less reliever use and 
higher ACT scores in both the children and adults.  A search of other publications 
by the authors did not yield any related studies, with all but one named author 
working for a health care provider based in California, USA.  The type of 
‘passive’ self-monitoring employed in this trial is exciting and seems likely to be 
where successful self-management interventions which require an element of 
self-monitoring will be heading in the future. 
7.4 Conclusion 
Overall this updated search for relevant RCTs, including those not yet published, 
suggests that while intensive interventions with integrated health professional 
support continue to be developed and evaluated and appear to be effective 
across certain outcomes, it is not yet clear whether their use will be sustained in 
the long term.  Interventions which are of low intensity like Bender [212], or 
that minimise the ‘intervention burden’ for participants featured within the 
abstract by Merchant [92] are an exciting development, and are more in line 
with what has been developed and described in this thesis.
 Chapter 8: Discussion 
8.1 Introduction 
The overall aim of this study was to explore the potential role of a digital 
intervention in promoting optimum asthma self-management to adults with 
asthma.  In order to achieve this aim, I have undertaken a metareview, a 
literature review, developed a website and carried out a pilot/feasibility 
randomised controlled trial (RCT).  
I followed best practice using the MRC Framework on developing and evaluating 
complex interventions [100], particularly around the use of theory during 
development [102, 218], including qualitative methods at multiple stages 
throughout the development [219], and the use of piloting and feasibility work. 
In the results chapters (4, 5 and 6) I discussed the findings of those particular 
stages of the project; in this penultimate chapter I discuss the findings from the 
project as a whole.  I reflect on how well I have answered the research questions 
and discuss issues arising from my findings, outlining the overall strengths and 
weaknesses of the project and finally commenting on what this study has added 
to the literature. In the final chapter (Chapter 9) I suggest directions for future 
research, implications for practice and policy and provide overall conclusions for 
this thesis. 
8.2 Reflections on individual research questions 
8.2.1 Research question 1 
What is known about the effects of online tools to promote self-management 
of asthma and what helps or hinders their utilisation by patients? 
 
Chapters 2 and 4 provide the answer to this question in full.  In summary, the 
research demonstrated that much of the published literature is of poor quality 
and short on detail.  Nevertheless, there is emerging evidence of the potential 
effectiveness of digital interventions and I concluded that this project would be 
contributing to a genuine gap in the available research. 
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The methods chosen initially to answer RQ 1, metareview, did not ultimately 
answer the question as I anticipated it would.  However, this review did indicate 
that there was a significant gap in the literature particularly surrounding 
qualitative articles looking at barriers to self-management.  I could not have 
appreciated this without undertaking the review.  Therefore, it is only with 
hindsight that I can say it may have been more helpful to have chosen an 
alternative method such as a synthesis of qualitative analyses, or a meta-analysis 
of the primary literature.  Work is underway to fill this gap by colleagues at the 
University of Southampton who are working on a project ‘Barriers to effective 
self-management of asthma: A systematic review’ which should be available 
later in 2015.  A recent systematic review of implementation studies of self-
management support interventions provides further insight into the facilitators 
and barriers of implementation [112].  This review synthesizes digital and non-
digital interventions so would not have been included in my metareview but the 
findings are pertinent.  In this review, Pinnock et al describe the benefits of a 
multi-level approach: patient, professional AND organisational [112].  This 
resonates with what has been described earlier in this thesis, that generally a 
‘whole systems approach’ to implementation would be most effective.   
Although the metareview did not answer my research question, the results 
heavily influenced the development, evaluation and reporting of our results.  
The failings in the current literature identified from the metareview, 
particularly around sparse use of theory, poor descriptions of participants and a 
lack of meaningful descriptions of intervention contents motivated me to ensure 
that this project did not repeat these mistakes.  I therefore published a full 
description of the Living Well with Asthma development and final contents [168] 
and articulated how we expected it to work. 
8.2.2 Research question 2 
What are the barriers and facilitators to the uptake and utilisation of a web-
based self-management tool from the perspective of adults with asthma, and 
primary care nurses who undertake asthma reviews? 
 
Focus groups were chosen as the best method to answer this research question, 
and the full results discussed in chapter 5.  Overall, this method worked well, 
and the findings fed directly into the website contents as planned.   
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As discussed in chapter 5, the main issue with the focus groups was the 
particularly wide inclusion/exclusion criteria.  While I had a minimum 
medication requirement (used reliever inhalers a couple of times a month at 
least) I did not stipulate any maximum medication, or asthma severity criteria.  
This meant that I had to include participants who were interested in 
participating even with the most severe of asthma.  One participant in the first 
focus group has such severe asthma she was on continuous subcutaneous 
salbutamol infusion.  While this is a very extreme example, many of the 
participants had moderate to severe asthma, rather than mild to moderate, and 
many had experienced multiple hospital admissions.  These participants focussed 
heavily on their personal experiences of hospital care and interactions with 
medical staff during the focus groups, and it required strong guidance to bring 
the discussion back to basic practicalities of self-management.  Nevertheless, 
they did provide other more relevant experiences, such as about managing their 
illness in public, gaps in information, and often demonstrated misunderstanding 
about asthma that fed into the website, for example with regards to side effects 
of medications or common concerns and queries.  However, in future studies it 
would be wise to restrict sampling to those who are more closely matched to the 
intended end users.  
One facilitator to increased engagement in adherence interventions is tailoring 
[60].  Specifically for asthma an example of tailoring is with action plans, which 
is thought to increase relevance and worth to the individual, and consequently 
use [64, 71].  Another example is thinking about goal setting where the aim is to 
agree goals relevant to the individual, rather than the health professional e.g. ‘I 
want to be able to play football again’ versus ‘I want to maintain my best peak 
flow’ [78]. Brown et al have shown that good quality user involvement during 
development can overcome perceived barriers such as socioeconomic status 
[31], therefore providing different versions of an intervention for more deprived 
versus less deprived populations seems a logical next step.  One area of tailoring 
which I didn’t explore, and to my knowledge has not been explored in the 
literature is to consider tailoring of self-management towards different asthma 
‘phenotypes’.  Asthma phenotypes are recognisable clusters of demographic, 
clinical, and pathophysiological characteristics [220]. Examples are allergic 
asthma, late onset asthma, obesity related asthma or neutrophilic asthma [220]. 
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It is already suggested that these different phenotypes have differing 
pharmacological needs [221], it is a natural progression that these different 
phenotypes will have different self-management needs, for example obesity 
related asthma having more focus on physical activity and weight loss, and 
allergic asthma focussing on adherence to inhaled steroids and trigger 
avoidance.  However, this area of research is still in its infancy, and whether it 
will become relevant to the field of digital interventions to support self-
management is plausible but not yet known.   
8.2.3 Research question 3 
Can evidence from the literature (asthma management and theory) and input 
from potential end users, be successfully incorporated into an intervention to 
promote self-management? 
 
How best to connect my findings from the literature and focus groups with the 
experience of the expert panel eluded me until I was pointed towards Campbell 
et al’s ‘key tasks’ for intervention development [115].  Agreeing these tasks with 
the expert panel was a pivotal event for me, and is detailed in full in Chapter 5.  
During this stage, I gained a feel for what we wanted the intervention to do, and 
crucially how we expected it to do it.  Understanding how we expected it to 
work clarified exactly what behaviours we were aiming to change, and to what 
effect.  This process is considered crucial for several reasons [102], but most 
importantly to allow us, as researchers, to understand the results of our 
evaluations, and work out what has contributed to these results, what worked 
and what did not work.  
Therefore, I need to consider what our results so far tell us about the 
intervention.  What I can say from the data available is limited on two counts.  
Firstly, this was a pilot study so we cannot comment yet about effectiveness, as 
it was not powered to tell us this.  Secondly, the qualitative analysis of the 
interviews with the intervention participants is not yet complete, and not part 
of this thesis.  However, within these caveats I can make some comments.  As 
the diagram shown in chapter 5 initially and repeated here (Figure 8.1) 
demonstrates, the central behaviour we aimed to change was for users of the 
website to use their medication optimally.  E.g. the health professionals 
Chapter 8 Discussion  233 
 
prescribing the best medication for an individual, and the individual making 
optimum use of that medication.  
Figure 8.1 How Living Well with Asthma was anticipated to work 
 
 
Thinking specifically about this, there was no evidence from this pilot RCT of any 
difference in attendance at annual reviews or actual prescribing, but as 
mentioned above it was not powered to show this.  However, there was a 
statistically significant difference in relation to adherence and reliance on 
reliever inhalers which both favoured the intervention.  These results have to be 
interpreted with caution, given the imbalance between randomised groups at 
baseline (described in Table 6.4, Chapter 6).  Nevertheless, they are consistent 
with the intervention having the desired effects in a proportion of our 
participants.  As expected the core modules were the most visited, and they 
focussed on the “recognising symptoms/don’t put up with them” behaviour, 
promoting ‘best’ medication used optimally.  The evidence suggests that a 
successful strategy for achieving these behaviours is increased use of asthma 
action plans, and it was an oversight that we did not collect data on action plan 
use at baseline and follow-up and this would be important for any future study.  
I had also hoped that by promoting optimum medication use participants would 
feel able to increase their physical activity, dedicating a whole section to this.  
While we did not try and measure changes in actual physical activity, we did 
collect a related measurement via the mini-AQLQ activity limitation domain.  
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Interestingly this domain improved by both statistically and clinically significant 
levels, which given this was a pilot study is very encouraging.  Even more 
encouraging is that out of the eight non-core modules, physical activity had the 
third highest number of visits, and the second highest amount of time spent on 
it.  Therefore the evidence available is consistent with users visiting these areas 
of the website, and undertaking at some level the desired behaviours with 
associated evidence of change in the desired outcomes.  
If it seems that this intervention exerts its effects at least in part by increasing 
physical activity it would be worth considering measuring this in a future full 
scale trial. This could be done using self-report measures such at the reported 
metabolic equivalent task (MET)- minutes per week from self-reported walking, 
vigorous and moderate exercise, or using the international Physical Activity 
Questionnaire (IPAQ) for example.[222] 
As well as using the literature as above to answer the key tasks, I also used it to 
directly influence the potential components of the website.  To my knowledge 
this was a novel way of incorporating findings from literature and user testing 
into resource development, and for the purposes of this project worked well, 
and the answer to the questions is certainly yes, as shown in chapter 5.  
8.2.3.1 Reflecting on the items I did not include. 
As described in chapter 5, four items had been suggested by either the focus 
groups or the literature that did not make it into the website, and I discuss two 
of those in more detail here. 
Standalone friends and family section 
One of these was a dedicated family and friends section, which I, along with the 
expert panel, felt was not necessary as it would be duplicating contents 
elsewhere.  During the study, I came to regret this decision, from talking to 
participants at visits and then re-reading the focus group and think aloud 
transcripts. 
It is the one time in this project where we, as the expert panel, decided that 
‘we knew best’ and overruled the opinions from the literature and user groups.  
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Re-reading the focus groups in particular but also the think aloud studies this 
was identified as a real gap, and the rationale for not doing it was duplication.  
However, this could as easily have been an argument for just doing it, as it 
would have been straightforward enough to generate pages based on the rest of 
the website but changing slightly so they were targeted to friends or family.  
However, we would have been unable to formally gauge acceptability, without 
requesting additional ethical approvals to actually test it out on family and 
friends of those with asthma.  
People’s attitudes about managing their asthma, their capacity for undertaking 
self-management and the level of social support were so intertwined [83] that 
facilitating support from this source should have been an important component 
of the website. Such a section could have been a prompt for users to encourage 
those closest to them finding out more about their illness and how it affects 
them, and importantly what they could do to help.  Given that this would not 
have been that much extra work, I feel I should have listened better to both the 
literature and the end users and provided this.    
Regular self-monitoring or medication trackers 
The literature discussed in chapter 2 suggests regular self-monitoring works, 
however it also confirms very few people will sustain any level of regular self-
monitoring  [84, 87].  It was felt that investing time in developing a website 
component which might work in a trial setting but is unlikely to translate into 
routine use, was not good use of my time.  For self-monitoring to work in real 
life situations, I believe it needs to be essentially ‘passive’, i.e. occurring 
without the individual having to do anything.  There is some innovative work 
occurring in this sphere for example using ‘smart inhalers’ which track how often 
the reliever is used and alerts the user via Bluetooth connections (e.g. to smart 
phones) that their reliever use has increased and action is required [92].  
Overall, I conclude that until a system can be developed where the monitoring 
requires virtually no input from the users that this aspect of asthma 
management should not be the focus of attention.  Consideration to the 
workload implications is crucial if self-management interventions are to be 
successful in the longer term, as we know that increasing treatment burden 
reduces an individuals capacity to manage other aspects of their lives or reduces 
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engagement with health care [223, 224].  A systematic review and meta-analysis 
examining interventions to reduce 30 day readmission rates found that those 
interventions which worked to support patients capacity for self-care were more 
effective [225]. 
However, knowing that self-monitoring can be effective led me to consider what 
we could do within the website to promote it, in a way acceptable to patients, 
yet within the confines of my capabilities and the software.  It was agreed that 
the website should promote recognising symptoms in more general terms, 
including use of the RCP 3 Q [163], the idea being that users would gain some of 
the benefit of self-monitoring (early warnings of deteriorating symptoms) 
without having to the do work when they were well. The salient point being that 
the burden of interacting with the website had to be less than the mild to 
moderate symptoms this patient population endured.  
Similarly, users in the focus groups had requested a medication tracker to be 
included, with the particular aim of helping users keep track of how much 
reliever medication they had used, and when their preventer inhaler would be 
running out.  There are several inhaler brands available more recently which 
included counters and it may be that this will increasingly be a feature of 
inhalers in the future.  Again, it was felt, probably correctly, that more typical 
users would not use this feature.  Instead, I included a table of typical inhalers 
and typical usage patterns with how many days a given inhaler should last if it is 
used X number of puffs a day.  For example, preventer inhaler Clenil Modulite 
has 200 doses per canister so if using 4 puffs a day, users would need to request 
it every 50 days, and a ‘print this table’ link provided.  I believe these were the 
right decisions for this intervention, particularly given the usage patterns we saw 
where most people only logged in once or twice over the study period. 
8.2.3.2 Is this really a complex intervention? 
Throughout this thesis, I have made the assumption that what I developed here 
‘Living Well with Asthma’ is indeed a complex intervention.  ‘Complex 
intervention’ has become a bit of a buzzword and the literature on this area has  
“grown exponentially as rapidly expanding problems in health and health 
inequities have demanded immediate, inventive and effective solutions.” pg 308 
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[226]. The MRC define complex interventions as: “interventions with several 
interacting components”.  They further recognise that there are several 
dimensions of complexity, and that complexity is not necessarily limited to the 
number of components within the intervention package itself, but can relate to 
outcomes, variability in the target population, number and/or difficulty of the 
behaviours required by those delivering or receiving the intervention.  On one 
hand, it could be argued that asking people to log on and click through a website 
is not a complex task, and where are the interacting components?  However, I 
would argue that, as described in chapter 5, the website was asking participants 
to undertake multiple behaviours, many of which were complicated such as 
signing up to the ‘4 weeks challenge’, and promoted behaviours such as 
interaction with health professionals and for this reason ‘Living well with 
Asthma’ merits being called a complex intervention.   
8.2.4 Research question 4 
What would be the feasibility of undertaking a randomised controlled trial of 
Living Well with Asthma, and how would such a website be used by adults 
with asthma.  What would be the effect on symptom score and quality of life 
measures? 
 
Chapter 6 demonstrates that undertaking this evaluation was feasible, and as 
planned provides estimation of effect sizes.  The complexity involved in 
evaluating a complex intervention is often under recognised [227], and 
awareness of this led me to give great consideration to our evaluation methods.  
This ultimately paid off, in that we recruited our target sample, and all received 
access to the intervention.  The process of undertaking this RCT was a steep 
learning curve, and arguably the stage of this project which lends itself most to 
debate about whether I did it the best way or not, and what would be done 
differently in our future RCT.  I am going to discuss this in terms of the PICOS 
terms to provide structure to this section.   
8.2.4.1 Participant considerations 
My metareview from chapter 4 had shown me how poorly described participants 
from digital asthma trials had been in the past.  In response to this, I 
characterised this RAISIN population in as much detail as possible.  Unlike these 
Chapter 8 Discussion  238 
 
previous studies, I collected data about age, gender, socioeconomic status (SES) 
and educational attainment, making this one of the best characterised asthma 
trial populations to my knowledge.  This study includes socioeconomic status, 
age and gender of those who screen failed.  I also recorded comorbidities of 
those enrolled which is important given that people with asthma have higher 
levels of co-morbidity than expected [38].  In addition, unlike most published 
studies, I did not have an upper age limit, and my oldest participant was 78 
years of age. Historically an upper age limit of 45-55 years has been used in 
asthma trials in order to reduce the chances that participants may actually have 
COPD instead of asthma.  I disagree with that argument as it makes generalising 
to a typical primary care asthma population more difficult, as a proportion of 
those may well be misdiagnosed.  Therefore, we tried to limit our inclusion/ 
exclusion criteria as much as possible, and ensured that we recruited 
participants from a range of primary care practices which would include 
participants from across deprivation deciles.  In particular, I was pleased to note 
that there was no difference in the spread of participants across deprivation 
deciles in those who were randomised versus those who were found to be 
ineligible.  For future studies maintaining a record of the spread of deprivation 
in those who were invited to participate, versus those who responded, and 
ultimately those who were randomised, would be of particular interest.  This 
would allow us to undertand better the reach of such an intervention.  
Our difficulties recruiting are well described in Chapter 6 and it is interesting to 
see newer more imaginative methods of recruitment being used in more recent 
protocol papers for example Arguel et al are making use of consumer groups, 
google, Facebook, twitter and online noticeboards such as Gumtree [204]. 
8.2.4.2 Intervention considerations 
From the usage patterns, and PETS questionnaire results there are two main 
conclusions which can be drawn.  The first is that despite having to be 
symptomatic to participate in the study, and 95% of users acknowledging within 
the first few pages of the website that asthma impacted on their lives, 41% still 
doubted the personal relevance of the website advice to their own situation.  
From clinical experience and the literature review I was aware that people with 
asthma frequently underestimate their symptoms, or assign them to another non 
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asthma related cause [2, 228].  As detailed in chapter 5 one of our key 
behaviours was therefore to ‘Recognise symptoms, don’t put up with them (aim 
for no symptoms)’.  However, these results suggest that despite my best efforts 
a proportion of individuals did not take on board that message from the website, 
and that would be one area where the website would warrant further 
development. This would likely involve the feedback being more explicit in what 
their answers mean in terms of their own symptoms and what they should be 
aiming for, and possibly reinforcing this throughout the website rather than just 
during the initial core modules.  
The second conclusion I draw is that the way the website is presented to users 
could be improved.  As I suggested in the discussion in chapter 6 (RCT) it would 
be worth only providing the core modules initially and then adding in additional 
sections each week, in order to increase the chances that users would click into 
the new section as it was made available to them.  
Intervention fidelity 
There are many reasons for choosing to deliver an intervention digitally: cost, 
convenience, increased reach, tailoring, or overcoming isolation for users  [229].  
Another reason may be ease of maintaining intervention fidelity – everyone gets 
the same intervention.  At least they do on the face of it.  However unlike public 
health based interventions which may well work entirely independently from 
health services (e.g. smoking cessation), interventions such as this to support 
self-management may be delivered independently from health professionals, but 
they cannot work independently from health professionals.  For example, one of 
the core behaviours for Living Well with Asthma was to optimise best medication 
use.  Any change in prescribing relies on an interaction between the user and 
multiple health professionals (practice receptionist, primary care team and 
pharmacists).  Access to, and quality of, health professional reviews for asthma 
may vary from practice to practice as indicated by our asthma participants in 
stage 2.  It is well recognised in the literature that many complex interventions 
fail to achieve any meaningful changes, and those that do in a trial setting are 
often hard to sustain in real-life settings, or be replicated in different contexts 
[102, 226] [100].  Hawe [226] argues that historical obsessions with standardising 
interventions and not allowing contextualisation of interventions has contributed 
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to many community based interventions showing very small or no effect, and I 
believe the digitally delivered interventions will not be immune to this. 
Arguments for increasing emphasis on standardising the function, rather than the 
form is gaining momentum [227, 230]: here intervention fidelity is assessed by 
how well the intended function, rather than form, matches. This fits with Michie 
et al’s taxonomy which aims to allow researchers to characterise an intervention 
by its constituent functions (in this case behaviour change techniques (BCTs)), 
allowing for the form each BCT takes to be contextualised within individual 
settings. 
Another researcher, in another setting, might look at our development processes 
and the BCTs we include in our intervention, and develop quite a different 
intervention, particularly with a different set of user testers.  This is not wrong, 
and in fact allowing for the ‘form’ of an intervention to incorporate local 
contexts is thought likely to increase the chances of effectiveness, where it 
exists, being demonstrated [230]. There are practical examples of this occuring 
[226, 231].  Again, the StopAdvisor smoking cessation website is a excellent 
example of this where it was ‘contextualised’ towards users with lower SES by 
all user testing being done by participants with low SES, to the degree that it 
then only worked in this group [31]. 
8.2.4.3 Comparison group considerations 
One area of contention when planning a RCT is what intervention, if any, should 
a comparison group get.  This is more so when the mode of delivery itself is 
considered part of the intervention, which historically was the case particularly 
with internet based evaluations.  For example in their systematic review Griffith 
et al [229] berate that most interventions are not compared to a traditional 
delivery method such as face to face, or classroom, but rather ‘usual care’.  
They claim that understanding the added benefit of using the Internet to deliver 
the intervention is of great importance.  This may have been the rationale for 
Ryan et al [186] providing their comparison group with a paper based version of 
their mobile phone based intervention rather than the mostly likely less 
intensive ‘usual care’.  However, this can lead to a situation, as happened with 
Ryan et al, where both groups demonstrated an improvement, and therefore 
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how to proceed is not very clear.  We do know that paper based self-
management interventions can work in trial settings [6, 65], however we also 
know that they do not become integrated into every day practice, either by 
patients or by health professionals [1, 5, 9, 68], questioning the rationale of 
using it as a comparison group.  Therefore, I feel this view is outdated, and 
potentially negatively impacting progress by diluting the potential effects of new 
interventions.  If the mode of delivery is novel, or of particular interest then at 
the very least the trial could have a third arm of ‘usual care’.  There are 
examples of this in the literature in other disease areas such as Lorig et al 
analysis of the Chronic Disease Self-Management Program (CDSMP) which 
evaluated their Internet version vs small groups (traditional methods) vs usual 
care [232], and asthma itself by Rasmussen et al  [209] which had an internet 
group, a specialist group and a usual care group.  
An alternative way of looking at the evaluation of internet based interventions is 
to focus the evaluation on the content itself, rather than the delivery method.  
A recent example of this is where the intervention group received an interactive 
smoking cessation behaviour change intervention and the control group were 
provided with a link to a static web page covering standard smoking cessation 
information [31].  Interestingly this allowed participants to be blinded as to 
whether they were in the intervention group or not, a feat that often eludes 
complex intervention evaluators.  In this particular intervention evaluation, they 
randomised over 4000 individuals, so providing a face to face, or paper based 
alternative would be futile and costly, as it would differ so hugely from the 
intervention under evaluation.  The beauty of a standalone internet based 
intervention is that it can be delivered (and potentially evaluated) at scale, and 
control groups should really reflect this.   
For future evaluation of Living Well with Asthma, I would particularly like to see 
two types of evaluation being undertaken in order to truly understand 
effectiveness, and implementation potential.  Firstly, a ‘traditional’ type as 
undertaken here, but clearly on a larger scale and incorporating changes 
suggested by our findings, but also a second parallel evaluation undertaken 
entirely remotely, with no face to face contact.  Ideally participants would be 
identified in the same way they would if this intervention was made freely 
Chapter 8 Discussion  242 
 
available – practice nurses mentioning it during asthma reviews. Those 
interested in the intervention would attempt to log in to use it, and would be 
screened and randomised online, and follow-up questionnaires etc. filled out 
online where available, or via post if required.  Users would be randomised to 
the intervention or a link to either some basic asthma information or Asthma UK 
website.  This could run alongside a more standard trial with typical ‘trial visits’ 
to allow for lung function and inflammation measures to be taken, as happened 
here.  Other study design considerations are discussed in section 8.2.4.5 below 
(Study Design Considerations). 
8.2.4.4 Outcome considerations 
Overall, the majority of the outcomes worked well in this study and as described 
in the RCT chapter (chapter 6), the main issue was with spirometry.  Potential 
solutions to this issue were described in chapter 6. 
At a more fundamental level many of my outcomes were patient reported 
outcomes and the trend for these has come and gone in the literature, with 
recent interest particularly in their potential role specifically as quality markers 
of clinical care [233].  The limitation of surrogate end points as proof of 
clinically relevant effects is well recognised, and in other disease areas the 
concentration on surrogate clinical markers has actually led to harm, particularly 
in diabetes [234].  Therefore, in this study we chose a range of both patient 
report and objective measures, alongside measuring medication use and health 
service contacts. 
8.2.4.5 Study design considerations 
The MRC Framework states that feasibility and piloting are crucial stages when 
developing complex interventions.  As discussed in Chapter 3, and described in 
Chapter 6, I chose to do both with this evaluation, in order to prepare as much 
as possible for a future RCT.  This could be seen as a risk, as feasibility outcomes 
could suggest that the intervention would need significant changes, potentially 
invalidating our pilot findings about recruitment and retention.  Given the 
degree of user involvement and work that went into developing the resource to 
having the best possible chance of being effective, I deemed this risk was 
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acceptable, and ultimately the suggested changes to the intervention 
summarised in section 8.2.4.2 earlier in this chapter are relatively minor and are 
unlikely to impact on recruitment and retention rates significantly.  One 
drawback to doing a pilot study at this stage was that 26 participants did not 
provide website use data, despite requiring a significant amount of work on our 
behalf for recruitment and study visits.  Formally providing website access to the 
comparison group at 12 weeks would have been an option, with a third 
streamlined data collection point at 24 weeks, where users could have self-
administered the questionnaires and posted or emailed them back to me, 
providing us with limited results and usage statistics on a further 26 individuals.  
Another option would have been to have proceeded with an uncontrolled pilot 
study as seen with an online smoking cessation intervention, also developed 
using LifeGuide [150].  They argued that including a control arm for an under 
powered analysis may not be necessary, and for the cost would have added little 
value in such well-established fields of research such as smoking cessation.  
Indeed many of the recent systematic reviews of adherence interventions in 
particular have lamented the number of underpowered studies included [62, 
235].  There is an argument that asthma is a similarly well researched field, 
however the use of online resources in asthma is not as well established as with 
smoking cessation.  My literature review found only one completely standalone 
intervention with no health professional (HP) involvement at all aimed at adults 
with asthma, and this was using mobile phones and based in the USA [212].  
There were two other interventions which could function without HP 
intervention but had it as an option and were set in Denmark [209] and 
Netherlands [94].  Therefore the absence of any UK based comparable 
interventions suggests that in this situation a control arm was warranted. We 
reported a non-significant difference in attrition rates between groups, 
combined with lack of use of the website in this group suggests that non-users in 
the intervention group may be less likely to comply with follow up, suggesting 
that this area is not well understood. 
8.3 RCT ethical considerations 
As with any clinical trial, there were some ethical considerations encountered 
and these are discussed here.  
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8.3.1 Collective ethics vs individual ethics 
There are two important ethical considerations applicable to all RCTS: collective 
ethics and individual ethics.  Collective ethics refers to the process of assessing 
new treatments so that future patients will be able to benefit from superior 
care, i.e. the individuals in the study may not gain any benefits themselves.  
Individual ethics takes the stance that individuals should receive the best 
available treatment for their condition. 
It is considered important that researchers balance collective ethics with 
individual ethics when considering clinical trials.  Randomisation is considered 
essential to satisfy collective ethics – otherwise there is a risk patients may be 
involved in trials which are likely to be biased, leading to conclusions which 
cannot be relied on, and therefore the patients have been exposed to individual 
risk without any collective gain [236] (page 455). 
In order to satisfy individual ethics potential participants must give their 
informed consent that they understand the purpose of the study, and their role 
within it.  Traditionally from a researcher point of view clinicians can only enter 
a patient into a trial if they are genuinely unsure if the intervention is helpful – 
any clinician who strongly believes one intervention to be better cannot enter a 
participant into a study – it would be unethical if they genuinely believed they 
might be exposing a person to an inferior treatment.  However, the MRC 
Framework states  “before undertaking a substantial evaluation you should first 
develop the intervention to the point where it can reasonably be expected to 
have a worthwhile effect”.  Considering these somewhat opposing views left me 
in a predicament.  I had developed an intervention which I genuinely believed to 
be beneficial to people with asthma, yet I had to be comfortable randomising 
individuals to the ‘usual care’ group.  This very dilemma became an issue during 
the very first patient visit.  During the visit, it appeared clear to me that this 
lady was suffering asthma symptoms due to not taking her preventer inhalers, 
due to misconceptions which I was fully aware were challenged within the 
website, and that if the website worked as I hoped the chances were she would 
start taking her preventer inhaler regularly and would feel better.  In particular, 
her personal circumstances were very similar to those contained within a 
vignette in the introduction module, that I was sure would resonate with her.  I 
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was taken aback at how strongly I wanted this participant to be randomised to 
the intervention group, and my disappointment was considerable when our 
automated system allocated her to the control group.  This was real 
confirmation to me that automated randomisation processes are truly essential 
to ensure that a researcher’s individual ethics do not interfere with allocation of 
subjects, which has unfortunately been shown to happen many times in the past. 
Later I reflected on this participant, and my own feelings about her allocation, 
and in particular, I questioned whether I could be the best person to be 
undertaking these baseline visits, if I felt so strongly that the intervention was 
beneficial.  Was it unethical of me to participate in the randomisation of 
individuals to a level of care which I believed to be inferior?  I strongly felt that 
the information provided in the intervention was beneficial to participants, 
however the information provided essentially matched what should be provided 
in a comprehensive face to face asthma review, which all adults with asthma 
have access to – including this one.  All researchers with an interest in asthma 
know that people who undertaken guided self-management have better 
outcomes.  With regard to the website, while I felt sure if she used it as I felt it 
was designed to be used she would have gained some benefit, I could of course 
not predict whether even if allocated to the website she would use it, whether 
she would visit the pages I personally thought would be most helpful and 
whether she would enact any of the behaviours we were promoting even if she 
did log in and visit every page.  Therefore, I realised that while I knew that 
optimum self-management works, I did not know whether supporting self-
management via this website would work, and therefore my concerns around 
individual ethics could be satisfied.  
8.3.2 Missing data 
As well as being disappointing from an analysis point of view the missing 
spirometry data (i.e. the 23 participants whose spirometry tests did not meet 
acceptability criteria), has ethical implications.  In 21 of these 23 cases, the 
data could not be analysed due to not meeting reproducibility standards.  When 
undertaking trial visits both KS and I were aware that this was occasionally 
happening, but it wasn’t until I undertook the final analysis that I appreciated 
how much of a problem this was going to be.  This is partly due to the fact that 
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both visits needed to meet the criteria, so if one didn’t then the other valid 
measurement didn’t count for anything.  Therefore although only 21 out of the 
45 (47%) who completed had both v1 and v2 measurements meeting ATS 
reproducibility criteria, 67 out of 96 (70%) of individual measurements met the 
criteria. 
Spirometry is not an easy investigation for participants to undertake;  most don’t 
like it, find it uncomfortable and tiring, and on several occasions it triggered 
symptoms that resulted in them requiring to take their reliever inhaler.  That 23 
individuals went through this procedure for no overall gain to the study is very 
disappointing.  It does however highlight the rationale for a pilot study, as had 
this been a main evaluation this number would have been much higher. 
This issue highlights the importance of either finding a machine that can 
facilitate meeting acceptability criteria, or considering a different outcome for a 
future evaluation.  It is likely that improved training may have made a slight 
difference as 63% of the first 30 spirometry tests were acceptable, compared to 
77% of the final 30 tests undertaken, but this would not be enough to markedly 
improve the numbers meeting acceptability criteria.  
8.4 Strengths and weaknesses of project 
Within each of the main results chapters (4, 5 and 6), I have provided the 
strengths and weaknesses of each section.  This section summarises the 
strengths and weaknesses of the project as a whole, focussing on overall 
methodological issues. 
8.4.1 Methodology 
A key strength of this project is the way that we followed best practice guidance 
during both the development and evaluation phases.  For this, I chose to use the 
MRC document Developing and Evaluating Complex Interventions: new guidance 
[100] as the overarching framework to follow, and Figure 8.2 below shows how 
my methodology maps onto this framework. 
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Figure 8.2 Project methods mapped to MRC Framework  
 
 
Using this guidance resulted in our intervention being theory informed and 
incorporating user testing, both of which are increasingly seen as essential [100, 
102, 219, 237].  I also considered implementation factors from the very 
beginning by making use of my experience of normalisation process theory [101].  
This led me to consider what would happen if I developed an intervention which 
ultimately was shown to be effective.  I made links with Asthma UK recognising 
that the popularity of their website could be utilised for the benefit of this 
intervention, and they agreed that they would be open to ultimately hosting and 
maintaining such a website in the future.   
I have latterly become familiar with Penelope Hawe’s work, and in particular her 
discussions around the merits of evaluations in ‘ideal world’ versus ‘real world’ 
contexts [226].  Ideal world evaluations are where the interventions are 
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designed in what researchers consider optimum conditions and are tested in 
randomised controlled trials, in so called efficacy trials.  The alternative 
approach Hawe proposes is the ‘real world’ approach where understanding 
effectiveness rather than efficacy is the aim.  Ultimately most trials fall 
somewhere between, and I believe our trial was as real world as possible as 
evidenced by unrestrictive inclusion/exclusion criteria, and that participants 
were simply provided with the website address, as they would be if this 
intervention was ultimately available. 
Hawe also discusses a ‘real world’ versus ‘ideal world’ approach to developing 
interventions.  Rather than the more traditional scenario where researchers 
develop an intervention and then test in the target populations she describes an 
alternative scenario where ‘community researchers’ identify promising areas of 
ongoing practice in real life community settings and seek ways to transfer and 
test these promising practices for wider use in other communities.  This 
resonates in some aspects with the MRC framework approach to developing 
interventions illustrated in chapter 3 (Figure 3.2) which demonstrates a 
continuous circular route between developing, feasibility/piloting, evaluation, 
and implementation, and back to developing again, without specifying which of 
these 4 individual elements should be the starting point [100].  Hawe calls this 
approach a ‘bottom up approach’ versus the more traditional ‘top down 
approach’.  I consider that this insight about the potential benefits of the 
bottom up approach provided by Hawe is not too dissimilar to the argument that 
implementation scientists have been making for many years: that understanding 
implementation potential has to start at the earliest stages of intervention 
development [111], to the point which is argued here by Hawe where 
implementation is considered first and foremost i.e. what is already seen to be 
working. 
Ultimately, Hawe is not stating one way or the other is necessarily superior, but 
that whichever camp you are in, you can benefit from considering the 
alternative view point.  In this study by understanding what was actually 
happening on the ground, both by using my own clinical experience, experience 
of the expert panel, and specifically looking for gaps in self-management 
support strategies via focus groups and the literature, then the intervention 
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contents naturally followed from this. Our aim was never to try and do what was 
being done better, it was to try and fill the gaps made by the current processes. 
Therefore what has been developed should work well alongside current practice, 
supplementing the currently available health professional review, but plugging 
gaps in the support and information available between reviews.  
With further reference to implementability, the content was developed 
specifically that it would not become ‘out of date’ too quickly, so for example 
actual knowledge, particularly about specifics of individual inhalers for example 
was kept to a minimum, with the focus on encouraging the user to think 
differently about their own asthma. 
My flexibility about choice of methods is a strength of this project. I was 
responsive to my results and where necessary modified methods, for example 
following the metareview.  Similarly, there were occasions where I selected, 
tried out and sometimes rejected techniques as I felt appropriate, for example 
when using NPT during the focus group analysis, when it became apparent that 
the data naturally fell into either barriers and facilitators and further more 
detailed analysis was unnecessary.   
One of the weaknesses of the study is the sampling of the participants in the 
focus groups, and to a lesser extent, the think aloud studies.  These individuals 
had much more severe asthma than those whom the intervention would be 
aimed at, as discussed in chapter 5.  This latter fact is important to acknowledge 
as there is increasing evidence that when interventions are co-designed with 
people similar to your target group they will be more effective in that target 
group.  This is seen with Brown et al smoking cessation [31] which was designed 
exclusively with smokers with low socioeconomic status.  Their results 
demonstrated that the intervention was only effective in populations with low 
socioeconomic status, illustrating the power of user testing with the right 
populations.  This was less of an issue with the think aloud studies which were 
much more focussed on usability issues and there is an argument that these do 
not even need to be done by those with the disease of interest, so long as 
someone is clicking through and trying to use the website and providing 
feedback on their experiences [116]. 
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I was more careful with the inclusion/exclusion criteria for the trial to ensure 
they matched the target populated defined during the ‘key task’ exercise in 
chapter 5.  
8.4.2 Is this truly a mixed methods study? 
This study was a mixed methods project, the merits of which are outlined in 
chapter 3.  However, I would like to spend a moment considering just how 
“mixed methods” it ultimately was.  In the first phase we hoped to include 
qualitative systematic reviews, however as described in chapter 4 I did not find 
any meeting my inclusion criteria.  In the second phase, I undertook focus groups 
and think aloud studies, both using qualitative methods of gathering data.  In 
both cases, I planned to undertake a framework analysis of transcripts informed 
by normalisation process theory (NPT) which I had used successfully in this way 
in past studies.  However, in both situations when I received the transcripts and 
attempted the analysis I found that it simply wasn’t working.  With regards to 
the focus groups, this was for 2 reasons.  Firstly, it had been difficult to 
maintain focus on the topic guide I had developed, and therefore there was a 
significant amount of data that was irrelevant to the aims of the phase.  
Secondly, the data that was relevant so obviously fitted into two main areas of 
barriers and facilitators, that further classification using NPT was not necessary.  
Qualitative data analysis usually means going beyond simple descriptions, but to 
transform the data into something new, gaining fresh perspectives on the data.  
At first look it appears that I did in fact simply describe the data.  However, this 
data was combined with extracts from the literature review, connections made, 
and new data generated in the form of ‘website features or components’ a 
process fully described in appendix 10 (intervention planning document).  
Therefore, although the results are not reported in the style of traditional 
qualitative results, the data gathering, and analysis, fit within the umbrella term 
of qualitative methods.  With the think aloud transcripts the vast majority of the 
data was specific to a given sentence on a page, or a page layout.  Therefore, 
the actual data that was analysable from a framework perspective was limited, 
and naturally fitted into groups entitled ‘content’, ‘layout and navigation’ and 
‘user experience’.  Comments relating to graphics used were considered 
somewhat separately, as I was advised that comments about graphics are often 
personal to participants and not generalizable to others (personal 
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communication Prof Lucy Yardley).  In addition, contrary to epistemological 
descriptions of qualitative methods I counted the number of responses in each 
category, particularly interested in whether they were positive or negative.  
However this is justified as we were looking for specific evidence that those 
participating in the think aloud studies had felt able to criticise it in front of me, 
given my role in the developing the website.   
This section provides evidence that although the qualitative analysis methods 
were perhaps not traditional in the sense of employing grounded theory 
methods, or typical framework analysis, they were chosen in response to the 
type of data gathered and the requirement of the research question, possibly in 
part influenced by my positivist leaning stance, but regardless they were right 
for this study.  So while it perhaps was not as ‘mixed method’ as it set out to be, 
it still is a mixed method study, and in doing so has broadened my own research 
experience and skill set considerably, and strengthened our findings by providing 
context and end user opinion.  
8.5 Summary 
This chapter illustrates how the project work has answered my research 
questions, and reflects on issues raised during the course of the project.  
Future research directions and implications for practice and policy are provided 
in the next chapter, along with my overall conclusion.
 Chapter 9: Future Directions & Overall 
Conclusions  
9.1 Introduction 
This final chapter discussion future research directions, and considers 
implications for practice and policy.  I then summarise the results and provide 
overall conclusions. 
9.2 Future research directions 
9.2.1 Promoting complexity versus intensity 
As discussed earlier complexity is not easily defined, never mind measured.  It 
could possibly be defined as the number of behaviour change techniques 
present, or how many ‘working parts’ there are to it, how long it takes an 
individual to ‘do’ an intervention, or on how many ‘levels’ it works at e.g. 
patient, professional or policy.  I use the term complexity as a way to describe 
the interventions itself (including evaluation), and intensity to refer only to the 
anticipated work that an intervention requires of a user.  There is evidence for 
increased effectiveness in several of these suggested components of 
‘complexity’.  Powell et al in their Cochrane review of self-management for 
asthma found that reducing the ‘intensity’ of the education or level of clinical 
review may reduce effectiveness [65], however this was based on one single trial 
of participants with asthma severe enough to require A&E attendance or 
secondary care referral.  The intensive intervention involved a structured theory 
informed programme, and the basic intervention was simply information delivery 
about self-management e.g. inhaler technique.  Therefore it could be argued 
they were really evaluating complexity as much as intensity. 
With regards specifically to behaviour change techniques the evidence so far 
suggests that interventions which incorporate more behaviour change techniques 
tended to have larger effect sizes compared to interventions that incorporated 
fewer techniques [141, 142].  Pinnock et al demonstrated that interventions that 
addressed patient, professional and organisational factors showed the most 
consistent improvement in outcomes [112].  Overall in the literature there 
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remains a lack of clarity of the terms complexity and intensity, although the 
situation is improving.   
On the surface the above findings suggest bigger is better, however I would 
argue that this is not as straightforward as it may at first seem.  What is missing 
from the literature is how does the complexity of an intervention, and its’ 
intensity impact on sustained engagement by patients – how likely are these 
complex intense interventions to be implemented, integrated and ultimately 
embedded in non-trial contexts.  The work put in to interacting with any 
intervention should be balanced ideally with reduced symptom burden, reduced 
work of monitoring their own illness, and reduced attendance with health 
professionals, all aspects of patient work which are increasingly being recognised 
across chronic illnesses, and this work can be considerable [224, 238, 239].  
However, in individuals with mild to moderate asthma with a variable disease 
burden it is difficult to see how the increased work involved in more intensive 
interventions e.g. those requiring daily self-monitoring for example, would ever 
be balanced in a population where even those found to be enduring very poorly 
controlled asthma symptoms, minimise their symptom burden, do not undertake 
any type of self-monitoring, and often do not attend health professionals  for 
their asthma [2]. 
From a health services perspective interventions need to demonstrate cost-
effectiveness, or at least cost neutrality, for them to be attractive to policy 
makers and health care providers.  This is where standalone internet 
interventions may find their place.  A recent comprehensive review of self-
management interventions by Panagioti et al across multiple disease areas found 
evidence of a consistent, but small, positive effect of self-management 
interventions (digital and non-digital) mainly in respiratory diseases and 
cardiovascular diseases [240].  Of most interest to me was the lack of difference 
in the effect size between less intensive interventions to support self-
management, and those more intensive interventions labelled as case-
management. 
Only 5% of interventions included in this review were ‘pure self-management’ 
working entirely independently of health professionals.  However, with such 
‘pure self-management interventions’ once developed, the running costs are 
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minimal, and even taking into account the costs for contextualisation at local 
levels, are comparatively easy to disseminate widely, when compared to 
interventions requiring integrated health professional support. Given the low 
percentage of stand-alone interventions in Panagioti et al’s review, this is 
clearly an under-researched area, further evidencing the need for studies such 
as this undertaken here.  
It seems likely that individuals with mild to moderate asthma are more likely to 
engage in interventions in the real world which require the least amount of work 
for them e.g. are less intensive.  While there is evidence above that more 
behaviour change technique and intervention components produce greater 
effect sizes, generally the evidence suggests these are not well implemented in 
real life [1, 90].  There is no evidence that more intense interventions are more 
effective than low intensity interventions in respiratory conditions [240].  This 
leads me to conclude that research should be focussing on standalone low 
intensity digital interventions such as this, and that featured in Bender et al 
[212], as their implementation potential is higher, and running costs likely to be 
lower.  I would conclude that the way forward from here is a website or App 
that promotes behaviour change tailored to the individual similar to that trialled 
here, coupled with infrequent automated telephone messages such as those used 
by Bender [212] or emails, would be a successful combination. Further 
qualitative work would be required to understand how these changes to this 
intervention would be received by end users, and potentially work in practice..  
In addition, further work examining the cost effectiveness of such interventions 
is merited. 
9.2.2 Implications for Living Well with Asthma website 
development 
Previous research on an asthma self-management website indicates that users 
like to spend 5-8 minutes per session [87].  Our exploration of usage patterns 
suggests that some users missed sections that they would potentially have 
benefited from accessing.  These two facts combined lead me to conclude that 
rather than presenting the whole site to the user and not changing it over the 
course of the study period it would be better to provide the core modules 
initially and then ‘release’ further sections fortnightly or monthly. This would 
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encourage the user to return to the site, and complete the new section, a 
strategy that has been used successfully for a weight loss intervention also 
developed using LifeGuide software [166]. 
Our PETS questionnaire results suggest that time and opportunity were the main 
barriers. It is worth noting that 41% acknowledged there were some barriers in 
the ‘doubts about efficacy’ subgroup.  However looking at the questions that 
feed into this subgroup they are: 
 I skipped the therapy because I was not sure it was helping 
 I skipped the therapy because it did not seem relevant to my symptoms and 
problems 
 I did not carry out the therapy because I was not convinced it was right for 
me 
Therefore I think it is truer to say that many individuals in the study felt that it 
was not relevant to their situation.  This links back to the initial problem 
explored in our planning stages in chapter 5 that showed people with asthma 
often underestimate their own symptoms and the impact asthma is having on 
them.  These PETS findings suggest to me that future iterations of the website 
needs to work harder at persuading individuals that they are candidates for 
enjoying better asthma related health, and the results of the qualitative 
interviews with intervention group participants may yield strategies for 
achieving this.  
9.2.3 Implications for future RCT study design 
Extrapolating the results from this study to inform the sample size for a full 
scale trial is not straightforward.  Depending on which outcome is used, whether 
baseline scores are taken into account, and whether we use the conservative 
attrition rate of 20%, or the average of 12%, the sample size required varies from 
114 up to 304.  Whether we take baseline scores into account depends mainly on 
whether we would change the length of the study period.  Given this is a rather 
simple intervention 3 months seems a reasonable timescale, but it would be wise 
in any future RCT to include a follow up at 12 months to see if any effects are 
sustained.  The mostly likely design would be using ACQ as the primary outcome, 
Chapter 9 Conclusions   256 
and given the likely longer study length in a full scale trial baseline adjusted 
calculations are less valid.  Using the higher attrition rate of 20% this results in 
sample size requirement of 210.  I speculate that guilt about not using the 
intervention contributed to the higher attrition in the intervention group and it 
is possible that more actively counselling against this at the baseline visit may 
ameliorate this slightly. It is true that we did say to do this to some extent, but 
this was balanced against not wanting to seem as though using the website did 
not matter at all, and I think in a future trial it would be worth being even more 
explicit about it. 
One of the most important areas to learn from our pilot trial is regarding 
recruitment (including screening).  Recruitment methods are highly dependent 
on choices made around data collection, and for similar face to face data 
collection methods as used here, we would have a range of options.  As 
discussed earlier making use of internet based strategies would be worth 
investigating.  Using disease specific websites such as Asthma UK would no doubt 
generate some participants, however they are unlikely to be typical of the 
participants we are targeting with this intervention (mild to moderate) as I 
discovered when recruiting for my user design groups (chapter 5).  This effect 
could be reduced by having upper ceilings for ACQ, or certain medications (e.g. 
those on BTS step 4 or higher could be excluded).  Other options would be a link 
from the NHS information pages, and general snowballing techniques using social 
media.  Other methods worthy of consideration could include local newspapers 
and bus stop advertising for example.  I did consider these for this study but 
costs seemed prohibitive (£3000-£5000).  However in reality I spent in excess of 
£5000 on mailings alone, and this cost did not include the considerable time 
spent making up recruitment packs, which could overall be estimated 
(conservatively) at 1 per minute – over 2 weeks of full time work, which could be 
avoided if initial contact was made through alternative means. 
The other option to consider is whether there needs to be a face to face visit at 
all for recruitment.  It is possible that recruitment, screening, consent, data 
collection and randomisation could happen online, and users simply allocated 
website access or not. Follow-up data could also be collected online.  It is likely 
this type of trial would be cheaper to run, however the type and volume of data 
available to collect would be significantly limited, and it is likely that attrition 
Chapter 9 Conclusions   257 
rates and missing data would be higher without the impetus of a face to face 
visit to encourage participants to complete the study.  This would need to be 
taken into account when calculating sample size calculations. This uncertainty 
about optimum recruitment strategies suggests that further exploratory work on 
optimising recruitment may be required before this intervention proceeded to a 
full scale RCT. 
When considering recruitment options, one strategy which would significantly 
facilitate recruitment would be to remove the requirement for participants to be 
symptomatic from the inclusion criteria.  The argument for doing so would be 
that asthma is characterised by variability and therefore just because a person is 
well controlled on one day, does not necessarily mean they would still be 
controlled even the following day.  This would more readily reflect real life, 
when if such a resource was made freely available in the future it would likely 
be so for anyone with asthma, not just those with symptomatic asthma.  If the 
evaluation was to be over a 12 month period, a potential timescale discussed 
earlier, removing a baseline symptom score criteria makes more sense.  This 
would have implications on choice of outcome measures.  It might suggest a 
move away from symptom score measure such as ACQ, unless there was scope 
for serial measures to allow for the analysis to take account of natural variation 
in scores.  Alternatives for the primary outcome could be asthma related quality 
of life measures which is commonly used as a primary outcome in asthma trials, 
or even patient activation measure, as a way to quantify if the resource has 
been successful for the individual.   
As well as consideration to recruitment strategies, further investigation of how 
this intervention might be presented to potential users, should efficacy be 
demonstrated, is warranted. In the trial setting 76% of those who were allocated 
to the intervention group logged in, which for this type of study is comparable to 
that seen in similar interventions. [42, 166]  What is not clear is how to best to 
translate this trial finding into everyday clinical settings. Participants in the 
focus groups and think aloud studies reported that the intervention being 
promoted by a health professional would have an important role in their decision 
to use it.  Further feasibility work with health professionals to explore this 
aspect would be essential before any further full scale evaluation, particularly 
as this could lead to new findings about potential recruitment strategies for such 
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trial.  There are still the findings from the qualitative interviews with 
intervention group participants to assimilate which may give some indications 
towards these issues. 
As alluded to above most of the outcomes worked well.  The main concern 
regarding choice of outcomes is around feasibility of undertaking spirometry in 
this setting.  Potential solutions are described in chapter 6 and careful 
consideration to including this outcome is required, as would be including the 
PAM with regards to the practical concerns about the ability to undertake the 
analysis.   
9.3 Implications for practice and policy 
Given this was a pilot study making assertions about the implications on practice 
and policy may seem premature. However there are some important issues 
highlighted by this study.  For those in practice it reiterates the ongoing issue 
that patients with asthma underplay symptoms and impact on daily life, and a 
need to actively elicit a true understanding of symptoms during reviews. 
Worryingly the focus groups and think aloud studies illustrate that practice 
nurses are increasingly time pressured during reviews to their apparent 
detriment.   Given the findings from the National Review on Asthma Deaths [1] 
which suggest primary care needs to do more to support self-management, and 
the importance of the quality of the relationship between patients and providers 
at influencing levels of adherence and outcomes suggests that this is an area 
where improvements can be made. 
My literature review and qualitative work confirm an ongoing appetite for digital 
self-management interventions, by both patients and health professionals. I have 
demonstrated that following the MRC Guidance is  feasible and I believe  
following it has enhanced the intervention developed, such that it shows promise 
already from the pilot study.  The benefits of undertaking a pilot study first are 
demonstrated by the recruitment being more difficult than we anticipated, and 
also our finding that spirometry in this way was not feasible. Further exploration 
of recruitment strategies would be worthwhile before progression to a full scale 
RCT, as would consideration to proposed strategies for engaging potential end 
users in the intervention in real life post trial settings.  
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9.4 Overall Conclusion 
There is ever increasing interest in the potential of digital interventions in the 
healthcare setting, yet how best to utilise this technology in the field of asthma 
is not yet clear [8].  Suboptimal self-management in asthma continues to 
contribute to poor outcomes globally, and the need for improving self-
management is clear, particularly given evidence of increasing prevalence [5] 
[1]. 
I have fully described the development and content of this intervention in an 
article recently published by BMC Medical Informatics & Decision Making [168].  
This transparency allows other researchers, policy makers and practitioners to 
fully understand and build on this work.   
Given that this pilot trial already shows some statistically significant results, it 
merits further development and evaluations.  However some important issues 
need to be addressed before doing so, in particular recruitment and 
implementation strategies need further consideration before a definitive 
evaluation in a full scale RCT.   This thesis adds to the body of literature in this 
ever advancing field of research. I argue within this thesis that researchers 
developing interventions to support self-management in individuals with mild to 
moderate asthma should  focus  on low intensity interventions (ideally with 
multiple behaviour change techniques) that work independently from health 
professionals, and further research is needed to confirm whether such 
interventions do indeed demonstrate more sustained use in real life settings and 
are cost effective.  
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Self-management Intervention (RAISIN): study
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Rekha Chaudhuri3 and Frances S Mair1*Abstract
Background: The financial costs associated with asthma care continue to increase while care remains suboptimal.
Promoting optimal self-management, including the use of asthma action plans, along with regular health professional
review has been shown to be an effective strategy and is recommended in asthma guidelines internationally. Despite
evidence of benefit, guided self-management remains underused, however the potential for online resources to
promote self-management behaviors is gaining increasing recognition. The aim of this paper is to describe the protocol
for a pilot evaluation of a website ‘Living well with asthma’ which has been developed with the aim of promoting
self-management behaviors shown to improve outcomes.
Methods/Design: The study is a parallel randomized controlled trial, where adults with asthma are randomly assigned
to either access to the website for 12 weeks, or usual asthma care for 12 weeks (followed by access to the website if
desired). Individuals are included if they are over 16-years-old, have a diagnosis of asthma with an Asthma Control
Questionnaire (ACQ) score of greater than, or equal to 1, and have access to the internet. Primary outcomes for this
evaluation include recruitment and retention rates, changes at 12 weeks from baseline for both ACQ and Asthma
Quality of Life Questionnaire (AQLQ) scores, and quantitative data describing website usage (number of times logged
on, length of time logged on, number of times individual pages looked at, and for how long). Secondary outcomes
include clinical outcomes (medication use, health services use, lung function) and patient reported outcomes (including
adherence, patient activation measures, and health status).
Discussion: Piloting of complex interventions is considered best practice and will maximise the potential of any future
large-scale randomized controlled trial to successfully recruit and be able to report on necessary outcomes. Here we
will provide results across a range of outcomes which will provide estimates of efficacy to inform the design of a future
full-scale randomized controlled trial of the ‘Living well with asthma’ website.
Trial registration: This trial is registered with Current Controlled Trials ISRCTN78556552 on 18/06/13.
Keywords: Asthma, Self-management, Adherence, E-health, Randomized controlled trial, Complex intervention, Inhaled
corticosteroids, Behaviour change* Correspondence: Frances.Mair@glasgow.ac.uk
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279Background
Asthma is common, affecting an estimated 300 million
people worldwide [1]. The financial costs associated
with asthma care continue to increase [2], while care re-
mains suboptimal - patients continue to overestimate
their asthma control, tolerating more symptoms and
greater limitations than necessary [3,4]. Promoting self-
management, including the use of asthma action plans,
along with regular health professional review has been
shown to be an effective strategy leading to improved
outcomes including improved quality of life, lower rates
of healthcare contacts, and fewer days off work and
school, and is a recommendation in worldwide asthma
guidelines [5-9]. Self-management support aims to im-
prove outcomes in a number of ways: better recognition
of deterioration of symptoms, more appropriate re-
sponses to exacerbations, and optimizing adherence to
medication [10]. Improving adherence to inhaled corti-
costeroids is crucial to avoid exacerbations, improve day
to day control, and reduce the risk of hospitalization
and death [11]. Adherence to treatments in many chronic
illnesses is low and asthma is no exception [12,13]. Re-
search into non-adherence suggests several rationales, but
in common with other chronic conditions recurring
themes relate to doubts about the need for the medica-
tions in the first place, and concerns about potential side-
effects of treatments [12,14].
Despite evidence of benefits, guided self-management
remains underused [9-11]. Online interactive tools to sup-
port asthma self-management in general have been trialed
out with the UK and there is increasing evidence that they
may be safe and effective, enabling patients to take a more
proactive role, improving asthma quality of life scores and
symptoms (and in some cases forced expiratory volume in
1 second (FEV1)) [15-18], and potentially demonstrating
cost-effectiveness [19]. This suggests that making effective
use of available technologies may have the potential to in-
crease uptake of self-management behaviors in those with
asthma, without additional cost. How best to achieve this
is still not clear [20].
‘Living well with asthma’ resource development
We developed an online resource ‘Living well with
asthma’ which aims to promote optimal self-management
behaviors known to lead to improved outcomes. Explora-
tory focus group discussions with adults with asthma and
primary care nurses clarified the key features deemed
most important in a website. These data, along with a pre-
ceding literature review [20], informed the initial develop-
ment of a prototype of the website. The actual content of
the pages within the website was developed and refined it-
eratively with input from adults with asthma, practice
nurses, general practitioners, a sociologist, human com-
puter interactions researchers, respiratory physicians, anda health psychologist. Further refinement of the content
was undertaken using ‘Think aloud’ studies with adults
with asthma. These were undertaken by DM, and partici-
pants fed back in real time their views on the contents
and usability. Initially this was on paper mock-ups of pro-
posed web pages, and latterly on actual ‘Living well with
asthma’ webpages. ‘Think aloud’ studies are a recog-
nized method of gaining information about users’ views
in real time as they navigate around a website, providing
information about usability and feeding into further de-
velopment and refinement of the website [21,22]. The
‘Living well with asthma’ website was developed as a
standalone resource which should complement face-to-
face asthma reviews, but does not require health profes-
sional involvement.
A full description of the website development will be
available in a forthcoming publication.
Rationale for the evaluation methods
Guidance for the development of complex interventions
recommends pilot and feasibility studies prior to formal
evaluations [23,24]. A pilot study is a version of the main
study that is run in miniature to test whether the com-
ponents of the main study can all work together [25],
whereas a feasibility study is used to estimate important
parameters that are needed to design the main study,
such as ease of recruitment, standard deviations of out-
come measures, and follow-up rates [25,26]. This study
aims to address both issues. Feasibility and piloting are
essential to ensure that planned progression to a full-
scale randomized controlled trial (RCT) is appropriate in
the first place and if it can be undertaken with appropri-
ate power to achieve definitive results. This early evalu-
ation must be broad enough to provide information
both about how a full-scale RCT may work in practice
but should also have consideration for how the resource
may be used beyond the evaluation. Feasibility is investi-
gated through measuring recruitment and retention
rates and collecting usability data about the website it-
self. Measuring clinical outcomes will allow for the col-
lection of important data on the efficacy of the
intervention and for the estimation of effect sizes in any
future larger RCT.
Study aims
This study aims firstly to assess the feasibility of con-
ducting a RCT of the clinical effectiveness of an online
asthma resource aimed at promoting adherence in adults
with poorly controlled asthma, using the ‘Living well
with asthma’ resource. Secondly, as a pilot study the aim
is to provide estimates of recruitment and retention
rates, as well as estimates of the variability of clinical
and behavioral outcome measures to inform power cal-
culations for a definitive trial. The study will collect a
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used, including but not limited to: the most and least
visited pages, the length of time the intervention was
accessed, and how often it was accessed. Finally, this
pilot and feasibility study also aims to identify any po-
tential problems to be addressed, and allow for further
development of the resource, before a further evaluation.
We hypothesize that this intervention, which has been
designed with end user involvement and aims to im-
prove adherence to therapy using multiple strategies
(educational information, attitudinal arguments, self-
monitoring, and reminders), will result in improved
symptom control and quality of life measures in adults
with asthma.Methods/Design
Ethical approval and trial registration
Ethical approval for this study was granted by the West of
Scotland Research Ethics Committee (ref 13/WOS/004) in
March 2013. All participants provided written informed
consent. The trial was conducted in accordance with na-
tional laws, Good Clinical Practice guidelines and the Dec-
laration of Helsinki 2002. This trial is registered with
Current Controlled Trials ISRCTN78556552.Recruitment, randomization and blinding
Participants are primarily being recruited from primary
care practices within the Greater Glasgow and Clyde
health board area and from posters in public places. We
aim to recruit 50 participants in total. See Table 1 for full
eligibility criteria.
Consenting participants fulfilling our inclusion and ex-
clusion criteria are being randomized using a third party
automated telephone interactive voice response system.
Participants will self-complete all questionnaires. Due to
the nature of the intervention the blinding of the re-
searcher is not practical, however data will be entered
and managed by the Robertson Centre for Biostatistics
(RCB), University of Glasgow, and the researcher willTable 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Written informed consent 1. Unstable asthma
2. Age 16 years or older 2. Presence of active lung
disease other than asthma
3. Diagnosis of asthma by a health
professional and duration of asthma
symptoms≥ 1 year.
3. Mental impairment or
language difficulties that make
informed consent impossible.
4. Asthma Control Questionnaire
score (6 questions version) greater
than or equal to 1 (suggesting
poorly controlled asthma)
4. Terminal illness
5. Ability to access the internet
(excluding via smart phone or tablet).
5. Cognitive impairment.take no role in this. The data will be analyzed by a re-
searcher blinded to the allocation of the groups.
Intervention
This is a parallel, two arm RCT. See study flow chart
(Figure 1) and SPIRIT (Standard Protocol Items: Recom-
mendations for Interventional Trials) checklist (Additional
file 1) for further details. The duration of participation is
12 weeks from randomization. Those randomized to the
intervention arm will have access to a purpose-built website
with the aim of facilitating adherence to asthma medica-
tions for 12 weeks. This will include the following five
areas: a) allow users to gain understanding of their current
degree of asthma control and how they can improve it, spe-
cifically by optimizing their use of prescribed medication;
b) challenge attitudes and concerns around taking medica-
tions for asthma; c) learn how to get the most out of their
annual asthma review; d) prompt those who do not have
one to seek an asthma action plan to be filled in with a
health professional; e) send reminders to participants such
as to get the flu vaccine or to order inhalers (participants
can opt out of this aspect).
This resource will not advise medication changes dir-
ectly, but if indicated, may suggest making an appoint-
ment with a nurse or doctor for review. Clear advice will
be presented for seeking help in an emergency.
Control group
Those randomized to usual care will be advised to con-
tinue to manage their asthma as they would usually.
After the follow-up visit at 12 weeks, participants in the
control group will be offered 12 weeks of access to the
website if they choose.
Outcomes
Primary endpoints
The primary endpoints for this study are: recruitment and
retention rates at 12 weeks from baseline, web usability,
and changes at 12 weeks from baseline for ACQ [27] and
AQLQ [28] scores. Recruitment and retention rates will
be measured as well as usage data at 12 weeks, including
number of times users logged in and total length of time
logged in, number of times individual pages were viewed,
and length of time spent on each page.
Secondary endpoints
The first secondary endpoint for this study will be
changes at 12 weeks from baseline for Patient Activation
Measure (PAM) score [29], EQ-5D score (generic meas-
ure of health related quality of life) [30], the Morisky
Medication Adherence Scale (MMAS) [31], lung func-
tion (via pre bronchodilator spirometry FEV1, FEV1/FVC
(forced vital capacity), peak expiratory flow (PEF) per-
formed to American Thoracic Society (ATS) standards
Figure 1 Study flow chart. ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FeNO, Fractional Exhaled Nitric
Oxide; GP, General Practitioner; MMAS, Morisky Medication Adherence Scale; PAM, Patient Activation Measure; PETS, Problems of Experienced
Therapy Scale.
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performed to ATS standards [33].
The second secondary endpoint will be changes in the
Problematic Experiences of Therapy Scale (PETS) [34]
score at 12 weeks in the intervention group only. The
third secondary endpoint will be self-reported healthcare
utilization including: routine visit to GP or practice
nurse because of asthma, visit to GP because of asthma
requiring oral steroids, hospital admission (and length of
stay) because of asthma requiring oral steroids, emer-
gency or out of hours’ visit because of asthma requiring
oral steroids, and emergency or out of hours’ visit of pa-
tients to the GP or GP visit to patient at home because
of asthma requiring oral steroids. The fourth secondaryendpoint will be self-reported medication utilization
including: changes in the level of adherence to pre-
scribed preventer medications, changes to the average
number of reliever puffs taken per week, intensification
of treatment, or step-up of asthma medications (as
defined by British Thoracic Society/Scottish Intercol-
legiate Guidelines Network (BTS/SIGN) guidelines, and
step-down of asthma medications (as defined by BTS/
SIGN guidelines).
Statistical considerations and data handling
While this study is not powered to detect differences in
clinical measures, we will report estimates of effect sizes
with a 95% confidence interval. The primary objectives
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inform the feasibility of running a full-scale trial. We
shall recruit 50 participants to estimate these quantities
with reasonable precision. For example, if we invite 100
participants to recruit 50, the recruitment rate would be
estimated with a confidence interval of ± 10%. Patient
characteristics and outcomes will be summarized at
baseline, at follow-up, and as changes over baseline.
Study groups will be compared using baseline-adjusted
linear regression (analysis of covariance (ANCOVA).
The effects of baseline and intermediate data on patient
outcomes will be explored using linear regression. The
variability of outcome data will be used to estimate the
sample size required for a definitive study.
Data management
The RCB, part of the Glasgow Clinical Trials Unit (a
fully registered UKCRN Clinical Trials Unit) are man-
aging the randomization procedures and the trial data.
Case report forms (CRF) will be used to collect study
data. The CRF has been developed by the researcher and
the RCB. The RCB are responsible for collating study
data.
Trial management group and patient safety
The routine management of the trial will be coordinated
by the trial management group. This will comprise the
chief investigator (DM) and four co-investigators (FM,
SW, NT, and AM). This group will monitor the progress
of the trial to ensure that the protocol is adhered
to. This group will meet bimonthly, with monthly re-
cruitment reports via email. Any changes to the study
protocol will be following agreement with the trial man-
agement group, and subject to approval from Research
and Development at NHS Greater Glasgow and Clyde,
and the West of Scotland Research Ethics Committee,
where required.
The study will end when the trial management group
agrees that either the planned sample size has been
achieved or the recruitment is so poor that completion
of the trial is not feasible.
Only adverse events that are outcome measures will
be recorded. All serious adverse events (SAEs) will be re-
corded at follow-up. All SAEs will be assessed for causal-
ity, expectedness, and severity. This assessment is the
responsibility of the chief investigator (CI). The trial
team will record all SAEs. The CI will endeavor to ob-
tain sufficient information to determine the causality of
the adverse event and must provide an opinion of the
causal relationship between each SAE and the study
intervention. The accumulated SAEs will be sent to the
sponsor and the West of Scotland Research Ethics Com-
mittee in an annual safety report. Detailed records of all
SAEs will be held in the trial master file.Annual safety reports
It shall be the responsibility of the trial management
group on behalf of the sponsor to submit, once a year
throughout the clinical trial, or on request, a safety report
to the West of Scotland Research Ethics Committee.
Discussion
The increasing burden of chronic disease on healthcare
providers is well known, and promoting self-care is a
strategy for shifting this burden away from healthcare
providers. The Internet may provide a cost-effective
medium for doing this. Piloting of complex interventions
is considered best practice and will maximize the poten-
tial of any future full-scale RCT to successfully recruit
and be able to report on necessary outcomes. Here we
report on feasibility outcomes such as recruitment, re-
tention, and usability of the intervention being investi-
gated, and undertake piloting of an intervention which
will aim to determine clinical efficacy.
Trial status
Recruitment was initiated in June 2013, with the first pa-
tient randomized in September 2013, and is ongoing as
of February 2014.
Additional file
Additional file 1: SPIRIT Checklist as appropriate to a non-CTIMP
(Controlled Trial of Investigational Medicinal Product).
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Abstract
Background: Around 300 million people worldwide have asthma and prevalence is increasing. Self-management
can be effective in improving a range of outcomes and is cost effective, but is underutilised as a treatment strategy.
Supporting optimum self-management using digital technology shows promise, but how best to do this is not
clear. We aimed to develop an evidence based, theory informed, online resource to support self-management in
adults with asthma, called ‘Living well with Asthma’, as part of the RAISIN (Randomized Trial of an Asthma Internet
Self-Management Intervention) study.
Methods: We developed Living well with Asthma in two phases.
Phase 1: A low fidelity prototype (paper-based) version of the website was developed iteratively through input from a
multidisciplinary expert panel, empirical evidence from the literature, and potential end users via focus groups
(adults with asthma and practice nurses). Implementation and behaviour change theories informed this process.
Phase 2: The paper-based designs were converted to a website through an iterative user centred process. Adults
with asthma (n = 10) took part in think aloud studies, discussing the paper based version, then the web-based
version. Participants considered contents, layout, and navigation. Development was agile using feedback from the
think aloud sessions immediately to inform design and subsequent think aloud sessions. Think aloud transcripts
were also thematically analysed, further informing resource development.
Results: The website asked users to aim to be symptom free. Key behaviours targeted to achieve this include:
optimising medication use (including inhaler technique); attending primary care asthma reviews; using asthma
action plans; increasing physical activity levels; and stopping smoking. The website had 11 sections, plus email
reminders, which promoted these behaviours. Feedback on the contents of the resource was mainly positive with
most changes focussing on clarification of language, order of pages and usability issues mainly relating to
navigation difficulties.
Conclusions: Our multifaceted approach to online intervention development underpinned by theory, using
evidence from the literature, co-designed with end users and a multidisciplinary panel has resulted in a resource
which end users find relevant to their needs and easy to use. Living well with Asthma is undergoing evaluation
within a randomized controlled trial.
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Background
Asthma is common, affecting 300 million people world-
wide, and its prevalence is increasing; an estimated add-
itional 100 million people will have asthma by 2025 [16].
Despite increasing costs associated with asthma [2], care
remains suboptimal, with many patients tolerating symp-
toms and lifestyle limitations unnecessarily, due to sub-
optimal use of proven available therapies [11, 26, 29, 32].
Supporting optimum self-management by providing
relevant self-management education including how to use
an asthma action plan (AAP), regular health professional
review, and optimal use of medications has been shown to
have positive effects on a range of asthma outcomes such
as improved quality of life, lower rates of healthcare con-
tacts, and fewer days off work and school [7]. Promoting
self-management is a recommendation in worldwide
asthma guidelines [4, 8]. Despite this, self-management as
a treatment strategy remains underused [8, 32, 34].
Recently, new information and communication technolo-
gies (ICTs) have been proposed as a means to improve
asthma self-management uptake. We conducted a meta-
review [22] which showed that online interactive resources
to support self-management of asthma can be safe and ef-
fective at improving some outcomes such as markers of
self-care, activity limitation, quality of life and medication
use. However, interventions were poorly described and it
was impossible to extract generalisable lessons about the
key ‘active ingredients’ of interventions. This challenge has
previously been recognised by Michie et al. [20] who in re-
sponse have developed a taxonomy of behaviour change
techniques (BCTs) which they propose researchers can
use to describe interventions, in order to overcome the
lack of a systematic way of determining the ‘active ingredi-
ents’ of a complex interventions [21].
Traditionally, development of online interventions has
been resource intensive with each intervention requiring
to be programmed individually by a team of program-
mers from scratch—a barrier to internet based interven-
tions being cost-effective when compared to face-to-face
or paper alternatives. A team in Southampton who have
recognised the increasing potential for delivering health
care online have developed an open access software
package called LifeGuide [10, 38, 41]. LifeGuide aims to
allow researchers from a non-computer programming
background to more easily and flexibly create and mod-
ify internet-delivered interventions. It has been used suc-
cessfully in a number of health related interventions [3,
33, 38]. A key design feature of LifeGuide is that it al-
lows researchers to easily test parts of an intervention
and immediately modify and improve it based on the
findings, and to trial it in the development phase.
Here we describe the development and optimisation of
the Living well with Asthma website which we devel-
oped using the LifeGuide open access software package
guided by the updated MRC guidance for the develop-
ment and evaluation of complex interventions [18]. The
Living well with Asthma website is currently undergoing
evaluation in a randomised controlled trial (RCT) called
RAISIN (Randomized Trial of an Asthma Internet Self-
Management Intervention) (ISRCTN 78556552) [23].
Methods
To develop the Living Well with Asthma website we
followed the steps outlined in the updated MRC guid-
ance which recommends that intervention development
should be systematic, include review of the evidence, be
theory based, and incorporate feasibility or user testing
[18]. In this section we describe the two phases of work
we undertook to incorporate these steps. Ethical ap-
proval was granted from the West of Scotland Research
Ethics Committee (12/WS/0068), and all participants
provided informed consent.
Phase 1: intervention planning
Phase 1 describes the process of developing a ‘first draft’
of the website. This phase consisted of three main work
packages (WP), all overseen by a multidisciplinary ‘ex-
pert panel’ made up of 3 general practitioners, a respira-
tory physician, a health psychologist, a social scientist,
and a human-computer-interaction researcher.
Work package 1—understanding the evidence &
incorporating theory (scoping review and expert panel)
Campbell et al. [5] describe 5 key tasks involved in de-
fining and understanding the ‘problem’ that your inter-
vention is aiming to solve, namely: 1) defining and
quantifying the problem; 2) identifying who is mostly
likely to benefit; 3) understanding the pathways which
contribute to the problem; 4) consideration of whether
(and how) these pathways are amenable to change; 5)
and attempting to quantify the potential for improve-
ment. We did a brief scoping review of the literature
and used the experience of our expert panel to work
through these tasks. We identified a list of features that
a resource should have, incorporating recommended be-
haviour change concepts [25].
Work package 2—getting user perspectives on a web
resource (focus groups)
In order to investigate the plausibility of this list with
potential end users we convened 2 focus groups, consist-
ing in total of 9 adults with asthma (6 female, 3 male),
and 4 practice nurses who undertake asthma reviews.
Recruitment was undertaken using a range of sources:
primary care, Asthma UK Research and Policy volun-
teers, Chest Heart Stroke Scotland volunteers and a
secondary care asthma clinic. Adults aged 18 and over
were eligible provided they had a diagnosis of asthma
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and could provide informed consent. There was no
upper age limit on participation. Participants could agree
to participate in a focus group, up to two think aloud
studies (described in phase 2), or both. Focus groups
were held at the Department of General Practice & Pri-
mary Care, University of Glasgow, and were audio re-
corded and transcribed. We used the implementation
theory Normalization Process Theory (NPT) [24] to in-
form the topic guide for these focus groups (Fig. 1). This
theory was used as it is being increasingly advocated as a
means to understand implementation processes and en-
hance the implementability of interventions [17, 24].
Discussion focused on the perceived barriers and facilita-
tors to sustained use of an online resource to support
self-management. This consideration of implementation
issues at such as early stage is a key message from the
MRC guidance. Our list of potential features derived
from WP 1 was explored using questions generated from
our topic guide (Fig. 1) and we sought suggestions for
additional features. The focus groups were transcribed
and any statements which were barriers or facilitators to
self-management were extracted, along with any sugges-
tions for features to include in our website.
Work package 3—developing a draft version of the
website (expert panel)
Using information gathered from WP 1 and 2, the list
of suggested features to include in the website was
reviewed and refined iteratively. As low fidelity proto-
type pages were generated (initially using Microsoft
Word or PowerPoint) (also referred to as draft pages)
they were reviewed initially by those in the panel with a
clinical background to ensure the content was factually
correct. Subsequently the pages were shown to members
of the expert panel with specific expertise in behaviour
change theory to ensure maximum opportunity for pro-
moting behaviour change was incorporated into each
page or section, using the behaviour change concepts
agreed on from WP1 [25]. From this a draft version of
each potential webpage was finalised, ready for think
aloud study evaluation.
Phase 2: iterative refinement of the resource contents of
the website (think aloud studies and expert panel)
Draft pages developed at the end of Phase 1 were grad-
ually translated into interactive webpages with input from
potential end users in the form of think aloud studies, and
review by the expert panel. While LifeGuide can be used
by researchers with no computing science background,
due to time constraints, a programmer transferred the
majority of the draft pages into LifeGuide initially. Think
aloud studies were undertaken by the first author at either
the participant’s home, or the Department of General
Practice & Primary Care, University of Glasgow, depend-
ing on individual participant preference. Participants were
recruited from the same pool as the focus groups, and
they could participate in a maximum of two think aloud
studies. There were two waves of think aloud studies: the
first 4 used draft webpages still on paper or PowerPoint
slide, the latter 6 were undertaken completely using the
prototype webpages on LifeGuide. Participants were asked
to say whatever they thought or felt about what they were
seeing, with prompts and questions used to elaborate on
responses. The participants were then encouraged to voice
any additional suggestions or opinions to improve the re-
source, for example what they liked and disliked, what was
intuitive and what was not, and how they envisaged using
such a website in real life in the future. The majority of
the findings from the think aloud studies were acted upon
immediately after the session by the researcher doing the
think aloud studies, in order to progress the resource
ready for the subsequent think aloud study. We also the-
matically analysed the transcriptions of the think aloud
studies with the aim of providing information for further
development of the resource following the pilot RCT.
Thematic analysis was undertaken using a coding frame
developed by DM. Both DM and SW independently coded
the first 2 transcripts, and results compared, after which
DM coded the remaining transcripts. Comments were
noted to be either a positive comment, where the user
liked or identified with what they saw, or a negative
comment where the user disliked or disagreed with
what they saw, or where the user suggested an improve-
ment or alternative way of presenting the data. The final
version of the Living well with Asthma website was for-
mally mapped to Michie and colleagues latest BCT tax-
onomy [21] in order to describe which BCTs were
present. Every page of the website was reviewed by the
first author (DM), and where relevant a BCT was
assigned. These were subsequently reviewed by SW. We
did this to provide a reliable record of the content of
this behaviour change intervention, and to confirm that
we included a range of BCTs as planned.
Fig. 1 Focus group topic guide (NPT informed)
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Results
This results section describes the key steps in our web-
site development.
Phase 1: initial planning stages
Work package 1—understanding the evidence &
incorporating theory (scoping review and expert panel)
The planning stage focussed on the 5 key tasks outlined by
Campbell et al. [5]. This process helped us understand that
the main problems we aimed to address centred round: 1)
the suboptimal use of preventative therapies; 2) the high
levels of symptom burden; and 3) the low rates of attend-
ance at asthma reviews and use of asthma action plans. We
anticipated that concepts derived from behaviour change
theory should help us address these identified problems,
and the full results of WP 1 are described in Table 1.
Work package 2—getting user perspectives on a web
resource (focus groups)
We shared our results from Table 1 with potential end
users in the focus groups. Excluding the practice nurses the
average age of participants was 41 years (range 23 to 56).
Six participants were female, 4 male, and included partici-
pants from highest and lowest deprivation deciles (median
4, IQR 1, 8). Table 2 describes the participants, illustrating
which focus group (or think aloud study) they participated
in. Participants were recruited from Asthma UK volunteers
(n = 5), primary care (n = 3) and hospital asthma clinic
(n = 2). Barriers to optimum self-management identified
by focus groups included not accepting diagnosis, difficul-
ties keeping track of medications and remembering to
order more, and the length of time between asthma re-
views resulting in knowledge loss. Facilitators to using an
online resource included staggering of information, a re-
source to bridge the gap between annual reviews and
reinforcement of material covered, provision of email re-
minders i.e. ordering medication and flu vaccinations, re-
source being promoted during annual reviews and making
users aware of different types of inhalers available and im-
portance of finding one that suits.
These barriers and facilitators were combined with
those from the literature (including asthma guidelines)
to provide a list of suggested features to include in a re-
source. This process is shown in full Additional file 1, il-
lustrating the rationale for the contents of the website.
Work package 3—developing a draft version of the
website (expert panel)
By the end of WP 1 and 2 we established there were 6 main
behaviours we wanted to promote within the website:
 Recognise symptoms, don’t put up with them (aim
for no symptoms)
 Optimise medication use (including inhaler technique)
 Attend for regular asthma review
 Use asthma action plans
 Increase physical activity
 Stop smoking
The expert panel reviewed the list of suggested fea-
tures from Additional file 1 which led to the removal of
four: a diary for tracking medication use, a diary for
tracking peak expiratory flow (PEF) rate, a tailored ac-
tion plan and a dedicated family & friends sections. The
expert panel felt that evidence and personal experience
suggested that use of diary tools was rarely sustained ex-
cept by a few very motivated individuals. Instead regular
prompts to think about current asthma symptoms based
on the ‘Royal College Physicians 3 Questions’ (RCP 3Q)
screening tool [27] was incorporated throughout the re-
source and in the automated emails. This asks the user
about difficulty sleeping because of asthma, asthma
symptoms during the day, and interference with usual
activities. If users answer yes to even one question then
further assessment of asthma control is indicated [28,
35]. Action plans work best when personalised to the in-
dividual [6] and the IT requirements of a truly tailored
action plan was considered beyond the scope of this pro-
ject. Instead a section was dedicated to promoting the
use of action plans, and encouraging individuals to visit
their health professional to agree one if they didn’t have
one. Rather than a dedicated family and friends section
the importance of positively involving family and friends
was discussed in general terms.
By the end of Phase 1 we had developed paper based
versions of the web pages ready for consideration by the
expert panel and for use in think aloud studies.
Phase 2: iterative refinement of the resource contents of
the website (think aloud studies and expert panel)
Eleven think aloud studies (see Table 2 for participant
details) were conducted although one study (TA 08) was
not completed as the website was not compatible with
her type of computer which converted website text into
braille (BrailleNote). Four of the 11 studies were under-
taken in the participants’ own home. Three of the partic-
ipants (participants 3, 4 and 10) undertook 2 studies
each. Each think aloud interview covered a slightly dif-
ferent range of topics as the resource was developed it-
eratively (Table 3). Table 4 explains the nature of the
changes made during this phase as a result of input from
the think aloud participants and the expert panel.
Thematic analysis of the think aloud transcripts identi-
fied three main thematic categories: 1) ‘content’—the actual
words on the pages, and how relevant and understandable
the information was; 2) ‘layout and navigation’—the layout
of pages or sections, and how easy it was to navigate
around sections; and 3)‘user experience’.
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Table 1 Defining and understanding the problem
Key Tasks [5] Commentary relating tasks to LWWA
Task 1: Define and quantify the problem Optimum self-management of asthma is an underused, yet proven treatment strategy
that improves a range of asthma outcomes (fewer visits to emergency room,
hospitalisations, unscheduled visits to doctors, and days off work and school, reduces
nocturnal asthma and improves quality of life) [7]. People with asthma have:
1) Suboptimal use of preventative therapies. Adherence to therapies in long term
conditions is around 50 % [39]. Low use of preventative (inhaled corticosteroids (ICS))
therapies and high use of short acting beta agonists (SABA) reliever inhalers, is a
pattern commonly seen which is associated with poorer asthma control [29].
2) High levels of symptom burden (46 % daytime symptoms and 30 % nocturnal
symptoms) [30], with lack of recognition of scope for improvement: 50 % of patients
reporting severe persistent symptoms report their own asthma as being completely
or well controlled [30]. This results in people with uncontrolled or deteriorating
asthma not seeking timely medical advice.
3) Suboptimal attendance at asthma reviews with low use of asthma action plans
(AAPs) [13, 32] as evidenced by the National Review of Asthma Deaths (NRAD)
where only 23 % of those who died having been provided with an AAP [32], and
attendance at asthma reviews in Scotland was only 65 %.
Task 2: Identify and quantify the population most affected,
most at risk, or most likely to benefit from the intervention
The Global Initiative for Asthma (GINA) guidelines lists risk factors for poor asthma
outcomes [8]:
• Uncontrolled asthma symptoms
• Increased use of short acting beta agonist (SABA) e.g. reliever therapy
• Inadequate inhaled corticosteroids (ICS), including poor technique.
• Low FEV1 (especially if <60 % predicted)
• Major psychological or socioeconomic problems
• Smoking
• Comorbidities: obesity, rhino-sinusitis, food allergy
• Previous exacerbations or intensive care admissions for asthma
The majority of these factors are related to uncontrolled asthma symptoms, and
therefore a key way of identifying those most likely to benefit is to target those with
uncontrolled asthma symptoms.
Task 3: Understand the pathways by which the problem is
caused
With reference to problems outlined in task 1:
1) Reasons for low adherence to asthma therapies are often related to concerns
about side effects, or perceptions that they don’t need to be on treatments [12].
2) The global asthma insights and reality surveys [29] provides evidence of suboptimal
asthma control and suggests reasons for it. First, people with asthma overestimate
how controlled their asthma is, therefore don’t consider themselves to be candidates
for gaining improvement with asthma treatments. Second, those who do acknowledge
they have symptoms and limitation of activities accept them as unavoidable
consequences of having asthma.
3) Patients reasons for not attending asthma reviews revolve around feelings that
their asthma is not serious enough [9]. Asthma Action plans are underused for
several reasons [31]:
i) Differences in beliefs and attitudes between health care professionals and people
with asthma.
ii) Perceived irrelevance of AAPs of the part of those who would potentially benefit
from them
iii) Health professionals only offer AAPs to select groups of patients (e.g. with well
controlled asthma, or those with higher levels of educational achievement).
In summary, people with asthma often underestimate their symptoms and overestimate
their control, not making use of available therapeutic options (medications, AAPs and
advice from health professionals). Those who do recognise they have symptoms may
not adhere to prescribed medications due to misunderstandings around medication
side effects, or perceived benefits of using AAPs.
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NVivo software allowed us to generate quantitative data
from the think aloud transcripts. Fifty one percent of the
comments were positive, 15 % negative and 34 % contain-
ing suggestions for improvement. This suggests that partici-
pants felt comfortable criticising or making suggestions for
improvement of the website. Most comments related to the
content of pages (78 %), and the majority of these were
positive (56 %). In contrast, most comments about the web-
site layout and navigation were negative (69 %) (Fig. 2). This
confirmed that the ground work done in Phase 1 around
content had been successful, but that greater emphasis was
needed on usability and presentation issues.
Content—making the website relevant and
understandable
Participants were positive about the contents, and in
particular the ‘level’ it was aimed at:
“it’s very clear in its intention, a website to help you
stay healthy and manage your asthma better that’s
Table 1 Defining and understanding the problem (Continued)
Task 4: Explore whether these pathways may be amenable
to change and, if so, at which points
With specific reference to the three ‘problems’ outlined in Task 1:
1) Prompting users to consider reasons why they don’t take medications regularly
(barriers) and consider strategies to overcome these barriers. Providing information
about benefits of inhaled corticosteroids, challenging misconceptions and negative
beliefs. Focussing on benefits meaningful to individuals such as fewer days off work,
managing that exercise class etc. Providing instructions (ideally including videos) to
demonstrate correct inhaler technique.
2) Promoting the message that users should be aiming for no symptoms. Providing
information to challenge the belief that having asthma symptoms is normal, and
asking validated questions to determine if users are currently putting up with
symptoms, providing feedback on response. Prompting users to recognise if they
avoid activities due to their asthma, or are limited in everyday tasks such as
housework, gardening, visiting friends. Turn these limitations into ‘goals’ to aim
towards, and describing how these goals are achievable for them.
3) Provide information that people who use AAPs and attend for reviews have
fewer symptoms and fewer asthma attacks. Provide quotes from practice nurses
encouraging attendance for reviews. Remove physical barrier to using AAPs by
providing a template that can be taken to health professionals (identical to those
provided by local health board).
The expert panel will ensure that behaviour change theory is incorporated into
the web page contents and full analysis of behaviour change techniques will be
done on final website (Table 6).
Task 5: Quantify the potential for improvement An estimated 300 million people worldwide have asthma and its prevalence
appears to be increasing with an estimated additional 100 million people with
asthma by 2025 [16]. Depending on criteria used to define poor control evidence
suggests that levels of uncontrolled asthma range from at least 25 %, and probably
higher [29, 30, 36]. Our primary outcomes in a full scale RCT would be symptom
level using a questionnaire. A good candidate would be the Asthma Control
Questionnaire and we would aim for a drop of 0.5 in score which is the minimally
important clinical difference [14]
Table 2 Demographics of participants in focus groups and think aloud studies
Participant numbera FG 1 FG 2 TA 1b TA 2b Female Male Age (yrs) SIMDc Ethnicity
1 ● ● (2) ● 44 1 White British
2 ● ●(3) ● 23 1 White British
3 ● ● (4) ● (11) ● 51 8 White British
4 ● ● (5) ● (9) ● 46 4 White British
5 ● ● (6) ● 23 1 White British
6 ● ● (7) ● 56 8 White British
7 ● ● (8) ● 55 3 White British
8 ● ● 41 6 White British
9 ● ● 29 10 White British
10 ●(1) ● (10) ● 48 10 White British
arefers to adults with asthma participating. Two practice nurses also present in each focus group, details not provided. bnumber in brackets refers to think aloud study number,
participant number 3, 4 and 10 participated in two think aloud studies each. cScottish Index ofMultiple Deprivation. Range from1 (most deprived) to 10 (most affluent)
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exactly what level I’m at, I don’t have a detailed
knowledge of what I’ve got or quite what I’ve got or
quite how to look after it so it’s perfect for me.”
(Participant 10,TA 01)
Users liked and identified with the key messages, for
example that people with asthma should be ‘aiming for
no symptoms’:
“I like a message of you know that’s what you should
be aiming for, it might not be what you get right
enough but at least you should be aiming for, or
aiming for it the majority of the time, you know but
you can if, you know going to have relapses, but I think
that that’s really good because I don’t think many
people actually say that to you to be honest.”
(Participant 1, TA02)
“That’s good to know because again I just was putting
up with it like if I was, if I wasn’t being able to breathe
I would just be like oh I'm just having a bad day
rather than being like ‘oh I should really be on the
brown inhaler to stop this from happening’,”
(Participant 3, TA04)
While there was universal agreement that quotes from
patients and practice nurses were desirable within the
website there was some disagreement about how they
should be presented:
“But I would give them maybe slightly more weight if
they weren’t anonymous bizarrely. And it’s a real living
patient that is living with asthma. And that kind of
makes it more of a human.” (Participant 10, TA01)
In the following think aloud study this point was
brought up by the interviewer:
“the quotes do you think, would you prefer to see
something like female age 53 or is it not relevant?
(researcher)
It’s not relevant to be honest because if I was twenty
one and I was reading and they were fifty I would be
thinking oh that doesn’t apply to me yet. The guy will
be reading it and thinking oh that’s a woman thing.”
(Participant 1, TA02)
Consequently, we kept quotes in the website but removed
descriptions of who said them, as illustrated in Fig. 3.
While patients on the whole agreed with the informa-
tion provided, the one area where there was scepticism
was in regard to how approachable participants’ prac-
tices nurses were:
“just trying to imagine sort of sitting down with my
asthma nurse and saying I have a goal and this is
what I want to achieve, I know what she’d say, she’d
say I haven’t got time to discuss this! Let’s just stick to
the tick boxes shall we?“(Participant 4, TA05)
Layout and navigation—making the website easy to use
The majority of the comments regarding layout were
page specific such as feeling that a given paragraph was
too long, and where appropriate were acted on immedi-
ately after the think aloud study in preparation for the
next one. However the importance of getting the home
page right was clearly important to participants and gen-
erated discussion.
Table 3 Think aloud studies—topics covered
Introduction My asthmaa Treatments Asthma review Exercise Concerns Queries Stress Anxiety Action plan 4 week challenge
TA01b ● ● ● ● ●
TA02 ● ● ● ● ●
TA03 ● ● ● ● ●
TA04c ● ● (s2) ● ● ● ●
TA05d ● ● (s3) ● ● ●
TA06 ● ● (s2) ● ●
TA07 ● ● (s2) ● ● ●
TA08e
TA09d ● ● (s3) ● ●
TA10b ● ● (s3) ● ● ● ●
TA11c ● ● (s2) ● ● ● ● ● ●
aMy asthma section eventually split into 3 sections numbered s1, s2, s3. With s1 being based mainly on the contents reviewed at the first 3 think alouds before
recognising need for 3 versions of this section: S1—I have never been prescribed or used a preventer inhaler; S2—I have a preventer inhaler but don’t really use it
as prescribed; S3—I have a preventer inhaler and mostly use it as prescribed. bTA01 and TA10 were same participant; cTA04 and TA11 were same participant;
dTA05 and TA09 were same participant: eTA08 used a Braillenote computer, which was not compatible with our software so we were unable to complete the
Think Aloud study.
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Table 4 Changes made during phase 2
Section (pages)a Topics Description of changes made
1 (13 pages) Introduction pagesb
Home page
Original one page introduction became 13+ page section.
• Both TA participants and expert panel highlighted that
people with asthma are well known for underestimating
their asthma severity, and suggested it was important to
challenge this idea right at the start and illustrate to users
how this resource could benefit them.
• First page presented user with questions designed to
tease out limitations due to asthma. Then feedback
provided for each question user ticked, along with
tailored advice about which sections of the resource
might benefit them most.
• Subsequent pages focused on identifying lifestyle
goals relevant to users.
• Other changes included addition of a ‘landing’ page,
combining links to sections to reduce the ‘buttons’ in
the navigation bar from 11 down to 7, and rearranging
the home page.
2 (24 pages) My Asthmab Initially just one section, but became apparent that
resource needed to be more tailored, and preventer
therapy use was a good method of stratifying users,
so users had to choose one of three options:
1) I have never used/been prescribed a preventer
2) I have been prescribed a preventer but don’t really use it
3) I mostly/always take my preventer inhaler as prescribed
The think aloud study confirmed the contents of this section,
with most changes focusing on improving readability,
removing repetition and trying to achieve the right balance
when explaining negative side effects versus potential
benefits of inhaled steroids.
3 (14 pages) Treatments Organization of this section completely altered. It initially
took the form of 6 pages users worked through with
sideway steps for more information about different treatments.
Section changed to have:
• its own homepage (i.e. spoke and wheel layout) which
allowed users to go directly to a treatment type without
having to work through potentially irrelevant pages.
• a visual representation of the asthma treatment ladder
adapted from the BTS/Sign guidelines.
We were unable to meet requests to have pictures of
individual inhalers.
4 (21 pages) Asthma Reviews • Focused on modifying the language used and
simplifying messages.
• Altering layout of both individual pages and order of pages.
• Main message was to “aim for no symptoms” and this was
very well received by users.
• Included a quiz covering what put people at risk of
attacks—this was streamlined and made optional.
5 (5 pages) Action Plans • Altered layout and clarity of wording, and quotes added to
dilute the very factual nature of the information provided.
• Added a template to a blank action plan that users could
print out and take to their health professional.
6 (17 pages) Physical Activity • Initially one generic section with the aim of promoting
physical activity but was altered to become tailored to the
individual’s activity status.
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Table 4 Changes made during phase 2 (Continued)
7 (18 pages) Common concerns and queries • Originally had 8 concerns and queries, and a further 7 were
added addressing topics originally not included as were felt
to be covered elsewhere, or had seemed ‘too basic’.
• Reviewing this section served as a reminder that people
quickly forget (or have never been told) even basic information
about their asthma, and that having it here for those who
need it was essential.
• Another major change was the wording of questions. One user
commented that questions were just statements and didn’t make
it clear than scenarios were amenable to change. So for example
‘I don’t exercise because of my asthma’ was changed to ‘I don’t
exercise because of my asthma. Could I?’
8 (5 pages) Stress & Anxiety • Received mainly positive feedback.
• Links to online resources aimed at reducing stress and anxiety
(e.g. online CBT) added.
9 (8 pages) Take the 4 week Challenge • This section was specifically for users who had chosen option
1 or 2 during the ‘My Asthma’ section.
• Initially much confusion about the nature of the challenge with
some users misunderstanding it completely. Thus pages were
modified and more explanation added.
• Layout of pages were altered, in particular, to make it clear that
there were 4 steps to work through, and it was made clearer how
you were progressing through them (e.g. colour strip across the top,
which illustrated progress).
• One of the steps to the four week challenge was to anticipate
barriers to taking preventer medication regularly and consider some
solutions. Template barriers and solutions were provided, and these
were added to by the think aloud participants.
10 Like to stop smoking? • This section was a link to an external site called ‘StopAdvisor’[19] and
therefore not covered during the think aloud studies.
11 (1 page) Useful info and links • Expanded during the think aloud to include more links to online mental
health resources and information about the GP exercise referral scheme.
aRefers to unique pages per section. Some pages are referred to in more than one section, but are only counted once here in the first section they appear
bAll users are directed through these two sections at first login, and can optionally visit again during future sessions
Fig. 2 Type of comment made during think aloud studies
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“it doesn’t quite feel like a home page, that’s maybe
not helpful. I’m trying to think what the best way to, it
looks the same as every other page, I don’t know if you
did something different to the header or something like
that.” (Participant 4, TA05)
Therefore the home page was modified as illustrated
in Fig. 4 in response to comments across the studies.
The second recurring theme related to users ‘knowing
where I am’.
“I say I might have said before maybe a little site map
you are on step 3 of 9, 4 of 9 and people know where
they are going.” (Participant 4, TA09)
As a result it became more obvious which section a
user was in at a given time, and within the 4 week chal-
lenge section it was made much more obvious how users
progressed through the 4 stages of preparing to sign up
to the ‘4 week challenge’.
User experiences
After completing the think aloud study users were asked
how they might use the website in a real life setting and
what would be barriers to its sustained use. Users felt
that they would have more confidence in such a re-
source if a health professional recommended it:
“I guess like in my annual review, if my nurse was
like oh have a look at this. Like a wee leaflet or a
wee business card or something like that and just
was like have a look at that.” (Participant 2, TA03)
This finding is relevant for both future large scale
RCTs, and the subsequent implementation and embed-
ding of such a resource.
Completion of this phase resulted in the final website
ready for evaluation in the RAISIN trial [23]. Table 5 de-
scribes the final contents of the resource, and further
sample screenshots are provided in Additional file 2.
BCTs present in website
We incorporated 20 BCTs in our Living well with
Asthma website as described in Table 6. The most
commonly used BCTs were ‘information about health
consequences’ and ‘demonstration of the behaviour’,
followed by ‘problem solving’ and ‘instruction on
how to perform a behaviour’. We also used ‘goals and
planning’ as a key behavioural technique within the
website.
Fig. 3 Screenshot of webpage illustrating use of quotes
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Early version of home page:
Final version of home page:
Fig. 4 Changes made to home page during Phase 2
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Discussion
We have demonstrated the feasibility of developing an
evidence-based, theory guided, user friendly behaviour
change intervention in the form of Living well with
Asthma—a website to support self-management in adults
with asthma. We have been guided by the MRC Frame-
work on developing and evaluating complex interventions,
and as a result directed much effort to the key, yet often
overlooked, planning stages [5, 18]. We undertook recom-
mended key tasks to guide our development methods [5],
see Table 1, through: synthesis of empirical evidence, using
expert knowledge and experience, and incorporating the-
oretical concepts with end user input, to produce an evi-
dence based behaviour change website. Our evidence
synthesis highlighted that self-management of asthma is
an underused, yet proven, treatment strategy [7] and that
people with asthma frequently do not use therapies opti-
mally, tolerate high levels of symptom burden, and do not
attend asthma reviews or make use of asthma action
plans. This underestimation of symptoms and overesti-
mation of control is a barrier to making use of available
therapies. Those who do recognise they are experiencing
asthma symptoms often do not adhere to therapies, often
due to perceived misunderstandings around medication
side-effects, or lack of perceived benefits to using asthma
action plans. This analysis provided us with pathways of
how a behaviour change intervention might work, focus-
sing on behaviour change concepts recommended in the
literature we developed a list of features which a website
should have. This list was iteratively modified with input
from end users and an expert panel, until a draft of pro-
posed web pages had been developed. These were then
gradually converted to working interactive webpages
and refined over 10 think aloud studies, to lead to the
final website which is being evaluated in the RAISIN
trial [23]. Our BCT mapping exercise demonstrates that
Table 5 Contents of Living Well with Asthma resource
Topic Summary of content
Introduction pagesa This section encourages users to recognise whether they are putting up with symptoms
unnecessarily, and introduces concepts such as goal setting and its potential benefits.
My Asthmaa There are three versions of this section tailored to current use of preventer therapy as
chosen by the user:
1) I have never used/been prescribed a preventer
2) I have been prescribed a preventer but don’t really use it
3) I mostly/always take my preventer inhaler as prescribed
This section covers adherence and challenges negative beliefs about inhaled steroids.
Treatments Provides information about different treatments. Links to videos to demonstrate inhaler
technique and encourages users to consider whether they are on the correct ‘step’ of
the asthma treatment ladder.
Asthma Reviews Promotes attendance at asthma reviews outlining potential benefits to symptoms and
quality of life. Prompts user to recognise if putting up with symptoms, and to recognise
if they are at risk of asthma attacks.
Action Plans Describes what action plans are and their potential benefits. Provides a template action
plan that can also be used by practice nurses during asthma reviews in local health boards.
Physical Activity Promotes benefits of physical activity, and challenges negative beliefs about exercising with
asthma. Provides practical advice and tips to encourage users to increase their activity levels.
Common concerns and queries Answers 15 common queries and concerns that people with asthma may have, developed
from the literature, focus groups and during think aloud studies. For example:. I am worried
about taking inhaled steroids long term, should I be? Why are some days better than others?
Stress & Anxiety Promotes recognition of the role of stress on asthma, and how having asthma symptoms
can lead to stress. Provides suggestions for reducing stress and anxiety.
Take the 4 week Challenge The user is prompted to commit to taking their preventer inhaler regularly for 4 weeks.
Users can choose from a list of provided ‘barriers’ to taking their inhalers and review
suggested strategies or can free text their own. They may sign up to receive weekly
emails during the challenge.
Like to stop smoking? This links to an external website called ‘StopAdvisor’ [19]. This has been developed using
LifeGuide software and further details are available elsewhere.
Useful info and links This re-lists information and useful links that have been included elsewhere in the website.
Email reminders These emails are sent every two months. They all include the RCP 3 Questions to encourage
the user to assess their current control and prompt them to visit the website or see their nurse
or doctor if appropriate. There are also reminders to order inhalers, or other medications
(e.g. in time for hay fever season), or if going on holidays.
aAll users are directed through these two sections at first login, and can optionally visit again during future sessions
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Table 6 Behaviour change technique mapping of Living Well with Asthma resource
No/ Label [21] Definition Sections Example within LWWA website
Goals and planning
1.1 Goal setting
(behaviour)
Set or agree on a goal defined in terms of
the behaviour to be achieved
4 week challenge Users commit to taking their preventer inhaler
regularly for 4 weeks.
1.2 Problem solving Analyse, or prompt the person to analyse,
factors influencing the behaviour and generate
or select strategies that include overcoming
barriers and/or increasing facilitators (includes
‘Relapse Prevention’ and ‘Coping Planning’)
My asthma Concerns &
queries 4 week challenge
Users are prompted to consider reasons why
they find it difficult to take their inhaler
regularly (choosing from a list or free texting
own). Users are then presented with sample
strategies to overcome identified barriers.
1.3 Goal setting
(outcome)
Set or agree on a goal defined in terms of
a positive outcome of wanted behaviour
Intro Users are asked to identify how their asthma
can negatively affect their everyday lives. They
are then asked to review positive outcome
goals to overcome these negative effects.
1.6 Discrepancy
between current
behaviour and goal
Draw attention to discrepancies between a
person’s current behaviour (in terms of the
form, frequency, duration, or intensity of that
behavior) and the person’s previously set
outcome goals, behavioural goals or action
plans (goes beyond self-monitoring of behaviour)
Asthma Review Asks validated questions to determine if
currently putting up with asthma symptoms
while believing themselves to be well
controlled.
1.9 Commitment Ask the person to affirm or reaffirm statements
indicating commitment to change the behaviour
Note: if defined in terms of the behaviour to be
achieved also code 1.1, Goal setting (behaviour)
4 week challenge Users tick three statements confirming they
are committed to taking their preventer
inhaler regularly for the duration of the
4 week challenge.
Social support
3.1 Social support
(unspecified)
Advise on, arrange or provide social support
(e.g. from friends, relatives, colleagues,’ buddies’
or staff ) or non-contingent praise or reward
for performance of the behaviour. It includes
encouragement and counselling, but only
when it is directed at the behaviour
Concerns & queries ‘Where can I talk to other people about
asthma’ section details and links to online
forum, local support groups, and advice lines.
Shaping knowledge
4.1 Instruction on
how to perform a
behavior
Advise or agree on how to perform the
behaviour (includes ‘Skills training’)
Treatments Asthma Review
Exercise
Users are given step by step instructions on
how to use an inhaler correctly. This is
followed up by a video demonstration.
4.3 Re-attribution Elicit perceived causes of behaviour and
suggest alternative explanations (e.g. external
or internal and stable or unstable)
Concerns & queries Describe common reasons why people with
asthma put up with symptoms, illustrating
that these beliefs are mistaken and providing
alternative explanations for the symptoms.
Natural consequences
5.1 Information
about health
consequences
Provide information (e.g. written, verbal, visual)
about health consequences of performing the
behaviour
Intro My asthma
Treatments Asthma review
Exercise Concerns & queries
Action plans
Information provided that people who attend
for regular asthma reviews have fewer
symptoms and fewer asthma attacks.
5.3 Information
about social and
environmental
consequences
Provide information (e.g. written, verbal, visual)
about social and environmental consequences
of performing the behaviour
Asthma review Exercise Information provided that people who attend
for regular asthma reviews have fewer days
off school and work, and fewer limitations
in activities.
5.6 Information
about emotional
consequences
Provide information (e.g. written, verbal, visual)
about emotional consequences of performing
the behaviour
Concerns & queries People with asthma describe feeling
embarrassed or ashamed taking inhalers in
public. Information provided to overcome
these concerns and increase confidence
about using medications in public.
Comparison of behaviour
6.1 Demonstration
of the behaviour
Provide an observable sample of the
performance of the behaviour, directly in person
or indirectly e.g. via film, pictures, for the person
to aspire to or imitate (includes ‘Modelling’).
My asthma Treatments
Asthma review Exercise
Action plans
Quotes for adults with asthma demonstrating
how their lives changed for the better when
they started taking their inhalers regularly.
6.2 Social
comparison
Draw attention to others’ performance to allow
comparison with the person’s own performance
My asthma Concerns &
queries
In those who have identified that their asthma
affects their work they are advised that this is
the case with up to 40 % of people with asthma.
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the resource makes use of multiple BCTs, a strategy
which in some health domains has been associated with
increased effect sizes [37]. In particular we use goals
and planning as a key behavioural technique, which has
been shown to be efficacious in asthma [1].
Strengths
This study followed recommended processes for devel-
oping complex evaluations, and was undertaken by a
multidisciplinary team with a range of essential skills,
knowledge and experience (including behaviour change
theory and implementation theory). A key strength of
this resource is in its co-design with potential end users,
who had opportunity for input both at the early develop-
ment planning stages in the form of focus groups, and
also towards the end where their input via think aloud
studies was invaluable in improving the usability of the
resource, in line with the Person Based Approach [15].
The use of LifeGuide software allowed for a streamlined
and iterative process of website development where the
researcher taking the think aloud studies could modify
the website directly following think aloud studies, or
from feedback from the expert panel. Most computer
programmers do not have a background in healthcare,
and therefore removing the need to communicate user
feedback to a programmer by using LifeGuide made the
process far more efficient.
Limitations
In the focus groups we invited both practice nurses and
adults with asthma which could be construed as a limi-
tation. However there are advantages to bringing to-
gether a diverse group of participants and we felt this
was the case here [40]. This can maximise the explor-
ation of different perspectives, which was pertinent here
where differences in health professional and patient
opinion is a recognised barrier to optimal uptake of self-
management practices [31].
The adults with asthma participating in the focus
groups and think aloud studies had more severe asthma
and were on more treatments than typical primary care
patients. This is almost certainly because of them being
Table 6 Behaviour change technique mapping of Living Well with Asthma resource (Continued)
6.3 Information
about others’
approval
Provide information about what other
people think about the behaviour. The
information clarifies whether others will like,
approve or disapprove of what the person is
doing or will do
Asthma review Quote from practice nurse praising people who
proactively attend for asthma reviews.
Associations
7.1 Prompts/cues Introduce or define environmental or social
stimulus with the purpose of prompting or
cueing the behaviour. The prompt or cue
would normally occur at the time or place
of performance
4 week challenge Emails Users who sign up to the 4 week challenge are
sent weekly emails to remind them of the
challenge and prompt them to continue.
Repetition and substitution
8.2 Behavior
substitution
Prompt substitution of the unwanted behaviour
with a wanted or neutral behaviour
Exercise Users are provided with sample strategies to
increase their levels of physical activity such as
walking to the shops rather than taking the car,
or giving up a TV programme for a dance class.
8.3 Habit formation Prompt rehearsal and repetition of the
behaviour in the same context repeatedly so
that the context elicits the behaviour
4 week challenge Strategies for prompting users to remember to
take inhalers are suggested such as using
them at the same time as teeth brushing or
the evening meal.
Comparison of outcomes
9.1 Credible source Present verbal or visual communication from
a credible source in favour of or against
the behaviour
Exercise Bradley Wiggins quote describing how asthma
doesn’t stop him exercising.
Antecedents
12.5 Adding objects
to the environment
Add objects to the environment in order to
facilitate performance of the behaviour.
4 week challenge Strategies for prompting users to remember
to take inhalers are suggested such having
an extra inhaler at work, if they regularly
forget their morning dose.
Self-belief
15.1 Verbal
persuasion about
capability
Tell the person that they can successfully
perform the wanted behaviour, arguing against
self-doubts and asserting that they can and
will succeed
Exercise (external video) Users are directed to a video which promotes
the message that anyone regardless of health
status and fitness levels can successfully
increase their levels of physical activity.
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recruited through their participation in asthma advocacy
organisations (Asthma UK). We managed this by tem-
pering the suggestions and feedback from these end
users with the practical experience of the respiratory
physicians and GPs on the expert panel and the practice
nurses present in the focus groups. In future studies
concentrating recruitment to end users more typical of a
primary care population would be worthwhile, although
may be difficult.
The same researcher who developed the website, also
undertook the think aloud studies. While this had bene-
fits in terms of speed of modifying the resource, we were
concerned that participants in the think aloud studies
may not have felt comfortable criticising the resource
openly in the presence of the person who was also devel-
oping it. In order to counter this it was explained that it
was easy to make changes with the LifeGuide software
and those critical comments were often the most help-
ful. Exploring the scope of this limitation by counting
negative comments was useful, as the high proportion of
negative comments or suggestions for improvements
suggests that participants did feel comfortable being crit-
ical of the website.
Future considerations
The ultimate aim of following the updated MRC guid-
ance on the development and evaluation of complex in-
terventions is to reduce the number of interventions
which are developed, but don’t translate into everyday
use, and avoiding costly large RCTs which due to un-
foreseen circumstances are unable to answer the re-
search question posed [18]. The iterative methods of
development used here should minimise this risk, and
the ongoing RAISIN pilot RCT should allow for mean-
ingful estimates of effect sizes and recruitment and re-
tention rates for any future full scale randomised
controlled trial. A qualitative evaluation, involving par-
ticipant interviews and using NPT to guide analysis, is
embedded in the RAISIN trial and will provide rich data
on the how the intervention can be improved and its fu-
ture implementability in the real world [24].
Conclusion
We have developed a resource which our preliminary
usability testing suggests is relevant and usable by its tar-
get audience. We have outlined the key steps undertaken
which included synthesis of knowledge and experience
from our expert panel, with a broad exploration of the
literature, overarching use of appropriate theory (behav-
iour change and implementation) and also with input
from potential stakeholders (adults with asthma and
practice nurses) from an early planning stage. Such
methods are rarely fully detailed in the literature and
thus the description of this process should be of interest
to the growing cadre of researchers developing digital in-
terventions. This paper demonstrates how data from a
wide range of sources can directly and practically influ-
ence the contents of such a self-management website.
Additional files
Additional file 1: Rationale behind choosing the contents for Living
Well with Asthma resource.
Additional file 2: Additional sample screenshots from Living Well
with Asthma.
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ABSTRACT
Objective: To evaluate the feasibility of a phase 3
randomised controlled trial (RCT) of a website (Living
Well with Asthma) to support self-management.
Design and setting: Phase 2, parallel group, RCT,
participants recruited from 20 general practices across
Glasgow, UK. Randomisation through automated voice
response, after baseline data collection, to website
access for minimum 12 weeks or usual care.
Participants: Adults (age≥16 years) with physician
diagnosed, symptomatic asthma (Asthma Control
Questionnaire (ACQ) score ≥1). People with unstable
asthma or other lung disease were excluded.
Intervention: ‘Living Well with Asthma’ is a desktop/
laptop compatible interactive website designed with
input from asthma/ behaviour change specialists, and
adults with asthma. It aims to support optimal
medication management, promote use of action plans,
encourage attendance at asthma reviews and increase
physical activity.
Outcome measures: Primary outcomes were
recruitment/retention, website use, ACQ and mini-
Asthma Quality of Life Questionnaire (AQLQ).
Secondary outcomes included patient activation,
prescribing, adherence, spirometry, lung inflammation
and health service contacts after 12 weeks. Blinding
postrandomisation was not possible.
Results: Recruitment target met. 51 participants
randomised (25 intervention group). Age range
16–78 years; 75% female; 28% from most deprived
quintile. 45/51 (88%; 20 intervention group) followed
up. 19 (76% of the intervention group) used the
website, for a mean of 18 min (range 0–49). 17 went
beyond the 2 ‘core’ modules. Median number of logins
was 1 (IQR 1–2, range 0–7). No significant difference
in the prespecified primary efficacy measures of ACQ
scores (−0.36; 95% CI −0.96 to 0.23; p=0.225), and
mini-AQLQ scores (0.38; −0.13 to 0.89; p=0.136). No
adverse events.
Conclusions: Recruitment and retention confirmed
feasibility; trends to improved outcomes suggest use of
Living Well with Asthma may improve self-management
in adults with asthma and merits further development
followed by investigation in a phase 3 trial.
Trial registration number: ISRCTN78556552;
Results.
INTRODUCTION
Asthma is a common condition affecting
over 300 million people worldwide, with
increasing global prevalence.1 While there
are newer pharmacological treatments for
individuals with severe asthma,2–5 improve-
ments in outcomes for the majority with
mild-to-moderate asthma have stalled.6 A
recent UK review of asthma deaths showed
potentially avoidable factors in the majority,
particularly relating to self-management and
adherence to treatment.7
Despite clear evidence that self-
management education, asthma action plan
Strengths and limitations of this study
▪ A recent UK review of asthma deaths showed
many could have been avoided if medication
management and other self-management strat-
egies had been better, so finding optimum
approaches to support self-management of
asthma is critical and digital interventions show
promise.
▪ The ‘Living Well with Asthma’ website was itera-
tively designed with input from experts in
asthma, self-management support, behaviour
change and adults with asthma themselves; it
aims to support optimal medication manage-
ment, promote use of action plans, encourage
attendance at asthma reviews and increase phys-
ical activity.
▪ We conducted a phase 2 parallel group, rando-
mised controlled trial; randomisation was
through automated voice response, after baseline
data collection but blinding of the researchers or
participants at outcome, measurement was not
possible.
▪ Our low response rate is a concern; however, we
have described our population in detail (unlike
previous reports of digital interventions for
asthma self-management), and our baseline
characteristics demonstrate that patients were
recruited from a range of socioeconomic
backgrounds.
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use and regular professional review improve outcomes,8
translation into everyday practice has proven difﬁcult,6
and most patients still lack an action plan and sufﬁcient
understanding to self-manage effectively. Poor adher-
ence to regular preventative medication (primarily with
inhaled corticosteroids, ICS) is a particular problem.
Using digital interventions to promote self-management
behaviours shows promise, but uncertainty persists as to
the most effective formulation of the intervention and
the target population.9
In this phase 2, pilot randomised controlled trial
(RCT), we evaluated the feasibility and effectiveness of
using a low-intensity online intervention aimed at pro-
moting effective self-management (especially adherence
to ICS) in adults with mild-to-moderate asthma, com-
pared with usual care. We developed the intervention
(‘Living Well with Asthma’) incorporating evidence
from the literature and relevant theory. Several phases of
user testing in alignment with the ‘person-based
approach’ to developing digital behaviour change inter-
ventions were undertaken.10 Following the Medical
Research Council (MRC) guidance on developing and
evaluating complex interventions,11 our objective was to
determine the feasibility of conducting a phase 3 RCT,
and obtained initial estimates of effects on outcomes.
METHODS
Our trial protocol is described in detail elsewhere.12
A brief summary is provided here.
Settings and participants
We recruited from 20 general practices in Glasgow, UK,
between 23/09/2013 and 21/02/2014, using clinical
databases to identify potential participants who were
invited by mail to participate and complete the Asthma
Control Questionnaire (ACQ). We recruited adults aged
16 years or older, with a physician diagnosis of asthma
and ACQ score ≥1, who provided written informed
consent. For full inclusion and exclusion criteria see
box 1. Our search strategy is shown in the online supple-
mentary data ﬁle.
Study design overview and intervention description
We conducted a non-blinded pilot RCT of access to the
‘Living Well with Asthma’ website versus usual care for
51 participants. Participants were assessed in their own
homes at baseline and at 12 weeks or as soon as possible
after this date.
The intervention development is described else-
where,13 but in summary aimed to (1) provide under-
standing of current level of asthma control and how to
improve it, speciﬁcally by optimising use of prescribed
medication; (2) challenge attitudes and concerns
around medications; (3) learn how to get the most out
of their annual asthma review; (4) prompt provision and
use of a personal asthma action plan from a health pro-
fessional and (5) send timely reminders for inﬂuenza
vaccination and reordering reﬁll inhaler prescriptions.
The website did not advise medication changes, but sug-
gested contacting a health professional if inadequate
control was identiﬁed, with clear advice for seeking help
in an emergency. The website is interactive, aiming to
engage the user in recognising that their asthma is
uncontrolled, and illustrate the beneﬁts via case vign-
ettes (based on real life examples) of taking their medi-
cations as prescribed. The website is tailored based on
their current use of preventer inhalers (never been pre-
scribed; prescribed but do not really use; use regularly).
There is a ‘4-week challenge’ that users can sign up to,
where they commit to taking their preventer regularly
for 4 weeks, are guided through establishing their per-
sonal barriers to regular use (see screenshot in online
supplementary data ﬁle for further illustration) and
developing potential solutions to these barriers.
The intervention group was given website login details
and a computer link, and advised to use the website as
much or as little as they wished (total time to visit all
pages once ∼90 min). We developed the website using
an open source software package called LifeGuide.14 15
Randomisation and blinding
Randomisation occurred after baseline data collection,
using a third party interactive voice response system
(IVRS) ensuring allocation concealment. The random-
isation schedule was generated in advance of the
study by the Robertson Centre for Biostatistics, in a 1:1
ratio, using the method of randomised permuted
blocks of length 4, without stratiﬁcation. Access to the
Box 1 Inclusion and exclusion criteria
Inclusion criteria
▸ Written informed consent
▸ Age 16 years or older
▸ Diagnosis of asthma by a health professional, and duration of
asthma symptoms >1 year
▸ Asthma Control Questionnaire score (ACQ; six-questions
version) ≥1 suggesting poorly controlled asthma
▸ Ability to access the internet via desktop or laptop (tablets and
smartphones not sufficient)
Exclusion criteria
▸ Unstable asthma as defined as the presence of one or more of
the following events in the 4 weeks prior to randomisation:
– Asthma-related hospital admission
– Emergency department attendance for asthma
– ‘Out of hours’ visit of patients to the general practitioner
(GP) for asthma
– GP visit to patient at home for asthma
▸ Presence of active lung disease other than asthma
▸ Mental impairment or language difficulties that make informed
consent impossible
▸ Frequent asthma exacerbations with >4 courses of oral pred-
nisolone in the 12 months prior to randomisation
▸ Cognitive impairment
▸ Terminal illness
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randomisation schedule was restricted to those within
the Centre with responsibility for provision of the IVRS.
The comparison group was offered access to the inter-
vention after the follow-up visit.
Primary outcomes
The primary end points were: recruitment and retention
rates at follow-up, website use, and changes from baseline
for ACQ16 and mini-Asthma Quality of Life
Questionnaire (AQLQ) scores.17 The ACQ and
mini-AQLQ have a minimal clinically important differ-
ence (MCID) of 0.5.18 This pilot study was not powered
to detect a difference in these two clinical outcomes; they
were included in order to assess feasibility and inform
sample size calculations for a future full-scale RCT.
Secondary outcomes
We evaluated a range of secondary outcomes in order to
assess their feasibility for use in a future full-scale RCT.
Individual domains of the mini-AQLQ were reported.
These comprise of symptoms, activity limitation, emo-
tional function and environmental stimuli. Knowledge,
skills and conﬁdence to manage health was measured
via the Patient Activation Measure (PAM).19
Self-reported adherence was assessed by both enquiring
what proportion of prescribed ICS were actually taken,
and via the Morisky Medication Adherence Scale
(MMAS).20 Airway inﬂammation is measured by fraction
exhaled nitric oxide (FeNO).21 Lung function was
assessed via prebronchodilator spirometry, including
forced expiratory volume in 1 s (FEV1); FEV1 percentage
predicted; and FEV1/forced vital capacity. Lung function
(spirometry) was performed to the American Thoracic
Society (ATS) standards,21 22 where possible, and the
proportion of tests not meeting these standards
recorded. As well as the asthma-speciﬁc mini-AQLQ,
generic quality of life was measured using the EuroQol
(EQ)-5D.23 We collected changes to medication use,
recorded numbers of health service contacts and severe
exacerbations were noted by recording the number of
oral prednisolone courses. These data were self-
reported. Those in the intervention group received the
problematic experience of therapies scale (PETS) to
facilitate understandings of barriers to using the website,
and following its advice.
Data analysis
Continuous data are summarised as mean and SD or
range, or as median and IQR, and categorical data as
counts and percentages. Linear regression was used to
estimate differences in continuous outcomes between
groups at follow-up, adjusting for baseline scores.
Estimated between-group differences are reported with a
95% CI and p value. For continuous outcomes that were
not normally distributed, changes from baseline were
compared between groups using Wilcoxon rank-sum
tests. Categorical variables were compared between
groups using Fisher’s exact test. All analyses were carried
out using SPSS Statistics V.22 and Microsoft Ofﬁce Excel.
The primary analysis was intention-to-treat and involved
all patients who were randomly assigned, except with
spirometry where only those meeting ATS/European
Respiratory Society (ERS) eligibility criteria will be
analysed.22
RESULTS
Baseline characteristics
The groups were largely well matched. Participants were
aged between 16 and 78 years, and 75% were female
(table 1).
Primary outcomes
Recruitment and retention)
Recruitment target of 50 participants was met (ﬁgure 1).
Participating practices were mostly urban, and spread
across deprivation categories. Response rate to the postal
invitation was 4.6%, lower than anticipated, and only
27% of those screened were subsequently randomised,
with the majority failing due to ACQ<1 (75%). Those
randomised were younger (45.5 vs 51.5 years) and more
likely to be female (75% vs 50%) than screen failures,
but with similar socioeconomic deprivation. The attri-
tion rate (not completing follow-up) was 12%: 20% in
the intervention group, 4% in the comparison group
(Fisher’s test p=0.10).
Website use
Nineteen of the 25 participants in the intervention
group logged in at least once (76%) with 17 going
beyond the initial ‘core’ section. The subsequent section
was tailored depending on which of three options was
chosen: (1) I have never been prescribed a preventer
inhaler (n=1); (2) I have been prescribed an inhaler but
do not really use it (n=6); or (3) I have a preventer and
usually use it as prescribed (n=10). The mean number
of logins was 1.8 (range 0–7), median 1, (IQR 1–2), and
the average time spent on the website during the study
period was 18 min (range 0–48.9). More detail is shown
in online supplementary ﬁgure A.
Beyond the core ‘introduction’ and ‘my asthma’ sec-
tions, the most popular sections were ‘take the 4-week
challenge’ (n=13), and ‘common concerns and queries’
(n=11). Further usage data are shown in online supple-
mentary table B. The majority (95%) of participants
acknowledged that asthma was impacting on their life
(online supplementary table C).
ACQ score
Our planned analysis was for the seven-question version
of the ACQ, which includes spirometry, for which there
was considerable missing data (n=23; table 1). There was
no signiﬁcant difference in the intervention group com-
pared with the control group (−0.42 (95% CI −0.95 to
0.11), p=0.121). We also analysed the equally valid six-
question version (without spirometry)24 which was
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available for all (n=45), and demonstrated a similar
result and it is this result which is presented in table 2.
Fifty-ﬁve per cent of the intervention group and 48%
of the comparison group achieved the MCID of an
improvement of at least 0.5 points (p=0.767).
AQLQ score
There was no signiﬁcant difference in mini-AQLQ
scores in the intervention group compared with the
control group (table 2). Fifty per cent of the interven-
tion group and 36% in the comparison group achieved
the MCID of improvement of at least 0.5 points
(p=0.379).
Secondary outcomes
The rationale for including a range of secondary out-
comes was to assess their feasibility for inclusion in any
future full-scale RCT. All outcomes were acceptable to
participants and feasible to measure and analyse, apart
from spirometry.
Mini-AQLQ domain scores
The ‘activity limitation’ domain of the mini-AQLQ
showed a statistically signiﬁcant improvement in scores
in favour of the intervention group (table 3). The
remaining individual domains of the mini-AQLQ
showed numerical improvement in the intervention
group, which were not statistically signiﬁcant.
Other patient-centred outcomes
There was a signiﬁcant improvement in PAM scores
(tables 3 and 4) in the intervention group compared
with the control group, indicating that intervention
patients were more highly activated in relation to man-
aging their own health.
There was no signiﬁcant difference in mean MMAS
scores in the intervention group (table 3) compared
with the control group. However, more participants in
the intervention group achieved the MCID≥2 compared
with usual care (30% vs 4%, p=0.034), although the
intervention group did have lower baseline scores.
The change in EQ-5D health utility score showed no
signiﬁcant between-group difference (table 4), with
median change in score of 0 in both groups.
Physiological and inflammatory outcomes
Spirometry analysis included only those meeting ATS
acceptability standards (22/45, 11 per group).22 Effect
sizes were small, and none achieved statistical signiﬁ-
cance (table 3).
Table 1 Baseline demographic characteristics of study population per group
Overall (n=51)
Comparison
(n=26)
Intervention
(n=25)
Age (years), mean (SD) 45.5 (15) 46.4 (14) 44.6 (17)
Female, n (%) 38 (75) 20 (77) 18 (72)
Ethnicity
White, n (%) 48 (94) 24 (92) 24 (96)
Other, n (%) 3 (6) 2 (8) 1 (4)
Smoking status:
Current, n (%) 5 (10) 2 (8) 3 (12)
Former smoker, n (%) 18 (35) 11 (42) 7 (28)
Never smoked, n (%) 28 (55) 13 (50) 15 (60)
SIMD quintile (1=most deprived, 5=least deprived)
SIMD 1, n (%) 14 (28) 7 (27) 7 (28)
SIMD 2, n (%) 11 (22) 6 (23) 5 (20)
SIMD 3, n (%) 9 (18) 4 (15) 5 (20)
SIMD 4, n (%) 5 (10) 3 (12) 2 (8)
SIMD 5, n (%) 12 (24) 6 (23) 6 (24)
Employment status
Employed, n (%) 25 (49) 11 (42) 14 (56)
Unemployed, n (%) 8 (16) 3 (12) 5 (20)
Retired, n (%) 9 (18) 5 (19) 4 (16)
Student, n (%) 2 (4) 1 (4) 1 (5)
Other, n (%) 7 (14) 6 (23) 1 (4)
Education level
Secondary education, n (%) 18 (35) 7 (27) 11 (44)
Tertiary/further education, n (%) 33 (65) 19 (73) 14 (56)
BMI (kg/m2), mean(SD) 30.4 (6.8) 31.3 (8.0) 29.4 (5.2)
Number of comorbidities (over and above index
condition), mean (SD)
2.6 (1.7) 2.6 (1.9) 2.6 (1.4)
Length of asthma diagnosis (years), median (IQR) 18.5 (8.6–28.6) 17.0 (8.6–27.8) 20.3 (9.7–28.6)
BMI, body mass index; SIMD, Scottish Index of Multiple Deprivation.
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Figure 1 Flow of participants
through study. *Actual search
terms refined iteratively through
recruitment (see online
supplementary data file for detail).
ACQ, Asthma Control
Questionnaire score; FeNO,
fractional exhaled nitric oxide;
NHS, National Health Service.
Table 2 Primary outcomes (ACQ and mini-AQLQ)
Intervention Control
Estimated
difference (95% CI) p Value
ACQ score 6-question version (continuous 0–6; 0=totally controlled, 6=severely uncontrolled)
Baseline Mean (SD) 1.87 (0.59) 1.97 (0.68)
Follow-up Mean (SD) 1.22 (0.91) 1.65 (1.15)
Change Mean (SD) −0.65 (1.08) −0.32 (0.94) −0.36 (−0.96 to 0.23) 0.225
ACQ score 6-question version (MCID improvement at follow-up)
Improvement ≥0.5 n (%) 11 (55%) 12 (48%) 0.767
Mini-AQLQ score (continuous 1–7; 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 4.97 (1.03) 4.65 (1.02)
Follow-up Mean (SD) 5.40 (1.01) 4.76 (1.30)
Change Mean (SD) 0.43 (0.78) 0.11 (0.88) 0.38 (−0.13 to 0.89) 0.136
Mini-AQLQ score (MCID improvement at follow-up)
Improvement ≥0.5 n (%) 10 (50%) 9 (36%) 0.379
Summaries of scores at baseline, follow-up and change from baseline, with estimated between-group difference from baseline-adjusted linear
regression model with 95% CI and p value. Summaries of achievement of an improvement by more than the MCID at follow-up, with Fisher’s
exact test p values to compare groups.
ACQ, Asthma Control Questionnaire (fall in score is desirable); AQLQ, Asthma Quality of Life Questionnaire (rise in score desirable); MCID,
minimum clinically important difference.
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FeNO levels (indicating airways eosinophilic inﬂamma-
tion) showed no signiﬁcant between-group difference
(table 4).
Medication changes and health service contacts
The median weekly number of puffs of reliever inhaler
used in the intervention group reduced from 11 to 5, but
remained unchanged in the control group at 4 puffs per
week at baseline and at follow-up (p=0.022) (table 4).
Although this between-group change in bronchodilator
use was statistically signiﬁcant, the groups were
imbalanced at baseline. There was no signiﬁcant
between-group difference in the percentage of recom-
mended ICS doses self-reportedly taken, nor the equiva-
lent beclometasone doses prescribed. There were no
signiﬁcant between-group differences in health service
contacts or prednisolone courses prescribed.
Further feasibility outcomes
The PETS results are shown in online supplementary
table A, illustrating barriers to using the website. The
biggest barriers relate to time and opportunity, rather
than content.
No serious adverse events were recorded.
Table 3 Secondary outcomes (continuous variables normally distributed)
Intervention Control
Estimated
difference (95% CI) p Value
Mini-AQLQ symptom domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 4.56 (1.10) 4.30 (0.84)
Follow-up Mean (SD) 5.15 (1.20) 4.38 (1.35)
Change Mean (SD) 0.59 (1.10) 0.08 (1.05) 0.56 (−0.08 to 1.22) 0.084
Mini-AQLQ activity limitation domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 5.30 (1.24) 5.31 (1.33)
Follow-up Mean (SD) 5.98 (0.92) 5.38 (1.33)
Change Mean (SD) 0.68 (1.01) 0.07 (1.10) 0.60 (0.05 to 1.15) 0.034
Mini-AQLQ emotional function domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 5.48 (1.09) 4.80 (1.48)
Follow-up Mean (SD) 5.75 (1.01) 4.84 (1.82)
Change Mean (SD) 0.27 (0.78) 0.04 (1.30) 0.35 (−0.33 to 1.03) 0.301
mini-AQLQ environmental domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 4.75 (1.39) 4.11 (1.54)
Follow-up Mean (SD) 4.85 (1.30) 4.23 (1.67)
Change Mean (SD) 0.10 (0.89) 0.12 (0.90) 0.08 (−0.46 to 0.62) 0.768
PAM (continuous, 0=no activation; 100=high activation)
Baseline Mean (SD) 65.7 (10.0) 66.2 (14.1)
Follow-up Mean (SD) 73.0 (13.9) 65.7 (16.5)
Change Mean (SD) 7.3 (11.3) −0.5 (12.5) 7.72 (0.53 to 14.90) 0.036
MMAS (continuous, range 0–8, 0=low adherence; 8=high adherence)
Baseline Mean (SD) 4.88 (1.97) 5.59 (1.85)
Follow-up Mean (SD) 5.46 (1.80) 5.82 (1.85)
Change Mean (SD) 0.58 (1.37) 0.23 (1.03) 0.19 (−0.50 to 0.88) 0.586
MMAS (MCID improvement at follow-up)
Improvement ≥2.0 n (%) 6 (30) 1 (4) 0.034
FEV1 (L) (continuous) (n=22)
Baseline Mean (SD) 2.62 (0.56) 2.66 (0.69)
Follow-up Mean (SD) 2.72 (0.58) 2.68 (0.49)
Change Mean (SD) 0.10 (0.18) 0.02 (0.31) 0.08 (−0.12 to 0.27) 0.428
FEV1% predicted (continuous) (n=22)
Baseline Mean (SD) 87.4 (13.6) 85.2 (17.1)
Follow-up Mean (SD) 90.6 (13.8) 85.7 (11.8)
Change Mean (SD) 3.3 (6.3) 0.6 (9.4) 3.4 (−2.8 to 9.5) 0.265
FEV1/FVC (%) (continuous) (n=22)
Baseline Mean (SD) 76.7 (7.0) 77.6 (10.9)
Follow-up Mean (SD) 79.1 (6.7) 80.2 (9.5)
Change Mean (SD) 2.4 (5.3) 2.6 (4.5) −0.4 (−3.9 to 3.1) 0.829
Summaries of scores at baseline, follow-up and change from baseline, with estimated between-group difference from baseline-adjusted linear
regression model with 95% CI and p value. Summaries of achievement of an improvement by more than the MCID at follow-up, with Fisher’s
exact test p values to compare groups. N=45 unless otherwise stated.
p Values in bold indicate significance <0.05.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; MCID, minimum clinically important difference; MMAS, Morisky Medication Adherence Score; PAM, Patient Activation Measure.
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The main source of missing data was from the spirom-
etry results where 23 participants had results not suitable
for analysis, due to not meeting ATS criteria. All ques-
tionnaires were completed sufﬁciently well to allow cal-
culation of scores, with only one response missing from
each of the mini-AQLQ, PAM and MMAS all from differ-
ent participants.
Sample size for a fully powered subsequent study
Using baseline-adjusted calculations of the change in
ACQ score above assuming a SD of 1.0, a sample size of
134 would be required to detect a between-group
change of ≥0.5 (MCID) in ACQ with 90% power at 0.05
signiﬁcance. Assuming a similar attrition rate of 12%,
the total sample size required would be 154.
DISCUSSION
Principal findings
This phase 2 pilot RCT of the Living well with Asthma
resource demonstrates that this website merits further
development, and that subsequent progression to a full-
scale phase 3 RCT is feasible. Recruitment targets were
achieved, and attrition rates were comparable to rates of
other published digital interventions.9 We had no upper
age limit, unlike similar asthma digital intervention
studies. This is important as our recent metareview only
found one study that included participants over 50 years
of age, and descriptions of participants’ characteristics
were limited, with socioeconomic status ignored.9 This
information is important to understand the ‘reach’ of
the intervention.
In terms of primary efﬁcacy outcomes, there were no
signiﬁcant between-group differences in terms of ACQ
and mini-AQLQ, although it is important to note that
this pilot trial was not powered to show such differences.
However, there are some interesting ﬁndings in analysis,
as both the ACQ and mini-AQLQ demonstrate encour-
aging and consistent trends in favour of the intervention
group, with one subdomain of the AQLQ (activity limita-
tion) reaching the MCID and statistical signiﬁcance. It is
worth noting that for both primary efﬁcacy outcomes, a
proportion of those in the comparison group demon-
strated an improvement in MCID scores as well as the
Table 4 Secondary outcomes (variables not normally distributed)
Intervention Comparison p Value
EQ-5D health utility (continuous, 0.000=dead; 1.000 perfect health)
Baseline Median (IQR) 0.848 (0.725, 1.000) 0.796 (0.620, 1.000)
Follow-up Median (IQR) 1.000 (0.796, 1.000) 0.796 (0.727, 1.000)
Change Median (IQR) 0.000 (0.000, 0.111) 0.0000 (−0.052, 0.194) 0.972
EQ-5D visual analogue scale (continuous, 0 worst health; 100 best health)
Baseline Median (IQR) 75 (70, 84) 80 (70, 90)
Follow-up Median (IQR) 80 (73, 88) 80 (70, 90)
Change Median (IQR) 2.5 (−6.5, 13.0) 1.0 (−10, 10) 0.409
FeNO (continuous, low score indicates low inflammation)
Baseline Median (IQR) 26.0 (16.0, 46.5) 25.0 (11.0, 36.0)
Follow-up Median (IQR) 23.0 (12.0, 44.5) 19.0 (10.0, 27.0)
Change Median (IQR) −2.5 (−11.5, 8.5) −2.0 (−15.0, 2.0) 0.615
Puffs reliever taken per average week(continuous)
Baseline Median (IQR) 11 (7, 28) 4 (2, 12)
Follow-up Median (IQR) 5 (0.5, 14) 4 (0, 28)
Change Median (IQR) −7 (−14, 1) 0 (−4, 4) 0.022
Percentage prescribed ICS reportedly taken (continuous)
Baseline Median (IQR) 85.7 (14.3, 100.0) 100.0 (71.4, 100.0)
Follow-up Median (IQR) 92.9 (71.4, 100.0) 100.0 (85.7, 100.0)
Change Median (IQR) 0.0 (0.0, 14.3) 0.0 (0.0, 7.1) 0.730
Equivalent beclometasone dose (μg) (continuous)
Baseline Median (IQR) 400 (300, 1000) 800 (400, 800)
Follow-up Median (IQR) 400 (300, 1000) 800 (400, 800)
Change Median (IQR) 0 (0, 0) 0 (0, 0) 0.209
Prednisolone course n (%) with at least one 1 (5) 3 (12) 0.617
Hospital/A&E visit n (%) with at least one 0 0 –
Non-routine GP/nurse visit n (%) with at least one 3 (15) 6 (24) 0.710
Routine GP/nurse visit (eg, asthma
review)
n (%) with at least one 5 (25) 8 (32) 0.745
Summaries of scores at baseline, follow-up and change from baseline. Summaries of prescribing and health service use over the study
period, with Fisher’s exact test for categorical data, and Mann-Whitney test to compare median differences between groups.
p Values in bold indicate significance <0.05.
A&E, accident and emergency; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; EQ-5D, EuroQol; FeNO,
fractional exhaled nitric oxide; GP, general practitioner; ICS, inhaled corticosteroids.
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intervention group. This is often the case in unblinded
complex intervention trials, and validates our approach
of making this a pilot RCT, and not just a feasibility
study. In terms of website use, 76% of individuals
logging in is comparable with other behaviour change
websites,25 26 and it is encouraging that an average of
only 18 min usage resulted in consistently positive trends
across almost all outcomes. Asthma-speciﬁc research
indicates that users like to spend 5–8 min per online
session.27 Our exploration of usage patterns suggests
that some users missed sections that they could poten-
tially have beneﬁted from. These two facts combined
lead us to conclude that it would be preferable to
provide the core modules initially and then ‘release’
further sections weekly or fortnightly, a strategy that has
been used successfully for a weight loss intervention also
developed using LifeGuide software.26 Qualitative
process evaluation interviews of those in the intervention
group have been completed and will be reported separ-
ately. Findings from this qualitative work will inform the
further development of this resource, prior to evaluation
in a full-scale trial.
We assessed the feasibility of collecting a range of sec-
ondary outcomes in any future RCT, and in doing so
demonstrated a signiﬁcant improvement in the PAM,
which indicates that those in the intervention group had
improved knowledge, conﬁdence and skills to manage
their asthma. Signiﬁcant between-group differences in
the numbers of patients showing a MCID improvement
in adherence and reliever use should be interpreted
with caution due to baseline between-group imbalances.
The feasibility of researchers undertaking spirometry in
the participants’ own homes using a portable handheld
device was found to be low, as reported in other
studies.28 Potential solutions include more intensive
training of research staff; use of a device providing
test-by-test acceptability information or undertaking trial
visits in a dedicated clinical research facility by staff
experienced in spirometry. However, this latter solution
could have a negative effect on recruitment, as 21% of
our study visits were undertaken in the evening and
weekend, which facilitated recruitment of a population
who can rarely make it into such RCTs (full-time
employed). There is a balance between precision of
measurements versus encouraging a more representative
sample. Whether spirometry is required at all in a study
aimed at people with mild-to-moderate asthma is not
clear, and there is precedence in the literature for not
including these outcome measures in similar primary
care-based trials or for using simpler to perform lung
function measures such as peak expiratory ﬂow rate.29 30
Lack of time and opportunity were the biggest bar-
riers to using the website and providing the contents
on a smartphone app or tablet would be worth investi-
gating. During the introduction questions at the start of
the website, 95% of users agreed to statements which
showed that asthma was negatively impacting on their
lives. However, at the end of the trial, 42% of users
doubted the personal relevance of the website, anec-
dotally reporting that the website would be more useful
for people with symptomatic asthma. To be in the trial
in the ﬁrst place, all users were symptomatic (as
deﬁned by ACQ score), so challenging this mismatch
between users’ perceptions and the reality would be
warranted in future versions of a mobile friendly digital
intervention.
Strengths and limitations
Blinding to group allocation during analysis was not pos-
sible due to the different numbers in each group being
known by the researcher undertaking the analysis. As
with many digital interventions, the ‘reach’ is a potential
issue and our low response rate is a concern, even
taking into account our very broad recruitment strategy.
Similar trials have described similar recruitment difﬁcul-
ties.31 However, given how common asthma is, improve-
ments in even a small proportion of patients could lead
to signiﬁcant beneﬁt overall, particularly with an inter-
vention such as that trialled here which is entirely inter-
net based and once developed is very economical to
make available to large numbers of people. Therefore,
what seems like a low reach can still improve outcomes
for a large number of people. We have described our
population in detail, and our baseline characteristics
demonstrate that patients were recruited from a range
of socioeconomic backgrounds. Those excluded due to
not having internet access were older than those who
were excluded for other reasons (data not shown), but
this is becoming less of an issue with year-on-year
increases in the number of households with internet
access (84% in 2014, UK).32
Comparable studies in the literature
Our recently published metareview suggests digital inter-
active interventions to support asthma self-management
show promise, but there is no clear picture about the
‘active ingredients’ of the interventions.9 In the develop-
ment of this intervention, we have described its contents
fully including an analysis of behaviour change techni-
ques used,13 allowing more meaningful future compari-
sons. When focusing on interventions aimed at those
with mild-to-moderate asthma, most have included con-
siderable health professional input as well as self-
monitoring work on the part of the participants, and
have not shown clinical improvements.33 This evaluation
of Living Well with Asthma adds to the literature on
digital asthma self-management suggesting that an inter-
vention not including regular user self-monitoring or
costly health professional input may have positive
results.
Future research
We have shown that evaluating the Living Well with
Asthma intervention was feasible and resulted in encour-
aging trends in clinical outcomes. Further qualitative
work to understand usage patterns with intervention
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group participants have been completed and will inform
a future version of the resource. To overcome the ‘prac-
tical barriers’ to using the intervention, future versions
need to be mobile and tablet compatible, and will
require further user testing. Following this development
work on the resource, these ﬁndings suggest that a
large-scale phase 3 RCT is merited, with some explor-
ation of recruitment strategies and minor modiﬁcation
to outcome measurement methods. Low-intensity digital
interventions that are easier to deliver at scale may be a
more successful strategy, particularly in those with
mild-to-moderate asthma.
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Title: A Qualitative and Quantitative Systematic Review of Reviews of the Use of Online/Web-
based/Computerised Asthma Self-care Interventions. 
Deborah Morrison, Karolina Agur, Neil Thomson, Sally Wyke, Alex McConnachie, Frances Mair 
Review question 
What is known about the evidence that web-based/online/computerised tools for self 
management of asthma can improve indices of asthma control, lung function, health care 
utilisation, patient quality of life, and patient satisfaction, and what helps or hinders the use of 
such interventions by patients, carers and health professionals. 
Objectives  
 To undertake a systematic review of all published reviews (quantitative and qualitative) of 
web-based/online/computerised self-management asthma interventions. 
 To establish if the use of web-based/online/computerised self care interventions have 
been found to have a positive effect on asthma symptom scores, lung function, 
medication use, health care utilisation, or asthma quality of life scores. 
 To identify the presence of techniques in these interventions known to promote 
behavioural change e.g. educational information, self monitoring, attitudinal arguments, 
and the use of prompts. 
 To examine what factors, if any, have been identified as promoting or inhibiting the 
uptake and utilisation of online tools by patients, carers and practitioners? 
Searches  
 Databases to be searched: MEDLINE, EMBASE, CINAHL, PsycINFO, ERIC, Cochrane Library 
(including CDSR, DARE, Central, and HTA databases), DoPHER and TROPHI (both produced 
by the EPPI Centre), Social Science Citation Index and Science Citation Index. These 
databases will be searched using a combination of subject headings where available (such 
as MeSH) and words in the title and abstracts.   
The search strategy combines 3 facets of search terms: 
1. Online technology 
2. Asthma  
3. Self management/behavior change/patient experience 
Searches employing more general terms, such as respiratory tract diseases, will be explored as 
they may identify records where in the full document it becomes clear that patients with asthma 
are included. 
To minimise the risk of missing relevant reviews a manual search of key resources and journals 
and of the reference lists of reviews captured by initial searches will be undertaken. The search 
can also be complemented by contacting experts in the topic under review and by carrying out 
citation searches for articles which cite individual studies that are known to be relevant to the 
topic. 
Types of study to be included/excluded 
Included: 
Reviews (qualitative and quantitative) describing the use of online/web-based/computerised 
decision support software interventions providing education and advice on managing asthma for 
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patients with asthma, or their carers.  Quantitative reviews which describe RCTs, and qualitative 
reviews which seek to understand the patients or providers’ experience of using these asthma 
interventions, and those which describe the theory behind the development of such 
interventions.  
Excluded: 
 Studies examining clinical decision support software for health professionals.  
 Where a review features online/computerised asthma interventions, but the results are 
indistinguishable from non asthma interventions, or non online/computerised 
interventions, these papers will be excluded.  
 Conference proceedings and theses are excluded. 
 
Condition or domain being studied 
Asthma is common, and Scotland has the highest prevalence of asthma symptoms in the world, 
with patients accepting higher levels of symptoms and lifestyle limitations than they need to, 
often as a result of not making full use of proven treatment strategies. The promotion of self-care 
is a strategy known to improve asthma control, and the use of mediums such as the internet and 
mobile phones are increasingly being considered as a tool to augment its use.  
This systematic review of reviews will deliver a position paper on the current knowledge regarding 
the use of online/web-based/computerised asthma self management tools, and identify gaps in 
the literature. 
Participants/ population 
Quantitative and qualitative studies from any geographical location, participants diagnosed with 
asthma; being treated in any setting: primary; secondary; tertiary care, e.g. in the hospital, 
community, home; describing a review of online/web-based/computerised asthma interventions. 
Intervention(s), exposure(s) 
Any review describing the use of online/web-based/computerised asthma interventions to 
facilitate patients to manage their asthma.  
We considered any digital mode of delivery so long as the intervention itself was providing some 
degree of information or feedback. It needed to be more than telemonitoring, i.e more than a 
method of communication between users and health professionals.  For example a computer 
programme that collected symptoms or peak flow data to allow a health professional to provide 
feedback would be excluded. 
Comparator(s)/ control  
Any comparison with usual care, or alternative modes of delivery of selfmanagement 
information/skills to participants with asthma or their carers. 
Outcome(s) 
Primary outcomes may include: 
 
 Measures of asthma control, Symptoms (e.g. diary card scores) 
 Measures of asthma quality of life  
 Exacerbations 
 Restricted activities (e.g. days of work/school/disturbed nights) 
 Lung function: e.g. spirometry & reversibility, peak expiratory flow 
 Medication utilisation – 
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 relief inhaled β agonist use 
 Compliance with medication 
 Health service utilisation (including scheduled/unscheduled, and primary/secondary care) 
 Biomarkers of airway inflammation (e.g. exhaled nitric oxide) 
 Facilitators of online asthma intervention use by patients and practitioners 
 Barriers to online asthma intervention use by patients and practitioners 
 Adverse events 
 
Secondary outcomes may include 
 What behavioural change theories are used, if any, to inform online asthma interventions 
 Patient satisfaction 
 Patient knowledge  
 Adherence to monitoring tools 
 Recruitment Retention rates 
 Markers of self care (action plan use, inhaler technique for example) 
 Data about economic benefits 
 
Study Design - Include review papers only. 
Definition of a review 
We considered a review paper to be one that provides an analytic account of the research 
literature related to a specific topic or closely related set of topics. It is intended to contribute to 
knowledge by answering a research question. Thus we include the following types of papers: 
1. Systematic reviews: where relevant literature has been identified by means of 
structured search of bibliographic and other databases; where transparent 
methodological criteria are used to exclude papers that do not meet an explicit 
methodological benchmark, and which presents rigorous conclusions about outcomes. 
2. Narrative reviews: where relevant literature has been purposively sampled from a field 
of research; where theoretical or topical criteria are used to include papers on the 
grounds of type, relevance, and perceived significance; with the aim of summarising, 
discussing, and critiquing conclusions. 
3. Qualitative metasyntheses or meta-ethnographies, where relevant literature has been 
identified by means of a structured search of bibliographic and other databases, where 
transparent methods had been used to draw together theoretical products, with the aim 
of elaborating and extending theory. 
 
We excluded the following: 
1. Secondary analyses (including qualitative metasyntheses or metaethnographies) of 
existing data-sets for the purposes of presenting cumulative outcomes from personal 
research programmes. 
2. Secondary analyses (including qualitative metasyntheses or metaethnographies) of 
existing data-sets for the purposes of presenting integrative outcomes from different 
research programmes. 
3. Discussions of literature included in contributions to theory building or critique. 
4. Summaries of literature for the purposes of information or commentary. 
5. Editorial discussions that argue the case for a field of research or a course of action. 
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Where the abstract states it is a review, but there is no supporting evidence in the main paper, 
such as details of databases searched or criteria for selection of papers (either on methodological 
or theoretical grounds), the paper is excluded. 
Data extraction, (selection and coding) 
Title, abstract and full paper screening will be carried out by two researchers independently using 
Distiller software. The full text of the potentially relevant studies will be retrieved and assessed 
independently for inclusion as per criteria mentioned. Excluded studies will be listed with reasons 
of exclusion.  Data extraction and data analysis will be carried out using a combination of Distiller 
software, NVivo software and Microsoft Word.  Any disagreements will be resolved by discussion, 
with a third party if necessary. 
 
Risk of bias (quality) assessment 
The AMSTAR tool has been validated as a means to assess the methodological quality of 
systematic reviews included, and will be utilised during the quality appraisal of included studies 
[1].  Those achieving 50% plus a ‘yes’ to question 7 will be included, with appropriate concessions 
for qualitative studies.   
 
Strategy for data synthesis 
Numerical data, e.g. the total number of participants will be analysed using descriptive statistics. 
Outcomes from the quantitative reviews will be analysed using appropriate statistical methods.  
Clinical and methodological heterogeneity will be assessed before pooling. 
Findings from the qualitative reviews will be extracted verbatim. A coding frame will be 
developed to undertake a content analysis of the extracted data from the included reviews. 
 
Analysis of subgroups or subsets 
None planned 
Dissemination plans 
The findings from this work will be disseminated through traditional academic media of 
conferences and peer reviewed journals but will also be circulated to relevant NHS bodies ,  
charity partners (Asthma UK, British Lung Foundation), and other key bodies such as Quality 
Improvement Scotland. 
 
Contact details for further information 
Deborah Morrison 
Academic Unit of General Practice and Primary Care, University of Glasgow, 
1 Horselethill Road, Glasgow, G12 9LX, UK.  Deborah.Morrison@glasgow.ac.uk 
 
Organisational affiliation of the review – University of Glasgow 
Review team 
Dr Deborah Morrison, University of Glasgow 
Euan Cameron, University of Glasgow 
Karolina Agur, University of Glasgow 
Prof Thomson, University of Glasgow 
Prof Wyke, University of Glasgow 
Dr Alex McConnachie, University of Glasgow 
Professor Frances Mair, University of Glasgow 
 
Other Information: 
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Details of any existing review of the same topic by the same authors - None 
Anticipated or actual start date - August 2011 
Anticipated completion date - July 2012 
Funding sources/sponsors - Chief Scientist Office, Scotland 
Conflicts of interest - None 
Other registration details - None 
Language - English 
Country - Scotland 
Key words - Asthma, self care, internet, web-based, online, computerised, quantitative, 
qualitative, patient education 
 
Protocol Amendment October 2013. 
Addition of search terms to. 
 Keyword searches for text messaging were added; 
 MeSH (Medical Subject Headings) terms “Cellular Phone” and “Social Networking” were 
added; 
 The search terms used for mobile phones were enhanced with the addition of 
“smartphone$ or smart-phone$ or smart-telephone$” and associated terminology such as 
iPhone, app(s), Apple, Android and Blackberry; 
 Newer technologies including tablet devices and social media tools were added as 
keyword terms; 
 The terms “m-health” and “mhealth” were added to search line 29 to reflect the 
emergence of a new sub-field of e-health concerned specifically with mobile devices.   
Electronic search updated to October 2013 
Review team updated:  R Docking, AM MacKenzie, V Raghuvir joined.  
Completion date – November 2013.  
Protocol Amendment January 2016. 
The Risk of bias (quality) assessment section is amended, to remove the following sentence: 
“Those achieving 50% plus a ‘yes’ to question 7 will be included, with appropriate concessions for 
qualitative studies.“  All studies meeting inclusion/exclusion criteria will be included and the 
AMSTAR score used only to describe the included reviews, and to inform discussion.  
Completion date – April 2016 
Reference List 
 1.  Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M 
(2009) AMSTAR is a reliable and valid measurement tool to assess the 
methodological quality of systematic reviews. Journal of Clinical Epidemiology 62: 
1013-1020. doi: 10.1016/j.jclinepi.2008.10.009. 
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The following databases and resources were searched: 
 MEDLINE and MEDLINE In-Process 
 EMBASE 
 CINAHL  
 PsycINFO 
 Cochrane Database of Systematic Reviews (CDSR) 
 Database of Abstracts of reviews of Effects (DARE) 
 Cochrane Central Register of Controlled Trials (CENTRAL) 
 Health Technology Assessment (HTA) database 
 NHS Economic Evaluation Database (NHS EED) 
 ERIC (Education Resources Information Center) 
 Science Citation Index (SCI) 
 Social Science Citation Index (SSCI) 
 DoPHER 
 TRoPHI  
Database results 
Resource Number of 
results 2013 
MEDLINE and MEDLINE In-Process 1590 
EMBASE 2426 
CINAHL  1020 
PsycINFO 155 
Cochrane Database of Systematic Reviews (CDSR) 15 
Database of Abstracts of reviews of Effects (DARE) 2 
Cochrane Central Register of Controlled Trials (CENTRAL) 247 
Health Technology Assessment (HTA) database 0 
NHS Economic Evaluation Database (NHS EED) 4 
ERIC (Education Resources Information Center) 16 
Science Citation Index (SCI) 1112 
Social Science Citation Index (SSCI) 331 
DoPHER 12 
TRoPHI 22 
Total  6952 
Total once duplicates removed  3798 
 
Sample search strategy 
The search strategy used in MEDLINE (OvidSP) is shown in below (October 2013). This was 
adapted appropriately to run in the other databases searched.  
1     (Computer or computers).hw.  
2     exp computers/  
3     exp Computer Systems/ 
4     Medical Informatics/  
5     Medical Informatics Applications/  
6     Decision Support Techniques/  
7     Educational Technology/  
8     Audiovisual Aids/  
9     Telecommunications/  
10     Multimedia/  
Appendix 5  Meta-review search results overview and sample search strategy 
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11     Computer-Assisted Instruction/  
12     User-Computer Interface/   
13     Hypermedia/  
14     Video Games/  
15     Electronic Health Records/  
16     Cellular Phone/  
17     Social Networking/  
18     (computer$ or microcomputer$ or PC or PCs or Mac or Macs or Internet or WWW or web or  
  website$1 or webpage$ or local area network$).ti,ab.  
19     software.ti,ab.  
20     (cellular phone$1 or cellular telephone$1 or mobile$1 or cell phone$1 or cell telephone$1 or  
  smartphone$ or smart-phone$ or smart-telephone$).ti,ab.  
21     (handset$ or hand-set$ or wireless or wire-less or wifi or wi-fi or GPS or global positioning  
 system$ or bluetooth or text messag$ or texting or SMS or short messag$ or multimedia  
 messag$ or multi-media messag$ or mms or instant messag$ or social media$ or facebook or  
 twitter or webcast$ or webinar$ or podcast$ or wiki or wikis or app or apps or Android$ or  
 Blackberr$ or Apple$ or iOS or iphone$ or ipad$ or S40 or Symbian$ or Windows).ti,ab.  
22     ((electronic$ or digital$ or device$) adj2 tablet$).ti,ab.  
23     (video$ or DVD or DVDs).ti,ab.  
24     (youtube or you tube or vimeo).ti,ab.  
25     (online or on line or interactive).ti,ab.  
26     (chat room$1 or chatroom$1).ti,ab.  
27     (blog$1 or web-log$1 or weblog$1).ti,ab.  
28     (bulletin board$1 or bulletinboard$1 or messageboard$1 or message board$1).ti,ab.  
29     (ehealth or e-health or mhealth or m-health).ti,ab.  
30     or/1-29  
31     exp Asthma/  
32     (asthma or asthmatic$1).ti,ab.  
33     exp Anti-Asthmatic Agents/ or exp Bronchodilator Agents/  
34     or/31-33  
35     (action plan or action plans).ti,ab.  
36     (self management or self managing).ti,ab.  
37     (patient$1 adj3 manag$).ti,ab.  
38     health education/  
39     education.ti,ab.  
40     self care/ or self administration/ or self medication/  
41     self care.ti,ab.  
42     self monitor$.ti,ab.  
43     self treat$.ti,ab.  
44     (behavio?r$ adj3 (chang$ or modif$ or condition$)).ti,ab.  
45     Patient Satisfaction/  
46     (patient$ adj3 (experience$ or attitude$ or view$1 or satisfaction$)).ti,ab.  
47     Qualitative research/  
48     exp Questionnaires/  
49     exp Interviews as Topic/  
50     qualitative.ti,ab.  
51     (interview$ or questionnaire$ or focus group$).ti,ab.  
52     or/35-51  
53     30 and 34 and 52  
54     animals/ not humans/  
55     53 not 54  
 
Key: 
/  indicates a subject heading 
exp  indicates an exploded subject heading 
$  truncation symbol 
adj3  words must appear with 3 words of each other 
.ti,ab.  searches are restricted to the title and abstract fields 
or/1-26  combine sets 1 to 26 using OR 
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Modified with further detail about qualitative/narrative reviews  (grey text is our own agreed 
rules/explanations).  
 
1  Was an “a priori” design provided? 
The research question and inclusion criteria should be established 
before the conduct of the review. 
It should be clearly stated that the criteria were agreed prior 
to the review starting, ideally with evidence of protocol 
registration provided.   If this is not mentioned – chose can’t 
answer. 
 
2. Was there duplicate study selection and data extraction? 
There should be at least two independent data extractors and a consensus 
procedure for disagreements should be in place. 
It should be clear that 2 people independently screened titles, 
abstracts and full papers AND extracted the data. 
If titles and abstracts only screened by one person then no 
point. If doesn’t explicitly say who screened what, then can’t 
answer. 
 
3. Was a comprehensive literature search performed? 
At least two electronic sources should be searched. The report must 
include years and databases used (e.g., Central, EMBASE, and 
MEDLINE). Key words and/or MESH terms must be stated, and where 
feasible, the search strategy should be provided. All searches should 
be supplemented by consulting current contents, reviews, textbooks, 
specialized registers, or experts in the particular field of study, and by 
reviewing the references in the studies found. 
Answer yes if at least one other form of supplementary searching is described, with 2 
databases, years searched and at least the key words provided.  
If qualitative/narrative accurate description of what has been 
done & why should be present and it should still be replicable 
from information provided. 
 
4.a c  Did the authors state that they searched for reports regardless 
of their publication type? 
The authors should state that they searched for reports regardless of 
their publication type. Was the status of publication (i.e., grey 
literature) used as an inclusion criterion? The authors should state 
whether or not they excluded any reports (from the systematic 
review), based on their publication status, language etc. 
 
Publication type should not be used as a filter when searching for 
articles.  However any inclusions/exclusion criteria based on 
publication status, language etc should be stated. 
AND 
4bc Was the status of publication (i.e. grey literature) used as an 
inclusion criterion? The authors should state that they searched for 
 Yes 
 No  
 Can’t answer a 
 Not applicable b 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
Appendix 6  AMSTAR 11 point checklist with guidance notes 
320
 
Appendix 6   AMSTAR checklist 
 
reports regardless of their publication type. The authors should state 
whether or not they excluded any reports (from the systematic 
review), based on their publication status, language etc. 
Answer no if any evidence that articles were excluded for 
publication type (e.g. conference proceedings, grey literature 
etc) or if exclusions based on language. 
 
5. Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. 
Included studies need to be listed in the main article. If 
excluded studies are not present in main body, but available 
as an appendix or on request from the author then can still 
answer yes.  
 
6. Were the characteristics of the included studies provided? 
In an aggregated form, such as a table, data from the original studies 
should be provided on the participants, interventions, and 
outcomes. The ranges of characteristics in all the studies analyzed, 
e.g., age, race, sex, relevant socioeconomic data, disease status, 
duration, severity, or other diseases should be reported. 
Answer yes if the following criteria are present as a minimum 
from each original study included:  
Participants – at least one participant variable described e.g 
age or gender. 
Intervention – intervention described beyond simple one or 
two word descriptions. I.e ‘internet’ or ‘patient education’ not 
sufficient.  Outcome measured are listed 
If qualitative/narrative and no specific intervention then aim 
of the study should be clearly described and what ‘question’ 
they were trying to answer.  
 
7. Was the scientific quality of the included studies assessed and 
documented? 
“A priori” methods of assessment should be provided (e.g., for 
effectiveness studies if the author(s) chose to include only 
randomized, double-blind, placebo-controlled studies, or allocation 
concealment as inclusion criteria); for other types of studies, 
alternative items will be relevant. 
The method of quality assessment should be provided, with 
the results of the assessment provided. 
 
8. Was the scientific quality of the included studies used 
appropriately in formulating conclusions? 
The results of the methodological rigor and scientific quality should be 
considered in the analysis and the conclusions of the review, and 
explicitly stated in formulating recommendations. 
Answer yes if the discussion and conclusion appropriately 
acknowledges the results of their quality assessment in 
coming to their conclusions. 
 
9. Were the methods used to combine the findings of studies 
appropriate? 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
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For the pooled results, a test should be done to ensure the studies 
were combinable, to assess their homogeneity (i.e., Chi-squared test 
for homogeneity, I2). If heterogeneity exists, a random effects model 
should be used and/or the clinical appropriateness of combining 
should be taken into consideration (i.e., is it sensible to combine?). 
Answer yes if the authors did not combine, and this was 
appropriate.  
 
10. Was the likelihood of publication bias assessed? 
If meta analysis this include a combination of graphical aids (e.g., 
funnel plot, other available tests) and/or statistical tests (e.g., Egger 
regression test).  
If not quantitative then chose not applicable 
 
11. Was the conflict of interest included? 
Potential sources of support should be clearly acknowledged in both 
the systematic review and the included studies. 
Answer yes if information about conflicts of interest are made 
available about both the review and included studies within it.   
Specific detailing of sources of funding not required, unless 
conflict of interest present.  
 
 
 
a      ‘Can't answer’ is chosen when the item is relevant but not described by the authors 
b     ‘not applicable’ is used when the item is not relevant, such as when a meta-analysis has not been 
possible or was not attempted by the authors.  
c     for clarity we split this question into two parts. 
 Yes 
 No  
 Can’t answer 
 Not applicable 
 
 Yes 
 No  
 Can’t answer 
 Not applicable 
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Appendix 7 Focus Group & Think aloud information leaflet for adults with 
asthma 
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Appendix 9  Focus Group topic guide 
 
 
 
The contents of this focus group guide will be informed by the finding of the ongoing 
literature review so may be subject to some changes in content. 
Background:  I will give a short ( 10 minute) presentation about asthma, the finding of the 
systematic review of all qualitative and quantitative reviews of online interactive self care 
asthma resources, and a review of the qualitative literature about knowledge and 
understanding of asthma. 
The following issues will then be addressed/explored: 
Topic 1: Respond to the information presented, gain current understanding of 
potential role of online resource. (coherence) 
What do you the participants think about the information reported in the current literature?  
Probe:  What do they agree with? What do they disagree with?  Specifically focusing on 
the notion of online self help – what are perceptions/ideas about the role of an online 
intervention? 
Topic 2: Are potential users of the resource open to the idea of an online self 
management website? (cognitive participation) 
Who or what helps participants just now to help manage their asthma?  What do they 
think are the barriers and facilitators to use of an asthma tool? 
Probe:  Who do they engage with – family, friends, or health professionals? What role do 
they take themselves? What are participants’ views about using an online tool? What are 
participants’ views about others having access to their information on the online tool – e.g. 
family, health professionals? GP practices could receive email updates automatically from 
the resource about changes in medication? What about automatic email or text reminders 
to use the resource? What would help to sustain use? What do practice nurses feel about 
such a resource, would they anticipate using it in consultation? 
Topic 3: What do people do currently to manage their asthma, and what role might 
an online resource have? (collective action) 
What tools are used currently – why – what are the benefits, drawbacks?  
Probe:  What makes managing asthma difficult?  Can barriers to use of internet resources 
be identified?  Would it be compatible with current ways asthma is managed?  Would 
there be concerns about the technology or confidentiality? What would make it attractive? 
What would put them off? 
To prompt this I could show examples of currently available online asthma resources e.g. 
you tube video of inhaler technique, asthma UK information, NHS websites. What features 
of an online resource would people with asthma, and practice nurses like to see 
incorporated into the development of this one. 
Appendix 9 Focus group topic guide 
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Topic 4:  What features would participants like to see, to provide evidence that the 
intervention is helpful (reflexive monitoring) 
What would be a sign to them that the intervention is having the desired effect?  
Probe:  How would they decide it is working? What outcomes would they like to see to 
show it was worth continuing to keep using it? What would put them off? How would 
participants feel about being involved in trying out the intervention during the development 
phase, in order to feedback and improve it? 
Any further areas of discussion: 
 Do any of the participants have anything further to add from what we have 
discussed today?  
Give thanks for participating.  
328
1 
 
 
 
 
 
 
 
Aim of intervention: reduce burden of symptoms and increase QOL through 
supporting use of medications. 
 
Methods:    Statements relating to adherence specifically were extracted from 
a previously undertaken literature review.  A relevant feature of the proposed 
website was attributed to the statement, resulting in a ‘suggested component’ 
to be a feature of the website. This led to the production of tables showing 
barriers and enablers from the literature.  Two articles were of specific 
relevance and these were looked at in detail individually, and tables relevant 
to their findings also produced in the same way as described above (GINA 
guidelines[1], chapter 4, and a review of adherence[2].  Finally analysis of the 
two focus groups provided information for a further set of tables describing 
identified barriers and enablers.  Finally the information relevant to each 
component was grouped together to produce a table for each, illustrating the 
source of the evidence.  
Appendix 10   Intervention Planning Document 
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m
a 
lit
er
at
u
re
 r
ev
ie
w
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
w
it
h
 a
 n
ew
 d
ia
gn
o
si
s 
la
ck
ed
 c
o
n
fi
d
en
ce
 in
 
u
si
n
g 
ac
ti
o
n
 p
la
n
s.
[4
] 
P
ro
vi
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
h
o
w
 t
o
 u
se
 a
ct
io
n
 p
la
n
s 
 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
u
si
n
g 
A
A
P
 u
se
, q
u
o
te
s 
ai
m
in
g 
to
 in
cr
ea
se
 c
o
n
fi
d
en
ce
 
G
u
id
ed
 s
el
f-
m
an
ag
e
m
en
t 
w
it
h
 a
st
h
m
a 
p
la
n
 (
in
cl
u
d
in
g 
h
ea
lt
h
 
p
ro
fe
ss
io
n
al
 r
ev
ie
w
 im
p
ro
ve
s 
as
th
m
a 
re
la
te
d
 o
u
tc
o
m
es
.[
6
] 
In
fo
rm
at
io
n
 p
ag
es
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e
 e
.g
. s
el
f-
m
o
n
it
o
r,
 u
se
 a
n
 A
A
P
, 
ro
le
 o
f 
go
al
s 
in
 s
el
f-
m
an
ag
em
en
t 
Se
lf
-m
an
ag
e
m
en
t 
ed
u
ca
ti
o
n
 im
p
ro
ve
s 
ac
ti
o
n
 p
la
n
 u
se
.[
7]
 
In
fo
 p
ag
e 
ab
o
u
t 
h
o
w
 t
o
 u
se
 a
n
 a
ct
io
n
 p
la
n
 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
u
si
n
g 
A
A
P
, q
u
o
te
s 
ai
m
in
g 
to
 in
cr
ea
se
 c
o
n
fi
d
en
ce
 in
 u
se
 
Fo
cu
s 
gr
o
u
p
 
P
ro
vi
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e 
to
 f
ac
ili
ta
te
 
ad
h
er
en
ce
.  
 
In
fo
 p
ag
es
 –
 h
o
w
 t
o
 u
se
 A
A
P
s 
an
d
 b
en
ef
it
s 
o
f 
u
si
n
g 
th
em
. 
 C
o
m
p
o
n
en
t:
  I
n
fo
 p
ag
e 
– 
h
o
w
 t
o
 s
el
f-
m
o
n
it
o
r 
&
 il
lu
st
ra
te
 t
h
e 
b
en
e
fi
ts
 o
f 
se
lf
-m
o
n
it
o
ri
n
g.
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
ea
tu
re
 o
f 
w
e
b
si
te
. 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
ar
e 
p
o
o
r 
at
 r
ec
o
gn
is
in
g 
d
et
er
io
ra
ti
o
n
 in
 
as
th
m
a 
sy
m
p
to
m
s,
 a
n
d
 t
h
er
ef
o
re
 u
n
ab
le
 t
o
 a
ct
 a
p
p
ro
p
ri
at
el
y.
[4
] 
P
ro
vi
d
e 
in
fo
 h
o
w
 t
o
 s
el
f-
m
o
n
it
o
r 
 
P
ro
vi
d
e 
in
fo
 t
o
 s
h
o
w
 b
en
ef
it
s 
o
f 
se
lf
-m
o
n
it
o
ri
n
g 
G
u
id
ed
 s
el
f-
m
an
ag
e
m
en
t 
w
it
h
 a
st
h
m
a 
p
la
n
 (
in
cl
u
d
in
g 
h
ea
lt
h
 
p
ro
fe
ss
io
n
al
  r
ev
ie
w
 im
p
ro
ve
s 
as
th
m
a 
re
la
te
d
 o
u
tc
o
m
es
.[
6
] 
In
fo
rm
at
io
n
 p
ag
es
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e
 e
.g
. s
el
f-
m
o
n
it
o
r,
 u
se
 a
n
 A
A
P
, 
ro
le
 o
f 
go
al
s 
in
 s
el
f-
m
an
ag
em
en
t.
  P
ro
vi
d
e 
ac
ti
o
n
 p
la
n
s 
Se
lf
-m
o
n
it
o
ri
n
g 
in
 o
rd
er
 t
o
 r
ec
o
gn
is
e 
lo
ss
 o
f 
as
th
m
a 
co
n
tr
o
l i
s 
a 
gr
ad
e 
A
 r
ec
o
m
m
en
d
at
io
n
 w
it
h
in
 t
h
e 
B
TS
/S
IG
N
 g
u
id
el
in
es
.[
8
].
   
 In
fo
 a
b
o
u
t 
h
o
w
 t
o
 m
o
n
it
o
r 
se
lf
 f
o
r 
d
et
er
io
ra
ti
o
n
 in
 s
ym
p
to
m
s 
W
ee
kl
y 
m
o
n
it
o
ri
n
g 
m
ay
 b
e 
su
ff
ic
ie
n
t 
in
 t
h
o
se
 w
it
h
 w
el
l o
r 
p
ar
tl
y 
co
n
tr
o
lle
d
 a
st
h
m
a,
 a
n
d
 t
h
at
 t
h
is
 c
o
u
ld
 s
af
el
y 
b
ec
o
m
e 
le
ss
 
fr
eq
u
en
t 
o
n
ce
 g
o
o
d
 c
o
n
tr
o
l i
s 
ac
h
ie
ve
d
.[
9
] 
In
fo
 a
b
o
u
t 
h
o
w
 t
o
 m
o
n
it
o
r 
se
lf
 f
o
r 
d
et
er
io
ra
ti
o
n
 i.
e.
 s
ym
p
to
m
s 
o
r 
vi
a 
P
EF
 
m
o
n
it
o
ri
n
g,
 a
n
d
 h
o
w
 o
ft
en
 t
o
 m
o
n
it
o
r.
 
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
  –
 k
ey
 
co
m
p
o
n
en
ts
 o
f 
su
cc
es
sf
u
l 
as
th
m
a 
ed
u
ca
ti
o
n
 
p
ro
gr
am
m
e.
[1
] 
 
Si
gn
s 
th
at
 s
u
gg
es
t 
as
th
m
a 
is
 w
o
rs
en
in
g 
an
d
 a
ct
io
n
s 
to
 t
ak
e.
 
 
M
o
n
it
o
ri
n
g 
co
n
tr
o
l o
f 
as
th
m
a.
 
In
fo
 a
b
o
u
t 
h
o
w
 t
o
 m
o
n
it
o
r 
se
lf
 f
o
r 
d
et
er
io
ra
ti
o
n
 in
 s
ym
p
to
m
s.
 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
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2
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1
. 
M
u
lt
if
ac
et
ed
 a
p
p
ro
ac
h
es
 w
o
rk
 b
es
t 
in
vo
lv
in
g 
co
m
b
in
at
io
n
s 
o
f 
st
ra
te
gi
es
 s
u
ch
 a
s 
p
ro
vi
d
in
g 
in
fo
rm
at
io
n
 a
n
d
 r
em
in
d
er
s,
 
si
m
p
lif
yi
n
g 
b
eh
av
io
u
r 
re
q
u
ir
ed
, p
ra
ct
ic
in
g 
o
n
go
in
g 
as
se
ss
m
en
t,
 
co
u
n
se
lli
n
g,
 s
el
f-
m
o
n
it
o
ri
n
g 
an
d
 p
ro
vi
d
in
g 
re
in
fo
rc
em
en
ts
. 
In
te
rv
en
ti
o
n
 w
ill
 u
ti
lis
e 
co
m
b
in
at
io
n
 o
f 
st
ra
te
gi
es
:  
in
fo
rm
at
io
n
 p
ro
vi
si
o
n
, t
o
o
ls
 
fo
r 
se
lf
-m
o
n
it
o
ri
n
g,
 r
em
in
d
er
 e
m
ai
ls
 
Fo
cu
s 
gr
o
u
p
  
P
ro
vi
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e 
to
 f
ac
ili
ta
te
 
ad
h
er
en
ce
.  
 
In
fo
 p
ag
es
 –
 h
o
w
 t
o
 s
el
f-
m
o
n
it
o
r 
re
co
gn
is
in
g 
d
et
er
io
ra
ti
n
g 
sy
m
p
to
m
s 
331
 C
o
m
p
o
n
en
t:
 I
n
fo
 p
ag
e 
- 
ch
al
le
n
ge
 a
tt
it
u
d
e 
(d
en
ia
l)
 a
n
d
 il
lu
st
ra
te
 b
e
n
e
fi
ts
 o
f 
ac
ce
p
ti
n
g 
d
ia
gn
o
si
s,
 a
n
d
 t
ak
in
g 
m
ed
ic
at
io
n
s.
 U
si
n
g 
q
u
o
te
s 
w
h
er
e 
ap
p
lic
ab
le
. 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
ea
tu
re
 o
f 
w
e
b
si
te
. 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
M
o
re
 h
o
lis
ti
c 
ap
p
ro
ac
h
 t
o
 a
ct
io
n
s 
p
la
n
s 
– 
‘li
vi
n
g 
w
it
h
 a
st
h
m
a 
p
la
n
’.[
10
, 1
1
] 
R
e
la
te
s 
to
 t
o
n
e 
o
f 
th
e 
in
te
rv
en
ti
o
n
 –
 m
ak
e 
re
le
va
n
t 
to
 u
se
r.
 D
is
cu
ss
 b
en
ef
it
s 
in
 
te
rm
s 
o
f 
b
en
ef
ic
ia
l i
m
p
ac
t 
o
n
 li
fe
, f
am
ily
, r
at
h
er
 t
h
an
 m
ed
ic
al
 is
su
es
 s
u
ch
 a
s 
h
o
sp
it
al
is
at
io
n
s.
  
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
  –
 k
ey
 
co
m
p
o
n
en
ts
 o
f 
su
cc
es
sf
u
l 
as
th
m
a 
ed
u
ca
ti
o
n
 
p
ro
gr
am
m
e.
[1
] 
 
D
is
cu
ss
io
n
 o
f 
ex
p
ec
ta
ti
o
n
s 
Ex
p
la
in
 c
an
 a
im
 f
o
r 
m
in
im
u
m
 s
ym
p
to
m
s,
 a
n
d
 m
in
im
al
 im
p
ac
t 
o
n
 d
ay
 t
o
 d
ay
 
lif
e
, p
ro
vi
d
e 
sa
m
p
le
 ‘g
o
al
s’
 f
o
r 
p
at
ie
n
ts
 t
o
 s
el
ec
t.
 P
ro
vi
d
e 
A
A
P
s 
to
 f
ac
ili
ta
te
 g
o
al
 
ac
h
ie
ve
m
en
t 
 
P
re
ve
n
ti
o
n
 o
f 
sy
m
p
to
m
s 
an
d
 a
tt
ac
ks
 
In
fo
 il
lu
st
ra
ti
n
g 
ri
sk
s 
o
f 
p
o
o
r 
ad
h
er
en
ce
 o
n
 s
ym
p
to
m
s 
an
d
 e
xa
ce
rb
at
io
n
 r
is
k.
 
 
A
cc
ep
ta
n
ce
 t
h
is
 is
 c
o
n
ti
n
u
in
g 
p
ro
ce
ss
es
 
 
En
co
u
ra
ge
 a
cc
ep
ta
n
ce
 o
f 
d
ia
gn
o
si
s 
b
y 
ill
u
st
ra
ti
n
g 
b
en
ef
it
s 
o
f 
ta
ki
n
g 
m
ed
s 
to
 
Q
O
L,
 a
ct
iv
it
ie
s,
 g
en
er
al
 li
fe
. 
 
Ex
p
re
ss
io
n
 o
f 
fe
ar
s 
an
d
 c
o
n
ce
rn
s 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
fe
ar
s 
an
d
 c
o
n
ce
rn
s 
fr
o
m
 li
te
ra
tu
re
 a
n
d
 f
o
cu
s 
gr
o
u
p
s 
w
h
ic
h
 
u
se
r 
m
ay
 id
en
ti
fy
 w
it
h
.  
U
se
 o
f 
q
u
o
te
s 
an
d
 in
fo
 t
o
 c
h
al
le
n
ge
 n
eg
at
iv
e 
b
el
ie
fs
 o
r 
at
ti
tu
d
es
, p
ar
ti
cu
la
rl
y 
ar
o
u
n
d
 f
ea
rs
 a
n
d
 c
o
n
ce
rn
s 
ab
o
u
t 
m
ed
ic
at
io
n
s.
 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
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2
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1
. 
A
n
 in
d
iv
id
u
al
’s
 b
el
ie
fs
 a
b
o
u
t 
th
e 
va
lu
e 
o
f 
th
e 
tr
ea
tm
en
t 
(i
.e
. 
lik
el
y 
ri
sk
s,
 b
en
ef
it
s 
an
d
 e
ff
ic
ac
y)
 a
n
d
 t
h
ei
r 
co
n
fi
d
en
ce
 t
h
at
 
p
ra
ct
ic
al
 b
ar
ri
er
s 
to
 a
d
h
er
en
ce
 c
an
 b
e 
o
ve
rc
o
m
e 
ar
e 
al
so
 
m
ea
n
in
gf
u
l i
n
 in
fl
u
en
ci
n
g 
m
o
ti
va
ti
o
n
 t
o
 a
d
h
er
e.
 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
id
en
ti
fi
ed
 b
ar
ri
er
s 
fr
o
m
 li
te
ra
tu
re
 t
o
 h
el
p
 u
se
r 
id
en
ti
fy
 a
n
y 
re
le
va
n
t 
to
 s
el
f.
  L
is
t 
p
ro
vi
d
ed
 in
 f
ig
u
re
 4
.1
-4
 G
IN
A
 g
u
id
el
in
es
[1
] 
p
ag
e 
an
d
 
p
o
te
n
ti
al
 s
tr
at
eg
ie
s 
to
 o
ve
rc
o
m
e.
  E
.g
. i
f 
re
co
gn
is
e 
a 
co
m
p
lic
at
ed
 r
eg
im
e 
co
n
tr
ib
u
ti
n
g 
th
en
 e
n
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
Q
u
o
te
s 
ill
u
st
ra
ti
n
g 
p
o
si
ti
ve
 e
xp
er
ie
n
ce
 o
f 
p
at
ie
n
ts
 w
h
o
 s
ta
rt
ed
 t
ak
in
g 
m
ed
ic
at
io
n
 a
n
d
 t
h
en
 f
el
t 
b
et
te
r 
fo
r 
ex
am
p
le
, a
n
d
 e
xa
m
p
le
s 
o
f 
h
o
w
 b
ar
ri
er
s 
to
 
ad
h
er
en
ce
 c
an
 b
e 
o
ve
rc
o
m
e.
 
In
d
iv
id
u
al
s 
w
h
o
 b
el
ie
ve
 t
h
at
 c
o
n
se
q
u
en
ce
s 
o
f 
n
o
n
-a
d
h
er
en
ce
 
ar
e
 s
ev
er
e 
ar
e 
m
o
re
 li
ke
ly
 t
o
 b
e 
ad
h
er
en
t 
th
an
 t
h
o
se
 w
h
o
 
b
el
ie
ve
 t
h
at
 c
o
n
se
q
u
en
ce
s 
le
ss
 s
er
io
u
s,
 a
n
d
 t
h
at
 lo
ss
 f
ra
m
in
g 
m
es
sa
ge
s 
ar
e 
sl
ig
h
tl
y 
m
o
re
 e
ff
ec
ti
ve
 t
h
an
 g
ai
n
-f
ra
m
ed
 
m
es
sa
ge
s.
 (
H
o
w
ev
e
r,
 e
vi
d
en
ce
 t
h
at
 w
h
en
 p
re
ve
n
ta
ti
ve
 
b
eh
av
io
u
rs
 a
re
 t
h
e 
ta
rg
et
 , 
as
 h
er
e,
 g
ai
n
 f
ra
m
in
g 
m
o
re
 
ef
fe
ct
iv
e.
)[
12
] 
In
fo
rm
at
io
n
 w
ill
 b
e 
p
re
se
n
te
d
 t
o
 p
ro
m
o
te
 t
h
e 
co
n
ti
n
u
at
io
n
 o
f 
a 
h
ea
lt
h
y 
sy
m
p
to
m
 f
re
e 
lif
e,
 r
at
h
er
 t
h
an
 t
h
e 
th
re
at
 o
f 
e.
g.
 h
o
sp
it
al
is
at
io
n
 t
o
 e
n
co
u
ra
ge
 
ad
h
er
en
ce
. T
h
is
 r
el
at
es
 t
o
 g
en
er
al
 t
o
n
e 
o
f 
in
te
rv
en
ti
o
n
 m
es
sa
ge
. 
Fo
cu
s 
gr
o
u
p
  
Ta
ki
n
g 
in
h
al
er
 is
 a
d
m
is
si
o
n
 t
o
 in
d
iv
id
u
al
 t
h
at
 t
h
ey
 h
av
e
 a
st
h
m
a.
   
En
co
u
ra
ge
 a
cc
ep
ta
n
ce
 o
f 
d
ia
gn
o
si
s 
b
y 
ill
u
st
ra
ti
n
g 
b
en
ef
it
s 
o
f 
ta
ki
n
g 
m
ed
s 
to
 
th
ei
r 
Q
O
L,
 a
ct
iv
it
ie
s 
an
d
 g
en
er
al
 li
fe
. 
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 C
o
m
p
o
n
en
t:
  I
n
fo
 –
 c
o
m
m
o
n
 b
ar
ri
er
s 
to
 a
d
h
er
en
ce
 a
n
d
 s
u
gg
es
ti
o
n
s 
to
 o
ve
rc
o
m
e
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
ea
tu
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
H
av
in
g 
th
e 
sa
m
e 
ty
p
e 
o
f 
in
h
al
er
 f
o
r 
re
lie
ve
r 
an
d
 p
re
ve
n
te
r 
im
p
ro
ve
s 
o
u
tc
o
m
es
 o
f 
as
th
m
a 
co
n
tr
o
l a
n
d
 e
xa
ce
rb
at
io
n
 
ra
te
.[
13
] 
H
e
lp
 p
at
ie
n
ts
 t
o
 id
en
ti
fy
 b
ar
ri
er
s 
to
 t
ak
in
g 
m
ed
s 
an
d
 if
 c
o
m
p
lic
at
ed
 r
eg
im
e 
co
n
tr
ib
u
ti
n
g 
th
en
 e
n
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
01
2
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1
. 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
m
u
st
 h
av
e
 t
h
e 
to
o
ls
 a
n
d
 s
tr
at
eg
ie
s 
n
ec
es
sa
ry
 a
n
d
 m
u
st
 h
av
e 
th
e 
ca
p
ac
it
y 
to
 o
ve
rc
o
m
e 
 b
ar
ri
e
rs
 t
o
 
ad
h
er
en
ce
 –
 s
o
 im
p
o
rt
an
t 
ta
sk
 f
o
r 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
 is
 h
el
p
 
p
at
ie
n
t 
id
en
ti
fy
 a
n
d
 o
ve
rc
o
m
e 
b
ar
ri
er
s 
to
 a
d
h
er
en
ce
. 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
id
en
ti
fi
ed
 b
ar
ri
er
s 
fr
o
m
 li
te
ra
tu
re
 t
o
 h
el
p
 u
se
r 
id
en
ti
fy
 a
n
y 
re
le
va
n
t 
to
 s
el
f.
  E
.g
. i
f 
re
co
gn
is
e 
a 
co
m
p
lic
at
ed
 r
e
gi
m
e 
co
n
tr
ib
u
ti
n
g 
th
en
 
en
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
A
 c
o
m
p
le
x 
tr
ea
tm
en
t 
re
gi
m
e 
is
 o
n
e 
o
f 
th
e 
m
o
st
 c
o
n
si
st
en
t 
b
ar
ri
er
s 
to
 s
u
cc
es
sf
u
l a
d
h
er
en
ce
. 
H
e
lp
 p
at
ie
n
ts
 t
o
 id
en
ti
fy
 b
ar
ri
er
s 
to
 t
ak
in
g 
m
ed
. I
f 
co
m
p
lic
at
ed
 r
eg
im
e 
co
n
tr
ib
u
ti
n
g 
th
en
 e
n
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
m
u
st
 h
av
e
 t
h
e 
to
o
ls
 a
n
d
 s
tr
at
eg
ie
s 
n
ec
es
sa
ry
 a
n
d
 m
u
st
 h
av
e 
th
e 
ca
p
ac
it
y 
to
 o
ve
rc
o
m
e 
 b
ar
ri
er
s 
to
 
ad
h
er
en
ce
 –
 s
o
 im
p
o
rt
an
t 
ta
sk
 f
o
r 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
 is
 h
el
p
 
p
at
ie
n
t 
id
en
ti
fy
 a
n
d
 o
ve
rc
o
m
e
 b
ar
ri
er
s 
to
 a
d
h
er
en
ce
. 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
id
en
ti
fi
ed
 b
ar
ri
er
s 
fr
o
m
 li
te
ra
tu
re
 t
o
 h
el
p
 u
se
r 
id
en
ti
fy
 a
n
y 
re
le
va
n
t 
to
 s
el
f.
  E
.g
. i
f 
re
co
gn
is
e 
a 
co
m
p
lic
at
ed
 r
eg
im
e 
co
n
tr
ib
u
ti
n
g 
th
en
 
en
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
A
n
 in
d
iv
id
u
al
’s
 b
el
ie
fs
 a
b
o
u
t 
th
e 
va
lu
e 
o
f 
th
e 
tr
ea
tm
en
t 
(i
.e
. 
lik
el
y 
ri
sk
s,
 b
en
ef
it
s 
an
d
 e
ff
ic
ac
y)
 a
n
d
 t
h
ei
r 
co
n
fi
d
en
ce
 t
h
at
 
p
ra
ct
ic
al
 b
ar
ri
er
s 
to
 a
d
h
er
en
ce
 c
an
 b
e 
o
ve
rc
o
m
e 
ar
e 
al
so
 
m
ea
n
in
gf
u
l i
n
 in
fl
u
en
ci
n
g 
m
o
ti
va
ti
o
n
 t
o
 a
d
h
er
e.
 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
id
en
ti
fi
ed
 b
ar
ri
er
s 
fr
o
m
 li
te
ra
tu
re
 t
o
 h
el
p
 u
se
r 
id
en
ti
fy
 a
n
y 
re
le
va
n
t 
to
 s
el
f.
  L
is
t 
p
ro
vi
d
ed
 in
 f
ig
u
re
 4
.1
-4
 G
IN
A
 g
u
id
el
in
es
[1
] 
p
ag
e 
an
d
 
p
o
te
n
ti
al
 s
tr
at
eg
ie
s 
to
 o
ve
rc
o
m
e.
  E
.g
. i
f 
re
co
gn
is
e 
a 
co
m
p
lic
at
ed
 r
eg
im
e 
co
n
tr
ib
u
ti
n
g 
th
en
 e
n
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
Fo
cu
s 
gr
o
u
p
  
P
ro
b
le
m
s 
w
it
h
 m
ed
ic
at
io
n
s 
(s
id
e
-e
ff
ec
ts
/i
n
h
al
er
 t
ec
h
n
iq
u
e)
 a
s 
a 
b
ar
ri
er
 t
o
 a
d
h
er
en
ce
 c
o
u
ld
 b
e 
o
ve
rc
o
m
e 
b
y 
ac
kn
o
w
le
d
gi
n
g 
p
o
te
n
ti
al
 is
su
es
 w
it
h
 a
d
vi
ce
 a
b
o
u
t 
al
te
rn
at
iv
es
.  
 
P
ro
vi
d
e 
ex
am
p
le
s 
o
f 
id
en
ti
fi
ed
 b
ar
ri
er
s 
to
 a
d
h
er
en
ce
 f
ro
m
 li
te
ra
tu
re
 t
o
 h
el
p
 
u
se
r 
id
en
ti
fy
 a
n
y 
re
le
va
n
t 
to
 s
el
f,
 a
n
d
 p
o
te
n
ti
al
 s
tr
at
eg
ie
s 
to
 o
ve
rc
o
m
e.
 
  C
o
m
p
o
n
en
t:
   
P
ro
vi
d
e 
lin
ks
 t
o
 r
el
ev
an
t 
w
eb
si
te
s 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
01
2
; 6
(1
):
74
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1
. 
M
en
ta
l h
ea
lt
h
 is
su
es
 r
ep
re
se
n
t 
an
o
th
er
 c
o
m
m
o
n
 b
ar
ri
er
 t
o
 
su
cc
es
sf
u
l a
d
h
er
en
ce
, a
n
d
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
s 
sh
o
u
ld
 a
ss
es
s 
fo
r 
th
e 
p
re
se
n
ce
 o
f 
su
ch
 is
su
es
 
P
o
in
t 
o
u
t 
th
is
 c
an
 b
e 
a 
b
ar
ri
er
 a
n
d
 p
ro
vi
d
e 
lin
ks
 t
o
 r
el
ev
an
t 
w
e
b
si
te
s 
e.
g 
w
w
w
.g
la
sg
o
w
st
ep
s.
co
m
 o
r 
ad
vi
ce
 t
o
 d
is
cu
ss
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
   
333
 C
o
m
p
o
n
en
t:
  I
n
fo
 p
ag
e 
– 
 b
en
ef
it
s 
o
f,
 a
n
d
 g
et
ti
n
g 
th
e 
m
o
st
 o
u
t 
o
f,
 t
h
e
 a
n
n
u
al
 r
e
vi
ew
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
. 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
G
o
al
 s
et
ti
n
g 
h
as
 b
ee
n
 a
 c
o
m
p
o
n
en
t 
o
f 
su
cc
es
sf
u
l i
n
te
rv
en
ti
o
n
s 
in
 a
st
h
m
a,
 w
it
h
 p
at
ie
n
t 
ce
n
tr
ed
 g
o
al
s 
d
e
sc
ri
b
ed
.[
1
4]
 
En
co
u
ra
ge
 u
se
r 
to
 c
o
n
si
d
er
 g
o
al
s 
to
 d
is
cu
ss
 a
t 
an
n
u
al
 r
e
vi
ew
. 
G
u
id
ed
 s
el
f-
m
an
ag
e
m
en
t 
w
it
h
 a
st
h
m
a 
p
la
n
 (
in
cl
u
d
in
g 
h
ea
lt
h
 
p
ro
fe
ss
io
n
al
  r
ev
ie
w
 im
p
ro
ve
s 
as
th
m
a 
re
la
te
d
 o
u
tc
o
m
es
.[
6
] 
In
fo
rm
at
io
n
 p
ag
es
 a
b
o
u
t 
ro
le
 o
f 
an
n
u
al
 r
ev
ie
w
. 
Sh
ar
ed
 d
ec
is
io
n
 m
ak
in
g 
 (
in
co
rp
o
ra
ti
n
g 
p
at
ie
n
t 
go
al
s 
an
d
 
p
re
fe
re
n
ce
s 
in
to
 t
h
e 
co
n
su
lt
at
io
n
) 
im
p
ro
ve
d
 a
d
h
er
en
ce
 t
o
 
m
ed
ic
at
io
n
 a
n
d
 c
lin
ic
al
 o
u
tc
o
m
es
.[
15
] 
En
co
u
ra
ge
 u
se
r 
to
 c
o
n
si
d
er
 g
o
al
s 
to
 d
is
cu
ss
 a
t 
an
n
u
al
 r
e
vi
ew
. 
 
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
  –
 k
ey
 
co
m
p
o
n
en
ts
 o
f 
su
cc
es
sf
u
l 
as
th
m
a 
ed
u
ca
ti
o
n
 
p
ro
gr
am
m
e.
[1
] 
 
D
ev
el
o
p
m
en
t 
o
f 
a 
p
ar
tn
er
sh
ip
 b
et
w
ee
n
 p
at
ie
n
t 
an
d
 h
ea
lt
h
 
p
ro
fe
ss
io
n
al
. 
 
Sh
ar
in
g 
o
f 
in
fo
rm
at
io
n
. 
P
ro
vi
d
e 
in
fo
 a
b
o
u
t 
b
en
ef
it
s 
o
f 
at
te
n
d
in
g 
fo
r 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
 r
e
vi
ew
. 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
01
2
; 6
(1
):
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1
. 
A
 c
o
m
p
le
x 
tr
ea
tm
en
t 
re
gi
m
e 
is
 o
n
e 
o
f 
th
e 
m
o
st
 c
o
n
si
st
en
t 
b
ar
ri
er
s 
to
 s
u
cc
es
sf
u
l a
d
h
er
en
ce
. 
H
e
lp
 p
at
ie
n
ts
 t
o
 id
en
ti
fy
 b
ar
ri
er
s 
to
 t
ak
in
g 
m
ed
s.
 If
 c
o
m
p
lic
at
ed
 r
eg
im
e 
co
n
tr
ib
u
ti
n
g 
th
en
 e
n
co
u
ra
ge
 d
is
cu
ss
io
n
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
M
en
ta
l h
ea
lt
h
 is
su
es
 r
ep
re
se
n
t 
an
o
th
er
 c
o
m
m
o
n
 b
ar
ri
er
 t
o
 
su
cc
es
sf
u
l a
d
h
er
en
ce
, a
n
d
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
s 
sh
o
u
ld
 a
ss
es
s 
fo
r 
th
e 
p
re
se
n
ce
 o
f 
su
ch
 is
su
es
 
P
o
in
t 
o
u
t 
th
is
 c
an
 b
e 
a 
b
ar
ri
er
 a
n
d
 p
ro
vi
d
e 
lin
ks
 t
o
 r
el
ev
an
t 
w
e
b
si
te
s 
e.
g 
w
w
w
.g
la
sg
o
w
st
ep
s.
co
m
 w
it
h
 a
d
vi
ce
 t
o
 d
is
cu
ss
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
. 
W
h
en
 in
d
iv
id
u
al
s 
ar
e 
ad
eq
u
at
el
y 
in
fo
rm
ed
, t
h
ey
 a
re
 b
et
te
r 
ab
le
 
to
 s
h
ar
e 
in
 t
h
e 
d
ec
is
io
n
s 
th
at
 a
ff
ec
t 
th
ei
r 
h
ea
lt
h
, a
n
d
 a
re
 m
o
re
 
co
m
m
it
te
d
 t
o
 r
eg
im
es
 t
h
at
 t
h
ey
 h
av
e
 h
ad
 a
 p
ar
t 
in
 c
h
o
o
si
n
g.
 
Se
t 
u
p
 r
em
in
d
er
 e
m
ai
l p
ri
o
r 
to
 d
at
e 
o
f 
d
u
e 
an
n
u
al
 r
ev
ie
w
, s
u
gg
es
ti
n
g 
u
se
r 
vi
si
ts
 
w
eb
si
te
 p
ri
o
r 
to
 a
n
n
u
al
 r
ev
ie
w
.  
In
fo
 a
b
o
u
t 
w
h
at
 t
o
 e
xp
ec
t 
fr
o
m
 t
h
e 
an
n
u
al
 
re
vi
ew
 a
n
d
 h
o
w
 t
o
 g
et
 t
h
e 
m
o
st
 f
ro
m
 it
. 
Fo
cu
s 
gr
o
u
p
  
P
ar
ti
ci
p
an
ts
 k
ee
n
 t
o
 h
av
e 
fa
ce
 t
o
 f
ac
e 
co
n
ta
ct
 a
s 
p
ar
t 
o
f 
th
e 
as
th
m
a 
re
vi
ew
. 
In
fo
rm
at
io
n
 a
b
o
u
t 
ge
tt
in
g 
th
e 
m
o
st
 o
f 
th
e 
an
n
u
al
 r
ev
ie
w
. 
 C
o
m
p
o
n
en
t:
  F
ac
ili
ta
ti
n
g 
re
ca
ll 
- 
 s
el
f 
te
st
 q
u
iz
ze
s 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
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2
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1
. 
P
ro
vi
d
in
g 
in
fo
rm
at
io
n
 t
o
 in
d
iv
id
u
al
s 
is
 e
ss
en
ti
al
, b
u
t 
n
o
t 
su
ff
ic
ie
n
t 
to
 e
n
su
re
 
ad
h
er
en
ce
. M
o
re
 in
fo
rm
at
io
n
 le
ad
s 
to
 im
p
ro
ve
d
 r
ec
al
l (
b
u
t 
p
at
ie
n
ts
 c
an
 
b
ec
o
m
e 
o
ve
rw
h
el
m
ed
) 
an
d
 b
et
te
r 
o
u
tc
o
m
es
 w
h
en
 p
h
ys
ic
ia
n
s 
as
se
ss
 
p
at
ie
n
ts
’ r
ec
al
l. 
P
ro
vi
d
e 
o
p
ti
o
n
al
 s
el
f 
te
st
 q
u
iz
ze
s 
W
h
en
 in
d
iv
id
u
al
s 
u
n
d
er
st
an
d
 c
le
ar
ly
 a
n
d
 r
em
em
b
er
 w
h
at
 t
h
ey
 a
re
 a
sk
ed
 t
o
 
d
o
, t
h
ey
 a
re
 m
u
ch
 m
o
re
 li
ke
ly
 t
o
 d
o
 it
.  
Se
lf
 t
es
t 
q
u
iz
ze
s 
m
ay
 a
id
 r
ec
al
l, 
as
 w
ill
 o
p
ti
o
n
 t
o
 p
ri
n
t 
sp
ec
if
ic
 p
ag
es
 
334
 C
o
m
p
o
n
en
t:
  I
n
fo
 p
ro
vi
d
ed
 m
u
st
 b
e 
co
n
si
st
e
n
t 
w
it
h
 t
h
at
 p
ro
vi
d
e
d
 b
y 
h
ea
lt
h
 c
ar
e
 p
ro
fe
ss
io
n
al
s 
an
d
 r
e
le
va
n
t 
ch
ar
it
ie
s.
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
01
2
; 6
(1
):
74
-9
1
. 
Th
er
e 
is
 e
vi
d
en
ce
 t
h
at
 d
u
ri
n
g 
th
e 
m
ed
ic
al
 v
is
it
 p
h
ys
ic
ia
n
s 
co
n
si
st
en
tl
y 
o
m
it
 c
ri
ti
ca
l e
le
m
en
ts
 o
f 
in
fo
rm
at
io
n
 r
eg
ar
d
in
g 
m
ed
ic
at
io
n
 u
se
, t
h
u
s 
co
n
tr
ib
u
ti
n
g 
to
 n
o
n
-a
d
h
er
en
ce
.  
C
o
n
te
n
t 
o
f 
w
eb
si
te
 t
o
 b
e 
co
n
si
st
en
t 
w
it
h
 g
u
id
el
in
e 
re
co
m
m
en
d
at
io
n
s,
 s
o
 w
ill
 
m
ir
ro
r 
w
h
at
 is
 d
is
cu
ss
ed
 w
it
h
 h
ea
lt
h
 p
ro
fe
ss
io
n
al
s.
 
Fo
cu
s 
gr
o
u
p
  
Le
n
gt
h
 o
f 
ti
m
e 
b
et
w
ee
n
 a
n
n
u
al
 r
ev
ie
w
s 
– 
d
if
fi
cu
lt
 t
o
 r
et
ai
n
 t
h
e 
in
fo
rm
at
io
n
.  
 
P
ro
vi
d
e 
in
fo
 w
h
ic
h
 m
ir
ro
rs
 t
h
at
 d
is
cu
ss
ed
 d
u
ri
n
g 
an
n
u
al
 r
ev
ie
w
, a
n
d
 c
an
 b
e 
re
vi
si
te
d
 b
y 
u
se
r 
at
 a
n
y 
ti
m
e.
 
W
eb
si
te
 t
o
 b
ri
d
ge
 t
h
e 
ga
p
 b
et
w
ee
n
 a
st
h
m
a 
re
vi
ew
s 
b
y 
b
ei
n
g 
so
u
rc
e 
o
f 
in
fo
rm
at
io
n
, a
n
d
 r
em
in
d
er
s 
(e
.g
. h
ay
 f
ev
er
 s
ea
so
n
, f
lu
 
ja
b
 d
u
e)
.  
In
fo
rm
at
io
n
 w
ill
 b
e 
av
ai
la
b
le
 a
t 
al
l t
im
es
 v
ia
 w
eb
si
te
, a
n
d
 w
ill
 m
ir
ro
r 
th
at
 
d
is
cu
ss
ed
 in
 a
n
n
u
al
 a
st
h
m
a 
re
vi
ew
s 
W
eb
si
te
 b
ei
n
g 
re
co
m
m
en
d
ed
 b
y 
n
u
rs
es
 d
u
ri
n
g 
as
th
m
a 
re
vi
ew
s.
  
In
fo
rm
at
io
n
 w
ill
 m
ir
ro
r 
th
at
 d
is
cu
ss
ed
 in
 a
n
n
u
al
 a
st
h
m
a 
re
vi
ew
s.
 
W
eb
si
te
 in
fo
rm
ed
 b
y 
in
cl
u
si
o
n
 o
f 
p
ra
ct
ic
e 
n
u
rs
es
 d
u
ri
n
g 
fo
cu
s 
gr
o
u
p
s 
st
u
d
ie
s 
 C
o
m
p
o
n
en
t:
  T
ai
lo
re
d
 a
st
h
m
a 
ac
ti
o
n
 p
la
n
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
fi
n
d
 a
ct
io
n
 p
la
n
s 
ar
e
 n
o
t 
re
le
va
n
t 
o
r 
u
se
fu
l t
o
 t
h
ei
r 
o
w
n
 
si
tu
at
io
n
[1
1
] 
Ta
ilo
r 
as
th
m
a 
ac
ti
o
n
 p
la
n
s 
(e
.g
. t
o
 s
ev
er
it
y,
 e
xp
er
ie
n
ce
, g
o
al
s)
 in
 t
h
e 
co
n
te
xt
 o
f 
liv
in
g 
 w
it
h
 a
st
h
m
a 
p
la
n
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
fe
e
l t
h
at
 a
ct
io
n
 p
la
n
s 
ar
e
 n
o
t 
re
le
va
n
t 
to
 t
h
ei
r 
si
tu
at
io
n
.[
5
] 
*T
h
o
se
 d
es
cr
ib
ed
 a
s 
co
m
p
lia
n
t 
(t
ak
in
g 
o
p
ti
m
al
 d
o
se
s 
o
f 
b
o
th
 r
e
lie
ve
r 
an
d
 
p
re
ve
n
te
r)
 f
e
lt
 a
ct
io
n
 p
la
n
s 
d
o
 n
o
t 
ac
kn
o
w
le
d
ge
 t
h
ei
r 
o
w
n
 e
xp
er
ie
n
ce
, 
ir
re
le
va
n
t 
* 
Th
o
se
 d
es
cr
ib
ed
 a
s 
n
o
n
-c
o
m
p
lia
n
t 
fe
lt
 t
h
at
 a
ct
io
n
 p
la
n
s 
co
u
ld
 b
e 
u
se
fu
l 
fo
r 
p
eo
p
le
 w
it
h
 “
m
o
re
 s
er
io
u
s”
 o
r 
“p
ro
p
er
” 
as
th
m
a.
 
 Ta
ilo
r 
ac
ti
o
n
 p
la
n
 b
as
ed
 o
n
 s
ev
er
it
y 
Se
ve
ra
l m
et
a-
an
al
ys
is
 h
av
e 
h
ig
h
lig
h
te
d
 t
h
e 
im
p
o
rt
an
ce
 o
f 
ta
ilo
ri
n
g 
to
 
o
b
ta
in
 o
p
ti
m
u
m
 e
ff
ec
ti
ve
n
es
s 
A
ct
io
n
 p
la
n
s 
ca
n
 b
e 
ta
ilo
re
d
 w
h
er
e 
p
o
ss
ib
le
. 
 C
o
m
p
o
n
en
t:
  D
ia
ry
 t
o
o
l f
o
r 
ke
ep
in
g 
tr
ac
k 
o
f 
m
e
d
ic
at
io
n
 u
se
d
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
Fo
cu
s 
gr
o
u
p
  
D
if
fi
cu
lt
 t
o
 k
ee
p
 t
ra
ck
 o
f 
w
h
at
 m
ed
ic
at
io
n
 h
as
 b
ee
n
 u
se
d
, a
n
d
 n
ee
d
 f
o
r 
o
rd
er
in
g 
m
o
re
. W
o
u
ld
 li
ke
 m
ea
n
s 
to
 t
ra
ck
 m
ed
ic
at
io
n
 u
se
, p
ar
ti
cu
la
rl
y 
re
lie
ve
r 
m
ed
ic
at
io
n
. 
P
ro
vi
d
e 
a 
d
ia
ry
 t
o
o
l f
o
r 
ke
e
p
in
g 
tr
ac
k 
o
f 
m
ed
ic
at
io
n
 u
se
. 
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 C
o
m
p
o
n
en
t:
  T
o
o
l f
o
r 
m
o
n
it
o
ri
n
g 
e
.g
. A
C
T 
o
r 
A
C
Q
 o
r 
P
EF
 d
ia
ry
/c
al
cu
la
to
r 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
ea
tu
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
o
ve
re
st
im
at
e 
th
ei
r 
co
n
tr
o
l a
n
d
 t
o
le
ra
te
 
u
n
n
ec
es
sa
ry
 s
ym
p
to
m
s[
16
]:
  
P
ro
vi
d
e 
to
o
l t
o
 a
ss
es
s 
co
n
tr
o
l/
sy
m
p
to
m
s 
e.
g.
 A
C
T,
 A
C
Q
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
ar
e 
p
o
o
r 
at
 r
ec
o
gn
is
in
g 
d
et
er
io
ra
ti
o
n
 in
 
as
th
m
a 
sy
m
p
to
m
s,
 a
n
d
 t
h
er
ef
o
re
 u
n
ab
le
 t
o
 a
ct
 a
p
p
ro
p
ri
at
el
y.
[4
] 
P
ro
vi
d
e 
to
o
ls
 f
o
r 
se
lf
-m
o
n
it
o
ri
n
g 
e.
g.
 A
C
T,
 A
C
Q
 w
it
h
 r
es
u
lt
an
t 
ac
ti
o
n
 p
la
n
s 
to
 
en
su
re
 a
p
p
ro
p
ri
at
e 
ac
ti
o
n
 t
ak
en
. 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
al
te
r 
m
ed
ic
at
io
n
s 
in
ap
p
ro
p
ri
at
el
y 
in
 
re
sp
o
n
se
 t
o
 a
 p
er
ce
iv
e
d
 d
et
er
io
ra
ti
o
n
 in
 s
ym
p
to
m
s.
[1
7
] 
To
o
l t
o
 a
id
 a
ss
es
sm
en
t 
o
f 
cu
rr
en
t 
co
n
tr
o
l e
it
h
er
 b
y 
P
EF
 o
r 
sy
m
p
to
m
 s
co
re
 
Se
lf
-m
o
n
it
o
ri
n
g 
in
 o
rd
er
 t
o
 r
ec
o
gn
is
e 
lo
ss
 o
f 
as
th
m
a 
co
n
tr
o
l i
s 
a 
gr
ad
e 
A
 r
ec
o
m
m
en
d
at
io
n
 w
it
h
in
 t
h
e 
B
TS
/S
IG
N
 g
u
id
el
in
es
.[
8
] 
  
 In
fo
 a
b
o
u
t 
h
o
w
 t
o
 m
o
n
it
o
r 
se
lf
 f
o
r 
d
et
er
io
ra
ti
o
n
 in
 s
ym
p
to
m
s 
To
o
l t
o
 u
se
 t
o
 a
ss
es
s 
cu
rr
en
t 
co
n
tr
o
l e
it
h
er
 s
ym
p
to
m
 s
co
re
 o
r 
P
EF
 
W
ee
kl
y 
m
o
n
it
o
ri
n
g 
m
ay
 b
e 
su
ff
ic
ie
n
t 
in
 t
h
o
se
 w
it
h
 w
el
l o
r 
p
ar
tl
y 
co
n
tr
o
lle
d
 a
st
h
m
a,
 a
n
d
 t
h
at
 t
h
is
 c
o
u
ld
 s
af
el
y 
b
ec
o
m
e 
le
ss
 
fr
eq
u
en
t 
o
n
ce
 g
o
o
d
 c
o
n
tr
o
l i
s 
ac
h
ie
ve
d
.[
9
] 
In
fo
 a
b
o
u
t 
h
o
w
 t
o
 m
o
n
it
o
r 
se
lf
 f
o
r 
d
et
er
io
ra
ti
o
n
 i.
e.
 s
ym
p
to
m
s 
o
r 
vi
a 
P
EF
 
m
o
n
it
o
ri
n
g,
 a
n
d
 h
o
w
 o
ft
en
 t
o
 m
o
n
it
o
r.
 
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
 [
1
] 
 
Si
gn
s 
th
at
 s
u
gg
es
t 
as
th
m
a 
is
 w
o
rs
en
in
g,
 a
n
d
 a
ct
io
n
s 
to
 t
ak
e 
 
M
o
n
it
o
ri
n
g 
co
n
tr
o
l  
H
o
w
 a
n
d
 w
h
en
 t
o
 s
ee
k 
m
ed
ic
al
 a
tt
en
ti
o
n
 
P
ro
vi
si
o
n
 o
f 
to
o
ls
 t
o
 f
ac
ili
ta
te
 s
el
f-
m
o
n
it
o
ri
n
g.
 
 
P
re
ve
n
ti
o
n
 o
f 
sy
m
p
to
m
s 
an
d
 a
tt
ac
ks
  
To
o
l t
o
 e
st
ab
lis
h
 c
u
rr
en
t 
le
ve
l o
f 
co
n
tr
o
l, 
an
d
 a
d
vi
ce
 o
n
 a
ct
io
n
 t
o
 t
ak
e.
  
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
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2
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1
. 
M
u
lt
if
ac
et
ed
 a
p
p
ro
ac
h
es
 w
o
rk
 b
es
t 
in
vo
lv
in
g 
co
m
b
in
at
io
n
s 
o
f 
st
ra
te
gi
es
 s
u
ch
 a
s 
p
ro
vi
d
in
g 
in
fo
rm
at
io
n
 a
n
d
 r
em
in
d
er
s,
 
si
m
p
lif
yi
n
g 
b
eh
av
io
u
r 
re
q
u
ir
ed
, p
ra
ct
ic
in
g 
o
n
go
in
g 
as
se
ss
m
en
t,
 
co
u
n
se
lli
n
g,
 s
el
f-
m
o
n
it
o
ri
n
g 
an
d
 p
ro
vi
d
in
g 
re
in
fo
rc
em
en
ts
. 
In
te
rv
en
ti
o
n
 w
ill
 u
ti
lis
e 
co
m
b
in
at
io
n
 o
f 
st
ra
te
gi
es
:  
in
fo
rm
at
io
n
 p
ro
vi
si
o
n
, t
o
o
ls
 
fo
r 
se
lf
-m
o
n
it
o
ri
n
g,
 r
em
in
d
er
 e
m
ai
ls
 
Fo
cu
s 
gr
o
u
p
  
N
o
t 
b
ei
n
g 
p
re
p
ar
ed
 f
o
r 
fl
ar
e 
– 
ei
th
er
 u
n
ex
p
ec
te
d
 w
o
rs
en
in
g 
o
f 
sy
m
p
to
m
s,
 o
r 
fo
r 
ti
m
e 
o
f 
ye
ar
 w
h
en
 s
ym
p
to
m
s 
re
gu
la
rl
y 
m
o
re
 
p
ro
b
le
m
at
ic
.  
P
ro
vi
d
e 
to
o
l t
o
 e
st
ab
lis
h
 if
 c
o
n
tr
o
l i
s 
p
o
o
r 
e
.g
. A
C
T,
 A
C
Q
 
U
se
 o
f 
re
m
in
d
er
 e
m
ai
ls
 e
.g
. i
n
 s
p
ri
n
g 
in
 c
as
e 
w
o
rs
en
s 
w
it
h
 p
o
lle
n
. 
P
ro
vi
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e 
to
 f
ac
ili
ta
te
 
ad
h
er
en
ce
.  
 
In
fo
 p
ag
es
 –
 h
o
w
 t
o
 s
el
f-
m
o
n
it
o
r 
re
co
gn
is
in
g 
d
et
er
io
ra
ti
n
g 
sy
m
p
to
m
s,
 h
o
w
 t
o
 
u
se
 A
A
P
s 
an
d
 b
en
ef
it
s 
o
f 
u
si
n
g 
th
em
. H
o
w
 t
o
 r
ec
o
gn
is
e 
b
ar
ri
er
s 
to
 a
d
h
er
en
ce
. 
To
o
ls
 –
 t
o
 m
o
n
it
o
r 
se
lf
 e
it
h
er
 w
it
h
 s
ym
p
to
m
s 
(A
C
Q
 o
r 
A
C
T)
 o
r 
vi
a 
P
EF
( 
vi
a 
ca
lc
u
la
to
r 
o
r 
d
ia
ry
) 
 T
o
o
ls
 t
o
 p
ro
m
o
te
 a
d
h
er
en
ce
 e
.g
. u
si
n
g 
go
al
 s
et
ti
n
g 
A
A
P
. 
 C
o
m
p
o
n
en
t:
  D
ia
ry
 t
o
o
l f
o
r 
ke
ep
in
g 
tr
ac
k 
o
f 
m
e
d
ic
at
io
n
 u
se
d
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
Fo
cu
s 
gr
o
u
p
  
D
if
fi
cu
lt
 t
o
 k
ee
p
 t
ra
ck
 o
f 
w
h
at
 m
ed
ic
at
io
n
 h
as
 b
ee
n
 u
se
d
, a
n
d
 n
ee
d
 f
o
r 
o
rd
er
in
g 
m
o
re
. W
o
u
ld
 li
ke
 t
ra
ck
er
, p
ar
ti
cu
la
rl
y 
re
lie
ve
r 
m
ed
ic
at
io
n
. 
P
ro
vi
d
e 
a 
d
ia
ry
 t
o
o
l f
o
r 
ke
e
p
in
g 
tr
ac
k 
o
f 
m
ed
ic
at
io
n
 u
se
. 
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 C
o
m
p
o
n
en
t:
  E
m
ai
l r
em
in
d
er
s 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
ea
tu
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
G
u
id
ed
 s
el
f-
m
an
ag
e
m
en
t 
w
it
h
 a
st
h
m
a 
p
la
n
 (
in
cl
u
d
in
g 
h
ea
lt
h
 
p
ro
fe
ss
io
n
al
  r
ev
ie
w
 im
p
ro
ve
s 
as
th
m
a 
re
la
te
d
 o
u
tc
o
m
es
.[
6
] 
Em
ai
l r
em
in
d
er
s 
ab
o
u
t 
at
te
n
d
in
g 
fo
r 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
 r
ev
ie
w
 
Sh
ar
ed
 d
ec
is
io
n
 m
ak
in
g 
 (
in
co
rp
o
ra
ti
n
g 
p
at
ie
n
t 
go
al
s 
an
d
 
p
re
fe
re
n
ce
s 
in
to
 t
h
e 
co
n
su
lt
at
io
n
) 
im
p
ro
ve
d
 a
d
h
er
en
ce
 t
o
 
m
ed
ic
at
io
n
 a
n
d
 c
lin
ic
al
 o
u
tc
o
m
es
.[
15
] 
Em
ai
l r
em
in
d
er
s 
to
 e
n
co
u
ra
ge
 v
ie
w
in
g 
o
f 
w
eb
si
te
 p
ri
o
r 
to
 a
n
n
u
al
 r
ev
ie
w
 
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
  –
 k
ey
 
co
m
p
o
n
en
ts
 o
f 
su
cc
es
sf
u
l 
as
th
m
a 
ed
u
ca
ti
o
n
 
p
ro
gr
am
m
e.
[1
] 
 
D
ev
el
o
p
m
en
t 
o
f 
a 
p
ar
tn
er
sh
ip
 b
et
w
ee
n
 p
at
ie
n
t 
an
d
 h
ea
lt
h
 
p
ro
fe
ss
io
n
al
. 
 
Sh
ar
in
g 
o
f 
in
fo
rm
at
io
n
. 
Em
ai
l r
em
in
d
er
s 
to
 f
ac
ili
ta
te
 a
tt
en
d
an
ce
 a
t 
re
vi
ew
 
 
P
er
so
n
 t
h
en
 r
eq
u
ir
es
 r
eg
u
la
r 
su
p
er
vi
si
o
n
, r
ev
is
io
n
, r
ew
ar
d
, 
re
in
fo
rc
em
en
t 
O
cc
as
io
n
al
 e
m
ai
l r
em
in
d
er
s 
to
 t
h
in
k 
ab
o
u
t 
re
ce
n
t 
co
n
tr
o
l e
.g
 R
C
P
 3
 q
u
es
ti
o
n
s,
 
if
 h
av
en
’t
 lo
gg
ed
 o
n
 f
o
r 
a 
se
t 
ti
m
e 
p
er
io
d
. ‘
C
o
n
gr
at
u
la
ti
o
n
s’
 m
es
sa
ge
 if
 
co
n
si
st
en
tl
y 
d
em
o
n
st
ra
te
s 
go
o
d
 c
o
n
tr
o
l w
h
en
 u
si
n
g 
as
se
ss
m
en
t 
to
o
l. 
If
 a
ch
ie
ve
 p
re
se
t 
go
al
, t
h
en
 r
ec
ei
ve
 e
m
ai
l o
r 
m
es
sa
ge
 r
ec
o
gn
is
in
g 
th
is
. 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
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2
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1
. 
M
u
lt
if
ac
et
ed
 a
p
p
ro
ac
h
es
 w
o
rk
 b
es
t 
in
vo
lv
in
g 
co
m
b
in
at
io
n
s 
o
f 
st
ra
te
gi
es
 s
u
ch
 a
s 
p
ro
vi
d
in
g 
in
fo
rm
at
io
n
 a
n
d
 r
em
in
d
er
s,
 
si
m
p
lif
yi
n
g 
b
eh
av
io
u
r 
re
q
u
ir
ed
, p
ra
ct
ic
in
g 
o
n
go
in
g 
as
se
ss
m
en
t,
 
co
u
n
se
lli
n
g,
 s
el
f-
m
o
n
it
o
ri
n
g 
an
d
 p
ro
vi
d
in
g 
re
in
fo
rc
em
en
ts
. 
In
te
rv
en
ti
o
n
 w
ill
 u
ti
lis
e 
co
m
b
in
at
io
n
 o
f 
st
ra
te
gi
es
:  
in
fo
rm
at
io
n
 p
ro
vi
si
o
n
, t
o
o
ls
 
fo
r 
se
lf
-m
o
n
it
o
ri
n
g,
 r
em
in
d
er
 e
m
ai
ls
 
It
 is
 c
ru
ci
al
 t
o
 a
ss
es
s,
 a
n
d
 t
o
 r
eg
u
la
rl
y 
tr
ac
k 
th
e 
co
n
ti
n
u
in
g 
ad
h
er
en
ce
 s
ta
tu
s 
o
f 
in
d
iv
id
u
al
 p
at
ie
n
ts
 a
s 
it
 is
 o
n
e 
o
f 
th
e 
b
es
t 
w
ay
s 
to
 e
st
im
at
e 
fu
tu
re
 b
eh
av
io
u
r.
 
O
cc
as
io
n
al
 e
m
ai
l r
em
in
d
er
s 
to
 t
h
in
k 
ab
o
u
t 
re
ce
n
t 
co
n
tr
o
l e
.g
 R
C
P
 3
 q
u
es
ti
o
n
s,
 
if
 h
av
en
’t
 lo
gg
ed
 o
n
 f
o
r 
a 
se
t 
ti
m
e 
p
er
io
d
. 
W
h
en
 in
d
iv
id
u
al
s 
ar
e 
ad
eq
u
at
el
y 
in
fo
rm
ed
, t
h
ey
 a
re
 b
et
te
r 
ab
le
 
to
 s
h
ar
e 
in
 t
h
e 
d
ec
is
io
n
s 
th
at
 a
ff
ec
t 
th
ei
r 
h
ea
lt
h
, a
n
d
 a
re
 m
o
re
 
co
m
m
it
te
d
 t
o
 r
eg
im
es
 t
h
at
 t
h
ey
 h
av
e
 h
ad
 a
 p
ar
t 
in
 c
h
o
o
si
n
g.
 
Se
t 
u
p
 r
em
in
d
er
 e
m
ai
l p
ri
o
r 
to
 d
at
e 
o
f 
d
u
e 
an
n
u
al
 r
ev
ie
w
, s
u
gg
es
ti
n
g 
u
se
r 
vi
si
ts
 
w
eb
si
te
 p
ri
o
r 
to
 a
n
n
u
al
 r
ev
ie
w
. 
Fo
cu
s 
gr
o
u
p
  
N
o
t 
b
ei
n
g 
p
re
p
ar
ed
 f
o
r 
fl
ar
e 
– 
ei
th
er
 u
n
ex
p
ec
te
d
 w
o
rs
en
in
g 
o
f 
sy
m
p
to
m
s,
 o
r 
fo
r 
ti
m
e 
o
f 
ye
ar
 w
h
en
 s
ym
p
to
m
s 
re
gu
la
rl
y 
m
o
re
 
p
ro
b
le
m
at
ic
.  
U
se
 o
f 
re
m
in
d
er
 e
m
ai
ls
 e
.g
. i
n
 s
p
ri
n
g 
in
 c
as
e 
w
o
rs
en
s 
w
it
h
 p
o
lle
n
. 
W
eb
si
te
 t
o
 b
ri
d
ge
 t
h
e 
ga
p
 b
et
w
ee
n
 a
st
h
m
a 
re
vi
ew
s 
b
y 
b
ei
n
g 
so
u
rc
e 
o
f 
in
fo
rm
at
io
n
, a
n
d
 r
em
in
d
er
s 
(e
.g
. h
ay
 f
ev
er
 s
ea
so
n
, f
lu
 
ja
b
 d
u
e)
.  
Em
ai
l r
em
in
d
er
s 
P
ro
vi
d
in
g 
m
ea
n
s 
to
 t
ra
ck
 u
se
 o
f 
m
ed
ic
at
io
n
s,
 o
r 
fl
ag
 u
p
 n
ee
d
 t
o
 
o
rd
er
 m
ed
s 
in
. 
Em
ai
l r
em
in
d
er
s 
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 C
o
m
p
o
n
en
t:
   
M
ak
e 
vi
su
al
ly
 a
p
p
ea
lin
g 
an
d
 a
cc
es
si
b
le
 a
s 
p
o
ss
ib
le
 e
.g
. g
ra
d
e
d
 I
n
fo
, v
id
e
o
s,
 im
ag
e
s,
 o
p
ti
o
n
 t
o
 p
ri
n
t 
p
ag
es
 r
el
ev
an
t 
to
 t
h
e 
in
d
iv
id
u
al
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
es
te
d
 f
ea
tu
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
Im
p
ai
re
d
 li
te
ra
cy
 is
 a
ss
o
ci
at
ed
 w
it
h
 r
ed
u
ce
d
 a
st
h
m
a 
kn
o
w
le
d
ge
 
an
d
 im
p
ro
p
er
 in
h
al
er
 u
se
,[
18
] 
re
d
u
ce
d
 a
u
ra
l l
it
er
ac
y 
is
 
as
so
ci
at
ed
 w
it
h
 p
o
o
re
r 
as
th
m
a 
co
n
tr
o
l m
ea
su
re
d
 b
y 
n
ig
h
ts
 w
it
h
 
sy
m
p
to
m
s.
[1
9
] 
P
ro
vi
d
e 
in
fo
rm
at
io
n
 in
 a
 g
ra
d
ed
 w
ay
, w
h
er
e 
u
se
r 
ca
n
 d
et
er
m
in
e 
d
ep
th
 o
f 
in
fo
rm
at
io
n
 r
e
q
u
ir
ed
.  
U
se
 im
ag
es
, v
id
eo
s.
  
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
 .[
1
] 
 
U
se
 o
f 
in
h
al
er
 d
ev
ic
es
 
 
D
if
fe
re
n
ce
 b
et
w
ee
n
 r
el
ie
ve
rs
 a
n
d
 p
re
ve
n
te
rs
 
In
fo
 t
o
 il
lu
st
ra
te
 d
if
fe
re
n
t 
in
h
al
er
s,
 a
n
d
 in
h
al
er
 t
ec
h
n
iq
u
e,
 c
o
m
b
in
ed
 w
it
h
 
vi
d
eo
s 
d
em
o
n
st
ra
ti
n
g 
te
ch
n
iq
u
e 
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
01
2
; 6
(1
):
74
-9
1
.. 
In
d
iv
id
u
al
s 
ar
e 
o
n
ly
 c
ap
ab
le
 o
f 
d
o
in
g 
w
h
at
 t
h
ey
 c
le
ar
ly
 
u
n
d
er
st
an
d
; u
n
in
te
n
ti
o
n
al
 n
o
n
-a
d
h
er
en
ce
 is
 o
ft
en
 r
o
o
te
d
 in
 
fa
ilu
re
s 
at
 t
h
is
 s
ta
ge
 o
f 
th
e 
p
ro
ce
ss
. 
U
se
r 
ca
n
 d
et
er
m
in
e 
d
ep
th
 o
f 
in
fo
rm
at
io
n
 b
y 
p
re
se
n
ti
n
g 
in
fo
 in
 g
ra
d
ed
 f
o
rm
  
P
ro
vi
d
e 
in
fo
rm
at
io
n
 w
h
ic
h
 h
as
 u
n
d
er
go
n
e 
u
se
r 
re
vi
ew
 (
th
in
k 
al
o
u
d
 s
tu
d
ie
s)
 t
o
 
o
p
ti
m
is
e 
u
se
rs
 a
b
ili
ty
 t
o
 u
n
d
er
st
an
d
 it
. 
Th
er
e 
is
 e
vi
d
en
ce
 t
h
at
 d
u
ri
n
g 
th
e 
m
ed
ic
al
 v
is
it
 p
h
ys
ic
ia
n
s 
co
n
si
st
en
tl
y 
o
m
it
 c
ri
ti
ca
l e
le
m
en
ts
 o
f 
in
fo
rm
at
io
n
 r
eg
ar
d
in
g 
m
ed
ic
at
io
n
 u
se
, t
h
u
s 
co
n
tr
ib
u
ti
n
g 
to
 n
o
n
-a
d
h
er
en
ce
.  
P
ro
vi
d
in
g 
al
te
rn
at
iv
e 
co
m
p
re
h
en
si
ve
 s
o
u
rc
e 
o
f 
in
fo
rm
at
io
n
 a
va
ila
b
le
 2
4
/7
 v
ia
 a
 
w
eb
si
te
. 
Se
ve
ra
l m
et
a-
an
al
ys
is
 h
av
e 
h
ig
h
lig
h
te
d
 t
h
e 
im
p
o
rt
an
ce
 o
f 
ta
ilo
ri
n
g 
to
 o
b
ta
in
 o
p
ti
m
u
m
 e
ff
ec
ti
ve
n
es
s 
U
se
r 
ca
n
 d
et
er
m
in
e 
d
ep
th
 o
f 
in
fo
rm
at
io
n
 b
y 
p
re
se
n
ti
n
g 
in
fo
 in
 g
ra
d
ed
 f
o
rm
. 
P
ro
vi
d
in
g 
in
fo
rm
at
io
n
 t
o
 in
d
iv
id
u
al
s 
is
 e
ss
en
ti
al
, b
u
t 
n
o
t 
su
ff
ic
ie
n
t 
to
 e
n
su
re
 a
d
h
er
en
ce
. M
o
re
 in
fo
rm
at
io
n
 le
ad
s 
to
 
im
p
ro
ve
d
 r
ec
al
l (
b
u
t 
p
at
ie
n
ts
 c
an
 b
ec
o
m
e 
o
ve
rw
h
el
m
ed
) 
an
d
 
b
et
te
r 
o
u
tc
o
m
es
 w
h
en
 p
h
ys
ic
ia
n
s 
as
se
ss
 p
at
ie
n
ts
’ r
ec
al
l. 
P
ro
vi
d
e 
a 
‘p
ri
n
t 
th
is
 p
ag
e’
 b
u
tt
o
n
 s
o
 t
h
at
 u
se
rs
 c
an
 p
ri
n
t 
o
ff
 p
ar
ti
cu
la
r 
p
ag
es
 
th
at
 a
re
 r
el
ev
an
t 
to
 t
h
em
. 
W
h
en
 in
d
iv
id
u
al
s 
u
n
d
er
st
an
d
 c
le
ar
ly
 a
n
d
 r
em
em
b
er
 w
h
at
 t
h
ey
 
ar
e
 a
sk
ed
 t
o
 d
o
, t
h
ey
 a
re
 m
u
ch
 m
o
re
 li
ke
ly
 t
o
 d
o
 it
.  
U
se
r 
ca
n
 d
et
er
m
in
e 
d
ep
th
 o
f 
in
fo
rm
at
io
n
 b
y 
p
re
se
n
ti
n
g 
in
fo
 in
 g
ra
d
ed
 f
o
rm
. 
P
ro
vi
d
e 
in
fo
rm
at
io
n
 w
h
ic
h
 h
as
 u
n
d
er
go
n
e 
u
se
r 
re
vi
ew
 (
th
in
k 
al
o
u
d
 s
tu
d
ie
s)
 t
o
 
o
p
ti
m
is
e 
u
se
rs
 a
b
ili
ty
 t
o
 u
n
d
er
st
an
d
 it
. 
Fo
cu
s 
gr
o
u
p
  
Le
n
gt
h
 o
f 
ti
m
e 
b
et
w
ee
n
 a
n
n
u
al
 r
ev
ie
w
s 
– 
d
if
fi
cu
lt
 t
o
 r
et
ai
n
 t
h
e 
in
fo
rm
at
io
n
.  
 
P
ro
vi
d
e 
in
fo
 w
h
ic
h
 m
ir
ro
rs
 t
h
at
 d
is
cu
ss
ed
 d
u
ri
n
g 
an
n
u
al
 r
ev
ie
w
, a
n
d
 c
an
 b
e 
re
vi
si
te
d
 b
y 
u
se
r 
at
 a
n
y 
ti
m
e.
  ‘
P
ri
n
t 
th
is
 p
ag
e 
o
p
ti
o
n
’ 
St
ag
ge
ri
n
g 
th
e 
av
ai
la
b
le
 in
fo
rm
at
io
n
 t
o
 b
e 
re
le
va
n
t 
as
 p
o
ss
ib
le
 
U
se
r 
ca
n
 d
et
er
m
in
e 
d
ep
th
 o
f 
in
fo
rm
at
io
n
 b
y 
p
re
se
n
ti
n
g 
in
fo
 in
 g
ra
d
ed
 f
o
rm
. 
P
ro
vi
d
e 
in
fo
rm
at
io
n
 w
h
ic
h
 h
as
 u
n
d
er
go
n
e 
u
se
r 
re
vi
ew
 (
th
in
k 
al
o
u
d
 s
tu
d
ie
s)
 t
o
 
o
p
ti
m
is
e 
u
se
rs
 a
b
ili
ty
 t
o
 u
n
d
er
st
an
d
 it
. 
W
eb
si
te
 t
o
 b
ri
d
ge
  g
ap
 b
et
w
ee
n
 a
st
h
m
a 
re
vi
ew
s:
 s
o
u
rc
e 
o
f 
in
fo
rm
at
io
n
, r
em
in
d
er
s 
(e
.g
. h
ay
 f
ev
er
 s
ea
so
n
, f
lu
 ja
b
 d
u
e)
.  
In
fo
rm
at
io
n
 w
ill
 b
e 
av
ai
la
b
le
 a
t 
al
l t
im
es
 v
ia
 w
eb
si
te
, a
n
d
 w
ill
 m
ir
ro
r 
th
at
 
d
is
cu
ss
ed
 in
 a
n
n
u
al
 a
st
h
m
a 
re
vi
ew
s 
M
ak
in
g 
th
e 
in
fo
rm
at
io
n
 f
u
n
 a
n
d
 a
tt
ra
ct
iv
e.
  
P
ro
vi
d
e 
in
fo
rm
at
io
n
 w
h
ic
h
 h
as
 u
n
d
er
go
n
e 
u
se
r 
re
vi
ew
 (
th
in
k 
al
o
u
d
 s
tu
d
ie
s)
 t
o
 
o
p
ti
m
is
e 
u
se
rs
 a
b
ili
ty
 t
o
 u
n
d
er
st
an
d
 it
. 
U
se
 im
ag
es
 a
n
d
 v
id
eo
s 
w
h
er
e 
re
le
va
n
t.
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 C
o
m
p
o
n
en
t:
  A
st
h
m
a 
ac
ti
o
n
 p
la
n
 (
A
A
P
) 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
H
e
al
th
 p
ro
fe
ss
io
n
al
s 
d
o
n
’t
 a
lw
ay
s 
o
ff
er
 a
ct
io
n
 p
la
n
s[
4
, 5
, 2
0
] 
P
ro
vi
d
e 
al
te
rn
at
iv
e 
m
ea
n
s 
o
f 
ac
ce
ss
in
g 
ac
ti
o
n
 p
la
n
 v
ia
 f
re
e
ly
 
av
ai
la
b
le
 w
eb
si
te
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
ar
e 
p
o
o
r 
at
 r
ec
o
gn
is
in
g 
d
et
er
io
ra
ti
o
n
 in
 a
st
h
m
a 
sy
m
p
to
m
s,
 a
n
d
 t
h
er
ef
o
re
 u
n
ab
le
 t
o
 a
ct
 a
p
p
ro
p
ri
at
el
y.
[4
] 
P
ro
vi
d
e 
to
o
ls
 f
o
r 
se
lf
-m
o
n
it
o
ri
n
g 
e.
g.
 A
C
T,
 A
C
Q
 w
it
h
 r
es
u
lt
an
t 
ac
ti
o
n
 p
la
n
s 
to
 e
n
su
re
 a
p
p
ro
p
ri
at
e 
ac
ti
o
n
 t
ak
en
. 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
al
te
r 
m
ed
ic
at
io
n
s 
in
ap
p
ro
p
ri
at
el
y 
in
 r
es
p
o
n
se
 t
o
 a
 
p
er
ce
iv
e
d
 d
et
er
io
ra
ti
o
n
 in
 s
ym
p
to
m
s.
[1
7
] 
P
ro
vi
d
e 
ac
ti
o
n
 p
la
n
 t
o
 g
u
id
e 
m
ed
ic
at
io
n
 a
lt
er
at
io
n
 
 
H
e
al
th
 p
ro
fe
ss
io
n
al
s 
b
el
ie
f 
th
at
 a
ct
io
n
s 
p
la
n
s 
o
n
ly
 s
u
it
ab
le
 f
o
r 
ce
rt
ai
n
 
p
at
ie
n
ts
 –
 e
.g
 w
el
l e
d
u
ca
te
d
 w
it
h
 w
el
l c
o
n
tr
o
lle
d
 a
st
h
m
a.
 [
5
] 
P
ro
vi
d
e 
al
te
rn
at
iv
e 
m
ea
n
s 
o
f 
ac
ce
ss
in
g 
ac
ti
o
n
 p
la
n
 v
ia
 f
re
e
ly
 
av
ai
la
b
le
 w
eb
si
te
 
G
u
id
ed
 s
el
f-
m
an
ag
e
m
en
t 
w
it
h
 a
st
h
m
a 
p
la
n
 (
in
cl
u
d
in
g 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
  
re
vi
ew
 im
p
ro
ve
s 
as
th
m
a 
re
la
te
d
 o
u
tc
o
m
es
.[
6
] 
P
ro
vi
d
e 
ac
ti
o
n
 p
la
n
s 
 
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
  –
 k
ey
 
co
m
p
o
n
en
ts
 o
f 
su
cc
es
sf
u
l 
as
th
m
a 
ed
u
ca
ti
o
n
 
p
ro
gr
am
m
e.
[1
] 
 
M
o
n
it
o
ri
n
g 
co
n
tr
o
l o
f 
as
th
m
a 
 
 
H
o
w
 a
n
d
 w
h
en
 t
o
 s
ee
k 
m
ed
ic
al
 a
tt
en
ti
o
n
 
P
ro
vi
si
o
n
 o
f 
A
A
P
 t
o
 g
u
id
e 
m
ed
ic
at
io
n
 c
h
an
ge
s,
 c
h
an
ge
s 
to
 
m
o
n
it
o
ri
n
g 
fr
eq
u
en
cy
, o
r 
to
 s
u
gg
es
t 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
 r
ev
ie
w
. 
 
P
re
ve
n
ti
o
n
 o
f 
sy
m
p
to
m
s 
an
d
 a
tt
ac
ks
  
To
o
l t
o
 e
st
ab
lis
h
 c
u
rr
en
t 
le
ve
l o
f 
co
n
tr
o
l, 
an
d
 a
d
vi
ce
 o
n
 a
ct
io
n
 t
o
 
ta
ke
.  
 
P
er
so
n
 t
h
en
 r
eq
u
ir
es
 a
 w
ri
tt
en
 a
st
h
m
a 
ac
ti
o
n
 p
la
n
 
P
ro
vi
d
e 
as
th
m
a 
ac
ti
o
n
 p
la
n
s,
 t
h
is
 c
an
 r
e
la
te
 t
o
 m
ed
ic
at
io
n
 c
h
an
ge
s,
 
fr
eq
u
en
cy
 o
f 
se
lf
-m
o
n
it
o
ri
n
g,
 w
h
en
 t
o
 s
ee
k 
in
p
u
t 
fr
o
m
 h
ea
lt
h
 
p
ro
fe
ss
io
n
al
.  
Fo
cu
s 
gr
o
u
p
  
P
ro
vi
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e 
to
 f
ac
ili
ta
te
 a
d
h
er
en
ce
.  
 
To
o
ls
 t
o
 p
ro
m
o
te
 a
d
h
er
en
ce
 e
.g
. u
si
n
g 
go
al
 s
et
ti
n
g 
an
d
 A
A
P
. 
 C
o
m
p
o
n
en
t:
  I
n
fo
 -
en
co
u
ra
ge
 p
o
si
ti
ve
 in
vo
lv
em
e
n
t 
o
f 
fa
m
ily
/f
ri
e
n
d
s 
in
 m
an
ag
e
m
e
n
t 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
R
o
le
 o
f 
so
ci
al
 r
el
at
io
n
sh
ip
s 
ca
n
 n
eg
at
iv
el
y 
im
p
ac
t 
o
n
 p
eo
p
le
 w
it
h
 a
st
h
m
as
 
ab
ili
ty
 t
o
 s
el
f-
m
an
ag
e
, e
.g
. p
er
ce
iv
e
d
 ‘n
ag
gi
n
g’
 f
ro
m
 f
am
ily
 m
em
b
er
s 
to
 
ta
ke
 m
ed
ic
at
io
n
, o
ve
r 
re
ac
ti
o
n
s,
 o
r 
in
d
if
fe
re
n
ce
.[
2
1]
 
P
ro
vi
d
e 
p
ag
e 
ai
m
ed
 a
t 
fa
m
ily
/f
ri
en
d
s 
ab
o
u
t 
h
o
w
 c
an
 s
u
p
p
o
rt
 t
h
e 
p
er
so
n
 w
it
h
 a
st
h
m
a 
to
 m
an
ag
e 
th
ei
r 
as
th
m
a 
as
 w
el
l a
s 
p
o
ss
ib
le
 
P
o
si
ti
ve
 s
o
ci
al
 r
el
at
io
n
sh
ip
s 
e.
g.
  h
el
p
fu
l r
em
in
d
er
s 
to
 t
ak
e 
m
ed
ic
at
io
n
s.
[2
1
] 
P
ro
vi
d
e 
in
fo
 t
o
 il
lu
st
ra
te
 p
o
te
n
ti
al
 b
en
ef
ic
ia
l r
o
le
 o
f 
fa
m
ily
 f
ri
en
d
s,
 
w
it
h
 p
ag
e 
ta
rg
et
ed
 t
o
 f
am
ily
 o
r 
fr
ie
n
d
s.
  
A
d
h
er
en
ce
 r
ev
ie
w
[2
]:
 
D
iM
at
te
o
 M
R
 e
t 
al
.  
H
ea
lt
h
 P
sy
ch
o
lo
g
y 
R
ev
ie
w
 
2
01
2
; 6
(1
):
74
-9
1
. 
C
u
lt
u
ra
l n
o
rm
s,
 f
am
ily
 m
em
b
er
s 
an
d
 f
ri
en
d
s 
al
so
 s
tr
o
n
gl
y 
in
fl
u
en
ce
 
p
at
ie
n
ts
’ d
ec
is
io
n
s 
ab
o
u
t 
h
ea
lt
h
 a
ct
io
n
s 
– 
p
ar
ti
cu
la
rl
y 
th
ro
u
gh
 t
h
ei
r 
go
al
s 
an
d
 in
te
n
ti
o
n
s 
– 
an
d
 a
d
h
er
en
ce
 t
o
 t
re
at
m
en
t 
is
 n
o
 e
xc
ep
ti
o
n
. 
P
ro
vi
d
e 
in
fo
 p
ag
e 
ta
rg
et
ed
 a
t 
fa
m
ily
/f
ri
en
d
s 
to
 e
n
co
u
ra
ge
 p
o
si
ti
ve
 
in
fl
u
en
ce
 o
n
 a
d
h
er
en
ce
. 
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 C
o
m
p
o
n
en
t:
  M
en
u
 o
f 
te
m
p
la
te
 g
o
al
s 
w
it
h
 a
ss
o
ci
at
ed
 a
ct
io
n
 p
la
n
s 
to
 a
ch
ie
ve
 g
o
al
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
G
o
al
 s
et
ti
n
g 
h
as
 b
ee
n
 a
 c
o
m
p
o
n
en
t 
o
f 
su
cc
es
sf
u
l i
n
te
rv
en
ti
o
n
s 
in
 a
st
h
m
a,
 
an
d
 p
at
ie
n
t 
ce
n
tr
ed
 g
o
al
s 
d
ec
ri
b
ed
.[
1
4
] 
P
ro
vi
d
e 
m
en
u
 t
em
p
la
te
 g
o
al
s 
(l
if
e
st
yl
e 
ra
th
er
 t
h
an
 m
ed
ic
at
io
n
) 
P
ro
vi
d
e 
ac
ti
o
n
 p
la
n
s 
to
 f
ac
ili
ta
te
 g
o
al
 a
ch
ie
ve
m
en
t 
( 
n
o
t 
ju
st
 
m
ed
ic
at
io
n
 r
e
la
te
d
, c
o
u
ld
 b
e 
e
xe
rc
is
e,
 s
el
f-
m
o
n
it
o
ri
n
g,
 s
to
p
p
in
g 
sm
o
ki
n
g)
 
M
o
re
 h
o
lis
ti
c 
ap
p
ro
ac
h
 t
o
 a
ct
io
n
s 
p
la
n
s 
– 
‘li
vi
n
g 
w
it
h
 a
st
h
m
a 
p
la
n
’.[
1
0
, 1
1
] 
R
e
la
te
s 
to
 t
o
n
e 
o
f 
th
e 
in
te
rv
en
ti
o
n
 –
  t
em
p
la
te
 g
o
al
s 
p
ro
vi
d
ed
 w
it
h
 
re
le
va
n
t 
ad
vi
ce
 t
o
 a
ch
ie
ve
 g
o
al
 r
el
ev
an
t 
to
 in
d
iv
id
u
al
. 
Sh
ar
ed
 d
ec
is
io
n
 m
ak
in
g 
 (
in
co
rp
o
ra
ti
n
g 
p
at
ie
n
t 
go
al
s 
an
d
 p
re
fe
re
n
ce
s 
in
to
 
th
e 
co
n
su
lt
at
io
n
) 
im
p
ro
ve
d
 a
d
h
er
en
ce
 t
o
 m
ed
ic
at
io
n
 a
n
d
 c
lin
ic
al
 
o
u
tc
o
m
es
.[
1
5
] 
P
ro
vi
d
e 
te
m
p
la
te
 g
o
al
s 
(l
if
es
ty
le
 r
at
h
er
 t
h
an
 m
ed
ic
at
io
n
) 
w
it
h
 a
ss
o
c 
ac
ti
o
n
 p
la
n
s 
to
 h
el
p
 a
ch
ie
ve
 g
o
al
s.
 
Q
u
al
it
at
iv
e 
w
o
rk
 s
h
o
w
s 
th
at
 f
ro
m
 a
 p
at
ie
n
ts
 p
er
sp
ec
ti
ve
 t
h
at
 w
h
ile
 t
h
es
e 
go
al
s[
n
o
 n
ig
h
t 
ti
m
e 
co
u
gh
 e
tc
] 
ar
e 
ac
kn
o
w
le
d
ge
d
 t
h
ey
 a
re
 m
ed
ia
to
ry
 a
n
d
 
p
at
ie
n
ts
 p
re
fe
r 
to
 c
o
n
si
d
er
 e
n
d
 s
ta
te
 li
fe
st
yl
e 
go
al
s 
su
ch
 ‘p
la
yi
n
g 
fo
o
tb
al
l 
ag
ai
n
’ o
r 
h
av
in
g 
‘a
 n
o
rm
al
 li
fe
’.
 [
2
2
] 
Ex
p
la
in
 c
an
 a
im
 f
o
r 
m
in
im
u
m
 s
ym
p
to
m
s,
 a
n
d
 m
in
im
u
m
 im
p
ac
t 
o
f 
d
ay
 t
o
 d
ay
 li
fe
, p
ro
vi
d
e 
sa
m
p
le
 ‘g
o
al
s’
 f
o
r 
p
at
ie
n
ts
 t
o
 s
el
ec
t 
w
h
ic
h
 
ar
e
 r
el
ev
an
t 
to
 o
w
n
 li
fe
, b
as
ed
 o
n
 t
h
is
 q
u
al
it
at
iv
e 
w
o
rk
. 
G
IN
A
 g
u
id
el
in
es
 c
h
ap
te
r 
4
, 
co
m
p
o
n
en
t 
1
  –
 k
ey
 
co
m
p
o
n
en
ts
 o
f 
su
cc
es
sf
u
l 
as
th
m
a 
ed
u
ca
ti
o
n
 
p
ro
gr
am
m
e.
[1
] 
 
D
is
cu
ss
io
n
 o
f 
ex
p
ec
ta
ti
o
n
s 
Ex
p
la
in
 c
an
 a
im
 f
o
r 
m
in
im
u
m
 s
ym
p
to
m
s,
 a
n
d
 m
in
im
al
 im
p
ac
t 
o
n
 
d
ay
 t
o
 d
ay
 li
fe
, p
ro
vi
d
e 
sa
m
p
le
 ‘g
o
al
s’
 f
o
r 
p
at
ie
n
ts
 t
o
 s
el
ec
t.
 P
ro
vi
d
e 
A
A
P
s 
to
 f
ac
ili
ta
te
 g
o
al
 a
ch
ie
ve
m
en
t 
 
Fo
cu
s 
gr
o
u
p
  
P
ro
vi
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
h
o
w
 t
o
 s
el
f-
m
an
ag
e 
to
 f
ac
ili
ta
te
 a
d
h
er
en
ce
.  
 
To
o
ls
 t
o
 p
ro
m
o
te
 a
d
h
er
en
ce
 e
.g
. u
si
n
g 
go
al
 s
et
ti
n
g 
an
d
 A
A
P
 
 C
o
m
p
o
n
en
t:
  T
ai
lo
re
d
 a
st
h
m
a 
ac
ti
o
n
 p
la
n
 
So
u
rc
e 
Fi
n
d
in
g 
re
le
va
n
t 
to
 a
d
h
er
en
ce
 
Su
gg
e
st
e
d
 f
e
at
u
re
 o
f 
w
e
b
si
te
, s
p
ec
if
ic
 t
o
 c
o
m
p
o
n
en
t.
 
A
st
h
m
a 
lit
er
at
u
re
 r
ev
ie
w
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
fi
n
d
 a
ct
io
n
 p
la
n
s 
ar
e
 n
o
t 
re
le
va
n
t 
o
r 
u
se
fu
l t
o
 t
h
ei
r 
o
w
n
 
si
tu
at
io
n
[1
1
] 
Ta
ilo
r 
as
th
m
a 
ac
ti
o
n
 p
la
n
s 
(e
.g
. t
o
 s
ev
er
it
y,
 e
xp
er
ie
n
ce
, g
o
al
s)
 in
 t
h
e 
co
n
te
xt
 o
f 
liv
in
g 
 w
it
h
 a
st
h
m
a 
p
la
n
 
P
eo
p
le
 w
it
h
 a
st
h
m
a 
fe
e
l t
h
at
 a
ct
io
n
 p
la
n
s 
ar
e
 n
o
t 
re
le
va
n
t 
to
 t
h
ei
r 
si
tu
at
io
n
.[
5
] 
*T
h
o
se
 d
es
cr
ib
ed
 a
s 
co
m
p
lia
n
t 
(t
ak
in
g 
o
p
ti
m
al
 d
o
se
s 
o
f 
b
o
th
 
re
lie
ve
r 
an
d
 p
re
ve
n
te
r)
 f
el
t 
ac
ti
o
n
 p
la
n
s 
d
o
 n
o
t 
ac
kn
o
w
le
d
ge
 t
h
ei
r 
o
w
n
 
ex
p
er
ie
n
ce
, i
rr
el
ev
an
t 
* 
Th
o
se
 d
es
cr
ib
ed
 a
s 
n
o
n
 c
o
m
p
lia
n
t 
fe
lt
 t
h
at
 a
ct
io
n
 
p
la
n
s 
co
u
ld
 b
e 
u
se
fu
l f
o
r 
p
eo
p
le
 w
it
h
 “
m
o
re
 s
er
io
u
s”
 o
r 
“p
ro
p
er
” 
as
th
m
a.
 
Ta
ilo
r 
ac
ti
o
n
 p
la
n
 b
as
ed
 o
n
 s
ev
er
it
y 
Se
ve
ra
l m
et
a-
an
al
ys
is
 h
av
e 
h
ig
h
lig
h
te
d
 t
h
e 
im
p
o
rt
an
ce
 o
f 
ta
ilo
ri
n
g 
to
 
o
b
ta
in
 o
p
ti
m
u
m
 e
ff
ec
ti
ve
n
es
s 
A
ct
io
n
 p
la
n
s 
ca
n
 b
e 
ta
ilo
re
d
 w
h
er
e 
p
o
ss
ib
le
. 
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 A
A
P
 –
 A
st
h
m
a 
ac
ti
o
n
 p
la
n
 (
th
is
 c
an
 r
ef
er
 t
o
 a
 p
la
n
 a
d
vi
si
n
g 
ab
o
u
t 
al
te
ri
n
g 
m
ed
ic
at
io
n
s,
 m
o
n
it
o
ri
n
g 
re
gi
m
es
, w
h
en
 t
o
 s
e
e
k 
h
ea
lt
h
 p
ro
fe
ss
io
n
al
 r
ev
ie
w
);
 A
C
Q
 –
 A
st
h
m
a 
co
n
tr
o
l 
q
u
es
ti
o
n
n
ai
re
; A
C
T 
– 
A
st
h
m
a 
C
o
n
tr
o
l T
e
st
; P
EF
 –
 p
ea
k 
ex
p
ir
at
o
ry
 f
lo
w
; R
C
P
 3
Q
 –
 R
o
ya
l C
o
lle
ge
 P
h
ys
ic
ia
n
s 
3
 Q
u
e
st
io
n
s 
(t
o
 a
ss
e
ss
 c
o
n
tr
o
l)
   
 
 R
e
fe
re
n
ce
s 
(I
n
te
rv
e
n
ti
o
n
 P
la
n
n
in
g 
d
o
cu
m
e
n
t,
 a
p
p
e
n
d
ix
 1
2
) 
 1.
 
G
lo
b
al
 S
tr
at
e
gy
 f
o
r 
A
st
h
m
a 
M
an
ag
e
m
e
n
t 
an
d
 P
re
ve
n
ti
o
n
 2
0
1
1
 (
U
p
d
at
e
) 
[h
tt
p
:/
/w
w
w
.g
in
as
th
m
a.
o
rg
/u
p
lo
ad
s/
u
se
rs
/f
ile
s/
G
IN
A
_R
e
p
o
rt
2
0
1
1
_M
ay
4
.p
d
f]
 
2
. 
D
iM
at
te
o
 M
R
, H
as
ka
rd
-Z
o
ln
ie
re
k 
K
B
, M
ar
ti
n
 L
R
: I
m
p
ro
vi
n
g 
p
at
ie
n
t 
ad
h
e
re
n
ce
: 
a 
th
re
e
-f
ac
to
r 
m
o
d
e
l t
o
 g
u
id
e
 p
ra
ct
ic
e
. H
ea
lt
h
 P
sy
ch
ol
 R
ev
 2
0
1
2
, 6
(1
):
7
4
-9
1
. 
3
. 
P
ar
tr
id
ge
 M
R
, D
al
 N
eg
ro
 R
W
, O
liv
ie
ri
 D
: 
U
n
d
e
rs
ta
n
d
in
g 
p
at
ie
n
ts
 w
it
h
 a
st
h
m
a 
an
d
 C
O
P
D
: 
in
si
gh
ts
 f
ro
m
 a
 E
u
ro
p
e
an
 s
tu
d
y
. P
ri
m
 C
a
re
 R
es
p
ir
 J
 2
0
1
1
, 2
0
(3
):
3
1
5
-3
2
3
, 3
1
7 
p
 f
o
llo
w
in
g 
3
2
3
. 
4
. 
D
o
u
gl
as
s 
J,
 A
ro
n
i R
, G
o
em
an
 D
, S
te
w
ar
t 
K
, S
aw
ye
r 
S,
 T
h
ie
n
 F
, A
b
ra
m
so
n
 M
: 
A
 q
u
a
lit
at
iv
e
 s
tu
d
y 
o
f 
a
ct
io
n
 p
la
n
s 
fo
r 
as
th
m
a
. B
M
J 
2
0
0
2
, 3
2
4
(7
3
4
4
):
1
0
0
3
. 
5
. 
Jo
n
es
 A
, P
ill
 R
, A
d
am
s 
S:
 Q
u
a
lit
at
iv
e
 s
tu
d
y 
o
f 
vi
e
w
s 
o
f 
h
e
al
th
 p
ro
fe
ss
io
n
al
s 
an
d
 p
at
ie
n
ts
 o
n
 g
u
id
e
d
 s
e
lf
-m
an
ag
e
m
e
n
t 
p
la
n
s 
fo
r 
as
th
m
a.
 B
M
J 
2
0
0
0
, 3
2
1
(7
2
7
5
):
1
5
0
7
-1
5
1
0
. 
6
. 
G
ib
so
n
 P
G
, P
o
w
el
l H
, W
ils
o
n
 A
, A
b
ra
m
so
n
 M
J,
 H
ay
w
o
o
d
 P
, B
au
m
an
 A
, H
en
sl
ey
 M
J,
 W
al
te
rs
 E
H
, R
o
b
er
ts
 J
J:
 S
e
lf
-m
an
ag
e
m
e
n
t 
e
d
u
ca
ti
o
n
 a
n
d
 r
e
gu
la
r 
p
ra
ct
it
io
n
e
r 
re
vi
e
w
 f
o
r 
ad
u
lt
s 
w
it
h
 a
st
h
m
a
. 
C
o
ch
ra
n
e 
D
a
ta
b
a
se
 o
f 
Sy
st
em
a
ti
c 
R
ev
ie
w
s 
2
0
0
2
(3
):
C
D
0
0
1
1
1
7
. 
7
. 
R
in
g 
N
, M
al
co
lm
 C
, W
yk
e 
S,
 M
ac
gi
lli
vr
ay
 S
, D
ix
o
n
 D
, H
o
sk
in
s 
G
, P
in
n
o
ck
 H
, S
h
ei
kh
 A
: 
P
ro
m
o
ti
n
g 
th
e
 u
se
 o
f 
P
e
rs
o
n
al
 A
st
h
m
a 
A
ct
io
n
 P
la
n
s:
 a
 s
ys
te
m
at
ic
 r
e
vi
e
w
. 
P
ri
m
 C
a
re
 R
es
p
 J
 2
0
0
7
, 1
6
(5
):
2
7
1
-2
8
3
. 
8
. 
B
ri
ti
sh
 T
h
o
ra
ci
c 
So
ci
et
y:
 B
ri
ti
sh
 G
u
id
e
lin
e
 o
n
 t
h
e
 M
an
ag
e
m
e
n
t 
o
f 
A
st
h
m
a,
 u
p
d
at
e
d
 2
0
1
2
. T
h
o
ra
x 
2
0
0
8
, 6
3
:S
u
p
p
l-
1
2
1
. 
9
. 
va
n
 d
er
 M
e
er
 V
, v
an
 S
te
l H
F,
 B
ak
ke
r 
M
J,
 R
o
ld
aa
n
 A
C
, A
ss
en
d
el
ft
 W
J,
 S
te
rk
 P
J,
 R
ab
e 
K
F,
 S
o
n
t 
JK
, G
ro
u
p
 S
S:
 W
e
e
kl
y 
se
lf
-m
o
n
it
o
ri
n
g 
an
d
 t
re
at
m
e
n
t 
ad
ju
st
m
e
n
t 
b
e
n
e
fi
t 
p
at
ie
n
ts
 w
it
h
 p
ar
tl
y 
co
n
tr
o
lle
d
 
an
d
 u
n
co
n
tr
o
lle
d
 a
st
h
m
a:
 a
n
 a
n
al
ys
is
 o
f 
th
e
 S
M
A
SH
IN
G
 s
tu
d
y.
 R
es
p
ir
 R
es
 2
0
1
0
, 1
1
:7
4
. 
1
0
. 
R
in
g 
N
, P
in
n
o
ck
 H
, W
ils
o
n
 C
, H
o
sk
in
s 
G
, J
e
p
so
n
 R
, W
yk
e 
S,
 S
h
ei
kh
 A
: 
A
st
h
m
a 
p
la
n
s:
 U
n
d
e
rs
ta
n
d
in
g 
w
h
at
 w
e
 m
e
an
.  
Li
n
gu
is
ti
c 
an
a
ly
si
s 
o
f 
te
rm
in
o
lo
gy
 a
s 
u
se
d
 in
 p
u
b
lis
h
e
d
 t
e
xt
s.
 P
ri
m
 C
a
re
 R
es
p
 J
 
2
0
1
1
, 2
0
(2
):
1
7
0
-1
7
7
. 
1
1
. 
R
in
g 
N
, J
ep
so
n
 R
, H
o
sk
in
s 
G
, W
ils
o
n
 C
, P
in
n
o
ck
 H
, S
h
ei
kh
 A
, W
yk
e 
S:
 U
n
d
e
rs
ta
n
d
in
g 
w
h
at
 h
e
lp
s 
o
r 
h
in
d
e
rs
 a
st
h
m
a 
ac
ti
o
n
 p
la
n
 u
se
: 
a 
sy
st
e
m
at
ic
 r
e
vi
e
w
 a
n
d
 s
yn
th
e
si
s 
o
f 
th
e
 q
u
al
it
at
iv
e
 li
te
ra
tu
re
. 
P
a
ti
en
t 
Ed
u
c 
C
o
u
n
s 
2
0
1
1
, 8
5(
2
):
e1
3
1
-1
4
3
. 
1
2
. 
P
o
la
k 
L:
 C
o
m
m
u
n
ic
at
in
g 
ri
sk
 t
o
 p
at
ie
n
ts
 a
n
d
 t
h
e
 p
u
b
lic
. B
rJ
 G
en
P
ra
ct
 2
0
1
2
, 6
2
(5
9
8
):
2
4
0
. 
1
3
. 
P
ri
ce
 D
, C
h
ry
st
yn
 H
, K
ap
la
n
 A
, H
au
gh
n
ey
 J
, R
o
m
an
-R
o
d
ri
gu
ez
 M
, B
u
rd
e
n
 A
, C
h
is
h
o
lm
 A
, H
ill
ye
r 
EV
, v
o
n
 Z
J,
 A
li 
M
 e
t 
a
l: 
Ef
fe
ct
iv
e
n
e
ss
 o
f 
sa
m
e
 v
e
rs
u
s 
m
ix
e
d
 a
st
h
m
a 
in
h
al
e
r 
d
e
vi
ce
s:
 a
 r
e
tr
o
sp
e
ct
iv
e
 
o
b
se
rv
at
io
n
a
l s
tu
d
y 
in
 p
ri
m
ar
y 
ca
re
. A
lle
rg
y 
A
st
h
m
a
 Im
m
u
n
o
lR
es
 2
0
1
2
, 4
(4
):
1
8
4
-1
9
1
. 
1
4
. 
A
rm
o
u
r 
C
, B
o
sn
ic
-A
n
ti
ce
vi
ch
 S
, B
ri
lla
n
t 
M
, B
u
rt
o
n
 D
, E
m
m
er
to
n
 L
, K
ra
ss
 I,
 S
ai
n
i B
, S
m
it
h
 L
, S
te
w
ar
t 
K
: 
P
h
ar
m
ac
y 
A
st
h
m
a 
C
ar
e
 P
ro
gr
am
 (
P
A
C
P
) 
im
p
ro
ve
s 
o
u
tc
o
m
e
s 
fo
r 
p
at
ie
n
ts
 in
 t
h
e
 c
o
m
m
u
n
it
y
. 
Th
o
ra
x 
2
0
0
7
, 6
2
(6
):
4
9
6
-5
0
2
. 
1
5
. 
W
ils
o
n
 S
R
, S
tr
u
b
 P
, B
u
is
t 
A
S,
 K
n
o
w
le
s 
SB
, L
av
o
ri
 P
W
, L
ap
id
u
s 
J,
 V
o
llm
er
 W
M
, B
et
te
r 
O
u
tc
o
m
es
 o
f 
A
st
h
m
a 
Tr
ea
tm
en
t 
St
u
d
y 
G
: 
Sh
ar
e
d
 t
re
at
m
e
n
t 
d
e
ci
si
o
n
 m
ak
in
g 
im
p
ro
ve
s 
ad
h
e
re
n
ce
 a
n
d
 o
u
tc
o
m
e
s 
in
 p
o
o
rl
y 
co
n
tr
o
lle
d
 a
st
h
m
a
. A
m
 J
 R
es
p
ir
 C
ri
t 
C
a
re
 M
ed
 2
0
1
0
, 1
8
1(
6
):
5
6
6
-5
7
7
. 
1
6
. 
R
ab
e 
K
F,
 A
d
ac
h
i M
, L
ai
 C
K
, S
o
ri
an
o
 J
B
, V
er
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Appendix 11 Correspondence to and from the Research Ethics Committee 
 
 
WoSRES 
West of Scotland Research Ethics Service 
 
 
 
 
 
 
 
Dr Deborah Morrison 
Clinical Academic Fellow 
University of Glasgow 
General Practice & Primary Care 
Institute of Health & Wellbeing 
University of Glasgow 
1 Horselethill Road 
Glasgow 
G12 9LX 
West of Scotland REC 4 
Ground Floor, Tennent Building 
Western Infirmary 
38 Church Street 
Glasgow 
G11 6NT 
www.nhsggc.org.uk 
Date 23 January 2013 
Direct line 0141-211-1722 
Fax 0141-211-1847 
e-mail evelyn.jackson@ggc.scot.nhs.uk 
 
 
Dear Dr Morrison 
 
 
 
 
 
D 
 
The Research Ethics Committee reviewed the above application at the meeting held on 11 
January 2013. Thank you for attending to discuss the application. 
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
 
Document Version Date 
Covering Letter - 17 December 2012 
REC application - 13 December 2012 
Protocol 1.1 13 December 2012 
Investigator CV - - 
Letter of invitation to participant 1.0 13 December 2012 
Participant Information Sheet: Leaflet 1.0 13 December 2012 
Participant Consent Form 1.0 13 December 2012 
GP/Consultant Information Sheets 1.0 13 December 2012 
Advertisement 1.0 13 December 2012 
Evidence of insurance or indemnity - 08 August 2012 
Study Title: A p ilot Randomised Controlled Trial of Asthma Internet 
Self Management Intervention.  The RAISIN Study. 
REC reference : 13/WS/0004 
Protocol numb er: GN12RM562 
IRAS project I : 120011 
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Interview Schedules/Topic Guides 1.0 13 December 2012 
Other: Reply slip 1.0 13 December 2012 
Other: Letter to GP confirming patient participation  1.0 13 December 2012  
Other: Letter from funder(CSO) - 21 June 2011 
Other: Letter from CSO(Dr Elaine Moir) - 23 May 2011 
Other: Academic Supervisor CV - Prof F Mair - - 
Other: Academic Supervisor CV - Prof S Wyke  - -   
Other: Academic Supervisor CV - Emeritus Prof NC Thomson - - 
Other: Academic Supervisor - Dr A McConnachie - - 
Other: CV - Karolina Agur - - 
Questionnaire: Asthma Control Questionnaire(ACQ) - - 
Questionnaire: Mini Asthma Quality of Life 
Questionnaire(MiniAQLQ) 
- - 
Questionnaire: Patient Activation Measure - - 
Questionnaire: EQ-5D - - 
Questionnaire: Moriskey Medication Adherence Scale - - 
Questionnaire: Problematic Experience of Therapy Scale(PETS) - - 
Referees or other scientific critique report - 03 May 2011 
 
Provisional opinion 
 
Ethical issues raised by the Committee in private discussion, together with responses 
given by the researcher when invited into the meeting: 
 
1. The Committee asked the researchers for information regarding the online self 
management resource. You explained that it is a standalone website which is still under 
construction, which can be accessed as often as required, with no limits. When a study 
participant logs onto the website they will initially be asked questions which are aimed at 
identifying if their asthma could be better controlled. There will also be the ability to 
navigate to other self help areas within the site. The researchers agreed that the site will 
partly be educational but also the tone will challenge the users' beliefs to promote better 
individual asthma control. 
 
2. The Committee asked if the website would not be fully developed before making it 
available to patients. Professor Mair expained that focus groups involving volunteers  
from Asthma UK are currently involved in the development of the website as a piloted 
website. 
 
3. The Committee asked why the invitation would be sent by the GP Practice as they felt 
that this could influence the potential participants to take part in the study. Professor  
Mair explained that this approach is common practice within Primary Care. 
 
4. The Committee asked how the researchers will ensure that all inclusion and exclusion 
criterion are adhered to and you explained that a list of potential participants will be 
prepared in each GP Practice and then these will be manually checked by someone in 
the GP Practice to ensure that the patients to be contacted meet the inclusion and 
exclusion criteria. 
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5. The Committee asked what "website access" will be given to participants in the study, as 
stated in the Participant Information Leaflet. You explained that this means that people 
who are in the Control Group who do not have a log-on to the website, but will be given  
a log-on to allow them to access the website for 12 weeks. 
 
The Committee is unable to give an ethical opinion on the basis of the information and 
documentation received so far. Before confirming its opinion, the Committee requests that you 
provide the further information set out below. 
 
Authority to consider your response and to confirm the Committee’s final opinion has been 
delegated to a meeting of the sub-committee of the REC. 
 
Further information or clarification required 
 
1. The Committee had significant concerns arising from a lack of information about the 
nature of the on-line material and how it might operate for any particular patient. The 
Committee therefore requested more information, including screen capture(s) of how the 
online asthma self management resource will appear and work. 
 
2. With regard to recruitment, the Committee decided that a potential participant who does 
not respond to the initial approach from the GP must not be contacted again by the 
researchers. 
 
3. In the IRAS application form, QA17-1, it is stated that the Juniper Asthma Control 
Questionnaire will be used to establish as an inclusion criteria. As this was not  
submitted as part of the application the Committee would like to see this. 
 
4. In the Participant Information Leaflet, section headed "What will happen to me if I take 
part?", second paragraph, give a clear explanation as to what website access for 12 
weeks means, i.e. a log-on for the website for 12 weeks and not a computer or internet 
access. 
 
If you would find it helpful to discuss any of the matters raised above or seek further 
clarification from a member of the Committee, you are welcome to contact Evelyn 
Jackson, contact details above. 
 
When submitting your response to the Committee, please send revised documentation where 
appropriate underlining or otherwise highlighting the changes you have made and giving revised 
version numbers and dates. 
 
If the committee has asked for clarification or changes to any answers given in the application 
form, please do not submit a revised copy of the application form; these can be addressed in a 
covering letter to the REC. 
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from the date 
of initial receipt of the application, excluding the time taken by you to respond fully to the above 
points.  A response should be submitted by no later than 22 February 2013. 
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Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed on the attached 
sheet. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
 
Yours sincerely 
 
For Dr Brian Neilly 
Chair 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments. 
 
Copy to: Dr Maureen Travers, R&D Office, Tennent Building, Western Infirmary 
13/WS/0004 Please quote this number on all correspondence 
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West of Scotland 
REC 4 
 
Attendance at Committee meeting on 11 January 
2013 Committee Members: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Also in attendance: 
 
Name Position (or reason for attending) 
Dr Judith Godden Scientific Adviser 
Ms Evelyn Jackson Committee Co-ordinator 
Ms Linda Renfrew, Consultant Physiotherapist in MS Observer  
 
Written comments received from: 
 
Name Position 
Mrs Cynthia Mendelsohn Retired (Lay member) 
 
  
Name Profession Present Notes 
Ms Lynda Brown Public Health Adviser Yes  
Dr Andrew Clark Consultant Haematologist No  
Ms Cristina Coelho Pharmacist Yes  
Dr Clair Evans Consultant Paediatric and Perinatal Pathologist Yes  
Dr Kenneth James Consultant Anaesthetist Yes  
Dr Grace Lindsay Reader Yes  
Miss Fiona Mackelvie (Retired) Lay member Yes  
Ms Margaret McDonald Retired (Lay Member) Yes  
Mrs Cynthia Mendelsohn Retired (Lay member) No  
Dr Brian Neilly (Chair) Consultant Physician Yes   
Dr Jackie Riley Statistician Yes  
Dr Ihab Shaheen Consultant Paediatric Nephrologist No  
Mrs Kathleen Tuck Retired Teacher Yes  
Mr Iain Wright Consultant Engineer (Lay member) Yes  
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General Practice & Primary Care  
Institute of Health & Wellbeing  
University of Glasgow  
1 Horselethill Road  
Glasgow  
G12 9LX 
 
20th February 2013 
 
West of Scotland REC 4  
Ground Floor, Tennent Building  
Western Infirmary  
38 Church Street  
Glasgow  
G11 6NT 
 
Dear Dr Neilly, 
 
Study Title: A pilot Randomised Controlled Trial of Asthma Internet Self 
Management Intervention. The RAISIN Study. 
REC reference:  13/WS/0004 
Protocol number:  GN12RM562 
IRAS project ID:  120011 
 
Many thanks for your correspondence following our attendance at the WOS REC 4 meeting 
on the 11th January 2013.  From your letter you highlighted four main areas requiring 
consideration. These are answered in turn below.  
 
 “1. The Committee had significant concerns arising from a lack of information about the nature of 
the on-line material and how it might operate for any particular patient. The Committee therefore 
requested more information, including screen capture(s) of how the online asthma self 
management resource will appear and work.” 
 
We appreciate your concerns about this lack of information.  Attached to this letter are 
word documents and section showing screen shots of how the website will appear.  We 
cannot yet provide a link to the website as it is still under construction but the attached 
documents provide examples of typical content of sections that will be available to 
participants in the remaining think aloud studies, and subsequently the trial.  The enclosed 
contents should allow members of the Committee to get a feel for what the website will be 
like.   Any changes to this content, or additional material, will be reviewed by our expert 
panel prior to inclusion in the website. This panel is: 
1) Professor Neil Thomson, Consultant Respiratory Physician, University of Glasgow 
2) Professor Frances Mair, GP and primary care researcher, University of Glasgow 
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3) Professor Sally Wyke, social scientist, University of Glasgow 
4) Professor Mike Thomas, GP, primary care researcher & Chief Medical Officer at 
Asthma UK, University of Southampton 
5) Professor Lucy Yardley, Health Psychologist, University of Southampton 
6) Dr Deborah Morrison, GP and primary care researcher, University of Glasgow 
 
Of note we have completed 3 ‘think aloud’ studies since the meeting on the 11th January 
using the material provided and user feedback has been very positive.  
 
In addition we have been fortunate enough to be allowed to link to another LifeGuide 
website aimed at facilitating smoking cessation with our asthma resource.1;2 If users click on 
the link “Like to stop smoking?” they will be directed to this online intervention which has 
already been piloted with positive results so far.2  A demonstration version of this is freely 
available to view by clicking on the link or copying and pasting it into a web browser: 
http://www.lifeguideonline.org/player/play/stopadvisordemonstration?thiz=welcomerct   
 
“2. With regard to recruitment, the Committee decided that a potential participant who does not 
respond to the initial approach from the GP must not be contacted again by the researchers.” 
 
We would respectfully ask  the Committee to reconsider this requirement because: 1) as we 
explain below we have genuine concerns that a single mailing will not allow us to achieve 
our recruitment target (and we provide below evidence to substantiate this assertion); 2) it 
is considered standard practice to contact potential participants a second time and there 
are many examples of this in the literature,3-6  and also with the first phase of this project 
(REC no 12/WS/0068) and 3) establishing recruitment rates is an important outcome of this 
pilot study, and being able to report response rates to initial mailings, second mailings and 
telephone contact will be an important finding in itself, and will inform the protocol of any 
future RCT that will stem from this work.  
 
Our main concern about not reaching recruitment targets with a single mailing is based on 
experience at the Asthma Research Unit at Gartnavel General Hospital.  We have experience 
of recruiting adults with asthma from primary care to RCTs which confirms how challenging 
it can be.7-9 Our experience is in keeping with the evidence base around the difficulties of 
recruitment.10-12  Recent positive response rates for trials conducted by our group (which 
include second mailings, and telephone reminders) have been poor ranging from 9-16% (See 
enclosed Table 1).  Furthermore, based on our earlier experience, only 25-55% of those who 
respond positively will fulfil our inclusion criteria and be randomised.  Thus, we know that 
recruitment will be challenging and based on our prior trials do not believe that a single 
mailing will yield sufficient participants. This was the case for the recent asthma RCT8 (Table 
1, trial 3) where second mailings, and reminder telephone calls were then utilised to 
successfully meet targets. These strategies had been approved at the initial REC submission 
stage (REC no 09/S0703/23), allowing them to be operationalised as soon as poorer than 
expected recruitment was identified, and was considered key to it achieving targets. 
 
We would however, be content to modify our protocol so that we ask for permission to 
write to non-responders a second time, OR to follow up with a telephone call reminder, 
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rather than do both as was requested in our initial application.  We would also give 
potential participants explicit opportunity to opt out of being contacted a second time.  
 
This is via a modification to the reply slip v1.0 which currently states: 
This section of the document could be reworded (reply slip  v1.1) to read: 
 
We hope that by explaining why we feel these measures are necessary, and giving potential 
participants explicit opportunity to opt out of a second contact you will reconsider your 
stance on this issue.  
 
“3. In the IRAS application form, QA17-1, it is stated that the Juniper Asthma Control 
Questionnaire will be used to establish as an inclusion criteria. As this was not submitted as part of 
the application the Committee would like to see this.” 
 
The Committee have pointed out that question A17-1 appears to refer to an additional 
patient measure ‘Juniper Asthma Control Questionnaire (6 question version)’.  This is the same 
as the Asthma Control Questionnaire (ACQ) which was submitted with the initial application, 
but without the final 7th question. This 7th question requires a measure of lung function, and 
this will only be done if the participant is included in the study.   
 
Therefore at telephone screening the first 6 questions will be asked to determine if a 
baseline visit is warranted. If, at the baseline visit inclusion criteria are fulfilled, then part of 
this visit includes a measure of lung function which will allow us to record the full 7 question 
ACQ score. 
 
The term Juniper is sometimes used to describe the questionnaire as it was developed by 
Prof Elizabeth Juniper.  
 
I cannot or do not wish to participate in this study.  
Name___________________________________________________ 
GP surgery_______________________________________________ 
(This is so we do not contact you again about this study) 
 
I cannot or do not wish to participate in this study. Please do not contact me 
again. 
Name___________________________________________________ 
GP surgery_______________________________________________ 
(We may contact those who don’t respond to the initial mailing one further time either by 
telephone or by post). 
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We apologise that it was not made sufficiently clear in our initial application that these 
measures were both referring to the same questionnaire set. 
 
 “4. In the Participant Information Leaflet, section headed "What will happen to me if I take part?", 
second paragraph, give a clear explanation as to what website access for 12 weeks means, i.e. a 
log-on for the website for 12 weeks and not a computer or internet access.” 
 
Many thanks to the Committee for highlighting this area of possible confusion to potential 
participants. The line in participant information sheet v1.0 (date 13/12/12): 
”If you didn’t have website access you will be given it now for 12 weeks.” 
 has been replaced by: 
“If you were in the group not using the website, you will be given a login now to 
access the website for 12 weeks.”  
in the updated participant information sheet v1.1 (date 12/02/13). 
 
Please find below a list of the documents enclosed with this letter: 
 
Appendix Content 
A Web section: Introduction and goal setting 
B Web section: My asthma sections example “I have never used a preventer inhaler”  
C Web section: SCREENSHOT Annual review (in powerpoint form to illustrate web 
appearance) 
D Web section: Physical activity and asthma 
E Web section: Common Concerns and Queries 
F Web section: Stress and Anxiety 
G Web section: Take the 4 week challenge 
H Web section: Action plans 
I Example email contents (to those who haven’t opted out, approximately 2 monthly) 
J Participant information Sheet v1.1 date 12/2/13 
K Participant reply slip v1.1 date 14/2/13 
L Table 1 – Examples of asthma trial recruitment 
 
Many thanks for the opportunity to respond to your concerns and queries. If you would like 
any further information please do not hesitate to get in touch. I look forward to hearing 
your response. 
 
Yours sincerely, 
 
 
 
Dr Deborah Morrison     Prof Frances S Mair 
Institute of Health & Wellbeing 
General Practice & Primary Care, 1 Horselethill Road, Glasgow. G12 9LX 
Deborah.Morrison@glasgow.ac.uk 
0141 330 8383  
The University of Glasgow, charity number SC004401 
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WoSRES 
West of Scotland Research Ethics Service 
 
 
 
 
 
 
 
Dr Deborah Morrison 
Clinical Academic Fellow 
University of Glasgow 
General Practice & Primary Care 
Institute of Health & Wellbeing 
1 Horselethill Road 
Glasgow 
G12 9LX 
West of Scotland REC 4 
Ground Floor, Tennent Building Western 
Infirmary 
38 Church Street 
Glasgow 
G11 6NT 
www.nhsggc.org.uk 
Date 19 March 2013 
Direct li ne 0141-211-1722 
Fax 0141-211-1847 
e-mail evelyn.jackson@ggc.scot.nhs.uk 
 
 
Dear Dr Morrison 
 
Study title: A pilot Random ised Controlled Trial of Asthma Internet Self 
Management Intervention.  The RAISIN Study 
REC reference: 13/WS/0004 
Protocol number:  
IRAS project ID: 120011 
 
Thank you for your letter of 22 February 2013, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information was considered, in correspondence by a sub-committee of the REC. A list of the 
sub-committee members is attached. 
 
We plan to publish your research summary wording for the above study on the NRES website, together 
with your contact details, unless you expressly withhold permission to do so. Publication will be no 
earlier than three months from the date of this favourable opinion letter. Should you wish to provide a 
substitute contact point, require further information, or wish to withhold permission to publish, please 
contact the Co-ordinator Ms Evelyn Jackson, evelyn.jackson@ggc.scot.nhs.uk. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research 
on the basis described in the application form, protocol and supporting documentation, as revised, 
subject to the conditions specified below. 
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Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions 
of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the study. 
 
Management permission or approval must be obtained from each host organisation prior to the start of 
the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research Application 
System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential participants 
to research sites ("participant identification centre"), guidance should be sought  from the R&D office on 
the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the procedures of 
the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start 
of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Covering Letter - 17 December 2012 
REC application - 13 December 2012 
Protocol 1.1 13 December 2012 
Investigator CV - - 
Letter of invitation to participant 1.0 13 December 2012 
Participant Information Sheet 1.1 12 February 2013 
Participant Consent Form 1.0 13 December 2012 
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GP/Consultant Information Sheets 1.0 13 December 2012 
Evidence of insurance or indemnity - 08 August 2012 
Interview Schedules/Topic Guides 1.0 13 December 2012 
Advertisement 1.0 13 December 2012 
Other: Reply slip 1.0 13 December 2012 
Other: Letter to GP confirming patient participation  1.0 13 December 2012  
Other: Letter from funder(CSO) - 21 June 2011 
Other: Letter from CSO(Dr Elaine Moir) - 23 May 2011 
Other: Academic Supervisor CV - Prof F Mair - - 
Other: Academic Supervisor CV - Prof S Wyke  - -   
Other: Academic Supervisor CV - Emeritus Prof NC Thomson - - 
Other: Academic Supervisor - Dr A McConnachie - - 
Other: CV - Karolina Agur - - 
Other: Web Sections x 8 - - 
Other: Example email contents - - 
Other: Participant Reply Slip 1.1 14 February 2013 
Other: Examples of asthma trial recruitment - - 
Questionnaire: Asthma Control Questionnaire(ACQ) - - 
Questionnaire: Mini Asthma Quality of Life 
Questionnaire(MiniAQLQ) 
- - 
Questionnaire: Patient Activation Measure - - 
Questionnaire: EQ-5D - - 
Questionnaire: Moriskey Medication Adherence Scale - - 
Questionnaire: Problematic Experience of Therapy Scale(PETS) - - 
Referees or other scientific critique report - 03 May 2011 
Response to Request for Further Information - 22 February 2013 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees 
in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed guidance on 
reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
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The NRES website also provides guidance on these topics, which is updated in the light of changes in 
reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure. If you wish to make your views known please use the 
feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ training 
days – see details at http://www.hra.nhs.uk/hra-training/ 
 
With the Committee’s best wishes for the success of this project. 
Yours sincerely 
 
 
 
For Dr Brian Neilly 
Chair 
 
Enclosures: List of names and professions of members who were present at the meeting and 
those who submitted written comments 
“After ethical review – guidance for researchers” 
 
Copy   to: Dr Maureen Travers, R&D Office, Tennent Building, Western Infirmary 
 
West of Scotland REC 4 
 
Participation in the Sub-Committee of the REC meeting held in correspondence 
 
 
Name Profession Present Notes 
Ms Cristina Coelho Pharmacist Yes  
Dr Kenneth James Consultant Anaesthetist Yes  
Dr Brian Neilly (Chair) Consultant Physician   Yes  
 
 
 
 
13/WS/0004 Please quote this number on all correspondence 
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Amendment 01 – summary of changes requested, submitted via IRAS online form 11th 
april 2013. 
 
There are 4 areas requiring review. 
1. Change to the section ‘Assessment and Reporting of Adverse Events’ found on page 
24 of Protocol v1.1.  This should be replaced with the updated version, as shown in 
Protocol v2.0. The wrong version was inadvertently sent in our initial application, 
and we apologise for this.  
2. Reduced use of the Problematic Experiences of Therapy Scale (PETS) than originally 
described. In Protocol v1.1, (pages 7 & 14), the PETS is listed as a questionnaire 
which is carried out at baseline and follow up by both groups. However this 
questionnaire is actually only completed once, by participants in intervention group, 
at the followup visit. It is a measure of how easy or difficult they found using the 
website. The use of PETS is correctly described in the original study flow chart. 
3. Change to wording of the PETS to make it more specific to this study. In consultation 
with the team who developed this scale, we have a version which is more 
appropriate to use when evaluating a website. In summary this involves changing the 
wording within questions from ‘skipped the therapy’ to ‘did not use/follow the 
Asthma website advice’, and from ‘carrying out the therapy’ to ‘use/follow the 
Asthma website advice’. There is no change to the actually underlying meaning of 
the question being asked. Full details of the changes are attached. Relevant 
documents: i. Original PETS questionnaire ii. New proposed version iii. Table 
showing changes to individual questions for comparison. 
4. Incorrect questionnaire listed in IRAS questions A11 and A58. It lists the Knowledge, 
Attitudes and Self Efficacy Questionnaire (KASEEQ) where it should list the Patient 
Activation Measure (PAM). The PAM is correctly listed in the original protocol v1.1, 
and was correctly submitted as supporting documents with the original application; 
however I apologise for omitting to correct the IRAS forms in these two instances.  
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WoSRES 
West of Scotland Research Ethics Service 
 
 
 
 
 
 
Dr Deborah Morrison 
Clinical Academic Fellow 
University of Glasgow 
General Practice & Primary Care 
Institute of Health & Wellbeing 
1 Horselethill Road 
Glasgow 
G12 9LX 
West of Scotland REC 4 
Ground Floor, Tennent Building 
Western Infirmary 
38 Church Street 
Glasgow 
G11 6NT 
www.nhsggc.org.uk 
Date 22 April 2013 
Direct li ne 0141-211-1722 
Fax 0141-211-1847 
e-mail evelyn.jackson@ggc.scot.nhs.uk 
 
 
Dear Dr Morrison 
 
s 
 
 
 
 
 
 
 
 
The above amendment was reviewed at a meeting of the Sub-Committee, held in 
correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the following amendments on the basis described in the notice of amendment 
form and supporting documentation: 
 
 Change to section “Assessment and Reporting of Adverse Events” of the protocol. 
 Reduced use of the Problematic Experiences of Therapy Scale (PETS). 
 Change to wording of the PETS. 
 Incorrect questionnaire listed in IRAS form. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 
Study title: A pilot Randomi  ed Controlled Trial of Asthma Internet 
Self Management Intervention.  The RAISIN Study. 
REC reference: 13/WS/0004 
Protocol number:  
Amendment number: AM01 
Amendment date: 08 April 2013 
IRAS project ID: 120011 
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Document Version Date 
Protocol 2.0 28 March 2013 
Notice of Substantial Amendment (non-CTIMPs) AM01 08 April 2013 
Covering Letter - 09 April 2013 
PETS original version - - 
Old and new verstion of SAE Assessment and Reporting 0.2 - 
List of PETS question changes - - 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached  
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
Yours sincerely 
 
For Dr Brian Neilly 
Chair 
 
Enclosures: List of names and professions of members who took part in the review 
 
Copy to: Dr Maureen Travers, R&D Office, Tennent Building, Western Infirmary 
West of Scotland REC 4 
 
List of names and professions of members who took part in the review 
 
Name Profession Capacity 
Dr Ken James Consultant Anaesthetist Expert 
Dr Brian Neilly (Chair) Consultant Physician Expert  
Dr Jackie Riley Statistician Expert 
 
13/WS/0004: Please quote this number on all correspondence 
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<GP PRACTICE HEADED NOTEPAPER> 
 
 
 
 
<Date> 
 
 
<Patient Name> 
<Patient Address> 
<Patient Address> 
<Patient Address> 
 
Dear  <Patient name>, 
 
We are writing to ask for your help with a study being undertaken by the Department of 
General Practice & Primary Care, at the University of Glasgow. 
 
We are supporting this exciting study which aims to test a website which has been developed 
to help people with asthma learn about, and manage, their asthma better.   The researchers 
are looking for people with asthma to test out the website to find out if it is helpful and 
useful to people like you. 
 
A leaflet is enclosed which gives more details about what this would mean for you. 
 
Please have a read of this, and if you have any questions then do not hesitate to contact 
the researcher involved – Dr Deborah Morrison – who is happy to answer any queries.  The 
contact details are on the back of the leaflet.  If you are interested simply post back the 
enclosed form in the reply paid envelope.  
 
Yours sincerely, 
 
 
 
<GP/Practice Name> 
Appendix 12 – Mailing pack for potential participants: Letter to patient, reply 
slip & participant information leaflet 
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A pilot Randomised Controlled Trial of an Asthma Internet Self Management 
Intervention – The RAISIN Study. 
 
I am interested in helping with this research 
 
I have read the participant information sheet and I am interested to hear 
more about the study.  Please contact me to discuss this further.  
 
Name   ………………………………………………………………………………………………….. 
Address ………………………………………………………………………………………………….. 
  ………………………………………………………………………………………………….. 
  ………………………………………….…..……  Post code………………….……….. 
Telephone number ……………………………………………………………………………………… 
 
Email address  ……………………………………………………………………………………… 
 
 
Which is the best way to contact you?   Telephone  Email  
 
 
Please fill this in and send it back to the research team in the reply paid envelope, or scan 
and email it.  
(Please keep the participant information sheet). 
 
Alternatively contact the researcher, Deborah Morrison, directly by:  
 
Email:     deborah.morrison@glasgow.ac.uk       or        Telephone:    0141 330 8383 
 
 
 
I cannot or do not wish to participate in this study. Please do not contact me again. 
Name___________________________________________________ 
GP surgery_______________________________________________ 
(We may contact those who don’t respond to the initial mailing one further time either by telephone 
or by post). 
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Supporting Self Care    
for Asthma 
A Randomised controlled 
trial of an Asthma Internet 
Self care Intervention 
We are testing a website for 
people with asthma & we 
would like your help! 
If you are 16 years old or over and would like to find out more 
please contact: 
Deborah Morrison on 0141 330 8383  or 
 deborah.morrison@glasgow.ac.uk 
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1. It is XX from the asthma website study.  Thank you for responding to the mailing, we 
appreciate you taking the time to do that. Is now a good time to have a quick it?  
2. Firstly, can I ask you some questions about your own health and your asthma to check if you 
are eligible for the study. Then if you are, I will tell you what the study involves and you can 
see if you would be interested in helping out? Would that be okay? 
3. Can I ask your age please?   (Ask postcode if phoned in, rather than responded to mailing) 
4. Do you have a diagnosis of asthma? 
5. Do you have any other lung conditions, or have you been told you have COPD or chronic 
bronchitis? 
6. Do you have the internet in your house? 
7. Is this on a laptop or computer? (website doesn’t work on  tablets and smartphones) 
8. Have you been to hospital or the doctors for your asthma in the last month? 
(postpone rest of screening if: 
a) Been to A&E,GEMS, hospitalised for asthma in last 4 weeks 
b) Been given oral steroids for asthma in last 4 weeks 
c) Been to see GP or nurse because of a flare in symptoms in last 4 weeks. 
a. (it is okay if been for annual review only, or if had a bit of a flare of symptoms that didn’t 
need to see doc or nurse for). 
9.  Can I ask you some questions about your asthma now?   ACQ……. 
10. That all sounds fine from our point of view.  
11. Can I tell you a little about the study just now? 
a. We have developed a website which we think will be of interest to people with asthma 
and we need people to try it out. If you agreed to take part we would come to your 
house, ask some more questions about your health and asthma and how it affects you.  
We would then do some simple breathing tests. If everything was okay we would then 
find out if you were to get the website now, which is the case for half of you, or whether 
you get it in 3 months time. If you are allocated to the website group we simply give you 
a login and you can use the website as much or as little as you like over the next 12 
weeks. This first visit takes about one hour. 
b. We would then arrange to visit you again after 12 weeks and repeat some of the 
questions and the breathing tests. If you have been given the website we would also like 
to ask you some questions about what you thought of the website.  
12. Does that sound like something you would be interested in helping out with? If yes…. 
13. Is there a time of day or a day of the week which would suit you best to visit? We can be 
flexible.  We can do early evenings some days of the week if that is better for you….  
14. I will drop you an email just now confirming the date and time, and then you can let us know 
if anything crops up that we need to re-arrange.  
15. The other thing to mention is that we would ask you to not use your inhalers the day we 
visit. This is because it can affect the results of the breathing tests. However we do say to 
people that if you need them in particular your reliever inhaler then you just go on ahead and 
take it – we can always adjust for it if needs be. We don’t want anyone going into a full blown 
asthma attack because of us. 
16. Please let us know if you have to see a doctor about your asthma  between now and then as 
we will need to postpone the visit.  
Appendix 14 Telephoning potential trial participants check list  
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 Conditions included for co-morbidity count 1 
1. hypertension  
2. cardiovascular 
3. rhinitis (perennial or allergic 
4. eczema/psoriasis 
5. musculoskeletal (covering osteoporosis, scoliosis, slipped disc) 
6. chronic lung disease 
7. anxiety 
8. depression 
9. liver disease 
10. renal tract disease 
11. epilepsy 
12. dyspepsia/ulcer 
13. dementia 
14. allergic condition (oral allergy syndrome) 
15. chronic neurological condition (e.g. cerebral palsy)  
 
                                                          
1
 This list is not meant to be a comprehensive list of all chronic medical conditions. I listed all the medical 
conditions which our participants had (both from our list, plus those ‘free texted’) and grouped related ones 
together, and removed those not considered to be a chronic condition (e.g. resolved (pregnancy induced) 
hypertension) 
Appendix 15  Chronic conditions included in co-morbidity count 
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 Participant No. Participant Initials Date of Visit Visit Number 
01 02 D      D      M      M Y Y Y Y 03 04 
RAISIN Study 
Protocol: v2.0 28th March 2013 
Version 1.0 (27th August 2013) 
Questionnaires Pack 
Page 1 of 2 
EQ-5D 
 
 
 
 
A. EQ-5D Questionnaire 
 
1. Describing your health TODAY 
 
Under each heading, mark ONE box that best describes your health TODAY. 
 
Mobility (walking about) 
I have no problems walking about 
I have some problems walking about 
I have a lot of problems walking about 
05 
 
 
 
Looking after myself 
I have no problems washing or dressing myself 
I have some problems washing or dressing myself  
I have a lot of problems washing or dressing myself 
06 
 
 
 
 
 
Doing usual activities (for example, going to school, hobbies, sports, 
playing, doing things with family and friends) 
I have no problems doing my usual activities 
I have some problems doing my usual activities  
I have a lot of problems doing my usual activities 
07 
 
 
 
 
Having pain or discomfort 
I have no pain or discomfort 
I have some pain or discomfort  
I have a lot of pain or discomfort 
08 
 
 
 
Feeling worried, sad or unhappy 
 
I am not worried, sad or unhappy 
I am a bit worried, sad or unhappy 
I am very worried, sad or unhappy 
09 
 
 
UK (English) © 2008 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group 
Appendix 16 Questionnaires used for patient reported outcomes 
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Participant No.   Participant Initials Date of Visit Visit Number 
01 02 D      D      M M       M Y Y Y Y 03 
04 
RAISIN Study 
Protocol: v2.0 28th March 2013 
Version 1.0 (27th August 2013) 
Questionnaires Pack 
Page 2 of 2 
EQ5D Cont. 
 
 
 
 
 
2. How good is your health TODAY. 
The best health 
you can imagine 
100 
 
We would like to know how good or bad your health is TODAY. 95 
This line is numbered from 0 to 100. 
100 means the best health you can imagine.
 90
 
Please mark an X on the line that shows how good or bad your health is 
TODAY. 85 
80 
75 
70 
65 
60 
55 
50 
45 
40 
35 
30 
25 
20 
15 
10 
5 
0 
UK (English) © 2008 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group 
The worst health   05 
you can imagine 
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 Participant No. Participant Initials Date of Visit Visit Number 
01 02 D      D      M      M Y Y Y Y 03 04 
RAISIN Study 
Protocol: v2.0 28th March 2013 
Version 1.0 (27th August 2013) 
Questionnaires Pack 
Page 1 of 1 
Morisky Medication Adherence Scale 
 
 
 
 
 
A. Morisky Medication Adherence Scale (MMAS) 
 
© Morisky Medication Adherence Scale (MMAS-8-Item). This is a generic adherence scale and the name of the 
health concern can be substituted in each question item. 
 
You indicated that you are taking medication for your asthma. 
Individuals have identified several issues regarding their medication-taking behaviour and we are interested in 
your experiences. There is no right or wrong answer. Please answer each question based on your personal 
experience with your asthma medication. 
 
 
 
1.  Do you sometimes forget to take your asthma medicine? 
Yes 
 
0 
No 
 
 
 
1 
  05  
2.  People sometimes miss taking their medications for reasons other than forgetting. Thinking 
 
0 
 
 
 
1 
over the past two weeks, were there any days when you did not take your asthma  06  
medicine?    
 
3.  Have you ever cut back or stopped taking your medication without telling your doctor 
 
0 
  
1 
because you felt worse when you took it?  07  
4.  When you travel or leave home, do you sometimes forget to bring along your asthma 
 
0 
  
1 
medicine?  08  
 
5.   Did you take your asthma medicine yesterday? 
 
0 
 
 
 
1 
  09  
 
6. When you feel like your asthma is under control, do you sometimes  stop taking 0 1 
your   medicine? 10 
 
7. Taking medication everyday is a real inconvenience for some people. Do you   ever feel 0 1
 
hassled about sticking to your asthma treatment plan? 
 
 
8. How often do you have difficulty remembering to take all your medications? 
Please tick 
 
 
 
 
 
 
 
 
 
 
© Moriskey Medication Adherence Scale (8-Item) 
11 
Never/Rarely 
 
 
 
4 
Once in a while  3 
Sometimes  2 
Usually  1 
All the time 
 
 
 
12 
0 
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Participant No. Participant Initials Date of Visit Visit Number 
01 02 D      D      M      M Y Y Y Y 03 04 
RAISIN Study 
Protocol: v2.0 28th March 2013 
Version 1.0 (27th August 2013) 
Questionnaires Pack 
Page 1 of 2 
MiniAQLQ 
 
 
 
 
 
A. Mini AQLQ 
 
Please complete all questions by circling the number that best describes how you have been during the last 2 weeks 
as a result of your asthma. 
 
IN GENERAL, HOW MUCH OF THE TIME DURING THE LAST 2 WEEKS DID YOU: 
 
 
 
 
 
1. Feel SHORT OF 
BREATH as a result of 
your asthma? 
 
2. Feel bothered by or 
 
 
 
 
1 2 3 4 5 6 
 
 
 
 
7 06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
your chest? 
 
The MINIAQLQ is copyrighted. It may not be altered, sold (paper or electronic), translated or adapted for another medium without the permission of 
Elizabeth Juniper.  ( ©2000, QOL Technologies, Ltd.) 
have to avoid 
DUST in the 
environment? 
 
3.   Feel FRUSTRATED as a 1 2 3 4 5 6 7 07 
result of your asthma?        
4.   Feel bothered by 1 
COUGHING? 
2 3 4 5 6 7 08 
5.   Feel AFRAID OF NOT 1 
HAVING YOUR ASTHMA 
MEDICATION 
2 3 4 5 6 7 09 
AVAILABLE? 
6.  Experience a feeling of 1 
CHEST TIGHTNESS or 
CHEST HEAVINESS 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 10 
7.  Feel bothered by or have 1 
to avoid CIGARETTE 
SMOKE in the 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 11 
environment? 
8.  Have DIFFICULTY 1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 12 
GETTING A GOOD        
NIGHT'S SLEEP as a        
result of your asthma?        
9.   Feel CONCERNED 1 2 3 4 5 6 7 13 
ABOUT HAVING        
ASTHMA?        
10. Experience a WHEEZE in 1 2 3 4 5 6 7 14 
 
All of the Most of A Good Some of A Little Hardly Any None of 
Time the Time Bit of the 
Time 
the Time of the 
Time 
of the Time the 
Time 
1 2 3 4 5 6 7 05 
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 Participant No. Participant Initials Date of Visit Visit Number 
01 02 D      D      M      M Y Y Y Y 03 04 
RAISIN Study 
Protocol: v2.0 28th March 2013 
Version 1.0 (27th August 2013) 
Questionnaires Pack 
Page 2 of 2 
MiniAQLQ 
 
 
 
 
 
A. Mini AQLQ Cont. 
 
IN GENERAL, HOW MUCH OF THE TIME DURING THE LAST 2 WEEKS DID YOU: 
 
All of the Most of A Good Some of A Little Hardly Any None of 
Time the Time Bit of the the Time of the of the Time the 
  Time  Time  Time 
 
11. Feel bothered by or have 
to avoid going outside 
because of WEATHER 
OR AIR POLLUTION? 
1 2 3 4 5 6 7 05 
 
HOW LIMITED HAVE YOU BEEN DURING THE LAST 2 WEEKS DOING THESE ACTIVITIES AS A RESULT OF 
YOUR ASTHMA? 
 
Totally Extremely Very Moderate Some A Little Not at all 
Limited Limited Limited Limitation Limitation Limitation Limited 
 
12. STRENUOUS 
ACTIVITIES (such as 
hurrying, exercising, 
running up stairs, sports) 
1 2 3 4 5 6 7 
06 
 
13. MODERATE ACTIVITIES 
(such as walking, 
housework, gardening, 
shopping, climbing stairs) 
1 2 3 4 5 6 7 
07 
 
14. SOCIAL ACTIVITIES 
(such as talking, playing 
with pets / children, visiting 
friends / relatives) 
1 2 3 4 5 6 7 
08 
 
15. WORK-RELATED 
ACTIVITIES* (tasks you 
have to do at work) 
1 2 3 4 5 6 7 
09 
 
*If you are not employed or self-employed, these should be tasks that you have to do most days 
 
 
 
The MINIAQLQ is copyrighted. It may not be altered, sold (paper or electronic), translated or adapted for another medium without the permission of 
Elizabeth Juniper.  ( ©2000, QOL Technologies, Ltd.) 
DOMAIN CODE: 
 
SYMPTOMS: 1, 4, 6, 8, 10 
ACTIVITY LIMITATION:  12, 13, 14, 15 
EMOTIONAL FUNCTION: 3, 5, 9 
ENVIRONMENTAL STIMULI:  2, 7, 11 
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Participant No. Participant Initials Date of Visit Visit Number 
01 02 D      D      M      M Y Y Y Y 03 04 
RAISIN Study 
Protocol: v2.0 28th March 2013 
Version 1.0 (27th August 2013) 
Questionnaires Pack 
Page 1 of 1 
Patient Activation Measure 
 
 
 
 
A. Patient Activation Measure (PAM) 
Below are some statements that people sometimes make when they talk about their health. Please indicate how much 
you agree or disagree with each statement as it applies to you personally by ticking your answer. Your answers should 
be what is true for you and not just what you think others want you to say. 
 
 Disagree 
Strongly 
Disagree Agree  Agree 
Strongly 
N/A  
 
1.   When all is said and done, I am the person who is 
 
1 
 
2 
  
3 
 
4 
  
5 
responsible for taking care of my health.      05  
 
2.   Taking an active role in my own health care is the most 
 
1 
 
2 
  
3 
 
4 
  
5 
important thing that affects my health      06  
 
3.   I am confident I can help prevent or reduce problems 
 
1 
 
2 
  
3 
 
4 
  
5 
associated with my health      07  
 
4.   I know what each of my prescribed medications do 
 
1 
 
2 
 
 
 
3 
 
4 
 
 
 
5 
      08  
 
5.   I am confident that I can tell whether I need to go to the 
 
1 
 
2 
  
3 
 
4 
  
5 
doctor or whether I can take care of a health problem      09  
myself        
6.   I am confident that I can tell a doctor concerns I have 1 2  3 4  5 
even when he or she does not ask      10  
 
7. I am confident that I can follow through on medical 
treatments I may need to do at home 
 
1 
 
2 
 
 
 
 
3 
 
4 
 
 
11 
 
5 
8.   I understand my health problems and what causes 
 
1 
 
2 
  
3 
 
4 
  
5 
them      12  
 
9.   I know what treatments are available for my health 
 
1 
 
2 
  
3 
 
4 
  
5 
problems      13  
 
10. I have been able to maintian (keep up with) lifestyle 
 
1 
 
2 
  
3 
 
4 
  
5 
changes, like eating right or exercising      14  
11. I know how to prevent problems with my health 
 
1 
 
2 
 
 
 
3 
 
4 
 
 
 
5 
      15  
 
12. I am confident I can figure out solutions when new 
problems arise with my health 
1 2 3 4 5 
16 
 
13. I am confident that I can maintian lifestyle changes, like 
eating right and exercising, even during times of stress 
1 2 3 4 5 
17 
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Problematic Experiences of Therapy Scale (PETS) (Online Asthma 
Intervention) 
 
We would like to know how easy or difficult it was for you to use/follow the website’s advice.  We want 
to find out if it was difficult in any way for you to use/follow, and if so, what difficulties were. 
 
 
 
Problems due to symptoms 
1 
I did not use/follow the Asthma Website advice 
because it made my symptoms worse. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
2 
I was prevented from using/following the Asthma 
Website advice by severe symptoms. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
3 
I could not use/follow the Asthma Website advice 
because it caused more symptoms. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
Problems due to uncertainty or doubts about the therapy 
4 
I could not use/follow the Asthma Website advice 
because I was unsure how to do it properly. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
5 
I was unable to use/follow the Asthma Website 
advice because it was difficult to know what to do. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
6 
I did not use/follow the Asthma Website advice 
because I was not sure if it was helping. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
7 
I did not use/follow the Asthma Website advice 
because it did not seem relevant to my symptoms 
and problems. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
8 
I did not use/follow the Asthma Website advice 
because I was not convinced it was right for me. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
Practical Problems 
9 
Lack of time prevented me from using/following the 
Asthma Website advice. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
10 
It was not possible to find suitable opportunities to 
use/follow the Asthma Website advice. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
11 
I was too busy to use/follow the Asthma Website 
advice. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
12 
I found it difficult to remember to use/follow the 
Asthma Website advice. 
Agree 
Strongly 
Agree 
Slightly 
Not Sure 
Disagree 
Slightly 
Disagree 
Strongly 
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